0001528988falseIf the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by the Trust. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.The Trust and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of the Trust’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2024. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees the Trust pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2024. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by the Trust (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of the Trust or a majority of the outstanding voting securities of the Trust), upon 90 days’ written notice by the Trust to the Manager.The Trust currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on the Trust’s average daily managed assets. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes). 0001528988 2022-12-31 2022-12-31 0001528988 cik0001528988:CommonStockMember 2022-10-01 2022-12-31 0001528988 cik0001528988:CommonStockMember 2022-07-01 2022-09-30 0001528988 cik0001528988:CommonStockMember 2022-04-01 2022-06-30 0001528988 cik0001528988:CommonStockMember 2022-01-01 2022-03-31 0001528988 cik0001528988:CommonStockMember 2021-10-01 2021-12-31 0001528988 cik0001528988:CommonStockMember 2021-07-01 2021-09-30 0001528988 cik0001528988:CommonStockMember 2021-04-01 2021-06-30 0001528988 cik0001528988:CommonStockMember 2021-01-01 2021-03-31 0001528988 cik0001528988:CommonStockMember 2022-12-31 2022-12-31 0001528988 cik0001528988:MarketRiskAndSelectionRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:SecuritiesLendingRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:SubsidiaryRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InvestmentCompaniesAndEtfsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:IlliquidInvestmentsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:RisksAssociatedWithPrivateCompanyInvestmentsMember 2022-12-31 2022-12-31 0001528988 cik0001528988:RepurchaseAgreementsAndPurchaseAndSaleContractsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ShortSalesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:WhenissuedAndDelayedDeliverySecuritiesAndForwardCommitmentsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DollarRollsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ReverseRepurchaseAgreementsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:LeverageRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CommodityPricingRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DepletionAndExplorationRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:SupplyAndDemandRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InnovativeSecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:RisksOfInvestingInUtilitiesInfrastructureAndPowerOpportunitiesIssuersMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CommoditiesMarketRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CommoditiesRelatedInvestmentsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:EnergyAndNaturalResourcesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:EnergySectorRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:HealthSciencesAndHealthcareCompaniesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ScienceAndTechnologyRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ConcentrationRiskOneMember 2022-12-31 2022-12-31 0001528988 cik0001528988:EmergingMarketsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ForeignCurrencytransactionsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ForeignSecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DerivativesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:StructuredProductsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:U.s.GovernmentObligationsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:JunkBondsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DebtSecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:RisksAssociatedWithTheTrustsOptionsStrategyMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InitialPublicOfferingsMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InvestmentStyleRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DividendpayingEquitySecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InvestmentsInUnseasonedCompaniesMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CanadianRoyaltyTrustRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:MasterLimitedPartnershipsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ReitInvestmentRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:DepositaryReceiptsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:WarrantsRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ConvertibleSecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:PreferredSecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:SmallAndMidcapitalizationCompanyRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CommonStockRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:EquitySecuritiesRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InvestmentAndMarketDiscountRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:LimitedTermRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:NondiversificationRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:InfectiousIllnessRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ValuationRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:CounterpartyCreditRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:ConcentrationRiskMember 2022-12-31 2022-12-31 0001528988 cik0001528988:LiborTransitionRiskMember 2022-12-31 2022-12-31 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES
Investment Company Act file number:
811-22606
 
Name of Fund:   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
Fund Address:   100 Bellevue Parkway, Wilmington, DE 19809
Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Utilities, Infrastructure & Power Opportunities Trust, 50 Hudson Yards, New York, NY 10001
Registrant’s telephone number, including area code: (800)
882-0052,
Option 4
Date of fiscal year end: 12/31/2022
Date of reporting period: 12/31/2022
 

Item 1 – Report to Stockholders
(a) The Report to Shareholders is attached herewith.
 

 
LOGO
 
DECEMBER 31, 2022
 
  
2022 Annual Report
 
 
BlackRock Energy and Resources Trust (BGR)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
BlackRock Enhanced Equity Dividend Trust (BDJ)
BlackRock Enhanced Global Dividend Trust (BOE)
BlackRock Enhanced International Dividend Trust (BGY)
BlackRock Health Sciences Trust (BME)
BlackRock Health Sciences Trust II (BMEZ)
BlackRock Innovation and Growth Trust (BIGZ)
BlackRock Resources & Commodities Strategy Trust (BCX)
BlackRock Science and Technology Trust (BST)
BlackRock Science and Technology Trust II (BSTZ)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
 
 
 
Not FDIC Insured • May Lose Value • No Bank Guarantee

Supplemental Information
(unaudited)
 
 
Section 19(a) Notices
BlackRock Energy and Resources Trust’s (BGR), BlackRock Enhanced Capital and Income Fund, Inc.’s (CII), BlackRock Enhanced Equity Dividend Trust’s (BDJ), BlackRock Enhanced Global Dividend Trust’s (BOE), BlackRock Enhanced International Dividend Trust’s (BGY), BlackRock Health Sciences Trust’s (BME), BlackRock Health Sciences Trust II’s (BMEZ), BlackRock Innovation and Growth Trust’s (BIGZ), BlackRock Resources & Commodities Strategy Trust’s (BCX), BlackRock Science and Technology Trust’s (BST), BlackRock Science and Technology Trust II’s (BSTZ) and BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (collectively, the “Trusts” or individually, a “Trust”) amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form
1099-DIV
each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.
December 31, 2022
 
     Total Cumulative Distributions
for the Fiscal Period
   
% Breakdown of the Total Cumulative
Distributions for the Fiscal Period
 
Trust Name
 
 
Net
Income
 
 
 
 

Net Realized

Capital Gains
Short-Term
 

 
 
 
 

Net Realized

Capital Gains
Long-Term
 

 
 
 
 

Return of

Capital 
 

(a)
 
 
 

Total Per

Common
Share
 

 
 
 

Net

Income
 

 
 
 

Net Realized

Capital Gains
Short-Term
 

 
 
 
 

Net Realized

Capital Gains
Long-Term
 

 
 
 
 

Return of

Capital
 

 
 
 

Total Per

Common
Share
 

 
 
BGR
  $ 0.424570     $     $     $ 0.153930     $ 0.578500       73             27     100
CII
    0.060860       0.431470       1.608040             2.100370       2       21       77             100  
BDJ
    0.158990       0.069630       0.868684             1.097304       15       6       79             100  
BOE
    0.202510             0.120920       0.432570       0.756000       27             16       57       100  
BGY
    0.101270             0.050400       0.253930       0.405600       25             12       63       100  
BME
    0.106430             2.266920       0.182650       2.556000       4             89       7       100  
BMEZ
          0.122840       1.120800       0.496360       1.740000             7       64       29       100  
BIGZ
                      0.990000       0.990000                         100       100  
BCX
    0.302550                   0.247850       0.550400       55                   45       100  
BST
                2.647720       0.352280       3.000000                   88       12       100  
BSTZ
                0.883950       1.420050       2.304000                   38       62       100  
BUI
    0.323160             0.365110       0.763730       1.452000       22             25       53       100  
 
 
(a)
 
EachTrust estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust’s investment performance and should not be confused with “yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share.
 
Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at
blackrock.com.
Section 19(b) Disclosure
The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Trust’s Board of Trustees (the “Board”), each has adopted a managed distribution plan, consistent with its investment objectives and policies, to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plans, the Trusts currently distribute the following fixed amounts per share on a monthly basis:
 
Exchange Symbol
 
Amount Per
Common Share
 
BGR
  $ 0.0585  
CII
    0.0995  
BDJ
    0.0562  
BOE
    0.0630  
BGY
    0.0338  
BME
    0.2130  
BMEZ
    0.1450  
BIGZ
    0.0700  
BCX
    0.0518  
BST
    0.2500  
BSTZ
    0.1920  
BUI
    0.1210  
The fixed amounts distributed per share are subject to change at the discretion of each Trust’s Board. Under its Plan, each Trust will distribute all available net income to its shareholders as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net income and short-term capital gains) is not earned on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board; however, each Trust may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the Investment Company Act of 1940, as amended (the “1940 Act”).
Shareholders should not draw any conclusions about each Trust’s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust’s total return performance is presented in its financial highlights table.
 
 
2
 
2 0 2 2
  B 
L A C K 
O C K  
N N U A L  
E P O R T  T O  
H A R E H O L D E R S

Supplemental Information  
(unaudited)
 
(continued)
 
 
The Board may amend, suspend or terminate a Trust’s Plan at any time without prior notice to the Trust’s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust’s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, changes in interest rates, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BME, BST and BUI’s prospectuses for a more complete description of each Trust’s risks.
 
 
U P P L E M E N T A L  
N F O R M A T I O N
  3

The Markets in Review
Dear Shareholder,
Significant economic headwinds emerged during the
12-month
reporting period ended December 31, 2022, as investors navigated changing economic conditions and volatile markets. The U.S. economy shrank in the first half of 2022 before returning to modest growth in the third quarter, marking a shift to a more challenging post-reopening economic environment. Changes in consumer spending patterns and a tight labor market led to elevated inflation, which reached a
40-year
high before beginning to moderate. Moreover, while the foremost effect of Russia’s invasion of Ukraine has been a severe humanitarian crisis, the ongoing war continued to present challenges for both investors and policymakers.
Equity prices fell as interest rates rose, particularly during the first half of the reporting period. Both large- and small-capitalization U.S. stocks fell, although equities began to recover in the second half of the year as inflation eased and economic growth resumed. Emerging market stocks and international equities from developed markets declined overall, pressured by rising interest rates and a strengthening U.S. dollar.
The
10-year
U.S. Treasury yield rose notably during the reporting period, driving its price down, as investors reacted to fluctuating inflation data and attempted to anticipate its impact on future interest rate changes. The corporate bond market also faced inflationary headwinds, and heightened uncertainty led to higher corporate bond spreads (the difference in yield between U.S. Treasuries and similarly-dated corporate bonds).
The U.S. Federal Reserve (the “Fed”), acknowledging that inflation has been more persistent than expected, raised interest rates seven times. Furthermore, the Fed wound down its bond-buying programs and is accelerating the reduction of its balance sheet. While the Fed suggested that additional rate hikes were likely, it also gave indications that the pace of increases would slow if inflation continued to subside.
The pandemic’s restructuring of the economy brought an ongoing mismatch between supply and demand, contributing to the current inflationary regime. While growth slowed in 2022, we believe that taming inflation requires a more dramatic economic decline to bring demand back to a level more in line with the economy’s capacity. The Fed has been raising interest rates at the fastest pace in decades, and seems set to overtighten in its effort to get inflation back to target. With this in mind, we believe the possibility of a U.S. recession in the near-term is high, but this prospect has not yet been fully priced in by markets. Investors should expect a period of higher volatility as markets adjust to the new economic reality and policymakers attempt to adapt to rapidly changing conditions.
In this environment, while we favor an overweight to equities in the long-term, the market’s concerns over excessive rate hikes from central banks moderate our outlook. Rising input costs and a deteriorating economic backdrop are likely to challenge corporate earnings, so we are underweight equities overall in the near term. However, we see better opportunities in credit, where valuations are attractive and higher yields provide income opportunities. We believe that global investment-grade corporates, global inflation-linked bonds, and U.S. mortgage-backed securities offer strong opportunities for a
six-
to twelve-month horizon.
Overall, our view is that investors need to think globally, position themselves to be prepared for a decarbonizing economy, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit
blackrock.com
for further insight about investing in today’s markets.
Sincerely,
 
LOGO
Rob Kapito
President, BlackRock Advisors, LLC
LOGO
Rob Kapito
President, BlackRock Advisors, LLC
 
Total Returns as of December 31, 2022
     
    
 6-Month 
 
12-Month
   
U.S. large cap equities
(S&P 500
®
Index)
  2.31%   (18.11)%
   
U.S. small cap equities
(Russell 2000
®
Index)
  3.91      (20.44)   
   
International equities
(MSCI Europe, Australasia,
Far East Index)
  6.36      (14.45)   
   
Emerging market equities
(MSCI Emerging Markets Index)  
  (2.99)      (20.09)   
   
3-month
Treasury bills
(ICE BofA
3-Month
U.S. Treasury Bill Index)
  1.32      1.47   
   
U.S. Treasury securities
(ICE BofA
10-Year
U.S. Treasury Index)
  (5.58)      (16.28)   
   
U.S. investment grade bonds
(Bloomberg U.S. Aggregate
Bond Index)
  (2.97)      (13.01)   
   
Tax-exempt
municipal bonds
(Bloomberg Municipal Bond Index)  
  0.50      (8.53)   
   
U.S. high yield bonds
(Bloomberg U.S. Corporate
High Yield 2%
Issuer Capped Index)
  3.50      (11.18)   
Past performance is not an indication of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.
 
 
 
4
 
T
H
I
S   
P
A
G
E   I
S   N
O
T   
P
A
R
T   O
F   
Y
O
U
R   
F
U
N
D   
R
E
P
O
R
T

Table of Contents
 
 
 
     
Page
 
     2  
     4  
     6  
     6  
Annual Report:
  
     7  
Financial Statements:
  
     44  
     135  
     138  
     141  
     147  
     152  
     164  
     179  
     180  
     181  
     207  
     211  
     212  
     215  
     219  
 
 
  5

Option Over-Writing Strategy
 
 
Overview
In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue these goals primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options in an effort to generate current gains from option premiums and to enhance each Trust’s risk-adjusted return. Each Trust’s objectives cannot be achieved in all market conditions.
Each Trust primarily writes single stock covered call options and may also from time to time write single stock put options. When writing (selling) a covered call option, a Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (“strike price”) within an agreed-upon time period. The Trust receives cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trust. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trust realizes gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.
Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by a Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. The premium that a Trust receives from writing a covered call option may not be sufficient to offset the potential appreciation on the underlying equity security above the strike price of the option that could have otherwise been realized by the Trust. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.
Option Over-Writing Strategy Illustration
To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at $37.15 per share; (2) a three-month call option is written by a Trust with a strike price of $40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives $2.45, or 6.6% of the common stock’s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to $34.70 per share), the option strategy would “break-even” from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of $40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above $40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust’s downside protection is eliminated and the stock could eventually become worthless.
Each Trust intends to write covered call and other options to varying degrees depending upon market conditions. Please refer to each Trust’s Schedule of Investments and the Notes to Financial Statements for details of written options.
Derivative Financial Instruments
The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. Pursuant to Rule
18f-4
under the 1940 Act, among other things, the Trusts must either use derivative financial instruments with embedded leverage in a limited manner or comply with an outer limit on fund leverage risk based on
value-at-risk.
The Trusts’ successful use of a derivative financial instrument depends on the investment adviser’s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts’ investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.
 
 
6
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Energy and Resources Trust (BGR)
 
 
Investment Objective
BlackRock Energy and Resources Trust’s (BGR) (the “Trust”)
investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
Symbol on New York Stock Exchange
  BGR
Initial Offering Date
      December 29, 2004    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($12.53)
(a)
  5.60%
Current Monthly Distribution per Common Share
(b)
  $0.0585
Current Annualized Distribution per Common Share
(b)
  $0.7020
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
   
12/31/21
   
Change
   
High
   
Low
 
Closing Market Price
    $    12.53       $    9.48       32.17%       $  13.63       $  9.48  
Net Asset Value
    14.21       10.77       31.94          15.19       10.77  
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that is designed to capture the large- and
mid-cap
segments across developed markets countries. All securities in the index are classified in the energy sector as per the Global Industry Classification Standard.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  7

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Energy and Resources Trust (BGR)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
    
1 Year   
   
5 Years   
   
10 Years   
 
Trust at NAV
(a)(b)
    38.51%       4.64%       2.51%  
Trust at Market Price
(a)(b)
    38.76          4.28          2.15     
MSCI World Energy Call Overwrite Index
(c)
    38.86          N/A          N/A     
MSCI World Energy Index
    46.01          5.63          3.48     
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
 
An index that incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s absolute performance based on NAV:
What factors influenced performance?
An overweight in ConocoPhillips, which benefited from its increased focus on shareholder returns, was the largest positive contributor to the Trust’s performance in 2022. Overweights in companies that stood to benefit from rising liquified natural gas exports stemming from the war in Ukraine, including Cheniere Energy and Tourmaline Oil Corp., also helped results. The exploration and production company Hess Corp. was an additional contributor, due in part to its announcement of new offshore discoveries.
A zero weighting in Occidental Petroleum Corp., which capitalized on stronger oil prices to
de-lever
its balance sheet, was the largest detractor. An underweight in the oilfield services energy
sub-sector
detracted, as well. Zero weightings in Schlumberger NV and Halliburton Co. were the leading detractors in this regard.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results during the reporting period. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
The investment adviser managed the Trust’s overall sensitivity to oil prices given the market’s near-term concerns about oil demand at a time of rising interest rates. The investment adviser initiated new positions in integrated oil companies trading at relatively depressed valuations, which reduced the extent of the Trust’s underweight in Europe. It also sought to rotate the portfolio’s holdings in the midstream distribution industry, and it reduced the portfolio’s allocation to refiners later in the year following continued weakness in global consumer indicators.
Describe portfolio positioning at period end.
The investment adviser maintained a bias towards higher-quality producers that it expects will gain the largest benefit from strength in oil and gas prices. It was also positioned to capitalize on a potential resurgence in the oilfield services sector, as well as the need for increased liquified natural gas output to replace Russian gas exports to Europe.
As of December 31, 2022, the Trust had in place an option overwriting program whereby 36.6% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 5.1% out of the money) and for maturities averaging 54 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
8
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Energy and Resources Trust (BGR)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
   
Security
(a)
 
Percent of
Total Investments
 
Exxon Mobil Corp.
    16.5
Chevron Corp.
    9.5  
Shell PLC
    9.4  
ConocoPhillips
    7.3  
TotalEnergies SE
    7.3  
BP PLC
    4.6  
EOG Resources, Inc.
    4.2  
Canadian Natural Resources Ltd.
    3.6  
Williams Cos., Inc.
    3.4  
Valero Energy Corp.
    3.3  
INDUSTRY ALLOCATION
 
   
Industry
(a)(b)
 
12/31/22
 
Oil, Gas & Consumable Fuels
    95.3
Energy Equipment & Services
    3.3  
Other*
    1.4  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  9

Trust Summary  
as of December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
 
 
Investment Objective
BlackRock Enhanced Capital and Income Fund, Inc.’s (CII) (the “Trust”)
investment objective is to provide current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  CII
Initial Offering Date
      April 30, 2004    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($17.12)
(a)
  6.97%
Current Monthly Distribution per Common Share
(b)
  $0.0995
Current Annualized Distribution per Common Share
(b)
  $1.1940
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
   
High
    
Low
 
Closing Market Price
  $  17.12      $  22.12        (22.60 )%    $  22.12      $  16.45  
Net Asset Value
    17.55        22.10        (20.59     22.26        17.29  
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that measures the performance of the
large-cap
segment of the U.S. equity universe. It is a subset of the Russell 3000
®
Index and includes approximately 1,000 of the largest securities based on a combination of their market capitalization and current index membership. The index represents approximately 93% of the U.S. market.
 
 
 
10
 
2 0 2 2   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
    
1 Year   
   
5 Years   
   
10 Years   
 
Trust at NAV
(a)(b)
    (10.95)%       7.92%       10.52%  
Trust at Market Price
(a)(b)
    (13.21)          8.43          11.47     
MSCI USA Call Overwrite Index
(c)
    (16.26)          N/A          N/A     
Russell 1000
®
Index
    (19.13)          9.13          12.37     
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
 
An index that incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest contribution to the Trust’s relative performance came from stock selection in the information technology (“IT”) sector. Notably, stock selection in software and IT services boosted relative returns. Stock selection in the consumer discretionary sector also contributed, as investment decisions in the multiline retail and automobiles industries proved additive. Other notable contributors included stock selection within financials and allocation decisions in the energy sector.
Conversely, investment decisions within the healthcare sector detracted the most from the Trust’s relative returns. Notably, the Trust’s lack of exposure to biotechnology and stock selection within the life sciences tools and services industry hurt relative performance. The Trust’s lack of exposure to utilities, which was based on the view that stock valuations in the sector were expensive, also weighed on relative results. Other notable detractors included allocation decisions in consumer staples, and at the industry level, the Trust’s overweight allocation to interactive media and services.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the reporting period.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy did not result in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the consumer staples, healthcare, and industrials sectors. The Trust reduced exposure to IT, communication services, and real estate.
Describe portfolio positioning at period end.
At period end, the Trust’s largest absolute allocations were in IT, consumer discretionary, and healthcare. Relative to the benchmark, the Trust’s most significant overweight exposures were in the consumer discretionary, communication services, and financials sectors. The Trust maintained its most significant relative underweight sector exposures to IT, utilities, and consumer staples.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 53% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3.9% out of the money) with an average time until expiration of 49 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  11

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
   
Security
(a)
 
Percent of
Total Investments
 
Microsoft Corp.
    6.1
Alphabet, Inc.
    4.0  
Amazon.com, Inc.
    3.9  
Apple, Inc.
    3.9  
Berkshire Hathaway, Inc.
    2.9  
Comcast Corp.
    2.8  
Visa, Inc.
    2.8  
UnitedHealth Group, Inc.
    2.7  
Ross Stores, Inc.
    2.7  
Sanofi
    2.4  
SECTOR ALLOCATION
 
   
Sector
(a)(b)
 
12/31/22
 
Information Technology
    22.4
Consumer Discretionary
    14.6  
Health Care
    14.5  
Financials
    13.9  
Communication Services
    10.1  
Industrials
    9.1  
Materials
    5.0  
Consumer Staples
    4.8  
Energy
    4.3  
Real Estate
    1.3  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector
sub-classifications
used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector
sub-classifications
for reporting ease.
 
 
12
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
 
Investment Objective
 
BlackRock Enhanced Equity Dividend Trust’s (BDJ) (the “Trust”)
primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  BDJ
Initial Offering Date
  August 31, 2005
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($9.01)
(a)
  7.49%
Current Monthly Distribution per Common Share
(b)
  $0.0562
Current Annualized Distribution per Common Share
(b)
  $0.6744
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. It does not include the distribution of undistributed income and/or capital gains from the Trust’s preceding fiscal year (commonly referred to as a “spillback distribution”).
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
   
High
    
Low  
 
Closing Market Price
  $  9.01      $  10.08        (10.62 )%    $  10.43      $  8.08    
Net Asset Value
    8.74        10.23        (14.57     10.55        8.42    
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that measures the performance of the
large-cap
value segment of the U.S. equity universe. It includes those Russell 1000 companies with lower
price-to-book
ratios and lower expected growth values.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  13

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
      Average Annual Total Returns    
    
1 Year
   
5 Years
   
10 Years
 
Trust at NAV
(a)(b)
    (3.71 )%      6.13     8.66
Trust at Market Price
(a)(b)
    0.74       8.42       10.53  
MSCI USA Value Call Overwrite Index
(c)
    (6.15     N/A       N/A  
Russell 1000
®
Value Index
    (7.54     6.67       10.29  
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust moved from a discount to NAV to a premium during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
 
An index that incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
Stock selection in the industrials sector made the largest contribution to the Trust’s relative performance. Notably, stock selection in the aerospace and defense and professional services industries boosted relative results. Stock selection in financials also lifted relative performance, as selection decisions in insurance and an overweight allocation to insurance proved additive. Other notable contributors included the Trust’s lack of exposure to real estate and its overweight allocation to energy.
Conversely, the largest detractor from relative returns came from stock selection in the healthcare sector. Security selection decisions in the healthcare equipment and supplies industry most notably weighed on total return. Allocation decisions in information technology (“IT”) also hurt relative results, particularly in regard to investment decisions in the IT services industry. Other notable detractors included allocation decisions in materials and stock selection within consumer staples.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the reporting period.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy did not result in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the energy, healthcare, and consumer staples sectors. The Trust reduced exposure to financials, industrials, and utilities.
Describe portfolio positioning at period end.
At period end, the Trust’s largest absolute allocations were to the healthcare, financials, and IT sectors. Relative to the benchmark, the Trust’s most significant overweight exposures were to the communication services, healthcare, and financials sectors. The Trust maintained its most significant relative underweight sector exposures to real estate, consumer staples, and industrials, maintaining no exposure to real estate at period end.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 50% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3.4% out of the money) with an average time until expiration of 50 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
14
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
 
   
Security
(a)
 
Percent of
Total Investments
 
Wells Fargo & Co.
    2.9
BP PLC
    2.9  
Citigroup, Inc.
    2.8  
Medtronic PLC
    2.5  
Enterprise Products Partners LP
    2.4  
Cognizant Technology Solutions Corp.
    2.4  
American International Group, Inc.
    2.3  
Laboratory Corp. of America Holdings
    2.3  
Willis Towers Watson PLC
    2.3  
General Motors Co.
    2.2  
SECTOR ALLOCATION
 
 
   
Sector
(a)(b)
 
12/31/22
 
Health Care
    22.4
Financials
    21.9  
Information Technology
    12.4  
Energy
    9.4  
Consumer Discretionary
    7.5  
Consumer Staples
    7.2  
Industrials
    7.0  
Communication Services
    6.6  
Utilities
    3.4  
Materials
    2.2  
(a)
 
Excludes short-term securities and options written.
(b)
For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector
sub-classifications
used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector
sub-classifications
for reporting ease.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  15

Trust Summary  
as of December 31, 2022 
  
BlackRock Enhanced Global Dividend Trust (BOE)
 
 
Investment Objective
BlackRock Enhanced Global Dividend Trust’s (BOE) (the “Trust”)
primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and by employing a strategy of writing (selling) call and put options. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
   BOE
Initial Offering Date
   May 31, 2005
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($9.56)
(a)
   7.91%
Current Monthly Distribution per Common Share
(b)
   $0.0630
Current Annualized Distribution per Common Share
(b)
   $0.7560
 
 
(a)
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 9.56      $  12.18        (21.51 )%     $  12.40      $  8.65  
Net Asset Value
    10.97        13.40        (18.13      13.48        9.92  
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that captures large- and
mid-cap
representation across certain developed and emerging markets.
 
 
 
16
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Global Dividend Trust (BOE)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
      Average Annual Total Returns    
    
1 Year
   
5 Years
   
10 Years
 
Trust at NAV
(a)(b)
    (11.87 )%      3.56     5.72
Trust at Market Price
(a)(b)
    (15.51     1.87       5.75  
MSCI ACWI Call Overwrite Index
(c)
    (16.57     N/A       N/A  
MSCI ACWI
    (18.36     5.23       7.98  
 
 
(a)
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
An index that incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
Stock selection within the healthcare, communication services, and consumer discretionary sectors contributed the most to the Trust’s relative performance. At the individual stock level, three healthcare stocks were the top contributors, proving to be defensive in a bearish market environment. AbbVie Inc. contributed the most to relative performance, as it continued to execute well in commercializing drugs coming through its pipeline, such as Skyrizi and Rinvoq. AstraZeneca plc was also a solid contributor as its stock got a boost from weakness in the British pound against the U.S. dollar and from broader outperformance across the pharmaceutical industry. Investors have also increasingly appreciated AstraZeneca’s oncology pipeline, most notably in two drugs
co-developed
with Japan’s Daiichi Sankyo. Enhertu showed excellent results in fighting breast cancer, and the drug
Dato-DXd
has generated excitement for potential use in multiple indications, including lung cancer. Lastly, Novo Nordisk A/S contributed, as the drug company posted double-digit percentage sales growth across all geographies except China. Growing demand and limited supply of anti-obesity drug Wegovy also helped boost the stock price. Novo Nordisk’s CEO has promised to relaunch the drug with increased production in early 2023, reassuring investors that supply chain issues from earlier in 2022 have been resolved.
Conversely, security selection in the financials and consumer staples and allocation decisions in energy were the primary detractors from relative performance. Among individual stocks, Fidelity National Information Services detracted the most from relative returns, as the merchant-acquiring company reported extremely disappointing financial results for the latest quarter and delivered a downbeat outlook. Although volumes had recovered, revenue had failed to keep pace, resulting in lost market share in its small and
medium-sized
business segment. That segment made the greatest contribution to the company’s overall revenue, and the management had highlighted the need to restructure the business entirely. Despite the belief that this was a resilient business that could deliver consistent cash flow, the company’s competitive market position had proven to be weaker than anticipated. Given the wide range of outcomes and management’s lack of clarity concerning the future trajectory of margin levels for the merchant business, the Trust exited its holding.
Mediatek also detracted due to weaker consumer spending in hardware categories such as smartphones, which caused a slowdown in demand in China. The company had made significant investments in the latest-generation chips, which should have ultimately translated to market share gains among Chinese smartphone manufacturers. Nevertheless, the demand slowdown translated into weak share-price performance, and there had also been concerns that a global economic slowdown would also hurt
end-market
demand. The Trust remained confident in the company’s attractiveness, reflecting the view that some recovery in smartphone volume should lead to further normalization in demand.
Lastly, Taylor Wimpey also detracted. Political controversy in the United Kingdom had a negative impact on share prices, as a previous chancellor’s
tax-cutting
policies ultimately led to a significant increase in mortgage rates, which in turn adversely affected the volume outlook for the business. More recently, Taylor Wimpey’s comments on cost inflation of 9% to 10% driven by both labor and materials have raised concerns about how sustainable its profit margins are.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the reporting period.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, the Trust added exposure to the energy, materials, and industrials sectors. The Trust reduced its exposure to information technology (“IT”), as well as to the utilities and consumer staples sectors.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  17

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced Global Dividend Trust (BOE)
 
Describe portfolio positioning at period end.
At period end, the Trust’s largest sector exposures were in IT and healthcare, driven by holdings in the IT services and pharmaceuticals industries respectively. The Trust had no exposure to the real estate sector. Regionally, the majority of the portfolio was listed in the United States or Europe, with significant exposure in the United Kingdom.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 43% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3% out of the money) with an average time until expiration of 51 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
 
   
Security
(a)
 
Percent of
Total Investments
 
Microsoft Corp.
    3.4
Sanofi
    3.1  
Reckitt Benckiser Group PLC
    3.1  
AstraZeneca PLC
    3.0  
Philip Morris International, Inc.
    2.8  
AbbVie, Inc.
    2.7  
Prudential PLC
    2.7  
Industria de Diseno Textil SA
    2.7  
Citizens Financial Group, Inc.
    2.6  
Intuit, Inc.
    2.6  
GEOGRAPHIC ALLOCATION
 
   
Country/Geographic Region
 
12/31/22
 
United States
    38.5
United Kingdom
    17.2  
France
    11.5  
Switzerland
    6.2  
Ireland
    4.4  
Taiwan
    4.2  
Spain
    2.7  
Canada
    2.2  
Denmark
    2.1  
Sweden
    2.0  
Mexico
    1.8  
Portugal
    1.7  
Japan
    1.5  
Singapore
    1.5  
Netherlands
    1.4  
Indonesia
    1.0  
India
    0.1  
 
(a)
 
Excludes short-term securities and options written.
 
 
18
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 
  
BlackRock Enhanced International Dividend Trust (BGY)
 
 
Investment Objective
BlackRock Enhanced International Dividend Trust’s (BGY) (the “Trust”)
primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by
non-U.S.
companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Trust Information
 
Symbol on New York Stock Exchange
  BGY
Initial Offering Date
      May 30, 2007    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($5.02)
(a)
  8.08%
Current Monthly Distribution per Common Share
(b)
  $0.0338
Current Annualized Distribution per Common Share
(b)
  $0.4056
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
    $   5.02        $   6.28        (20.06)      $   6.40        $   4.34  
Net Asset Value
    5.78        6.81        (15.12)        6.84        4.98  
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that captures large- and
mid-cap
representation across certain developed markets countries (excluding the U.S.) and certain emerging markets countries.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  19

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced International Dividend Trust (BGY)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
    
1 Year
   
5 Years
   
10 Years
 
Trust at NAV
(a)(b)
    (8.33 )%      3.38     4.09
Trust at Market Price
(a)(b)
    (13.67     2.12       4.13  
MSCI ACWI ex USA Call Overwrite Index
(c)
    (15.19     N/A       N/A  
MSCI ACWI ex USA Index
    (16.00     0.88       3.80  
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
From a sector perspective, the Trust’s stock selection in financials, healthcare, and industrials contributed the most to returns. Among individual stocks, Novo Nordisk A/S was the top contributor, benefiting from rising momentum in prescription volumes for its
GLP-1
drug. The pharmaceutical company largely worked through manufacturing problems, although it will take some time to resupply the market. BAE Systems also contributed, as the aerospace and defense company benefited from a more constructive industry environment generally, particularly after the Russian invasion of Ukraine prompted expectations that defense spending would increase. Lastly, Bankinter also contributed to relative performance, as the higher-rate environment added to its margin.
By contrast, underweight positions in materials and energy were the largest detractors from relative performance. Stock selection in consumer staples also detracted. Among individual stocks, Taiwanese semiconductor company Mediatek was the leading detractor, as it struggled amid challenges within the semiconductor value chain. Markets were concerned about weaker consumer spending, which could feed into weaker demand for consumer durables in China and thereby prevent Mediatek from gaining market share in Chinese smartphone markets. Taylor Wimpey also detracted, as shares of the United Kingdom homebuilder weakened as the mortgage market deteriorated. Rising interest rates weakened the outlook for sales volume. Lastly, Kering also detracted from relative performance, as multiple stock analysts downgraded target prices on the stock.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the period.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, the Trust reduced its exposure to information technology (“IT”), particularly within the IT services industry. It also reduced exposure to consumer staples, notably in the personal products and textile and apparel industries. Conversely, the Trust added exposure to the healthcare, consumer discretionary, and financials sectors.
Describe portfolio positioning at period end.
At period end, the Trust’s largest sector exposures were in healthcare, industrials, and consumer staples. Regionally, the majority of the portfolio’s securities were listed in Europe, with particularly significant exposure in Europe excluding the United Kingdom.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 40.4% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3.0% out of the money) with an average time until expiration of 52 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
20
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Enhanced International Dividend Trust (BGY)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
   
Security
(a)
 
Percent of
Total Investments
 
Novo Nordisk A/S
    4.2
Reckitt Benckiser Group PLC
    4.0  
Diageo PLC
    3.8  
Prudential PLC
    3.7  
RELX PLC
    3.6  
LVMH Moet Hennessy Louis Vuitton SE
    3.6  
Ferguson PLC
    3.4  
Sanofi
    3.3  
Taiwan Semiconductor Manufacturing Co. Ltd.
    3.3  
Kering SA
    3.2  
GEOGRAPHIC ALLOCATION
 
   
Country/Geographic Region
 
12/31/22
 
United Kingdom
    23.8
France
    17.0  
United States
    10.0  
Taiwan
    5.5  
Spain
    5.3  
Switzerland
    4.8  
Singapore
    4.5  
Denmark
    4.2  
Netherlands
    3.9  
Japan
    3.3  
India
    3.2  
Sweden
    3.0  
Canada
    2.9  
Mexico
    2.7  
China
    2.3  
Indonesia
    2.0  
Germany
    1.6  
 
(a)
 
Excludes short-term securities and options written.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  21

Trust Summary  
as of December 31, 2022 
  
BlackRock Health Sciences Trust (BME)
 
 
Investment Objective
BlackRock Health Sciences Trust’s (BME) (the “Trust”)
investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
Symbol on New York Stock Exchange
  BME
Initial Offering Date
      March 31, 2005    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($43.58)
(a)
  5.87%
Current Monthly Distribution per Common Share
(b)
  $0.2130
Current Annualized Distribution per Common Share
(b)
  $2.5560
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $  43.58      $  48.50        (10.14 )%    $  48.50      $  38.27  
Net Asset Value
    43.30        47.96        (9.72      47.96        39.35  
GROWTH OF $10,000 INVESTMENT
 
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An unmanaged index that features companies involved in medical services or health care in the Russell 3000
®
Index, which includes the largest 3,000 U.S. companies as determined by total market capitalization.
 
 
 
22
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Health Sciences Trust (BME)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
     Average Annual Total Returns  
  
 
 
 
     
1 Year
    
5 Years
    
10 Years
 
Trust at NAV
(a)(b)
     (4.19 )%       10.3      13.54
Trust at Market Price
(a)(b)
     (4.64      9.96        13.55  
MSCI USA Investable Market Index Health Care Call Overwrite Index
(c)
     (6.29      N/A        N/A  
Russell 3000
®
Health Care Index
     (6.10      11.38        14.64  
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
The Trust’s premium to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
An index that incorporates an option overlay component on the MSCI USA IMI Health Care Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The global equity markets fell sharply in 2022, reflecting the combination of elevated inflation and rising interest rates. While defensive,
large-cap
stocks in the healthcare sector held up reasonably well, faster-growing companies—particularly those on the smaller end of the capitalization range—generally lagged the broader market.
Stock selection in the medical devices and supplies and biotechnology
sub-sectors
were the largest sector-level contributors to the Trust’s relative performance.
An overweight in the managed-care provider Cigna Corp., which benefited from investors’ flight to higher-quality stocks, was the leading individual contributor to the Trust’s relative performance. Additionally, the company delivered multiple strong earnings reports that demonstrated revenue growth across its health services businesses. An underweight in Moderna, Inc., which lagged due to slowing demand for
COVID-19
vaccines, also helped performance. An
out-of-benchmark
position in the pharmaceutical giant AstraZeneca PLC was another top contributor. The company received approval for its breast cancer treatment from the Food and Drug Administration. Consistently strong quarterly financials and a robust oncology pipeline also supported the stock.
Security selection in the pharmaceuticals
sub-sector
was the largest detractor at the industry level. An underweight allocation to the
sub-sector
detracted, as well.
An underweight in biotechnology company AbbVie, Inc. was the most significant detractor. The company provided a positive outlook for 2023, highlighting strong demand for some of its flagship treatments. Similarly, underweights in the health insurance provider Humana, Inc. and the
mega-cap
pharmaceutical company Johnson & Johnson were key detractors.
The Trust made use of options, principally writing call options on individual stocks, to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy contributed to results.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
The Trust’s allocations to the pharmaceuticals and biotechnology
sub-sectors
increased, while its weighting in the health care providers and supplies and medical devices and supplies industries decreased.
Describe portfolio positioning at period end.
The investment adviser continued to seek opportunities in companies with attractive valuations, stable growth, and promising product pipelines over the
medium-to-long
term. It also considered new innovations and technological developments for selective growth opportunities in the biotechnology, pharmaceuticals and medical devices industries
The investment adviser was encouraged by the healthcare sector’s resilience in the midst of the extraordinary macroeconomic and geopolitical challenges that characterized 2022. It believed the longer-term, secular drivers for the sector—innovation in medical technology and aging demographics in both developed and developing countries—remain in place. The investment adviser continued to identify investment opportunities in stable, cash-flow generating companies across the sector.
As of December 31, 2022, the Trust’s largest overweight position was in the biotechnology
sub-sector.
The investment adviser continued to seek compelling areas of innovation in biotech, particularly in oncology. The Trust also held an overweight position in the medical devices and supplies
sub-sector,
which the investment adviser believed
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  23

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Health Sciences Trust (BME)
 
could benefit from easing supply chain concerns following China’s decision to end its
zero-COVID
policy. The Trust’s largest underweight was in the pharmaceuticals
sub-sector,
which could be vulnerable to a rotation back into riskier assets once investors gain more clarity regarding the macroeconomic environment.
As of December 31, 2022, the Trust had in place an option overwriting program whereby 35.6% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 6.5% out of the money) and for maturities averaging 53 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
   
Security
(a)
 
Percent of
Total Investments
 
UnitedHealth Group, Inc.
    8.9
Eli Lilly & Co.
    5.8  
Johnson & Johnson
    5.5  
Merck & Co., Inc.
    4.3  
Thermo Fisher Scientific, Inc.
    4.1  
Boston Scientific Corp.
    3.4  
Elevance Health, Inc.
    3.2  
Amgen, Inc.
    3.2  
Abbott Laboratories
    3.1  
Danaher Corp.
    3.1  
INDUSTRY ALLOCATION
 
   
Industry
(a)(b)
 
12/31/22
 
Pharmaceuticals
    24.5
Biotechnology
    21.9  
Health Care Providers & Services
    21.2  
Health Care Equipment & Supplies
    20.4  
Life Sciences Tools & Services
    11.8  
Other*
    0.2  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.
 
 
24
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
 
 
Investment Objective
BlackRock Health Sciences Trust II’s (BMEZ) (the “Trust”)
investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  BMEZ
Initial Offering Date
      January 30, 2020    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($15.43)
(a)
  11.28%
Current Monthly Distribution per Common Share
(b)
  $0.1450
Current Annualized Distribution per Common Share
(b)
  $1.7400
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 15.43      $ 25.36        (39.16 )%     $  25.59      $  14.50  
Net Asset Value
    18.76        26.47        (29.13      26.63        17.42  
GROWTH OF $10,000 INVESTMENT
 
LOGO
BMEZ commenced operations on January 30, 2020.
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that captures large- and
mid-cap
representation across certain developed and emerging markets.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  25

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Health Sciences Trust II (BMEZ)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
 
 
 
1 Year 
 
 
 

Since

Inception
 

(a)
 
Trust at NAV
(b)(c)
    (21.66)     4.80
Trust at Market Price
(b)(c)
    (32.75)       (1.99)  
MSCI Custom ACWI SMID Growth HC Call Overwrite Index
(d)
    (15.17)       (15.17)  
MSCI ACWI 25% Call Overwrite Index
(e)
    (4.37)       11.29  
MSCI ACWI
    (18.36)       4.08  
 
 
(a)
 
BMEZ commenced operations on January 30, 2020.
 
 
(b)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(c)
 
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(d)
 
An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. The MSCI ACWI SMID Cap Growth Index captures
mid-
and
small-cap
securities exhibiting overall growth style characteristics across certain Developed and Emerging Markets countries. The index commenced on March 31, 2022 and therefore the
1-year
index return and since inception return presented are for the period March 31, 2022 through December 31, 2022.
 
 
(e)
 
An index that incorporates an option overlay component on the MSCI ACWI Index with a 25% overwrite level. Effective on March 31, 2022, this index was discontinued and the Trust changed its benchmark to the MSCI Custom ACWI SMID Growth HC Call Overwrite index. The investment adviser believes the new benchmark is a more appropriate benchmark for the Trust. Because the index was discontinued on March 31, 2022, the index returns presented are as follows: the
1-year
return is for the period from January 1, 2022 through March 31, 2022 and the since inception return is for the period from January 30, 2020 through March 31, 2022.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The global equity markets fell sharply in 2022, reflecting the combination of elevated inflation and rising interest rates. While defensive,
large-cap
stocks in the healthcare sector held up reasonably well, faster-growing companies—particularly those on the smaller end of the capitalization range—generally lagged the broader market.
Security selection in the biotechnology
sub-sector
was the largest detractor from the Trust’s relative performance, followed by an underweight allocation to the medical devices and supplies
sub-sector.
An overweight position in Masimo Corp. was the largest detractor at the individual security level. Masimo’s unexpected acquisition of the consumer electronics company Sound United was not well received by market participants. Investors struggled to see how the unlikely pairing would fit together given the latter company’s focus outside of medical technology.
An overweight in the biopharmaceutical company Kymera Therapeutics, Inc. which reported consistently weak earnings, further detracted. The Trust was also hurt by its overweight in the U.S. genetics testing company Natera, Inc. The stock declined after an unfavorable report from a short seller alleged that the company had deceptive billing practices and misleading testing results.
On the positive side, an overweight in the biotechnology industry and an underweight in healthcare providers and services industries contributed to performance.
An overweight position in Vertex Pharmaceuticals, Inc. was the largest individual contributor. The company reported consistently strong earnings and provided positive clinical trial results for a treatment for sickle cell disease. The Trust also benefited from an overweight in Imago Biosciences, Inc., which was acquired by Merck. An overweight in Daiichi Sankyo Co., Ltd. was an additional contributor. The Japanese biotechnology company received approval from the Food and Drug Administration for a breast cancer treatment it developed in partnership with AstraZeneca.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to relative performance.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
The Trust’s weightings the pharmaceuticals and biotechnology
sub-sectors
increased during the period, while its allocation to the medical devices and supplies and health care providers and services
sub-sectors
decreased.
 
 
26
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Health Sciences Trust II (BMEZ)
 
Describe portfolio positioning at period end.
The investment adviser continued to seek opportunities in companies with attractive valuations, stable growth, and promising product pipelines over the
medium-to-long
term. It also considered new innovations and technological developments for selective growth opportunities in the biotechnology, pharmaceuticals and medical devices industries.
The investment adviser was encouraged by the healthcare sector’s resilience in the midst of the extraordinary macroeconomic and geopolitical challenges that characterized 2022. It believed the longer-term, secular drivers for the sector—innovation in medical technology and aging demographics in both developed and developing countries—remain in place. The investment adviser continued to identify investment opportunities in stable, cash-flow generating companies across the sector.
The Trust’s largest weighting was in the biotechnology
sub-sector
as of
year-end,
reflecting the investment adviser’s view that many companies in the industry offered the combination of attractive valuations and robust fundamentals.
As of December 31, 2022, the Trust had in place an option overwriting program whereby 24% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 8.8% out of the money) and for maturities averaging 57 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
   
Security
(a)
 
Percent of
Total Investments
 
Vertex Pharmaceuticals, Inc.
    3.4
Alcon, Inc.
    2.5  
Daiichi Sankyo Co. Ltd.
    2.4  
Alnylam Pharmaceuticals, Inc.
    2.1  
Dexcom, Inc.
    2.1  
Imago Biosciences, Inc.
    2.0  
Penumbra, Inc.
    2.0  
BioMarin Pharmaceutical, Inc.
    1.9  
Waters Corp.
    1.9  
Insulet Corp.
    1.9  
INDUSTRY ALLOCATION
   
Industry
(a)(b)
  
12/31/22
 
Biotechnology
     41.8
Health Care Equipment & Supplies
     26.3  
Life Sciences Tools & Services
     15.1  
Pharmaceuticals
     7.3  
Health Care Providers & Services
     6.9  
Other*
     2.6  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  27

Trust Summary  
as of December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
 
 
Investment Objective
BlackRock Innovation and Growth Trust’s (BIGZ) (the “Trust”)
investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest primarily in equity securities issued by
mid-
and small-capitalization companies that the Trust’s adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trust’s adviser focuses on
mid-
and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  BIGZ
Initial Offering Date
      March 29, 2021    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($6.81)
(a)
  12.33%
Current Monthly Distribution per Common Share
(b)
  $0.0700
Current Annualized Distribution per Common Share
(b)
  $0.8400
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 6.81      $ 14.54        (53.16 )%     $  14.97      $  6.48  
Net Asset Value
    8.82        16.72        (47.25      16.72        8.50  
GROWTH OF $10,000 INVESTMENT
 
LOGO
BIGZ commenced operations on March 29, 2021.
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that measures the performance of the small to
mid-cap
growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher growth earning potential as defined by FTSE Russell’s leading style methodology.
 
 
 
28
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Innovation and Growth Trust (BIGZ)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
 
 
 
1 Year 
 
 
 

Since

Inception
 

(a)
     
Trust at NAV
(b)(c)
    (41.14)     (31.66)
Trust at Market Price
(b)(c)
    (47.74)       (41.01)  
MSCI USA SMID Growth Call Overwrite Index
(d)
    (23.61)       N/A    
Russell 2500
Growth Index
    (26.21)       (13.06)  
 
 
(a)
 
BIGZ commenced operations on March 29, 2021.
 
 
(b)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(c)
 
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(d)
 
A custom benchmark that is made up of the MSCI USA SMID Growth Index, MSCI USA SMID Growth 25% Call Overwrite Cash and MSCI USA SMID Growth 25% Call Overwrite Option. The MSCI USA SMID Growth Index captures mid and small cap representations of securities exhibiting overall growth style characteristics in the U.S.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest detractor from relative performance from a sector perspective was the Trust’s security selection within the healthcare sector, most notably within the healthcare equipment and supplies industry. Within this space, Masimo Corp. and FIGS Inc. were the most significant detractors among individual stocks. Elsewhere in healthcare, an overweight position in life sciences tools and services company, 10X Genomics Inc. weighed on performance, due to its significant exposure to China and the potential impact on its business from worsening macroeconomic conditions and supply chain issues. Stock selection in the information technology (“IT”) sector also weighed on relative performance, mostly within the software industry, where positions in Bill.com Holdings Inc. and Siteminder Ltd. detracted. Lastly, positioning in the energy sector was a significant detractor, most notably due to the Trust’s lack of exposure to the oil, gas and consumable fuels
sub-sector.
By contrast, positioning in the real estate sector was the largest contributor to relative performance at the sector level, particularly due to the Trust’s lack of investments in real estate management and development companies. Within industrials, positioning in the aerospace and defense industry was a substantial contributor, stemming largely from an overweight allocation to technology and
non-lethal
weapons specialist Axon Enterprise Inc. The Trust’s lack of exposure to the media industry within communication services also boosted relative performance, most notably by avoiding programmatic marketing automation technology provider Trade Desk Inc. Lastly, the Trust’s lack of positions in the consumer finance sector boosted relative performance, specifically avoiding
AI-powered
lending platform company Upstart Holdings Inc.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the period.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
Due to a combination of market changes and portfolio activity since then, the Trust’s exposure to financials and consumer discretionary stocks increased. Conversely, the Trust’s exposure to the healthcare and IT sectors decreased. The Trust also added four new privately held companies during the year, increasing its allocation from 18% to 28% as the management team continued to increase exposure to this investment segment.
Describe portfolio positioning at period end.
At period end, the Trust’s largest sector overweight positions in the public equity portion of the portfolio were in the IT and consumer discretionary sectors, while the largest underweight positions were in industrials and materials.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 11.3% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 10% out of the money) with an average time until expiration of 61 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  29

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Innovation and Growth Trust (BIGZ)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
   
Security
(a)
 
Percent of
Total Investments
 
Axon Enterprise, Inc.
    3.9
Five9, Inc.
    2.9  
Planet Fitness, Inc.
    2.9  
Tradeweb Markets, Inc.
    2.6  
Entegris, Inc.
    2.5  
The Production Board LLC.
    2.3  
Monolithic Power Systems, Inc.
    2.3  
Fox Factory Holding Corp.
    2.2  
Paylocity Holding Corp.
    2.2  
HEICO Corp.
    2.1  
INDUSTRY ALLOCATION
   
Industry
(a)(b)
  
12/31/22
 
Software
     22.5
Semiconductors & Semiconductor Equipment
     11.9  
Life Sciences Tools & Services
     9.0  
Aerospace & Defense
     7.8  
Hotels, Restaurants & Leisure
     6.6  
Capital Markets
     5.9  
IT Services
     4.7  
Diversified Consumer Services
     3.0  
Health Care Technology
     2.9  
Health Care Equipment & Supplies
     2.5  
Internet & Direct Marketing Retail
     2.4  
Auto Components
     2.2  
Biotechnology
     2.1  
Interactive Media & Services
     2.0  
Road & Rail
     2.0  
Entertainment
     1.8  
Leisure Products
     1.8  
Machinery
     1.6  
Food Products
     1.3  
Wireless Telecommunication Services
     1.2  
Internet Software & Services
     1.2  
Air Freight & Logistics
     1.1  
Other*
     2.5  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.
 
 
30
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
 
 
Investment Objective
BlackRock Resources
 & Commodities Strategy Trust’s (BCX) (the “Trust”)
primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objectives will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  BCX
Initial Offering Date
      March 30, 2011    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($9.97)
(a)
  6.23%
Current Monthly Distribution per Common Share
(b)
  $0.0518
Current Annualized Distribution per Common Share
(b)
  $0.6216
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 9.97      $ 9.35        6.63    $  11.53      $  8.09  
Net Asset Value
    11.23        10.21        9.99        12.11        9.15  
GROWTH OF $10,000 INVESTMENT
 
LOGO
(a)
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
(b)
 
An index that includes approximately 90 of the largest publicly-traded companies in the natural resources and commodities businesses that meet specific investability requirements across three primary commodity-related sectors: agribusiness, energy, and metals and mining.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  31

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Resources & Commodities Strategy Trust (BCX)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
     Average Annual Total Returns   
 
 
 
1 Year
 
 
 
5 Years
 
 
 
10 Years
 
Trust at NAV
(a)(b)
    16.31     8.18     4.96
Trust at Market Price
(a)(b)
    12.76       7.46       5.15  
MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index
(c)
    10.21       N/A       N/A  
S&P Global Natural Resources Net Index
    9.59       6.64       4.23  
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
 
An index that incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s absolute performance based on NAV:
What factors influenced performance?
Natural resource equities performed well in 2022 thanks to rising commodity prices and investors’ preference for stocks with the potential to offset the effects of inflation.
An overweight position in the diversified miner Glencore PLC was a notable contributor to the Trust’s performance during the reporting period. The lack of a positions in Russian mining company Norilsk Nickel PJSC also helped performance, as the value of the stock was written down to zero in the benchmark. The exploration and production company Hess Corp. was an additional contributor, thanks in part to its announcement of new offshore discoveries. An overweight in ConocoPhillips, which benefited from its increased focus on shareholder returns, further aided results.
Positions in the Russian companies Polyus PJSC and Gazprom PJSC—which also were written down to near zero in late February 2022—were the largest detractors from performance. Russian companies have always been part of the Trust’s investment universe, and the investment adviser believed both companies had high-quality assets. However, the investment adviser did not anticipate either a full-scale invasion of Ukraine or the events that followed. A position in the Dutch nutrition company Koninklijke DSM N.V. also underperformed even though it launched three new business lines in its animal nutrition and health business. A zero weighting in Occidental Petroleum Corp., which outperformed as it capitalized on stronger oil prices to
de-lever
its balance sheet, was another key detractor.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy marginally detracted from performance during the reporting period.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
The investment adviser decreased the extent of the Trust’s overweight in the energy sector in response to volatility in oil prices. However, the supply of fossil fuels has been curtailed at a faster rate than demand has been eroded, creating support for prices. While the Russia-Ukraine crisis exacerbated the supply issues, the trend was underway many months before the invasion.
The investment adviser increased the Trust’s weighting in the mining sector, moving the allocation from an underweight to an overweight. This shift reflected the investment adviser’s view that demand for a range of commodities—such as copper, lithium and steel—could potentially be boosted by the accelerated adoption of lower-carbon technologies, like wind and solar.
In the agriculture sector, improving crop prices appear likely to benefit upstream companies such as those in the agriculture equipment and fertilizer industries. The investment adviser also continued to identify structural growth opportunities in the nutrition area.
Describe portfolio positioning at period end.
As the close of the period, 35.7% of the portfolio was invested in the energy sector, 35.7% in the mining sector and 26.0% in the agriculture sector, and 2.6% was held in cash.
As of December 31, 2022, the Trust had in place an option overwriting program whereby 30.7% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 4.8% out of the money) and for maturities averaging 51 days.
 
 
32
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Resources & Commodities Strategy Trust (BCX)
 
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
   
Security
(a)
 
Percent of
Total Investments
 
Glencore PLC
    7.7
Shell PLC
    6.7  
Exxon Mobil Corp
    5.7  
TotalEnergies SE
    5.2  
BHP Group Ltd.
    4.3  
Nutrien Ltd.
    4.0  
Vale SA
    3.9  
BP PLC
    3.8  
Teck Resources Ltd.
    3.6  
Deere & Co.
    3.3  
INDUSTRY ALLOCATION
   
Industry
(a)(b)
  
12/31/22
 
Metals & Mining
     36.1
Oil, Gas & Consumable Fuels
     35.8  
Chemicals
     11.5  
Food Products
     8.0  
Machinery
     6.1  
Paper & Forest Products
     2.1  
Containers & Packaging*
     0.4  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  33

Trust Summary  
as of December 31, 2022
  
BlackRock Science and Technology Trust (BST)
 
 
Investment Objective
BlackRock Science and Technology Trust’s (BST) (the “Trust”)
investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of U.S. and
non-U.S.
science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks). The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
   
Symbol on New York Stock Exchange
  BST
Initial Offering Date
      October 30, 2014    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($28.37)
(a)
  10.57%
Current Monthly Distribution per Common Share
(b)
  $0.2500
Current Annualized Distribution per Common Share
(b)
  $3.0000
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 28.37      $ 49.97        (43.23 )%     $  50.99      $  28.07  
Net Asset Value
    29.11        52.40        (44.45      52.59        28.47  
GROWTH OF $10,000 INVESTMENT
 
LOGO
BST commenced operations on October 30, 2014.
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that includes large- and
mid-cap
securities across certain Developed Markets countries and certain Emerging Markets countries. All securities in the index are classified in the Information Technology sector as per the Global Industry Classification Standard.
 
 
 
34
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Science and Technology Trust (BST)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
 
 
 
1 Year
 
 
 
5 Years
 
 
 

Since

Inception
 

(a)
 
Trust at NAV
(b)(c)
    (39.56)     9.05     13.08
Trust at Market Price
(b)(c)
    (38.23)       9.32       12.09  
MSCI ACWI Information Technology Call Overwrite Index
(d)
    (29.62)       N/A       N/A  
MSCI ACWI Information Technology Index
    (31.07)       12.08       14.55  
 
 
(a)
 
BST commenced operations on October 30, 2014.
 
 
(b)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(c)
 
The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(d)
 
An index that incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest detractor from the Trust’s relative performance at the
sub-sector
level was security selection within the services and internet
sub-sectors.
At the individual position level, the Trust’s
off-benchmark
position in privately held
buy-now-pay-later
company Klarna Inc. was the largest detractor from relative performance. The fintech company’s latest funding round had a significantly lower implied valuation, and Klarna subsequently announced layoffs to protect its margins. Elsewhere, an
off-benchmark
position in electric vehicle (“EV”) manufacturer Tesla Inc. was another notable detractor. During the third quarter of 2022, CEO Elon Musk completed his purchase of social media company Twitter, leading to investor concerns that Tesla’s management team was distracted. Additionally, the stock declined in anticipation of slowing EV sales during a potential recession. Lastly, an underweight position in Apple Inc. was among the most significant detractors. Apple continued to report strong earnings throughout the period, with record revenue in the first quarter of 2022 and better-than-anticipated financial results in the second and third quarters. The company also benefited from investors’ broader flight to quality and to
mega-cap
stocks within equity markets during the volatile period.
Conversely, an underweight allocation to the semiconductors
sub-sector
and an overweight allocation to new industries were the most significant contributors to the Trust’s relative performance. An underweight position in semiconductor chip manufacturer Nvidia Corp. was the largest contributor to relative performance among individual positions. Market participants grew concerned about the sustainability of Nvidia’s sales momentum, given a potential downturn in consumer spending and its impact on Nvidia’s gaming business. Elsewhere, an
off-benchmark
position in privately held GrubMarket also contributed. The food delivery company acquired two produce software providers during the summer, increasing the company’s valuation and paving the way for future growth into new markets. Lastly, an
off-benchmark
position in privately held PsiQuantum contributed to relative returns. The world’s largest quantum computing company received a grant from the United States government during the fall of 2022 to support further development of the first quantum computer.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, the Trust increased its exposure to the semiconductors and hardware
sub-sectors.
It decreased exposure to the internet
sub-sector.
Exposure to the software and services
sub-sectors
was largely unchanged. From a regional perspective, the Trust’s allocation to the United States increased, while exposure to China and other emerging markets decreased.
Describe portfolio positioning at period end.
At period end, the Trust held 29% of its net asset value in the software
sub-sector,
22% in semiconductors, 17% in services, 15% in internet, 5% in new industries, and 2% in content & infrastructure. These industry exposures were the result of
bottom-up
stock selection.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 32% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 8.5% out of the money) with an average time until expiration of 47 days.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  35

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Science and Technology Trust (BST)
 
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
   
Security
(a)
 
Percent of
Total Investments
 
Apple, Inc.
    6.7
Microsoft Corp.
    6.6  
Mastercard, Inc.
    3.5  
Visa, Inc.
    2.8  
ASML Holding NV
    2.4  
Cadence Design Systems, Inc.
    1.8  
Bolt Financial, Inc.
    1.8  
Wolfspeed, Inc.
    1.7  
Soitec SA
    1.7  
Grubmarket, Inc.
    1.6  
INDUSTRY ALLOCATION
   
Industry
(a)(b)
  
12/31/22
 
Software
     29.2
Semiconductors & Semiconductor Equipment
     22.1  
IT Services
     16.9  
Technology Hardware, Storage & Peripherals
     7.2  
Interactive Media & Services
     4.6  
Internet & Direct Marketing Retail
     2.8  
Electronic Equipment, Instruments & Components
     2.4  
Entertainment
     2.4  
Road & Rail
     2.0  
Food & Staples Retailing
     1.6  
Automobiles
     1.3  
Chemicals
     1.2  
Food Products
     1.0  
Other*
     5.3  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.
 
 
36
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
 
 
Investment Objective
BlackRock Science and Technology Trust II’s (BSTZ) (the “Trust”)
investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by U.S. and
non-U.S.
science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
Symbol on New York Stock Exchange
  BSTZ
Initial Offering Date
      June 27, 2019    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($15.64)
(a)
  14.73%
Current Monthly Distribution per Common Share
(b)
  $0.1920
Current Annualized Distribution per Common Share
(b)
  $2.3040
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
  $ 15.64      $ 38.94        (59.84 )%     $   39.04      $   15.34  
Net Asset Value
    19.53        38.82        (49.69      38.84        19.08  
GROWTH OF $10,000 INVESTMENT
LOGO
BSTZ commenced operations on June 27, 2019.
 
(a)
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
An index that captures large- and mid-cap representation across certain developed and emerging markets.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  37

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Science and Technology Trust II (BSTZ)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
 
 
 
1 Year
 
 
 
Since
Inception
 
(a)
     
Trust at NAV
(b)(c)
    (43.98 )%      7.03
Trust at Market Price
(b)(c)
    (55.27     0.47  
MSCI Custom ACWI SMID Growth IT Call Overwrite Index
(d)
    (20.87     (20.87
MSCI ACWI 25% Call Overwrite Index
(e)
    (4.37     12.29  
MSCI ACWI
    (18.36     6.11  
 
 
(a)
 
BSTZ commenced operations on June 27, 2019.
 
 
(b)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(c)
 
The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(d)
 
An index representing the Information Technology (IT) sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. An index that captures
mid-
and
small-cap
securities exhibiting overall growth style characteristics across certain Developed and Emerging Markets. The index commenced on March 31, 2022 and therefore the
1-year
index return and since inception return presented are for the period March 31, 2022 through December 31, 2022.
 
 
(e)
 
An index that incorporates an option overlay component on the MSCI ACWI Index with a 25% overwrite level. Effective on March 31, 2022, this index was discontinued and the Trust changed its benchmark to the MSCI Custom ACWI SMID Growth IT Call Overwrite index. The investment adviser believes the new benchmark is a more appropriate benchmark for the Trust. Because the index was discontinued on March 31, 2022, the index returns presented are as follows: the
1-year
return is for the period from January 1, 2022 through March 31, 2022 and the since inception return is for the period from June 27, 2019 through March 31, 2022.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest detractor from the Trust’s relative performance at the
sub-sector
level was security selection within the services and software
sub-sectors.
At the individual position level, the Trust’s
off-benchmark
position in privately held
buy-now-pay-later
company Klarna Inc. was the largest detractor from relative performance. The fintech company’s latest funding round had a significantly lower implied valuation, and Klarna subsequently announced layoffs to protect its margins. Elsewhere, an
off-benchmark
position in electric vehicle (EV) manufacturer Tesla Inc. was another notable detractor. During the third quarter of 2022, CEO Elon Musk completed his purchase of social media company Twitter, leading to investor concerns that Tesla’s management team was distracted. Additionally, the stock declined in anticipation of slowing EV sales in a potential recession. Lastly, an overweight position in semiconductor manufacturer Marvell Technology was among the most significant detractors. Negative returns were driven primarily by a decline from the stock’s record-high valuations in 2021. Marvell’s ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization fell by roughly half, dropping from 31 at the end of 2021 to 16 at the end of 2022. This drop came despite continued strength in revenue, margin growth, and market share.
Conversely, overweight allocations to the new industries and services
sub-sectors
were the most significant contributors to the Trust’s relative performance. An
off-benchmark
position in privately held GrubMarket was the largest contributor at the individual position level, as the food delivery company acquired two produce software providers during the summer, increasing the company’s valuation and paving the way for future growth into new markets. Elsewhere, an overweight position in Credo Technology also contributed to relative returns. The semiconductor company provides solutions for the data infrastructure market and was one of the few major technology companies to complete an initial public offering in 2022. Over the period, Credo Technology reported positive revenue growth and provided strong earnings guidance. Lastly, an
off-benchmark
position in privately held PsiQuantum contributed to returns. The world’s largest quantum computing company received a grant from the United States government during the fall of 2022 to support further development of the first quantum computer.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
During the period, the Trust reduced its exposure to high-multiple, high-growth companies. It increased exposure to high-quality, economically stable stocks that may prove more resilient amid continuing economic uncertainty, including those within the hardware and semiconductor
sub-sectors.
Over the long-term, we have continued to focus on companies that are exposed to long-term secular demand. This includes companies seeing heightened demand from the migration to remote work and increased adoption of emerging technologies, such as artificial intelligence, cloud computing, digital transformation, and
e-commerce.
During the period, the Trust did not make any new investments in privately held technology companies.
 
 
38
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Science and Technology Trust II (BSTZ)
 
Describe portfolio positioning at period end.
The Trust continued to perform due diligence on multiple new opportunities with the expectation of managing exposure to private investments over the coming quarters, given the current allocation to private equity. As of December 31, 2022, the Trust held 22 private investments, comprising 33.2% of total assets for a total commitment of approximately $508 million.
At period end, the Trust held 29% of assets in software, 26% in semiconductors, 13% in services, 11% in internet, 10% in hardware, 7% in new industries, and 3% in content and infrastructure. These industry exposures were the result of
bottom-up
stock selection.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 25.9% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 10.0% out of the money) with an average time until expiration of 51 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  39

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Science and Technology Trust II (BSTZ)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
   
Security
(a)
 
Percent of
Total Investments
 
ByteDance Ltd.
    3.4
Databricks, Inc.
    3.1  
Credo Technology Group Holding Ltd.
    2.9  
Synopsys, Inc.
    2.7  
SambaNova Systems, Inc.
    2.7  
PsiQuantum Corp.
    2.7  
GrubMarket, Inc.
    2.6  
Wolfspeed, Inc.
    2.1  
Soitec SA.
    2.1  
Lasertec Corp.
    2.0  
INDUSTRY ALLOCATION
 
   
Industry
(a)(b)
 
12/31/22
 
Semiconductors & Semiconductor Equipment
    27.2
Software
    24.1  
IT Services
    14.0  
Interactive Media & Services
    5.5  
Electronic Equipment, Instruments & Components
    4.5  
Entertainment
    3.0  
Food & Staples Retailing
    2.6  
Technology Hardware, Storage & Peripherals
    2.3  
Internet & Direct Marketing Retail
    2.1  
Hotels, Restaurants & Leisure
    1.7  
Electrical Equipment
    1.6  
Road & Rail
    1.5  
Diversified Consumer Services
    1.5  
Automobiles
    1.5  
Media
    1.4  
Food Products
    1.1  
Banks
    1.1  
Professional Services
    1.0  
Other*
    2.3  
 
(a)
 
Excludes short-term securities and options written.
(b)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
*
Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.
 
 
40
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
 
Investment Objective
BlackRock Utilities, Infrastructure
 & Power Opportunities Trust’s (BUI) (the “Trust”)
investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically
through
the use of derivatives.
No assurance can be given that the Trust’s investment objective will be achieved.
Trust Information
 
Symbol on New York Stock Exchange
  BUI
Initial Offering Date
      November 25, 2011    
Current Distribution Rate on Closing Market Price as of December 31, 2022 ($20.77)
(a)
  6.99%
Current Monthly Distribution per Common Share
(b)
  $0.1210
Current Annualized Distribution per Common Share
(b)
  $1.4520
 
 
(a)
 
Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.
 
 
(b)
 
The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.
 
Market Price and Net Asset Value Per Share Summary
 
    
12/31/22
    
12/31/21
    
Change
    
High
    
Low
 
Closing Market Price
    $  20.77        $  26.62        (21.98)      $  27.28        $  19.02  
Net Asset Value
    22.37        25.86        (13.50)        25.86        19.61  
GROWTH OF $10,000 INVESTMENT
LOGO
 
 
(a)
 
Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
An index that captures large- and
mid-cap
representation across certain developed and emerging markets.
 
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  41

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
Performance
Returns for the period ended December 31, 2022 were as follows:
 
    Average Annual Total Returns  
 
 
 
 
    
1 Year
   
5 Years
   
10 Years
 
Trust at NAV
(a)(b)
    (7.73 )%      8.13     8.70
Trust at Market Price
(a)(b)
    (16.78     6.04       8.99  
MSCI World Select Energy, Utilities and Industry Call Overwrite Index
(c)
    (14.81     N/A       N/A  
MSCI ACWI
    (18.36     5.23       7.98  
 
 
(a)
 
All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
 
 
(b)
 
The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.
 
 
(c)
 
An index that incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level.The benchmark commenced on December 31, 2018 and therefore the benchmark does not have
5-
and
10-year
returns.
 
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
blackrock.com.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest contributor to relative returns was the Trust’s position in U.S. solar and renewable power companies, such as First Solar, following positive regulatory news from delayed implementation of the U.S. anti-circumvention rules. More importantly, the passing of the United States Inflation Reduction Act is expected to produce a significant increase in demand for U.S. solar technology and drive manufacturing of sustainable energy technologies back onshore. Elsewhere, wind turbine manufacturer Vestas ended the year strongly after reporting a significant increase in order intake. The group confirmed installation of a prototype of its largest
15-megawatt
turbine for the offshore market, which is expected to see accelerating investment in Europe. Lastly, clean power utility RWE contributed positively. Investors viewed warmer weather and higher natural gas storage levels as reducing the risk of further political intervention.
The largest detractors from relative returns were the Trust’s positions in industrial energy efficiency companies, such as Kingspan and Schneider Electric, both of which saw share prices fall as wider economic growth expectations deteriorated. Wind power companies China Longyuan Power also detracted due to weakness in the Chinese wind farm industry. Concerns over the timeline of asset injections of renewable energy assets from its parent company also weighed on returns. Lastly, an overweight allocation to TC Energy detracted, due to a cost overrun at one of its pipeline projects.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the
12-month
period.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.
Describe recent portfolio activity.
At the beginning of the period, the Trust moved to reduce its exposure to more economically sensitive companies following the Fed’s commitment to raise interest rates to combat inflation and after Russia’s invasion of Ukraine in February 2022. The Trust increased exposure to companies viewed as better able to maintain earnings growth in a more challenging economic environment, as well as in companies that would see fewer impacts from rising input costs. This included adding to positions in clean power utility and industrial efficiency companies.
Describe portfolio positioning at period end.
At period end, the utilities sector accounted for 50.3% of the Trust’s assets. The Trust had 27.7% and 10.1% of its assets invested in the industrials and energy sectors respectively, and the remainder was invested in other infrastructure- and power-related sectors.
As of December 31, 2022, the Trust had an options overwriting program in place whereby 33.9% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3.5% out of the money) with an average time until expiration of 52 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.
 
 
42
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trust Summary  
as of December 31, 2022 (continued)
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
Overview of the Trust’s Total Investments
 
TEN LARGEST HOLDINGS
 
Security
(a)
 
Percent of
Total Investments
 
NextEra Energy, Inc.
    8.4
Enel SpA
    4.2  
RWE AG
    4.0  
Waste Management, Inc.
    3.1  
Sempra Energy
    3.1  
American Electric Power Co., Inc.
    3.1  
Vinci SA
    3.0  
Vestas Wind Systems A/S
    3.0  
Williams Cos., Inc.
    2.8  
Kinder Morgan, Inc.
    2.7  
INDUSTRY ALLOCATION
 
Industry
(a)(b)
 
12/31/22
 
Electric Utilities
    29.9
Multi-Utilities
    11.8  
Oil, Gas & Consumable Fuels
    10.3  
Independent Power and Renewable Electricity Producers
    9.6  
Electrical Equipment
    6.7  
Building Products
    6.0  
Semiconductors & Semiconductor Equipment
    5.4  
Machinery
    5.3  
Commercial Services & Supplies
    5.2  
Construction & Engineering
    5.0  
Chemicals
    3.9  
Electronic Equipment, Instruments & Components
    0.9  
 
(a)
 
Excludes short-term securities and options written.
(b)
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
 
 
T
R
U
S
T   
S
U
M
M
A
R
Y
  43

Schedule of Investments  
December 31, 2022
 
  
BlackRock Energy and Resources Trust (BGR)
(Percentages shown are based on Net Assets)
 
 
Security
 
Shares
    
Value
 
Common Stocks
    
Energy Equipment & Services — 3.3%
 
Patterson-UTI
Energy, Inc.
(a)
    118,150      $ 1,989,646  
Schlumberger Ltd.
(a)
    123,600        6,607,656  
Tenaris SA
    264,500        4,638,722  
    
 
 
 
       13,236,024  
Food Products — 0.4%
        
Darling Ingredients, Inc.
(a)(b)
    29,124        1,822,871  
    
 
 
 
Metals & Mining — 0.9%
        
Glencore PLC
    513,550        3,424,682  
    
 
 
 
Oil, Gas & Consumable Fuels — 94.2%
        
ARC Resources Ltd.
    319,380        4,304,789  
BP PLC
    3,130,300        18,061,648  
Canadian Natural Resources Ltd.
    257,859        14,319,364  
Cenovus Energy, Inc.
    518,806          10,065,756  
Cheniere Energy, Inc.
(a)
    44,050        6,605,738  
Chevron Corp.
(a)
    208,920        37,499,051  
ConocoPhillips
(a)
    244,893        28,897,329  
Diamondback Energy, Inc.
(a)
    53,400        7,304,052  
Eni SpA
    578,150        8,220,981  
EOG Resources, Inc.
(a)
    128,129        16,595,268  
Exxon Mobil Corp.
(a)(c)
    590,545        65,137,113  
Galp Energia SGPS SA
    384,850        5,191,865  
Gazprom PJSC
(d)
    879,200        119  
Hess Corp.
(a)
    82,390        11,684,550  
Kinder Morgan, Inc.
(a)
    486,900        8,803,152  
Kosmos Energy Ltd.
(a)(b)
    495,584        3,151,914  
Marathon Petroleum Corp.
(a)
    87,125        10,140,479  
Ovintiv, Inc.
(a)
    75,350        3,820,998  
Santos Ltd.
    926,136        4,554,918  
Shell PLC, ADR
(a)
    651,022        37,075,703  
TC Energy Corp.
    317,200        12,645,832  
TotalEnergies SE
    457,498        28,718,584  
Security
 
Shares
    
Value
 
Oil, Gas & Consumable Fuels (continued)
        
Tourmaline Oil Corp.
    120,033      $ 6,056,613  
Valero Energy Corp.
(a)
    101,374        12,860,306  
Williams Cos., Inc.
(a)
    413,132        13,592,043  
    
 
 
 
       375,308,165  
    
 
 
 
Total Long-Term Investments — 98.8%
(Cost: $255,848,980)
 
     393,791,742  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 1.9%
            
BlackRock Liquidity Funds,
T-Fund,
Institutional Class, 4.03%
(e)(f)
    7,695,475        7,695,475  
    
 
 
 
Total Short-Term Securities — 1.9%
(Cost: $7,695,475)
 
     7,695,475  
    
 
 
 
Total Investments Before Options Written — 100.7%
(Cost: $263,544,455)
 
     401,487,217  
    
 
 
 
Options Written — (0.6)%
(Premiums Received: $(4,901,028))
 
     (2,475,779
    
 
 
 
Total Investments, Net of Options Written — 100.1%
(Cost: $258,643,427)
 
     399,011,438  
Liabilities in Excess of Other Assets — (0.1)%
 
     (518,854
    
 
 
 
Net Assets — 100.0%
     $   398,492,584  
    
 
 
 
 
(a)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(b)
 
Non-income
producing security.
(c)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(d)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(e)
 
Affiliate of the Trust.
(f)
 
Annualized
7-day
yield as of period end.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds,
T-Fund,
Institutional Class
  $   2,725,280     $ 4,970,195
(a)
 
  $     $     $     $ 7,695,475       7,695,475     $ 93,963     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call                                                   
Chevron Corp.
     473          01/06/23        USD     180.00        USD     8,490        $   (111,628)  
ConocoPhillips
     122          01/06/23        USD     132.00        USD     1,440          (976)  
 
 
44
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Energy and Resources Trust (BGR)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Exxon Mobil Corp.
     246          01/06/23        USD     113.00        USD     2,713        $ (14,391
Hess Corp.
     146          01/06/23        USD     148.00        USD     2,071          (11,315
Kinder Morgan, Inc.
     517          01/06/23        USD     19.00        USD     935          (776
Marathon Petroleum Corp.
     155          01/06/23        USD     124.00        USD     1,804          (2,713
Valero Energy Corp.
     124          01/06/23        USD     136.00        USD     1,573          (2,790
Williams Cos., Inc.
     154          01/06/23        USD     34.00        USD     507          (1,540
Williams Cos., Inc.
     464          01/06/23        USD     35.00        USD     1,527          (4,640
Chevron Corp.
     74          01/13/23        USD     185.00        USD     1,328          (13,357
ConocoPhillips
     160          01/13/23        USD     129.00        USD     1,888          (6,560
EOG Resources, Inc.
     142          01/13/23        USD     139.50        USD     1,839          (9,940
Exxon Mobil Corp.
     556          01/13/23        USD     109.00        USD     6,133          (184,870
Hess Corp.
     168          01/13/23        USD     148.00        USD     2,383          (32,760
Kinder Morgan, Inc.
     639          01/13/23        USD     18.50        USD     1,155          (11,502
Marathon Petroleum Corp.
     177          01/13/23        USD     115.00        USD     2,060          (71,685
Valero Energy Corp.
     137          01/13/23        USD     133.00        USD     1,738          (21,577
Williams Cos., Inc.
     154          01/13/23        USD     34.00        USD     507          (3,850
Williams Cos., Inc.
     519          01/13/23        USD     35.00        USD     1,708          (3,893
ARC Resources Ltd.
     331          01/20/23        CAD     21.50        CAD     604          (1,222
ARC Resources Ltd.
     255          01/20/23        CAD     20.50        CAD     465          (1,883
Canadian Natural Resources Ltd.
     180          01/20/23        CAD     80.00        CAD     1,353          (7,112
Cenovus Energy, Inc.
     316          01/20/23        CAD     31.00        CAD     830          (1,050
Cheniere Energy, Inc.
     122          01/20/23        USD     175.00        USD     1,830          (3,050
ConocoPhillips
     225          01/20/23        USD     130.00        USD     2,655          (13,275
ConocoPhillips
     225          01/20/23        USD     120.00        USD     2,655          (72,562
Darling Ingredients, Inc.
     58          01/20/23        USD     90.00        USD     363          (4,350
Diamondback Energy, Inc.
     73          01/20/23        USD     166.19        USD     998          (1,095
EOG Resources, Inc.
     171          01/20/23        USD     132.20        USD     2,215          (54,720
Exxon Mobil Corp.
     1,160          01/20/23        USD     115.00        USD     12,795          (138,040
Kosmos Energy Ltd.
     555          01/20/23        USD     7.50        USD     353          (2,775
Ovintiv, Inc.
     71          01/20/23        USD     65.00        USD     360          (888
Patterson-UTI
Energy, Inc.
     232          01/20/23        USD     20.00        USD     391          (5,800
Shell PLC, ADR
     614          01/20/23        USD     57.50        USD     3,497          (70,610
TC Energy Corp.
     598          01/20/23        CAD     64.00        CAD     3,228          (2,650
Tourmaline Oil Corp.
     273          01/20/23        CAD     84.25        CAD     1,865          (1,512
Valero Energy Corp.
     124          01/20/23        USD     140.00        USD     1,573          (9,796
Williams Cos., Inc.
     279          01/20/23        USD     34.00        USD     918          (11,160
Chevron Corp.
     246          01/27/23        USD     180.00        USD     4,415          (146,370
ConocoPhillips
     183          01/27/23        USD     121.00        USD     2,159          (65,880
EOG Resources, Inc.
     173          01/27/23        USD     135.50        USD     2,241          (48,872
Exxon Mobil Corp.
     259          01/27/23        USD     111.00        USD     2,857          (86,117
Kinder Morgan, Inc.
     640          01/27/23        USD     18.00        USD     1,157          (38,720
Schlumberger Ltd.
     235          01/27/23        USD     57.00        USD     1,256          (29,140
ARC Resources Ltd.
     636          02/17/23        CAD     19.00        CAD     1,161          (46,737
Canadian Natural Resources Ltd.
     366          02/17/23        CAD     86.00        CAD     2,752          (15,002
Canadian Natural Resources Ltd.
     363          02/17/23        CAD     84.00        CAD     2,729          (23,056
Cenovus Energy, Inc.
     321          02/17/23        CAD     29.00        CAD     843          (17,781
Cheniere Energy, Inc.
     45          02/17/23        USD     173.07        USD     675          (7,447
Darling Ingredients, Inc.
     36          02/17/23        USD     66.00        USD     225          (9,070
Diamondback Energy, Inc.
     130          02/17/23        USD     145.00        USD     1,778          (62,400
Kosmos Energy Ltd.
     549          02/17/23        USD     7.29        USD     349          (15,451
Ovintiv, Inc.
     216          02/17/23        USD     51.50        USD     1,095          (84,267
Patterson-UTI
Energy, Inc.
     197          02/17/23        USD     19.00        USD     332          (13,298
Shell PLC, ADR
     577          02/17/23        USD     60.00        USD     3,286          (66,355
TC Energy Corp.
     598          02/17/23        CAD     58.00        CAD     3,228          (19,212
Tourmaline Oil Corp.
     184          02/17/23        CAD     82.00        CAD     1,257          (11,483
Canadian Natural Resources Ltd.
     71          03/17/23        CAD     80.00        CAD     534          (14,971
Cenovus Energy, Inc.
     1,335          03/17/23        CAD     27.00        CAD     3,507          (187,827
Kosmos Energy Ltd.
     560          03/17/23        USD     6.15        USD     356          (47,094
                          
 
 
 
                           $   (1,970,863
                          
 
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  45

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Energy and Resources Trust (BGR)
    
 
OTC Options Written
 
 
 
Description
  
Counterparty
  
Number of
Contracts
    
Expiration
Date
  
Exercise Price
    
Notional
Amount (000)
  
Value
 
 
 
Call                                               
Eni SpA
   Morgan Stanley & Co. International PLC      122,000      01/05/23      EUR       14.57      EUR    1,621    $ (145
Santos Ltd.
   Morgan Stanley & Co. International PLC      36,550      01/05/23      AUD       7.58      AUD    261      (66
Shell PLC, ADR
   Barclays Bank PLC      65,800      01/05/23      USD       58.93      USD    3,747      (7,587
Shell PLC, ADR
   JPMorgan Chase Bank N.A.      61,400      01/05/23      USD       56.33      USD    3,497      (72,279
BP PLC
   Morgan Stanley & Co. International PLC      619,300      01/10/23      GBP       5.10      GBP    2,941      (3,467
Santos Ltd.
   Goldman Sachs International      148,600      01/11/23      AUD       7.44      AUD    1,061      (3,538
TotalEnergies SE
   Royal Bank of Canada      33,063      01/11/23      EUR       60.77      EUR    1,939      (9,894
Tenaris SA
   Royal Bank of Canada      68,500      01/13/23      EUR       17.22      EUR    1,116      (7,396
Galp Energia SGPS SA
   Goldman Sachs International      73,100      01/17/23      EUR       12.21      EUR    922      (46,611
TotalEnergies SE
   Morgan Stanley & Co. International PLC      104,700      01/17/23      EUR       58.51      EUR    6,141      (144,469
Eni SpA
   Goldman Sachs International      91,900      01/31/23      EUR       13.59      EUR    1,221      (27,859
Santos Ltd.
   JPMorgan Chase Bank N.A.      166,800      01/31/23      AUD       7.60      AUD    1,191      (10,353
Galp Energia SGPS SA
   Goldman Sachs International      73,100      02/01/23      EUR       12.21      EUR    922      (55,850
BP PLC
   Morgan Stanley & Co. International PLC      642,000      02/02/23      GBP       4.92      GBP    3,049      (74,665
Tenaris SA
   Goldman Sachs International      30,300      02/02/23      EUR       17.05      EUR    493      (11,122
TotalEnergies SE
   Goldman Sachs International      32,513      02/02/23      EUR       60.76      EUR    1,907      (29,615
                      
 
 
 
                       $   (504,916
                      
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
      
Swap
Premiums
Received
      
Unrealized
Appreciation
      
Unrealized
Depreciation
      
Value
 
Options Written
   $ N/A        $ N/A        $ 2,772,102        $ (346,853      $   (2,475,779)  
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
    
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $   2,475,779     $     $     $     $  2,475,779  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options purchased
(a)
   $      $      $ (1,290,525    $      $      $      $ (1,290,525
Options written
                   (20,422,274                           (20,422,274
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ (21,712,799    $      $      $      $ (21,712,799
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options written
   $      $      $ 1,104,316      $      $      $      $ 1,104,316  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Options:
  
 
 
 
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 3,178,025  
 
 
(a)
 
Derivative not held at any
quarter-end.
The risk exposure table serves as an indicator of activity during the period.
 
 
 
46
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Energy and Resources Trust (BGR)
    
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $ 2,475,779  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
              2,475,779  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (1,970,863
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 504,916  
  
 
 
      
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
    
 

Derivatives
Available
for Offset
 
 
 
    
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
    
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 7,587        $        $      $        $ 7,587  
Goldman Sachs International
     174,595                                   174,595  
JPMorgan Chase Bank N.A
     82,632                                   82,632  
Morgan Stanley & Co. International PLC
     222,812                   (222,812                
Royal Bank of Canada
     17,290                                   17,290  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
   $ 504,916        $        $ (222,812    $        $ 282,104  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
     
Level 1
      
Level 2
      
Level 3
      
Total
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Energy Equipment & Services
   $ 8,597,302        $ 4,638,722        $        $ 13,236,024  
Food Products
     1,822,871                            1,822,871  
Metals & Mining
              3,424,682                   3,424,682  
Oil, Gas & Consumable Fuels
     310,560,050          64,747,996          119          375,308,165  
Short-Term Securities
                 
Money Market Funds
     7,695,475                            7,695,475  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $   328,675,698        $     72,811,400        $             119        $   401,487,217  
  
 
 
      
 
 
      
 
 
      
 
 
 
Derivative Financial Instruments
(a)
                 
Liabilities
                 
Equity Contracts
   $ (1,807,534      $ (668,245      $        $ (2,475,779
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  47

Schedule of Investments
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Common Stocks
    
Auto Components — 1.3%
 
Aptiv PLC
(a)
    106,700      $      9,936,971  
    
 
 
 
Automobiles — 1.5%
            
General Motors Co.
(b)
    355,591        11,962,081  
    
 
 
 
Banks — 3.0%
            
First Citizens BancShares, Inc., Class A
    11,860        8,994,150  
JPMorgan Chase & Co.
(b)
    103,311        13,854,005  
    
 
 
 
       22,848,155  
Beverages — 1.7%
            
Monster Beverage Corp.
(a)
    128,830        13,080,110  
    
 
 
 
Capital Markets — 3.4%
            
Charles Schwab Corp.
    149,540        12,450,701  
Intercontinental Exchange, Inc.
(b)
    132,007        13,542,598  
    
 
 
 
       25,993,299  
Chemicals — 3.5%
            
Axalta Coating Systems Ltd.
(a)
    341,375        8,694,821  
Corteva, Inc.
(b)
    314,158        18,466,207  
    
 
 
 
       27,161,028  
Communications Equipment — 2.0%
            
Ciena Corp.
(a)
    296,642        15,122,809  
    
 
 
 
Consumer Finance — 0.9%
            
Capital One Financial Corp.
(b)
    72,610        6,749,826  
    
 
 
 
Containers & Packaging — 1.5%
            
Sealed Air Corp.
(b)
    231,110        11,527,767  
    
 
 
 
Diversified Financial Services — 3.3%
            
Berkshire Hathaway, Inc., Class B
(a)(b)
    71,408        22,057,931  
Voya Financial, Inc.
    62,750        3,858,498  
    
 
 
 
       25,916,429  
Entertainment — 0.7%
            
World Wrestling Entertainment, Inc., Class A
(b)
    83,324        5,709,360  
    
 
 
 
Food Products — 1.8%
            
Mondelez International, Inc., Class A
(b)
    207,110        13,803,881  
    
 
 
 
Health Care Providers & Services — 8.0%
            
Elevance Health, Inc.
    23,005        11,800,875  
Humana, Inc.
(b)
    25,548        13,085,430  
Laboratory Corp. of America Holdings
(b)
    66,265        15,604,082  
UnitedHealth Group, Inc.
(b)
    39,893        21,150,471  
    
 
 
 
       61,640,858  
Health Care Technology — 0.8%
            
Veeva Systems, Inc., Class A
(a)(b)
    37,786        6,097,905  
    
 
 
 
Hotels, Restaurants & Leisure — 1.1%
            
Las Vegas Sands Corp.
(a)(b)
    183,868        8,838,535  
    
 
 
 
Insurance — 3.3%
            
Progressive Corp.
    105,430        13,675,326  
Reinsurance Group of America, Inc.
(b)
    84,970        12,073,387  
    
 
 
 
       25,748,713  
Interactive Media & Services
(a)
— 5.7%
            
Alphabet, Inc., Class A
    352,800        31,127,544  
Meta Platforms, Inc., Class A
(b)
    107,439        12,929,209  
    
 
 
 
       44,056,753  
Security
 
Shares
    
Value
 
Internet & Direct Marketing Retail — 3.9%
            
Amazon.com, Inc.
(a)(b)
    361,750      $    30,387,000  
    
 
 
 
IT Services — 6.8%
            
Cognizant Technology Solutions Corp., Class A
    133,320        7,624,571  
Fidelity National Information Services, Inc.
    178,851        12,135,040  
FleetCor Technologies, Inc.
(a)
    60,870        11,180,602  
Visa, Inc., Class A
(b)
    102,710        21,339,029  
    
 
 
 
       52,279,242  
Life Sciences Tools & Services — 1.4%
            
Avantor, Inc.
(a)
    513,750        10,834,988  
    
 
 
 
Machinery
(b)
— 5.8%
            
Caterpillar, Inc.
    70,050        16,781,178  
Fortive Corp.
    241,343        15,506,288  
Otis Worldwide Corp.
    164,977        12,919,349  
    
 
 
 
       45,206,815  
Media
(b)
— 3.6%
            
Comcast Corp., Class A
    621,332        21,727,980  
Fox Corp., Class A
    204,018        6,196,027  
    
 
 
 
       27,924,007  
Multiline Retail
(b)
— 3.1%
            
Dollar General Corp.
    54,188        13,343,795  
Dollar Tree, Inc.
(a)
    74,382        10,520,590  
    
 
 
 
       23,864,385  
Oil, Gas & Consumable Fuels — 4.2%
            
BP PLC, ADR
    270,540        9,449,962  
ConocoPhillips
(b)
    116,658        13,765,644  
EQT Corp.
(b)
    285,167        9,647,200  
    
 
 
 
       32,862,806  
Personal Products — 1.3%
            
Unilever PLC, ADR
(b)
    205,088        10,326,181  
    
 
 
 
Pharmaceuticals — 4.2%
            
Novo Nordisk A/S, ADR
(b)
    104,883        14,194,865  
Sanofi, ADR
    385,010        18,646,035  
    
 
 
 
       32,840,900  
Professional Services — 1.4%
            
Dun & Bradstreet Holdings, Inc.
    863,120        10,581,851  
    
 
 
 
Real Estate Management & Development — 1.3%
        
CBRE Group, Inc., Class A
(a)(b)
    132,914        10,229,061  
    
 
 
 
Road & Rail — 1.9%
            
Norfolk Southern Corp.
(b)
    59,510        14,664,454  
    
 
 
 
Semiconductors & Semiconductor Equipment
(b)
— 3.6%
 
Analog Devices, Inc.
    89,120        14,618,353  
Applied Materials, Inc.
    139,070        13,542,637  
    
 
 
 
       28,160,990  
Software — 6.0%
            
Microsoft Corp.
(b)(c)
    195,281        46,832,289  
    
 
 
 
Specialty Retail
(b)
— 3.5%
            
Bath & Body Works, Inc.
    144,270        6,079,538  
Ross Stores, Inc.
    181,818        21,103,615  
    
 
 
 
       27,183,153  
 
 
48
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Technology Hardware, Storage & Peripherals — 3.9%
 
Apple, Inc.
(b)
    229,468      $ 29,814,777  
    
 
 
 
Total Long-Term Investments — 99.4%
(Cost: $579,756,295)
 
     770,187,379  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 1.9%
            
BlackRock Liquidity Funds,
T-Fund,
Institutional Class, 4.03%
(d)(e)
    14,661,156        14,661,156  
    
 
 
 
Total Short-Term Securities — 1.9%
(Cost: $14,661,156)
 
     14,661,156  
    
 
 
 
Total Investments Before Options Written — 101.3%
 
(Cost: $594,417,451)
 
     784,848,535  
    
 
 
 
Options Written — (1.0)%
(Premiums Received: $(13,089,762))
 
     (7,689,724
    
 
 
 
Total Investments, Net of Options Written — 100.3%
 
(Cost: $581,327,689)
 
     777,158,811  
Liabilities in Excess of Other Assets — (0.3)%
 
     (2,491,739
    
 
 
 
Net Assets — 100.0%
     $   774,667,072  
    
 
 
 
(a)
Non-income
producing security.
(b)
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(c)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(d)
 
Affiliate of the Trust.
(e)
Annualized
7-day
yield as of period end.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry
sub-classifications
used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry
sub-classifications
for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds,
T-Fund,
Institutional Class
  $ 10,297,753     $   4,363,403
(a)
 
  $     $     $     $   14,661,156       14,661,156     $   382,413     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call                                                   
Corteva, Inc.
     700          01/05/23        USD     66.00        USD     4,115        $ (8
Fortive Corp.
     1,004          01/05/23        USD     65.00        USD     6,451          (57,728
Alphabet, Inc., Class A
     133          01/06/23        USD     99.00        USD     1,173          (333
Amazon.com, Inc.
     111          01/06/23        USD     96.00        USD     932          (333
Analog Devices, Inc.
     151          01/06/23        USD     175.00        USD     2,477          (1,888
Apple, Inc.
     109          01/06/23        USD     157.50        USD     1,416          (109
Bath & Body Works, Inc.
     208          01/06/23        USD     44.00        USD     877          (8,840
BP PLC, ADR
     485          01/06/23        USD     36.00        USD     1,694          (5,820
Capital One Financial Corp.
     169          01/06/23        USD     105.00        USD     1,571          (845
Caterpillar, Inc.
     143          01/06/23        USD     245.00        USD     3,426          (17,446
Charles Schwab Corp.
     263          01/06/23        USD     85.00        USD     2,190          (11,572
Comcast Corp., Class A
     441          01/06/23        USD     37.00        USD     1,542          (1,764
ConocoPhillips
     109          01/06/23        USD     132.00        USD     1,286          (872
Dollar Tree, Inc.
     69          01/06/23        USD     155.00        USD     976          (345
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  49

Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Elevance Health, Inc.
     36          01/06/23        USD     530.00        USD     1,847        $         (5,220)  
EQT Corp.
     667          01/06/23        USD     46.00        USD     2,256          (50,025)  
General Motors Co.
     128          01/06/23        USD     42.00        USD     431          (256)  
Microsoft Corp.
     440          01/06/23        USD     260.00        USD     10,552          (3,960)  
Mondelez International, Inc., Class A
     393          01/06/23        USD     67.00        USD     2,619          (16,702)  
Monster Beverage Corp.
     217          01/06/23        USD     106.00        USD     2,203          (2,170)  
Norfolk Southern Corp.
     153          01/06/23        USD     260.00        USD     3,770          (12,240)  
Ross Stores, Inc.
     69          01/06/23        USD     120.00        USD     801          (3,105)  
UnitedHealth Group, Inc.
     144          01/06/23        USD     550.00        USD     7,635          (7,200)  
Visa, Inc., Class A
     149          01/06/23        USD     220.00        USD     3,096          (1,341)  
Delphi Automotive PLC
     188          01/09/23        USD     111.00        USD     1,751          (223)  
Otis Worldwide Corp.
     539          01/10/23        USD     79.25        USD     4,221          (47,071)  
Visa, Inc., Class A
     76          01/10/23        USD     216.00        USD     1,579          (7,201)  
World Wrestling Entertainment, Inc., Class A
     150          01/10/23        USD     78.00        USD     1,028          (45)  
Progressive Corp.
     380          01/11/23        USD     130.00        USD     4,929          (75,906)  
Alphabet, Inc., Class A
     133          01/13/23        USD     100.00        USD     1,173          (1,264)  
Amazon.com, Inc.
     111          01/13/23        USD     98.00        USD     932          (1,443)  
Analog Devices, Inc.
     141          01/13/23        USD     172.50        USD     2,313          (17,272)  
Apple, Inc.
     175          01/13/23        USD     148.00        USD     2,274          (1,838)  
Bath & Body Works, Inc.
     433          01/13/23        USD     46.00        USD     1,825          (20,567)  
BP PLC, ADR
     617          01/13/23        USD     36.00        USD     2,155          (20,361)  
Capital One Financial Corp.
     175          01/13/23        USD     99.00        USD     1,627          (13,563)  
Caterpillar, Inc.
     152          01/13/23        USD     245.00        USD     3,641          (46,132)  
Charles Schwab Corp.
     167          01/13/23        USD     81.00        USD     1,390          (55,527)  
Charles Schwab Corp.
     168          01/13/23        USD     83.00        USD     1,399          (34,188)  
Comcast Corp., Class A
     417          01/13/23        USD     36.00        USD     1,458          (15,220)  
ConocoPhillips
     552          01/13/23        USD     129.00        USD     6,514          (22,632)  
Elevance Health, Inc.
     36          01/13/23        USD     530.00        USD     1,847          (9,810)  
EQT Corp.
     667          01/13/23        USD     46.00        USD     2,256          (10,005)  
General Motors Co.
     392          01/13/23        USD     41.00        USD     1,319          (784)  
JPMorgan Chase & Co.
     203          01/13/23        USD     136.00        USD     2,722          (41,209)  
Las Vegas Sands Corp.
     273          01/13/23        USD     48.00        USD     1,312          (45,318)  
Microsoft Corp.
     367          01/13/23        USD     250.00        USD     8,801          (78,171)  
Mondelez International, Inc., Class A
     200          01/13/23        USD     68.00        USD     1,333          (8,000)  
Monster Beverage Corp.
     216          01/13/23        USD     105.00        USD     2,193          (11,340)  
Norfolk Southern Corp.
     150          01/13/23        USD     255.00        USD     3,696          (25,875)  
Ross Stores, Inc.
     487          01/13/23        USD     122.00        USD     5,653          (38,960)  
UnitedHealth Group, Inc.
     13          01/13/23        USD     555.00        USD     689          (2,815)  
Visa, Inc., Class A
     38          01/13/23        USD     215.00        USD     789          (5,624)  
Visa, Inc., Class A
     38          01/13/23        USD     220.00        USD     789          (2,318)  
Alphabet, Inc., Class A
     133          01/20/23        USD     100.00        USD     1,173          (2,594)  
Alphabet, Inc., Class A
     415          01/20/23        USD     92.00        USD     3,662          (57,892)  
Amazon.com, Inc.
     210          01/20/23        USD     107.50        USD     1,764          (1,470)  
Apple, Inc.
     230          01/20/23        USD     160.00        USD     2,988          (805)  
Applied Materials, Inc.
     260          01/20/23        USD     105.00        USD     2,532          (37,050)  
Avantor, Inc.
     1,042          01/20/23        USD     22.50        USD     2,198          (28,655)  
Axalta Coating Systems Ltd.
     143          01/20/23        USD     27.00        USD     364          (3,218)  
Axalta Coating Systems Ltd.
     355          01/20/23        USD     28.00        USD     904          (14,200)  
Bath & Body Works, Inc.
     296          01/20/23        USD     45.00        USD     1,247          (25,160)  
Berkshire Hathaway, Inc., Class B
     293          01/20/23        USD     300.00        USD     9,051          (365,517)  
Caterpillar, Inc.
     160          01/20/23        USD     240.00        USD     3,833          (98,000)  
CBRE Group, Inc., Class A
     428          01/20/23        USD     75.00        USD     3,294          (141,240)  
Ciena Corp.
     450          01/20/23        USD     47.00        USD     2,294          (198,000)  
Cognizant Technology Solutions Corp., Class A
     32          01/20/23        USD     60.00        USD     183          (1,600)  
Cognizant Technology Solutions Corp., Class A
     237          01/20/23        USD     65.00        USD     1,355          (1,778)  
Comcast Corp., Class A
     192          01/20/23        USD     35.50        USD     671          (13,344)  
ConocoPhillips
     70          01/20/23        USD     120.00        USD     826          (22,575)  
Corteva, Inc.
     701          01/20/23        USD     65.00        USD     4,120          (8,763)  
Delphi Automotive PLC
     298          01/20/23        USD     105.00        USD     2,775          (29,055)  
Dollar General Corp.
     158          01/20/23        USD     260.00        USD     3,891          (20,540)  
Dollar Tree, Inc.
     212          01/20/23        USD     160.00        USD     2,999          (3,286)  
Elevance Health, Inc.
     62          01/20/23        USD     550.00        USD     3,180          (10,230)  
 
 
50
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
EQT Corp.
     667          01/20/23        USD     46.00        USD     2,256        $      (10,005
First Citizens BancShares, Inc., Class A
     88          01/20/23        USD     860.00        USD     6,674          (88,000
FleetCor Technologies, Inc.
     208          01/20/23        USD     200.00        USD     3,821          (35,360
Fortive Corp.
     564          01/20/23        USD     65.00        USD     3,624          (69,090
Fox Corp., Class A
     784          01/20/23        USD     33.00        USD     2,381          (9,800
General Motors Co.
     392          01/20/23        USD     41.00        USD     1,319          (1,568
Humana, Inc.
     52          01/20/23        USD     530.00        USD     2,663          (29,380
Humana, Inc.
     52          01/20/23        USD     520.00        USD     2,663          (47,060
Intercontinental Exchange, Inc.
     363          01/20/23        USD     105.00        USD     3,724          (52,635
JPMorgan Chase & Co.
     353          01/20/23        USD     135.00        USD     4,734          (107,488
Laboratory Corp. of America Holdings
     169          01/20/23        USD     250.00        USD     3,980          (21,970
Las Vegas Sands Corp.
     397          01/20/23        USD     45.00        USD     1,908          (155,822
Meta Platforms, Inc., Class A
     86          01/20/23        USD     130.00        USD     1,035          (16,512
Microsoft Corp.
     367          01/20/23        USD     240.00        USD     8,801          (264,240
Microsoft Corp.
     181          01/20/23        USD     260.00        USD     4,341          (17,557
Norfolk Southern Corp.
     110          01/20/23        USD     250.00        USD     2,711          (47,300
Novo Nordisk A/S, ADR
     390          01/20/23        USD     115.00        USD     5,278          (799,500
Otis Worldwide Corp.
     430          01/20/23        USD     75.00        USD     3,367          (172,000
Otis Worldwide Corp.
     26          01/20/23        USD     80.00        USD     204          (2,600
Progressive Corp.
     305          01/20/23        USD     135.00        USD     3,956          (27,450
Reinsurance Group of America, Inc.
     50          01/20/23        USD     145.00        USD     710          (10,500
Ross Stores, Inc.
     187          01/20/23        USD     120.00        USD     2,171          (34,595
Sanofi, ADR
     811          01/20/23        USD     48.00        USD     3,928          (113,540
Sealed Air Corp.
     326          01/20/23        USD     50.00        USD     1,626          (42,380
Sealed Air Corp.
     477          01/20/23        USD     52.00        USD     2,379          (36,701
Unilever PLC, ADR
     431          01/20/23        USD     49.00        USD     2,170          (78,657
UnitedHealth Group, Inc.
     102          01/20/23        USD     540.00        USD     5,408          (83,385
Veeva Systems, Inc., Class A
     122          01/20/23        USD     190.00        USD     1,969          (3,355
Visa, Inc., Class A
     41          01/20/23        USD     215.00        USD     852          (8,815
Voya Financial, Inc.
     148          01/20/23        USD     68.30        USD     910          (3,334
World Wrestling Entertainment, Inc., Class A
     182          01/20/23        USD     80.00        USD     1,247          (1,365
Alphabet, Inc., Class A
     198          01/27/23        USD     99.00        USD     1,747          (8,514
Alphabet, Inc., Class A
     152          01/27/23        USD     94.00        USD     1,341          (18,392
Amazon.com, Inc.
     208          01/27/23        USD     93.00        USD     1,747          (21,424
Analog Devices, Inc.
     64          01/27/23        USD     170.00        USD     1,050          (21,440
Apple, Inc.
     103          01/27/23        USD     152.50        USD     1,338          (2,009
Apple, Inc.
     53          01/27/23        USD     142.00        USD     689          (6,069
Applied Materials, Inc.
     388          01/27/23        USD     110.00        USD     3,778          (36,472
BP PLC, ADR
     656          01/27/23        USD     35.00        USD     2,291          (72,816
Comcast Corp., Class A
     192          01/27/23        USD     36.00        USD     671          (15,840
ConocoPhillips
     70          01/27/23        USD     121.00        USD     826          (25,200
Dollar General Corp.
     27          01/27/23        USD     245.00        USD     665          (21,600
Dollar Tree, Inc.
     105          01/27/23        USD     152.50        USD     1,485          (10,658
Elevance Health, Inc.
     15          01/27/23        USD     505.00        USD     769          (32,325
Fox Corp., Class A
     315          01/27/23        USD     30.00        USD     957          (37,800
General Motors Co.
     463          01/27/23        USD     41.00        USD     1,558          (2,778
Humana, Inc.
     62          01/27/23        USD     525.00        USD     3,176          (46,810
JPMorgan Chase & Co.
     166          01/27/23        USD     136.00        USD     2,226          (51,045
Las Vegas Sands Corp.
     100          01/27/23        USD     51.00        USD     481          (12,550
Meta Platforms, Inc., Class A
     282          01/27/23        USD     124.00        USD     3,394          (141,000
Monster Beverage Corp.
     108          01/27/23        USD     102.00        USD     1,097          (25,650
Ross Stores, Inc.
     129          01/27/23        USD     122.00        USD     1,497          (20,962
Visa, Inc., Class A
     24          01/27/23        USD     210.00        USD     499          (14,940
Voya Financial, Inc.
     80          01/30/23        USD     66.00        USD     492          (6,353
Voya Financial, Inc.
     90          01/30/23        USD     64.01        USD     553          (11,520
Fox Corp., Class A
     315          01/31/23        USD     31.00        USD     957          (29,620
Amazon.com, Inc.
     83          02/03/23        USD     88.00        USD     697          (30,710
Apple, Inc.
     230          02/03/23        USD     140.00        USD     2,988          (53,015
Capital One Financial Corp.
     128          02/03/23        USD     94.00        USD     1,190          (57,600
Mondelez International, Inc., Class A
     235          02/03/23        USD     68.00        USD     1,566          (27,025
Applied Materials, Inc.
     255          02/10/23        USD     103.00        USD     2,483          (94,350
Avantor, Inc.
     1,042          02/10/23        USD     23.00        USD     2,198          (49,211
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  51

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
    
 
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
General Motors Co.
     47          02/10/23        USD     36.00        USD     158        $ (5,123
Sealed Air Corp.
     775          02/10/23        USD     53.00        USD     3,866          (81,153
Alphabet, Inc., Class A
     529          02/17/23        USD     100.00        USD     4,667          (66,918
Apple, Inc.
     371          02/17/23        USD     155.00        USD     4,820          (23,002
Apple, Inc.
     220          02/17/23        USD     145.00        USD     2,858          (42,570
Berkshire Hathaway, Inc., Class B
     199          02/17/23        USD     310.00        USD     6,147          (203,975
CBRE Group, Inc., Class A
     435          02/17/23        USD     80.00        USD     3,348          (92,437
Ciena Corp.
     443          02/17/23        USD     50.00        USD     2,258          (141,760
Cognizant Technology Solutions Corp., Class A
     273          02/17/23        USD     62.00        USD     1,561          (28,994
Dollar General Corp.
     167          02/17/23        USD     260.00        USD     4,112          (65,965
Fidelity National Information Services, Inc.
     122          02/17/23        USD     80.00        USD     828          (9,150
FleetCor Technologies, Inc.
     187          02/17/23        USD     185.00        USD     3,435          (175,780
Intercontinental Exchange, Inc.
     495          02/17/23        USD     105.00        USD     5,078          (158,400
Laboratory Corp. of America Holdings
     10          02/17/23        USD     240.00        USD     235          (8,500
Novo Nordisk A/S, ADR
     317          02/17/23        USD     140.00        USD     4,290          (110,950
Otis Worldwide Corp.
     26          02/17/23        USD     80.00        USD     204          (6,175
Otis Worldwide Corp.
     51          02/17/23        USD     82.50        USD     399          (7,140
Unilever PLC, ADR
     431          02/17/23        USD     52.50        USD     2,170          (31,247
Visa, Inc., Class A
     44          02/17/23        USD     220.00        USD     914          (18,040
Voya Financial, Inc.
     148          02/17/23        USD     67.50        USD     910          (13,320
                          
 
 
 
                           $ (6,644,037
                          
 
 
 
OTC Options Written
 
 
 
Description
  
Counterparty
    
Number of
Contracts
    
Expiration
Date
  
Exercise Price
    
Notional
Amount (000)
  
Value
 
 
 
Call
                      
Dun & Bradstreet Holdings, Inc.
     Barclays Bank PLC        62,500      01/05/23      USD       13.69      USD    766    $ (1,851
Dun & Bradstreet Holdings, Inc.
     Barclays Bank PLC        62,500      01/11/23      USD       13.69      USD    766      (6,814
Sanofi, ADR
     JPMorgan Chase Bank N.A.        81,200      01/12/23      USD       46.55      USD    3,933      (182,234
Dun & Bradstreet Holdings, Inc.
     BNP Paribas SA        75,000      01/18/23      USD       13.80      USD    920      (4,967
Dun & Bradstreet Holdings, Inc.
     BNP Paribas SA        75,000      01/25/23      USD       13.80      USD    920      (8,162
Fidelity National Information Services, Inc.
     Citibank N.A.        52,000      01/30/23      USD       71.02      USD    3,528      (93,264
Reinsurance Group of America, Inc.
     Barclays Bank PLC        27,000      01/30/23      USD       140.42      USD    3,836      (173,825
Veeva Systems, Inc., Class A
     Citibank N.A.        14,000      01/31/23      USD       182.00      USD    2,259      (24,231
World Wrestling Entertainment, Inc., Class A
     Goldman Sachs International        24,300      01/31/23      USD       75.48      USD    1,665      (10,525
Ciena Corp.
     Barclays Bank PLC        53,000      02/10/23      USD       46.42      USD    2,702      (303,512
Delphi Automotive PLC
     Citibank N.A.        23,700      02/10/23      USD       100.25      USD    2,207      (62,931
Fidelity National Information Services, Inc.
     Citibank N.A.        52,000      02/10/23      USD       71.02      USD    3,528      (118,436
Axalta Coating Systems Ltd.
     JPMorgan Chase Bank N.A.        60,800      02/13/23      USD       26.80      USD    1,549      (43,684
Axalta Coating Systems Ltd.
     JPMorgan Chase Bank N.A.        35,600      02/13/23      USD       28.33      USD    907      (11,251
                      
 
 
 
                       $  (1,045,687
                      
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
      
Swap
Premiums
Received
      
Unrealized
Appreciation
      
Unrealized
Depreciation
      
Value
 
Options Written
   $ N/A        $ N/A        $ 6,813,721        $ (1,413,683      $   (7,689,724)  
 
 
52
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
    
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
    
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $ 7,689,724     $     $     $     $   7,689,724  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options written
   $      $      $   25,137,981      $      $      $      $  25,137,981  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options written
   $      $      $ 5,998,603      $      $      $      $ 5,998,603  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Options:
  
 
 
 
Average value of option contracts written
   $ 8,600,658  
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $  7,689,724  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
              7,689,724  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (6,644,037
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 1,045,687  
  
 
 
      
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to

an MNA by
Counterparty
 
 
 

 
 
    
 

Derivatives
Available

for Offset
 
 

 
    
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
    
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 486,002        $        $ (392,345    $        $ 93,657  
BNP Paribas SA
     13,129                                   13,129  
Citibank N.A
     298,862                   (298,862                
Goldman Sachs International
     10,525                                   10,525  
JPMorgan Chase Bank N.A
     237,169                   (237,169                
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
   $ 1,045,687        $        $ (928,376    $        $ 117,311  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  53

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
    
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
     
Level 1
      
Level 2
      
Level 3
      
Total
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
   $ 770,187,379        $        $                 —        $ 770,187,379  
Short-Term Securities
                 
Money Market Funds
     14,661,156                            14,661,156  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $ 784,848,535        $        $        $ 784,848,535  
  
 
 
      
 
 
      
 
 
      
 
 
 
Derivative Financial Instruments
(a)
                 
Liabilities
                 
Equity Contracts
   $ (6,208,969      $ (1,480,755      $        $ (7,689,724
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
See notes to financial statements.
 
 
54
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Common Stocks
    
Aerospace & Defense — 2.8%
 
Airbus SE
    114,764      $ 13,645,713  
BAE Systems PLC
    1,596,311        16,487,341  
L3Harris Technologies, Inc.
(a)
    76,017        15,827,500  
    
 
 
 
       45,960,554  
Auto Components — 0.5%
 
Lear Corp.
(a)
    64,750        8,030,295  
    
 
 
 
Automobiles — 2.1%
 
General Motors Co.
(a)(b)
    1,017,714        34,235,899  
    
 
 
 
Banks
(a)
— 11.3%
 
Bank of America Corp.
    683,721        22,644,840  
Citigroup, Inc.
    957,550        43,309,986  
Citizens Financial Group, Inc.
    304,570        11,990,921  
First Citizens BancShares, Inc., Class A
    36,117        27,389,688  
JPMorgan Chase & Co.
    252,448        33,853,277  
Wells Fargo & Co.
    1,108,398        45,765,753  
    
 
 
 
       184,954,465  
Beverages — 1.0%
 
Constellation Brands, Inc., Class A
(a)
    72,949        16,905,931  
    
 
 
 
Capital Markets
(a)
— 1.2%
 
Charles Schwab Corp.
    125,035        10,410,414  
Raymond James Financial, Inc.
    88,889        9,497,790  
    
 
 
 
       19,908,204  
Chemicals — 1.1%
 
PPG Industries, Inc.
    138,693        17,439,258  
    
 
 
 
Communications Equipment — 2.0%
 
Cisco Systems, Inc.
(a)
    690,200        32,881,128  
    
 
 
 
Consumer Finance — 0.3%
 
Capital One Financial Corp.
(a)
    44,289        4,117,105  
    
 
 
 
Containers & Packaging — 1.1%
 
Sealed Air Corp.
(a)
    350,582        17,487,030  
    
 
 
 
Diversified Financial Services
(a)
— 1.3%
 
Apollo Global Management, Inc.
    248,624        15,859,725  
Equitable Holdings, Inc.
    177,646        5,098,440  
    
 
 
 
       20,958,165  
Diversified Telecommunication Services
(a)
— 1.5%
 
AT&T, Inc.
(b)
    647,732        11,924,746  
Verizon Communications, Inc.
    316,430        12,467,342  
    
 
 
 
       24,392,088  
Electric Utilities
(a)
— 1.4%
            
American Electric Power Co., Inc.
    94,679        8,989,771  
Edison International
    133,522        8,494,670  
Exelon Corp.
    121,359        5,246,349  
    
 
 
 
       22,730,790  
Entertainment — 0.7%
 
Activision Blizzard, Inc.
    160,046        12,251,521  
    
 
 
 
Food & Staples Retailing — 1.0%
 
Walmart, Inc.
(a)(b)
    116,470        16,514,281  
    
 
 
 
Food Products
(a)
— 2.1%
 
Kraft Heinz Co.
    675,949        27,517,884  
Mondelez International, Inc., Class A
    97,339        6,487,644  
    
 
 
 
       34,005,528  
Health Care Equipment & Supplies — 6.5%
 
Baxter International, Inc.
(a)
    428,940        21,863,072  
Security
 
Shares
   
Value
 
Health Care Equipment & Supplies (continued)
 
Koninklijke Philips NV
    932,729     $ 14,034,968  
Medtronic PLC
(a)
    503,180       39,107,150  
Zimmer Biomet Holdings, Inc.
(a)
    243,166       31,003,665  
   
 
 
 
      106,008,855  
Health Care Providers & Services
(a)
—8.8%
 
AmerisourceBergen Corp.
    60,866       10,086,105  
Cardinal Health, Inc.
    275,019       21,140,710  
Cigna Corp.
    76,854       25,464,804  
Elevance Health, Inc.
    52,200       26,777,034  
Humana, Inc.
    47,088       24,118,003  
Laboratory Corp. of America Holdings
(b)
    152,772       35,974,751  
   
 
 
 
      143,561,407  
Household Durables — 1.4%
 
Newell Brands, Inc.
(a)
    811,566       10,615,283  
Panasonic Holdings Corp.
    1,527,900       12,787,024  
   
 
 
 
      23,402,307  
Industrial Conglomerates — 0.8%
 
Siemens AG, Registered Shares
    95,422       13,154,037  
   
 
 
 
Insurance — 6.9%
           
Allstate Corp.
(a)
    80,857       10,964,209  
American International Group, Inc.
(a)
    571,914       36,167,841  
Fidelity National Financial, Inc.
(a)
    452,735       17,031,891  
Prudential PLC
    864,805       11,791,865  
Willis Towers Watson PLC
(a)
    146,245       35,768,602  
   
 
 
 
      111,724,408  
Interactive Media & Services — 0.4%
 
Alphabet, Inc., Class A
(a)(c)
    68,645       6,056,548  
   
 
 
 
Internet & Direct Marketing Retail — 0.4%
 
Amazon.com, Inc.
(a)(c)
    74,026       6,218,184  
   
 
 
 
IT Services
(a)
— 7.1%
 
Cognizant Technology Solutions Corp., Class A
    644,498       36,858,841  
Fidelity National Information Services, Inc.
(b)
    500,470       33,956,889  
SS&C Technologies Holdings, Inc.
    545,946       28,421,949  
Visa, Inc., Class A
    79,331       16,481,809  
   
 
 
 
      115,719,488  
Machinery — 1.1%
 
Fortive Corp.
(a)
    74,754       4,802,945  
Komatsu Ltd.
    581,100       12,559,961  
   
 
 
 
      17,362,906  
Media
(a)
— 3.0%
 
Comcast Corp., Class A
    943,515       32,994,719  
Fox Corp., Class A
    539,407       16,381,791  
   
 
 
 
      49,376,510  
Multiline Retail — 1.2%
 
Dollar General Corp.
(a)
    82,026       20,198,903  
   
 
 
 
Multi-Utilities
(a)
— 1.9%
 
Public Service Enterprise Group, Inc.
    326,198       19,986,152  
Sempra Energy
    67,691       10,460,967  
   
 
 
 
      30,447,119  
Oil, Gas & Consumable Fuels — 9.0%
 
BP PLC
    7,828,407       45,169,451  
ConocoPhillips
(a)
    74,813       8,827,934  
Enterprise Products Partners LP
(a)
    1,542,031       37,193,788  
EQT Corp.
(a)
    413,523       13,989,483  
Formentera Partners Fund II LP
(d)(e)
   
(f)
 
    11,435,463  
 
 
 
S
C
H
E
D
U
L
E
   
O
F   
I
N
V
E
S
T
M
E
N
T
S
  55

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Oil, Gas & Consumable Fuels (continued)
 
Hess Corp.
(a)
    113,878      $ 16,150,178  
Shell PLC
    510,170        14,382,109  
    
 
 
 
       147,148,406  
Personal Products — 2.0%
 
Unilever PLC, ADR
(a)
    635,218        31,983,226  
    
 
 
 
Pharmaceuticals — 6.2%
 
AstraZeneca PLC
    220,765        29,873,777  
Bayer AG, Registered Shares
    449,334        23,127,243  
Eli Lilly & Co.
(a)
    24,850        9,091,124  
Novo Nordisk A/S, ADR
(a)
    61,707        8,351,425  
Sanofi
    314,572        30,333,086  
    
 
 
 
       100,776,655  
Professional Services
(a)
— 1.6%
 
Leidos Holdings, Inc.
    197,171        20,740,417  
Robert Half International, Inc.
    79,220        5,848,813  
    
 
 
 
       26,589,230  
Road & Rail — 0.4%
 
Union Pacific Corp.
(a)
    32,021        6,630,589  
    
 
 
 
Software — 1.7%
 
Microsoft Corp.
(a)
    114,535        27,467,784  
    
 
 
 
Specialty Retail — 0.8%
 
Ross Stores, Inc.
(a)
    116,255        13,493,718  
    
 
 
 
Technology Hardware, Storage & Peripherals — 1.1%
 
Samsung Electronics Co. Ltd., GDR, Registered Shares
    16,154        17,893,921  
    
 
 
 
Textiles, Apparel & Luxury Goods — 0.7%
 
Ralph Lauren Corp.
(a)
    102,403        10,820,925  
    
 
 
 
Tobacco
(a)
— 0.8%
            
Altria Group, Inc.
    181,118        8,278,904  
British American Tobacco PLC, ADR
    127,980        5,116,640  
    
 
 
 
       13,395,544  
Security
 
Shares
    
Value
 
Wireless Telecommunication Services — 0.7%
 
Rogers Communications, Inc., Class B
    236,112      $ 11,050,530  
    
 
 
 
Total Long-Term Investments — 95.9%
(Cost: $1,347,790,184)
 
     1,563,253,442  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 4.7%
            
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(g)(h)
    76,042,437        76,042,437  
    
 
 
 
Total Short-Term Securities — 4.7%
(Cost: $76,042,437)
 
     76,042,437  
    
 
 
 
Total Investments Before Options Written — 100.6%
(Cost: $1,423,832,621)
 
     1,639,295,879  
    
 
 
 
Options Written — (0.9)%
(Premiums Received: $(21,781,553))
 
     (13,840,189
    
 
 
 
Total Investments, Net of Options Written — 99.7%
(Cost: $1,402,051,068)
 
     1,625,455,690  
Other Assets Less Liabilities — 0.3%
 
     4,185,877  
    
 
 
 
Net Assets — 100.0%
     $ 1,629,641,567  
    
 
 
 
 
(a)
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(b)
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(c)
Non-income producing security.
(d)
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.
(e)
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(f)
Investment does not issue shares.
(g)
Affiliate of the Trust.
(h)
Annualized 7-day yield as of period end.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
  
Value at
12/31/21
    
Purchases
at Cost
   
Proceeds
from Sales
    
Net
Realized
Gain (Loss)
    
Change in
Unrealized
Appreciation
(Depreciation)
    
Value at
12/31/22
    
Shares
Held at
12/31/22
    
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
   $ 62,262,015      $ 13,780,422
(a)
 
  $      $      $      $ 76,042,437        76,042,437      $ 1,115,866     $  
SL Liquidity Series, LLC, Money Market Series
(b)
            3
(a)
 
           (3                           33
(c)
 
  $  
          
 
 
    
 
 
    
 
 
       
 
 
   
 
 
 
           $ (3    $      $ 76,042,437         $ 1,115,899     $  
          
 
 
    
 
 
    
 
 
       
 
 
   
 
 
 
 
 
(a)
Represents net amount purchased (sold).
 
 
(b)
 
As of period end, the entity is no longer held.
 
 
(c)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
 
 
56
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call                                                   
Fortive Corp.
     223          01/05/23        USD     65.00        USD     1,433        $ (12,822)  
Alphabet, Inc., Class A
     88          01/06/23        USD     99.00        USD     776          (220)  
American International Group, Inc.
     358          01/06/23        USD     62.00        USD     2,264          (58,175)  
American International Group, Inc.
     583          01/06/23        USD     64.00        USD     3,687          (27,692)  
Capital One Financial Corp.
     3          01/06/23        USD     105.00        USD     28          (15)  
Cardinal Health, Inc.
     598          01/06/23        USD     81.00        USD     4,597          (8,970)  
Charles Schwab Corp.
     537          01/06/23        USD     85.00        USD     4,471          (23,628)  
Cigna Corp.
     90          01/06/23        USD     325.00        USD     2,982          (72,900)  
Cisco Systems, Inc.
     1,354          01/06/23        USD     49.00        USD     6,450          (8,124)  
Citigroup, Inc.
     643          01/06/23        USD     50.00        USD     2,908          (965)  
Comcast Corp., Class A
     445          01/06/23        USD     37.00        USD     1,556          (1,780)  
Elevance Health, Inc.
     97          01/06/23        USD     520.00        USD     4,976          (30,070)  
Enterprise Products Partners LP
     1,244          01/06/23        USD     25.00        USD     3,001          (2,488)  
EQT Corp.
     810          01/06/23        USD     46.00        USD     2,740          (60,750)  
General Motors Co.
     1,344          01/06/23        USD     42.00        USD     4,521          (2,688)  
Hess Corp.
     95          01/06/23        USD     148.00        USD     1,347          (7,363)  
Kraft Heinz Co.
     1,306          01/06/23        USD     40.00        USD     5,317          (115,581)  
Medtronic PLC
     638          01/06/23        USD     80.00        USD     4,959          (12,760)  
Microsoft Corp.
     294          01/06/23        USD     260.00        USD     7,051          (2,646)  
Mondelez International, Inc., Class A
     263          01/06/23        USD     67.00        USD     1,753          (11,178)  
Ross Stores, Inc.
     234          01/06/23        USD     120.00        USD     2,716          (10,530)  
Union Pacific Corp.
     88          01/06/23        USD     220.00        USD     1,822          (1,100)  
Verizon Communications, Inc.
     580          01/06/23        USD     39.00        USD     2,285          (42,630)  
Visa, Inc., Class A
     124          01/06/23        USD     220.00        USD     2,576          (1,116)  
Walmart, Inc.
     518          01/06/23        USD     152.50        USD     7,345          (777)  
Wells Fargo & Co.
     1,795          01/06/23        USD     48.00        USD     7,412          (3,590)  
Visa, Inc., Class A
     48          01/10/23        USD     216.00        USD     997          (4,548)  
Alphabet, Inc., Class A
     88          01/13/23        USD     100.00        USD     776          (836)  
American International Group, Inc.
     938          01/13/23        USD     64.00        USD     5,932          (91,455)  
AmerisourceBergen Corp.
     76          01/13/23        USD     175.00        USD     1,259          (9,120)  
AT&T, Inc.
     1,187          01/13/23        USD     19.50        USD     2,185          (2,374)  
Bank of America Corp.
     1,591          01/13/23        USD     34.00        USD     5,269          (84,323)  
Baxter International, Inc.
     1,270          01/13/23        USD     55.00        USD     6,473          (15,875)  
Capital One Financial Corp.
     38          01/13/23        USD     99.00        USD     353          (2,945)  
Charles Schwab Corp.
     75          01/13/23        USD     81.00        USD     624          (24,937)  
Charles Schwab Corp.
     75          01/13/23        USD     83.00        USD     624          (15,263)  
Cisco Systems, Inc.
     663          01/13/23        USD     50.00        USD     3,159          (6,962)  
Comcast Corp., Class A
     1,010          01/13/23        USD     36.00        USD     3,532          (36,865)  
Constellation Brands, Inc., Class A
     169          01/13/23        USD     260.00        USD     3,917          (6,760)  
Dollar General Corp.
     200          01/13/23        USD     250.00        USD     4,925          (65,000)  
Elevance Health, Inc.
     124          01/13/23        USD     530.00        USD     6,361          (33,790)  
Enterprise Products Partners LP
     1,921          01/13/23        USD     24.50        USD     4,633          (46,104)  
EQT Corp.
     810          01/13/23        USD     46.00        USD     2,740          (12,150)  
General Motors Co.
     954          01/13/23        USD     43.00        USD     3,209          (1,908)  
Hess Corp.
     96          01/13/23        USD     148.00        USD     1,361          (18,720)  
Humana, Inc.
     100          01/13/23        USD     560.00        USD     5,122          (15,000)  
JPMorgan Chase & Co.
     473          01/13/23        USD     136.00        USD     6,343          (96,019)  
Kraft Heinz Co.
     487          01/13/23        USD     40.00        USD     1,983          (54,057)  
Leidos Holdings, Inc.
     362          01/13/23        USD     108.75        USD     3,808          (30,790)  
Medtronic PLC
     1,136          01/13/23        USD     79.00        USD     8,829            (117,008)  
Microsoft Corp.
     175          01/13/23        USD     250.00        USD     4,197          (37,275)  
Mondelez International, Inc., Class A
     272          01/13/23        USD     68.00        USD     1,813          (10,880)  
Verizon Communications, Inc.
     580          01/13/23        USD     39.00        USD     2,285          (44,950)  
Visa, Inc., Class A
     67          01/13/23        USD     215.00        USD     1,392          (9,916)  
Visa, Inc., Class A
     66          01/13/23        USD     220.00        USD     1,371          (4,026)  
Walmart, Inc.
     353          01/13/23        USD     149.00        USD     5,005          (8,649)  
Wells Fargo & Co.
     808          01/13/23        USD     45.00        USD     3,336          (8,888)  
Allstate Corp.
     223          01/20/23        USD     135.00        USD     3,024          (76,935)  
Alphabet, Inc., Class A
     87          01/20/23        USD     100.00        USD     768          (1,697)  
Altria Group, Inc.
     700          01/20/23        USD     47.50        USD     3,200          (16,800)  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  57

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
American Electric Power Co., Inc.
     357          01/20/23        USD     95.00        USD     3,390        $       (69,615)  
American International Group, Inc.
     1,177          01/20/23        USD     62.50        USD     7,443          (241,285)  
AmerisourceBergen Corp.
     129          01/20/23        USD     160.00        USD     2,138          (99,975)  
Apollo Global Management, Inc.
     206          01/20/23        USD     65.00        USD     1,314          (34,505)  
AT&T, Inc.
     1,187          01/20/23        USD     20.00        USD     2,185          (2,374)  
Bank of America Corp.
     518          01/20/23        USD     40.00        USD     1,716          (1,295)  
Bank of America Corp.
     271          01/20/23        USD     34.00        USD     898          (18,157)  
Baxter International, Inc.
     480          01/20/23        USD     57.50        USD     2,447          (4,800)  
British American Tobacco PLC, ADR
     350          01/20/23        USD     42.07        USD     1,399          (3,614)  
Cardinal Health, Inc.
     597          01/20/23        USD     80.00        USD     4,589          (43,282)  
Cigna Corp.
     178          01/20/23        USD     320.00        USD     5,898            (267,890)  
Cisco Systems, Inc.
     956          01/20/23        USD     50.00        USD     4,554          (16,730)  
Citigroup, Inc.
     1,467          01/20/23        USD     50.00        USD     6,635          (27,873)  
Citizens Financial Group, Inc.
     140          01/20/23        USD     42.50        USD     551          (3,500)  
Citizens Financial Group, Inc.
     511          01/20/23        USD     40.00        USD     2,012          (51,100)  
Cognizant Technology Solutions Corp., Class A
     1,802          01/20/23        USD     65.00        USD     10,306          (13,515)  
Comcast Corp., Class A
     1,665          01/20/23        USD     35.00        USD     5,823          (151,515)  
Comcast Corp., Class A
     1,034          01/20/23        USD     35.50        USD     3,616          (71,863)  
ConocoPhillips
     355          01/20/23        USD     130.00        USD     4,189          (20,945)  
Constellation Brands, Inc., Class A
     184          01/20/23        USD     240.00        USD     4,264          (48,300)  
Edison International
     238          01/20/23        USD     67.50        USD     1,514          (7,140)  
Eli Lilly & Co.
     50          01/20/23        USD     370.00        USD     1,829          (37,000)  
Enterprise Products Partners LP
     1,244          01/20/23        USD     25.00        USD     3,001          (18,660)  
Enterprise Products Partners LP
     678          01/20/23        USD     24.00        USD     1,635          (38,985)  
EQT Corp.
     810          01/20/23        USD     46.00        USD     2,740          (12,150)  
Equitable Holdings, Inc.
     434          01/20/23        USD     31.85        USD     1,246          (2,239)  
Exelon Corp.
     354          01/20/23        USD     40.00        USD     1,530          (122,130)  
Fidelity National Financial, Inc.
     1,032          01/20/23        USD     38.00        USD     3,882          (79,981)  
First Citizens BancShares, Inc., Class A.
     152          01/20/23        USD     860.00        USD     11,527          (152,000)  
Fortive Corp.
     188          01/20/23        USD     65.00        USD     1,208          (23,030)  
Fox Corp., Class A
     1,546          01/20/23        USD     33.00        USD     4,695          (19,325)  
General Motors Co.
     654          01/20/23        USD     41.00        USD     2,200          (2,616)  
Hess Corp.
     234          01/20/23        USD     145.00        USD     3,319          (94,770)  
Humana, Inc.
     50          01/20/23        USD     530.00        USD     2,561          (28,250)  
Humana, Inc.
     49          01/20/23        USD     520.00        USD     2,510          (44,345)  
JPMorgan Chase & Co.
     906          01/20/23        USD     135.00        USD     12,149          (275,877)  
Kraft Heinz Co.
     800          01/20/23        USD     40.00        USD     3,257          (98,800)  
Laboratory Corp. of America Holdings
     305          01/20/23        USD     240.00        USD     7,182          (125,050)  
Lear Corp.
     174          01/20/23        USD     135.00        USD     2,158          (30,450)  
Leidos Holdings, Inc.
     316          01/20/23        USD     108.34        USD     3,324          (45,215)  
Medtronic PLC
     638          01/20/23        USD     80.00        USD     4,959          (59,972)  
Microsoft Corp.
     66          01/20/23        USD     240.00        USD     1,583          (47,520)  
Microsoft Corp.
     137          01/20/23        USD     260.00        USD     3,286          (13,289)  
Newell Brands, Inc.
     2,390          01/20/23        USD     14.00        USD     3,126          (35,850)  
Novo Nordisk A/S, ADR
     242          01/20/23        USD     110.00        USD     3,275          (618,310)  
Public Service Enterprise Group, Inc.
     412          01/20/23        USD     57.79        USD     2,524          (157,229)  
Ralph Lauren Corp.
     308          01/20/23        USD     105.00        USD     3,255          (132,440)  
Raymond James Financial, Inc.
     244          01/20/23        USD     115.00        USD     2,607          (7,930)  
Robert Half International, Inc.
     235          01/20/23        USD     79.52        USD     1,735          (6,439)  
Rogers Communications, Inc., Class B
     1,206          01/20/23        CAD     60.00        CAD     7,642          (345,144)  
Ross Stores, Inc.
     234          01/20/23        USD     120.00        USD     2,716          (43,290)  
Sealed Air Corp.
     778          01/20/23        USD     52.00        USD     3,881          (59,861)  
Sempra Energy
     290          01/20/23        USD     160.00        USD     4,482          (37,700)  
SS&C Technologies Holdings, Inc.
     1,050          01/20/23        USD     55.00        USD     5,466          (39,375)  
Unilever PLC, ADR
     1,988          01/20/23        USD     49.00        USD     10,010          (362,810)  
Union Pacific Corp.
     88          01/20/23        USD     220.00        USD     1,822          (7,700)  
Verizon Communications, Inc.
     580          01/20/23        USD     39.00        USD     2,285          (49,010)  
Visa, Inc., Class A
     52          01/20/23        USD     215.00        USD     1,080          (11,180)  
Wells Fargo & Co.
     1,957          01/20/23        USD     47.50        USD     8,080          (8,807)  
Willis Towers Watson PLC
     322          01/20/23        USD     240.00        USD     7,875          (264,040)  
Zimmer Biomet Holdings, Inc.
     365          01/20/23        USD     125.00        USD     4,654          (169,725)  
Alphabet, Inc., Class A
     132          01/27/23        USD     99.00        USD     1,165          (5,676)  
 
 
58
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Amazon.com, Inc.
     204          01/27/23        USD     93.00        USD     1,714        $       (21,012)  
American International Group, Inc.
     375          01/27/23        USD     64.00        USD     2,372          (60,937)  
AmerisourceBergen Corp.
     129          01/27/23        USD     170.00        USD     2,138          (36,765)  
Bank of America Corp.
     790          01/27/23        USD     34.00        USD     2,616          (61,620)  
Cigna Corp.
     177          01/27/23        USD     340.00        USD     5,865          (90,270)  
Cisco Systems, Inc.
     877          01/27/23        USD     51.00        USD     4,178          (19,732)  
Citigroup, Inc.
     1,345          01/27/23        USD     48.00        USD     6,083          (87,425)  
Comcast Corp., Class A
     1,035          01/27/23        USD     36.00        USD     3,619          (85,387)  
Constellation Brands, Inc., Class A
     48          01/27/23        USD     255.00        USD     1,112          (4,320)  
Dollar General Corp.
     131          01/27/23        USD     245.00        USD     3,226          (104,800)  
Edison International
     496          01/27/23        USD     65.55        USD     3,156          (41,934)  
Elevance Health, Inc.
     66          01/27/23        USD     505.00        USD     3,386          (142,230)  
Eli Lilly & Co.
     49          01/27/23        USD     370.00        USD     1,793          (42,385)  
Enterprise Products Partners LP
     1,921          01/27/23        USD     24.50        USD     4,633          (77,800)  
Fox Corp., Class A
     792          01/27/23        USD     30.00        USD     2,405          (95,040)  
General Motors Co.
     559          01/27/23        USD     36.00        USD     1,880          (35,496)  
Humana, Inc.
     59          01/27/23        USD     525.00        USD     3,022          (44,545)  
JPMorgan Chase & Co.
     356          01/27/23        USD     136.00        USD     4,774          (109,470)  
Kraft Heinz Co.
     1,124          01/27/23        USD     42.00        USD     4,576          (44,398)  
Medtronic PLC
     677          01/27/23        USD     78.00        USD     5,262          (140,477)  
Ross Stores, Inc.
     368          01/27/23        USD     122.00        USD     4,271          (59,800)  
Citizens Financial Group, Inc.
     512          01/31/23        USD     39.50        USD     2,016          (66,506)  
Fox Corp., Class A
     791          01/31/23        USD     31.00        USD     2,402          (74,379)  
Amazon.com, Inc.
     203          02/03/23        USD     88.00        USD     1,705          (75,110)  
Capital One Financial Corp.
     202          02/03/23        USD     94.00        USD     1,878          (90,900)  
Enterprise Products Partners LP
     2,037          02/03/23        USD     24.29        USD     4,913          (104,633)  
Public Service Enterprise Group, Inc.
     602          02/06/23        USD     59.00        USD     3,688          (195,642)  
General Motors Co.
     559          02/10/23        USD     36.00        USD     1,880          (60,931)  
Sealed Air Corp.
     746          02/10/23        USD     53.00        USD     3,721          (78,116)  
Allstate Corp.
     229          02/17/23        USD     135.00        USD     3,105          (135,110)  
Altria Group, Inc.
     300          02/17/23        USD     47.50        USD     1,371          (23,550)  
American Electric Power Co., Inc.
     163          02/17/23        USD     100.00        USD     1,548          (17,522)  
Apollo Global Management, Inc.
     581          02/17/23        USD     67.50        USD     3,706          (127,820)  
Baxter International, Inc.
     550          02/17/23        USD     57.50        USD     2,803          (24,750)  
British American Tobacco PLC, ADR
     350          02/17/23        USD     42.07        USD     1,399          (14,774)  
Citigroup, Inc.
     378          02/17/23        USD     47.50        USD     1,710          (44,604)  
Citizens Financial Group, Inc.
     512          02/17/23        USD     40.00        USD     2,016          (76,800)  
Cognizant Technology Solutions Corp., Class A
     1,566          02/17/23        USD     65.25        USD     8,956          (73,741)  
Cognizant Technology Solutions Corp., Class A
     208          02/17/23        USD     62.00        USD     1,190          (22,091)  
Dollar General Corp.
     120          02/17/23        USD     260.00        USD     2,955          (47,400)  
Equitable Holdings, Inc.
     543          02/17/23        USD     30.00        USD     1,558          (59,730)  
Exelon Corp.
     367          02/17/23        USD     44.33        USD     1,587          (40,652)  
Fidelity National Financial, Inc.
     1,032          02/17/23        USD     38.10        USD     3,882          (215,209)  
Fidelity National Information Services, Inc.
     289          02/17/23        USD     80.00        USD     1,961          (21,675)  
Hess Corp.
     201          02/17/23        USD     150.00        USD     2,851          (116,580)  
L3Harris Technologies, Inc.
     428          02/17/23        USD     230.00        USD     8,911          (77,040)  
Laboratory Corp. of America Holdings
     305          02/17/23        USD     240.00        USD     7,182          (259,250)  
Leidos Holdings, Inc.
     474          02/17/23        USD     110.00        USD     4,986          (98,355)  
Newell Brands, Inc.
     2,389          02/17/23        USD     14.52        USD     3,125          (81,501)  
Novo Nordisk A/S, ADR
     109          02/17/23        USD     140.00        USD     1,475          (38,150)  
Public Service Enterprise Group, Inc.
     780          02/17/23        USD     60.00        USD     4,779          (234,000)  
Ralph Lauren Corp.
     255          02/17/23        USD     119.34        USD     2,695          (60,325)  
Raymond James Financial, Inc.
     244          02/17/23        USD     115.00        USD     2,607          (44,530)  
Robert Half International, Inc.
     200          02/17/23        USD     80.00        USD     1,477          (30,000)  
Rogers Communications, Inc., Class B
     108          02/17/23        CAD     64.00        CAD     684          (17,109)  
Sempra Energy
     82          02/17/23        USD     165.00        USD     1,267          (13,325)  
SS&C Technologies Holdings, Inc.
     83          02/17/23        USD     55.00        USD     432          (11,205)  
SS&C Technologies Holdings, Inc.
     1,050          02/17/23        USD     55.50        USD     5,466          (109,346)  
Unilever PLC, ADR
     1,988          02/17/23        USD     52.50        USD     10,010          (144,130)  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  59

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Visa, Inc., Class A
     99          02/17/23        USD     220.00        USD     2,057        $ (40,590
Zimmer Biomet Holdings, Inc.
     285          02/17/23        USD     129.50        USD     3,634          (125,899
                          
 
 
 
                           $  (11,065,649
                          
 
 
 
OTC Options Written
 
 
 
Description
 
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
 
 
Call
               
BAE Systems PLC
  Morgan Stanley & Co. International PLC     522,000       01/05/23       GBP       7.86       GBP       4,468     $ (441,826
Koninklijke Philips NV
  Morgan Stanley & Co. International PLC     121,200       01/05/23       EUR       15.01       EUR       1,697       (1,901
Panasonic Holdings Corp.
  Morgan Stanley & Co. International PLC     261,500       01/05/23       JPY       1,373.40       JPY       290,396       (9
Samsung Electronics Co. Ltd., GDR, Registered Shares
  Morgan Stanley & Co. International PLC     2,900       01/05/23       USD       1,181.96       USD       3,205       (3,163
Shell PLC, ADR
  Morgan Stanley & Co. International PLC     127,000       01/05/23       GBP       24.59       GBP       2,954       (1,322
BP PLC
  Morgan Stanley & Co. International PLC     1,527,000       01/10/23       GBP       4.89       GBP       7,252       (61,197
Airbus SE
  Morgan Stanley & Co. International PLC     41,800       01/11/23       EUR       111.91       EUR       4,641       (78,678
Koninklijke Philips NV
  JPMorgan Chase Bank N.A.     217,800       01/11/23       EUR       15.21       EUR       3,050       (8,561
Prudential PLC
  Goldman Sachs International     123,000       01/11/23       GBP       10.48       GBP       1,387       (126,127
Sanofi
  Goldman Sachs International     78,400       01/11/23       EUR       89.95       EUR       7,043       (105,446
Siemens AG, Registered Shares
  Goldman Sachs International     71,300       01/11/23       EUR       138.40       EUR       9,243       (6,871
Zimmer Biomet Holdings, Inc.
  Bank of America N.A.     36,500       01/11/23       USD       124.54       USD       4,654       (153,202
AstraZeneca PLC
  Goldman Sachs International     96,300       01/13/23       GBP       114.17       GBP       10,803       (92,900
Bayer AG, Registered Shares
  Morgan Stanley & Co. International PLC     75,900       01/13/23       EUR       53.55       EUR       3,668       (3,961
Panasonic Holdings Corp.
  Societe Generale     261,500       01/13/23       JPY       1,373.40       JPY       290,396       (963
Shell PLC, ADR
  Morgan Stanley & Co. International PLC     213,800       01/13/23       GBP       24.31       GBP       4,973       (27,186
Komatsu Ltd.
  UBS AG     160,000       01/17/23       JPY       3,172.87       JPY       460,160       (3,784
Panasonic Holdings Corp.
  UBS AG     106,000       01/17/23       JPY       1,262.60       JPY       117,713       (499
Komatsu Ltd.
  UBS AG     160,000       01/25/23       JPY       3,203.67       JPY       460,160       (6,423
Samsung Electronics Co. Ltd., GDR, Registered Shares
  Morgan Stanley & Co. International PLC     1,750       01/25/23       USD       1,199.78       USD       1,934       (17,189
Zimmer Biomet Holdings, Inc.
  Bank of America N.A.     36,500       01/25/23       USD       125.76       USD       4,654       (166,429
Sanofi
  Goldman Sachs International     69,300       01/27/23       EUR       89.66       EUR       6,226       (162,271
Fidelity National Information Services, Inc.
  Barclays Bank PLC     85,600       01/30/23       USD       77.97       USD       5,808       (43,753
Airbus SE
  UBS AG     21,400       01/31/23       EUR       114.76       EUR       2,376       (42,410
Apollo Global Management, Inc
  Goldman Sachs International     58,000       01/31/23       USD       66.66       USD       3,700       (83,651
BAE Systems PLC
  UBS AG     356,000       01/31/23       GBP       8.77       GBP       3,047       (67,523
Panasonic Holdings Corp
  JPMorgan Chase Bank N.A.     211,300       01/31/23       JPY       1,257.21       JPY       234,649       (4,961
Willis Towers Watson PLC
  Barclays Bank PLC     27,400       01/31/23       USD       251.44       USD       6,701       (105,994
Samsung Electronics Co. Ltd., GDR, Registered
               
Shares
  Morgan Stanley & Co. International PLC     1,750       02/01/23       USD       1,199.78       USD       1,934       (23,545
AstraZeneca PLC
  Morgan Stanley & Co. International PLC     25,200       02/02/23       GBP       114.69       GBP       2,827       (51,940
Bayer AG, Registered Shares
  Goldman Sachs International     22,000       02/02/23       EUR       50.34       EUR       1,063       (18,629
Willis Towers Watson PLC
  JPMorgan Chase Bank N.A.     24,900       02/06/23       USD       238.50       USD       6,090       (287,896
Bayer AG, Registered Shares
  Morgan Stanley & Co. International PLC     149,300       02/08/23       EUR       53.68       EUR       7,215       (50,258
BP PLC
  Morgan Stanley & Co. International PLC     1,667,000       02/08/23       GBP       4.91       GBP       7,917       (236,699
Koninklijke Philips NV
  JPMorgan Chase Bank N.A.     137,200       02/08/23       EUR       14.62       EUR       1,921       (69,616
Prudential PLC
  Goldman Sachs International     281,900       02/08/23       GBP       11.45       GBP       3,178       (146,927
Fidelity National Information Services, Inc.
  Barclays Bank PLC     85,600       02/10/23       USD       77.97       USD       5,808       (70,830
               
 
 
 
                $   (2,774,540
               
 
 
 
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
 
 
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
 
 
Options Written
   $ N/A      $ N/A      $ 10,610,806      $ (2,669,442    $  (13,840,189)  
 
 
60
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
 
 
 
   
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
 
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $ 13,840,189     $     $     $     $  13,840,189  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
 
 
 
   
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
 
 
Net Realized Gain (Loss) from:
             
Options purchased
(a)
  $     $     $  (11,959,671   $     $     $     $  (11,959,671
Options written
                14,771,308                         14,771,308  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $     $     $ 2,811,637     $     $     $     $ 2,811,637  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
             
Options written
  $     $     $ 9,784,869     $     $     $     $ 9,784,869  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
 
 
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 16,239,995  
 
 
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
    
Liabilities
 
Derivative Financial Instruments
     
Options
   $      $ 13,840,189  
  
 
 
    
 
 
 
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities
            13,840,189  
  
 
 
    
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
            (11,065,649
  
 
 
    
 
 
 
Total derivative assets and liabilities subject to an MNA
   $      $ 2,774,540  
  
 
 
    
 
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  61

Consolidated Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    
 

Derivatives
Available
for Offset
 
 
 
    
 

Non-Cash
Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
    
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Bank of America N.A
   $ 319,631        $        $ (319,631    $        $  
Barclays Bank PLC
     220,577                   (220,577                
Goldman Sachs International
     742,822                   (742,822                
JPMorgan Chase Bank N.A
     371,034                   (371,034                
Morgan Stanley & Co. International PLC
     998,874                   (998,874                
Societe Generale
     963                   (963                
UBS AG
     120,639                   (96,076               24,563  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
   $ 2,774,540        $        $  (2,749,977)      $        $ 24,563  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Aerospace & Defense
   $ 15,827,500        $ 30,133,054        $        $    45,960,554  
Auto Components
     8,030,295                            8,030,295  
Automobiles
     34,235,899                            34,235,899  
Banks
     184,954,465                            184,954,465  
Beverages
     16,905,931                            16,905,931  
Capital Markets
     19,908,204                            19,908,204  
Chemicals
     17,439,258                            17,439,258  
Communications Equipment
     32,881,128                            32,881,128  
Consumer Finance
     4,117,105                            4,117,105  
Containers & Packaging
     17,487,030                            17,487,030  
Diversified Financial Services
     20,958,165                            20,958,165  
Diversified Telecommunication Services
     24,392,088                            24,392,088  
Electric Utilities
     22,730,790                            22,730,790  
Entertainment
     12,251,521                            12,251,521  
Food & Staples Retailing
     16,514,281                            16,514,281  
Food Products
     34,005,528                            34,005,528  
Health Care Equipment & Supplies
     91,973,887          14,034,968                   106,008,855  
Health Care Providers & Services
     143,561,407                            143,561,407  
Household Durables
     10,615,283          12,787,024                   23,402,307  
Industrial Conglomerates
              13,154,037                   13,154,037  
Insurance
     99,932,543             11,791,865                      111,724,408  
Interactive Media & Services
     6,056,548                            6,056,548  
Internet & Direct Marketing Retail
     6,218,184                            6,218,184  
IT Services
       115,719,488                            115,719,488  
Machinery
     4,802,945          12,559,961                   17,362,906  
Media
     49,376,510                            49,376,510  
Multiline Retail
     20,198,903                            20,198,903  
Multi-Utilities
     30,447,119                            30,447,119  
Oil, Gas & Consumable Fuels
     76,161,383          59,551,560          11,435,463          147,148,406  
Personal Products
     31,983,226                            31,983,226  
Pharmaceuticals
     17,442,549          83,334,106                   100,776,655  
 
 
62
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Equity Dividend Trust (BDJ)
    
 
Fair Value Hierarchy as of Period End (continued)
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Common Stocks (continued)
                 
Professional Services
   $ 26,589,230        $        $        $ 26,589,230  
Road & Rail
     6,630,589                            6,630,589  
Software
     27,467,784                            27,467,784  
Specialty Retail
     13,493,718                            13,493,718  
Technology Hardware, Storage & Peripherals
              17,893,921                   17,893,921  
Textiles, Apparel & Luxury Goods
     10,820,925                            10,820,925  
Tobacco
     13,395,544                            13,395,544  
Wireless Telecommunication Services
     11,050,530                            11,050,530  
Short-Term Securities
                 
Money Market Funds
     76,042,437                            76,042,437  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $  1,372,619,920        $  255,240,496        $  11,435,463        $  1,639,295,879  
  
 
 
      
 
 
      
 
 
      
 
 
 
Derivative Financial Instruments
(a)
                 
Liabilities
                 
Equity Contracts
   $ (9,358,163      $ (4,482,026      $        $ (13,840,189
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  63

Schedule of Investments  
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Common Stocks
   
Canada — 2.2%
           
TELUS Corp.
    792,734     $ 15,298,478  
   
 
 
 
Denmark — 2.1%
           
Novo Nordisk A/S, Class B
    105,861       14,377,571  
   
 
 
 
France — 11.5%
           
Air Liquide SA
    79,016       11,215,158  
EssilorLuxottica SA
    54,412       9,844,924  
Kering SA
    30,878       15,714,663  
LVMH Moet Hennessy Louis Vuitton SE
    9,512       6,921,810  
Sanofi
    220,925       21,303,031  
Schneider Electric SE
    99,823       14,018,601  
   
 
 
 
          79,018,187  
India — 0.1%
           
Jasper Infotech Private Ltd., Series I, (Acquired 08/31/18, Cost: $2,637,143)
(a)(b)
    566,400       505,741  
   
 
 
 
Indonesia — 1.0%
           
Bank Rakyat Indonesia Persero Tbk PT
    22,422,100       7,108,929  
   
 
 
 
Ireland
(c)
— 4.3%
           
Accenture PLC, Class A
    59,299       15,823,345  
Medtronic PLC
    182,236       14,163,382  
   
 
 
 
      29,986,727  
Japan — 1.5%
           
KDDI Corp.
    352,200       10,681,129  
   
 
 
 
Mexico — 1.8%
           
Wal-Mart de Mexico SAB de CV
    3,446,031       12,129,591  
   
 
 
 
Netherlands — 1.4%
           
Koninklijke KPN NV
    3,096,591       9,584,736  
   
 
 
 
Portugal — 1.7%
           
EDP - Energias de Portugal SA
    2,315,427       11,541,952  
   
 
 
 
Singapore — 1.5%
           
DBS Group Holdings Ltd.
    405,168       10,255,452  
   
 
 
 
Spain — 2.7%
           
Industria de Diseno Textil SA
    697,885       18,536,547  
   
 
 
 
Sweden — 2.0%
           
Epiroc AB, Class A
    768,133       13,987,015  
   
 
 
 
Switzerland — 6.2%
           
Lonza Group AG, Registered Shares
    26,531       13,023,415  
TE Connectivity Ltd.
(c)
    129,478       14,864,075  
Zurich Insurance Group AG
    31,721       15,165,087  
   
 
 
 
      43,052,577  
Taiwan — 4.2%
           
MediaTek, Inc.
    560,000       11,322,597  
Taiwan Semiconductor Manufacturing Co. Ltd.
    1,200,000       17,428,151  
   
 
 
 
      28,750,748  
United Kingdom — 17.2%
           
AstraZeneca PLC
    150,668       20,388,296  
Diageo PLC
    322,878       14,132,969  
Ferguson PLC
    125,838       15,798,182  
Prudential PLC
    1,361,788       18,568,371  
Security
 
Shares
    
Value
 
United Kingdom (continued)
            
Reckitt Benckiser Group PLC
    301,550      $ 20,902,336  
RELX PLC
    528,663        14,644,519  
Taylor Wimpey PLC
    11,467,215        14,043,874  
    
 
 
 
       118,478,547  
United States
(c)
— 37.5%
            
AbbVie, Inc.
(d)
    116,053        18,755,338  
Assurant, Inc.
    89,581        11,203,000  
Baker Hughes Co.
(d)
    337,789        9,974,909  
Chevron Corp.
    37,667        6,760,850  
Citizens Financial Group, Inc.
    454,614        17,898,153  
Estee Lauder Cos., Inc., Class A
    34,655        8,598,252  
Intercontinental Exchange, Inc.
    168,744        17,311,447  
International Flavors & Fragrances, Inc.
    73,744        7,731,321  
Intuit, Inc.
    45,078        17,545,259  
M&T Bank Corp.
    79,314        11,505,289  
Microsoft Corp.
(d)
    96,423        23,124,164  
Otis Worldwide Corp.
    200,423        15,695,125  
Paychex, Inc.
    116,371        13,447,833  
Philip Morris International, Inc.
(d)
    189,817        19,211,378  
Synchrony Financial
(d)
    303,546        9,974,521  
United Parcel Service, Inc., Class B
(d)
    81,795        14,219,243  
UnitedHealth Group, Inc.
(d)
    26,643        14,125,586  
Visa, Inc., Class A
    64,863        13,475,937  
Williams Cos., Inc.
    226,242        7,443,362  
    
 
 
 
       258,000,967  
    
 
 
 
Total Long-Term Investments — 98.9%
(Cost: $647,598,133)
       681,294,894  
    
 
 
 
Short-Term Securities
 
Money Market Funds — 1.0%
 
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(e)(f)
    6,643,752        6,643,752  
    
 
 
 
Total Short-Term Securities — 1.0%
(Cost: $6,643,752)
       6,643,752  
    
 
 
 
Total Investments Before Options Written — 99.9%
(Cost: $654,241,885)
       687,938,646  
    
 
 
 
Options Written — (0.6)%
            
(Premiums Received: $(7,666,872))
       (4,281,155
    
 
 
 
Total Investments, Net of Options Written — 99.3%
(Cost: $646,575,013)
       683,657,491  
Other Assets Less Liabilities — 0.7%
       4,806,394  
    
 
 
 
Net Assets — 100.0%
     $  688,463,885  
    
 
 
 
 
(a)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(b)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $505,741, representing 0.1% of its net assets as of period end, and an original cost of $2,637,143.
(c)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(d)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(e)
 
Affiliate of the Trust.
(f)
 
Annualized 7-day yield as of period end.
 
 
64
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $ 11,262,594     $     $ (4,618,842 )
(a)
 
  $     $     $ 6,643,752       6,643,752     $ 98,337     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call                                                   
AbbVie, Inc.
     268          01/06/23        USD     160.00        USD     4,331        $ (73,834
Chevron Corp.
     65          01/06/23        USD     180.00        USD     1,167          (15,340
Medtronic PLC
     282          01/06/23        USD     80.00        USD     2,192          (5,640
Microsoft Corp.
     125          01/06/23        USD     260.00        USD     2,998          (1,125
Philip Morris International, Inc.
     539          01/06/23        USD     100.00        USD     5,455          (95,672
Synchrony Financial
     31          01/06/23        USD     36.00        USD     102          (2,325
United Parcel Service, Inc., Class B
     205          01/06/23        USD     190.00        USD     3,564          (3,485
UnitedHealth Group, Inc.
     7          01/06/23        USD     550.00        USD     371          (350
Visa, Inc., Class A
     2          01/06/23        USD     220.00        USD     42          (18
Williams Cos., Inc.
     159          01/06/23        USD     34.00        USD     523          (1,590
Williams Cos., Inc.
     218          01/06/23        USD     35.00        USD     717          (2,180
Baker Hughes Co.
     478          01/10/23        USD     31.05        USD     1,412          (11,981
Otis Worldwide Corp.
     670          01/10/23        USD     79.25        USD     5,247          (58,512
Visa, Inc., Class A
     74          01/10/23        USD     216.00        USD     1,537          (7,012
Chevron Corp.
     65          01/13/23        USD     180.00        USD     1,167          (25,025
Intuit, Inc.
     52          01/13/23        USD     430.00        USD     2,024          (7,800
Microsoft Corp.
     168          01/13/23        USD     250.00        USD     4,029          (35,784
Philip Morris International, Inc.
     315          01/13/23        USD     105.00        USD     3,188          (8,663
Synchrony Financial
     682          01/13/23        USD     37.00        USD     2,241          (10,230
United Parcel Service, Inc., Class B
     163          01/13/23        USD     180.00        USD     2,834          (21,597
UnitedHealth Group, Inc.
     99          01/13/23        USD     555.00        USD     5,249          (21,433
Visa, Inc., Class A
     11          01/13/23        USD     215.00        USD     229          (1,628
Visa, Inc., Class A
     10          01/13/23        USD     220.00        USD     208          (610
Williams Cos., Inc.
     160          01/13/23        USD     34.00        USD     526          (4,000
Williams Cos., Inc.
     218          01/13/23        USD     35.00        USD     717          (1,635
AbbVie, Inc.
     29          01/20/23        USD     160.00        USD     469          (11,600
Accenture PLC, Class A
     155          01/20/23        USD     295.00        USD     4,136          (6,975
Assurant, Inc.
     145          01/20/23        USD     130.00        USD     1,813          (17,038
Baker Hughes Co.
     215          01/20/23        USD     32.00        USD     635          (5,913
Baker Hughes Co.
     490          01/20/23        USD     29.00        USD     1,447          (69,825
Citizens Financial Group, Inc.
     1,162          01/20/23        USD     42.50        USD     4,575          (29,050
Citizens Financial Group, Inc.
     294          01/20/23        USD     40.00        USD     1,157          (29,400
Estee Lauder Cos., Inc., Class A
     32          01/20/23        USD     220.00        USD     794          (94,400
Estee Lauder Cos., Inc., Class A
     28          01/20/23        USD     240.00        USD     695          (37,240
Intercontinental Exchange, Inc.
     567          01/20/23        USD     105.00        USD     5,817          (82,215
International Flavors & Fragrances, Inc.
     265          01/20/23        USD     105.00        USD     2,778          (73,537
Intuit, Inc.
     68          01/20/23        USD     420.00        USD     2,647          (28,900
M&T Bank Corp.
     153          01/20/23        USD     175.00        USD     2,219          (32,895
M&T Bank Corp.
     203          01/20/23        USD     155.00        USD     2,945          (26,390
Medtronic PLC
     282          01/20/23        USD     80.00        USD     2,192          (26,508
Microsoft Corp.
     140          01/20/23        USD     240.00        USD     3,357          (100,800
Otis Worldwide Corp.
     57          01/20/23        USD     80.00        USD     446          (5,700
Paychex, Inc.
     214          01/20/23        USD     130.00        USD     2,473          (2,675
TE Connectivity Ltd.
     342          01/20/23        USD     130.00        USD     3,926          (5,985
TELUS Corp.
     1,883          01/20/23        CAD     29.00        CAD     4,920          (2,086
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  65

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
    
 
Exchange-Traded Options Written (continued)
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)                                                   
Visa, Inc., Class A
     37          01/20/23        USD     215.00        USD     769        $ (7,955
Williams Cos., Inc.
     36          01/20/23        USD     34.00        USD     118          (1,440
AbbVie, Inc.
     127          01/27/23        USD     162.50        USD     2,052          (39,941
Accenture PLC, Class A
     111          01/27/23        USD     270.00        USD     2,962          (77,145
Intuit, Inc.
     82          01/27/23        USD     410.00        USD     3,192          (70,520
Medtronic PLC
     73          01/27/23        USD     78.00        USD     567          (15,148
Synchrony Financial
     652          01/27/23        USD     35.00        USD     2,142          (40,750
UnitedHealth Group, Inc.
     13          01/27/23        USD     540.00        USD     689          (13,000
Visa, Inc., Class A
     120          01/27/23        USD     210.00        USD     2,493          (74,700
Estee Lauder Cos., Inc., Class A
     95          01/30/23        USD     231.50        USD     2,357          (204,544
Citizens Financial Group, Inc.
     295          01/31/23        USD     39.50        USD     1,161          (38,319
Paychex, Inc.
     426          02/10/23        USD     125.10        USD     4,923          (31,118
AbbVie, Inc.
     214          02/17/23        USD     165.00        USD     3,458          (86,135
Assurant, Inc.
     258          02/17/23        USD     130.00        USD     3,227          (73,530
Citizens Financial Group, Inc.
     294          02/17/23        USD     40.00        USD     1,157          (44,100
Intercontinental Exchange, Inc.
     192          02/17/23        USD     105.00        USD     1,970          (61,440
International Flavors & Fragrances, Inc.
     66          02/17/23        USD     110.00        USD     692          (17,985
Otis Worldwide Corp.
     58          02/17/23        USD     80.00        USD     454          (13,775
Otis Worldwide Corp.
     116          02/17/23        USD     82.50        USD     908          (16,240
TE Connectivity Ltd.
     240          02/17/23        USD     120.00        USD     2,755          (78,000
TELUS Corp.
     1,090          02/17/23        CAD     29.00        CAD     2,848          (4,830
Visa, Inc., Class A
     37          02/17/23        USD     220.00        USD     769          (15,170
TELUS Corp.
     1,387          03/17/23        CAD     29.00        CAD     3,624          (8,195
                          
 
 
 
                           $  (2,140,581
                          
 
 
 
OTC Options Written
 
Description
  
Counterparty
    
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call
                             
AstraZeneca PLC
     Goldman Sachs International        16,300          01/05/23        GBP     110.75        GBP     1,829        $ (39,392
DBS Group Holdings Ltd.
     UBS AG        73,200          01/05/23        SGD     35.60        SGD     2,483          (119
Epiroc AB, Class A
    
Morgan Stanley & Co.
International PLC
 
 
     19,858          01/05/23        SEK     192.46        SEK     3,770          (2,856
Ferguson PLC
     UBS AG        27,800          01/05/23        GBP     102.57        GBP     2,902          (86,403
MediaTek, Inc.
     Citibank N.A.        88,000          01/05/23        TWD     780.03        TWD     55,000           
Reckitt Benckiser Group PLC
     JPMorgan Chase Bank N.A.        27,600          01/05/23        GBP     60.02        GBP     1,588          (514
Wal-Mart de Mexico SAB de CV
     Citibank N.A.        662,900          01/05/23        MXN     75.29        MXN     45,468          (4
Epiroc AB, Class A
     UBS AG        43,900          01/10/23        SEK     192.78        SEK     8,334          (9,522
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
     BNP Paribas SA        94,000          01/10/23        TWD     521.09        TWD     42,159          (1
Diageo PLC
     UBS AG        6,500          01/11/23        GBP     38.47        GBP     237          (205
Ferguson PLC
     Royal Bank Of Canada        13,100          01/11/23        GBP     96.77        GBP     1,368          (125,963
Koninklijke KPN NV
     UBS AG        789,100          01/11/23        EUR     2.95        EUR     2,280          (14,588
Novo Nisk, Class B
     Goldman Sachs International        10,900          01/11/23        DKK     906.10        DKK     10,224          (57,572
Prudential PLC
     Goldman Sachs International        152,100          01/11/23        GBP     10.48        GBP     1,715          (155,966
Sanofi
     Goldman Sachs International        49,200          01/11/23        EUR     89.95        EUR     4,420          (66,173
Taylor Wimpey PLC
     Merrill Lynch International        766,000          01/11/23        GBP     1.05        GBP     779          (16,030
Zurich Insurance Group AG
     Goldman Sachs International        6,700          01/11/23        CHF     456.52        CHF     2,963          (5,093
EDP-Energias de Portugal SA
     Goldman Sachs International        55,400          01/13/23        EUR     4.78        EUR     258          (2,237
EDP-Energias de Portugal SA
    
Morgan Stanley & Co.
International PLC
 
 
     510,000          01/13/23        EUR     4.62        EUR     2,375          (58,731
Epiroc AB, Class A
     Goldman Sachs International        57,000          01/13/23        SEK     199.20        SEK     10,821          (5,591
Industria de Diseno Textil SA
    
Morgan Stanley & Co.
International PLC
 
 
     127,100          01/13/23        EUR     25.68        EUR     3,158          (19,758
KDDI Corp.
     Societe Generale        81,300          01/13/23        JPY     4,200.47        JPY     323,737          (4,789
Lonza Group AG, Registered Shares
     Goldman Sachs International        6,000          01/13/23        CHF     538.26        CHF     2,719          (176
RELX PLC
     Merrill Lynch International        104,000          01/13/23        EUR     27.49        EUR     2,687          (1,900
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
     Goldman Sachs International        44,000          01/13/23        TWD     510.64        TWD     19,734          (22
Epiroc AB, Class A
     Goldman Sachs International        87,600          01/17/23        SEK     198.58        SEK     16,631          (12,643
KDDI Corp.
     BNP Paribas SA        112,500          01/17/23        JPY     4,108.47        JPY     447,975          (19,569
Kering SA
     Barclays Bank PLC        6,200          01/17/23        EUR     543.50        EUR     2,948          (1,029
Zurich Insurance Group AG
     Barclays Bank PLC        7,600          01/17/23        CHF     459.92        CHF     3,361          (8,017
 
 
66
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
    
 
OTC Options Written (continued)
 
 
 
Description
 
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
 
 
Call (continued)
               
EDP-Energias de Portugal SA
  Barclays Bank PLC     488,100       01/18/23       EUR       4.61       EUR       2,273     $ (65,457
Epiroc AB, Class A
  Goldman Sachs International     46,700       01/18/23       SEK       203.90       SEK       8,866       (3,323
Essilorluxottica SA
  Goldman Sachs International     34,800       01/18/23       EUR       182.65       EUR       5,888       (15,628
RELX PLC
  Royal Bank Of Canada     56,000       01/18/23       EUR       27.49       EUR       1,447       (2,101
Taylor Wimpey PLC
  Merrill Lynch International     766,000       01/18/23       GBP       1.05       GBP       779       (22,948
Epiroc AB, Class A
  Royal Bank Of Canada     46,700       01/25/23       SEK       203.90       SEK       8,866       (6,111
Ferguson PLC
  Morgan Stanley & Co. International PLC     15,800       01/25/23       GBP       109.28       GBP       1,650       (19,571
Industria de Diseno Textil SA
  Morgan Stanley & Co. International PLC     121,869       01/25/23       EUR       25.26       EUR       3,028       (58,913
Koninklijke KPN NV
  Goldman Sachs International     604,400       01/25/23       EUR       3.00       EUR       1,747       (19,545
Schneider Electric SE
  Goldman Sachs International     16,800       01/25/23       EUR       144.57       EUR       2,196       (3,661
Taylor Wimpey PLC
  Merrill Lynch International     766,000       01/25/23       GBP       1.05       GBP       779       (29,013
Air Liquide SA
  Morgan Stanley & Co. International PLC     35,600       01/27/23       EUR       146.47       EUR       4,713       (4,882
Prudential PLC
  Goldman Sachs International     169,800       01/27/23       GBP       11.30       GBP       1,914       (80,888
Sanofi
  Goldman Sachs International     57,900       01/27/23       EUR       89.66       EUR       5,202       (135,577
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
  Citibank N.A.     182,000       01/30/23       TWD       431.84       TWD       81,627       (118,351
Diageo PLC
  Goldman Sachs International     30,100       01/31/23       GBP       37.54       GBP       1,099       (16,075
Industria de Diseno Textil SA
  Goldman Sachs International     65,049       01/31/23       EUR       25.28       EUR       1,616       (36,440
Reckitt Benckiser Group PLC
  UBS AG     74,100       01/31/23       GBP       59.02       GBP       4,264       (69,298
RELX PLC
  JPMorgan Chase Bank N.A.     77,900       01/31/23       EUR       26.97       EUR       2,013       (17,059
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
  Goldman Sachs International     100,000       01/31/23       TWD       480.37       TWD       44,850       (9,613
Wal-Mart de Mexico SAB de CV
  Morgan Stanley & Co. International PLC     719,400       01/31/23       MXN       70.27       MXN       49,344       (57,379
Taylor Wimpey PLC
  Merrill Lynch International     766,000       02/01/23       GBP       1.07       GBP       779       (25,596
AstraZeneca PLC
  Morgan Stanley & Co. International PLC     42,500       02/02/23       GBP       114.69       GBP       4,768       (87,597
Diageo PLC
  Morgan Stanley & Co. International PLC     46,400       02/02/23       GBP       37.74       GBP       1,694       (23,125
EDP-Energias de Portugal SA
  Morgan Stanley & Co. International PLC     220,000       02/02/23       EUR       4.82       EUR       1,024       (16,384
Lonza Group AG, Registered Shares
  UBS AG     5,900       02/02/23       CHF       456.40       CHF       2,673       (94,309
Novo Nisk, Class B
  Goldman Sachs International     21,400       02/02/23       DKK       952.75       DKK       20,073       (70,127
Prudential PLC
  Goldman Sachs International     90,700       02/02/23       GBP       11.36       GBP       1,023       (45,943
Schneider Electric SE
  Goldman Sachs International     18,200       02/02/23       EUR       137.93       EUR       2,379       (27,989
Taylor Wimpey PLC
  UBS AG     1,100,000       02/02/23       GBP       1.06       GBP       1,118       (43,991
AstraZeneca PLC
  Morgan Stanley & Co. International PLC     9,100       02/08/23       GBP       118.56       GBP       1,021       (11,708
DBS Group Holdings Ltd.
  JPMorgan Chase Bank N.A.     109,100       02/08/23       SGD       35.54       SGD       3,701       (16,978
Epiroc AB, Class A
  Goldman Sachs International     43,900       02/08/23       SEK       210.08       SEK       8,334       (7,311
Kering SA
  Goldman Sachs International     4,600       02/08/23       EUR       545.69       EUR       2,187       (7,835
LVMH Moet Hennessy Louis Vuitton SE
  Goldman Sachs International     3,400       02/08/23       EUR       545.69       EUR       2,312       (42,013
MediaTek, Inc.
  JPMorgan Chase Bank N.A.     108,000       02/08/23       TWD       753.90       TWD       67,500       (792
Novo Nisk, Class B
  JPMorgan Chase Bank N.A.     15,400       02/08/23       DKK       975.00       DKK       14,445       (40,003
Prudential PLC
  Goldman Sachs International     64,100       02/08/23       GBP       11.45       GBP       723       (33,409
Taylor Wimpey PLC
  Morgan Stanley & Co. International PLC     996,200       02/08/23       GBP       1.07       GBP       1,013       (38,768
               
 
 
 
                $  (2,140,574
               
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
Options Written
   $ N/A      $ N/A      $ 4,011,904      $ (626,187    $  (4,281,155)  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  67

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
    
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Liabilities — Derivative Financial Instruments
                    
Options written
                    
Options written at value
   $      $      $ 4,281,155      $      $      $      $ 4,281,155  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options purchased
(a)
   $      $      $  (9,124,476    $      $      $      $  (9,124,476
Options written
                   15,583,351                             15,583,351  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ 6,458,875      $      $      $      $ 6,458,875  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options written
   $      $      $ 5,008,021      $      $      $      $ 5,008,021  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Options:
  
 
 
 
Average value of option contracts purchased
     $             —
(a)
 
Average value of option contracts written
     $5,836,742  
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
    
Liabilities
 
Derivative Financial Instruments
     
Options
   $      $ 4,281,155  
  
 
 
    
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
            4,281,155  
  
 
 
    
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
            (2,140,581
  
 
 
    
 
 
 
Total derivative assets and liabilities subject to an MNA
   $      $ 2,140,574  
  
 
 
    
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
  
 

Derivatives
Available
for Offset
 
 
 
  
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
  
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 74,503      $      $ (74,503    $      $  
BNP Paribas SA
     19,570                             19,570  
Citibank N.A.
     118,355               (118,355              
Goldman Sachs International
     900,242               (900,242              
JPMorgan Chase Bank N.A.
     75,346               (75,346              
Merrill Lynch International
     95,487               (95,487              
Morgan Stanley & Co. International PLC
     399,672               (399,672              
Royal Bank Of Canada
     134,175               (134,175              
 
 
68
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced Global Dividend Trust (BOE)
    
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
  
 

Derivatives
Available
for Offset
 
 
 
  
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
  
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Societe Generale
   $ 4,789      $      $      $      $ 4,789  
UBS AG
     318,435               (318,435              
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 2,140,574      $      $  (2,116,215    $      $ 24,359  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Investments
           
Long-Term Investments
           
Common Stocks
           
Canada
   $     15,298,478      $      $      $     15,298,478  
Denmark
            14,377,571               14,377,571  
France
            79,018,187               79,018,187  
India
                   505,741        505,741  
Indonesia
            7,108,929               7,108,929  
Ireland
     29,986,727                      29,986,727  
Japan
            10,681,129               10,681,129  
Mexico
     12,129,591                      12,129,591  
Netherlands
            9,584,736               9,584,736  
Portugal
            11,541,952               11,541,952  
Singapore
            10,255,452               10,255,452  
Spain
            18,536,547               18,536,547  
Sweden
            13,987,015               13,987,015  
Switzerland
     14,864,075        28,188,502               43,052,577  
Taiwan
            28,750,748               28,750,748  
United Kingdom
            118,478,547               118,478,547  
United States
     258,000,967                      258,000,967  
Short-Term Securities
           
Money Market Funds
     6,643,752                      6,643,752  
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ 336,923,590      $ 350,509,315      $ 505,741      $ 687,938,646  
  
 
 
    
 
 
    
 
 
    
 
 
 
Derivative Financial Instruments
(a)
           
Liabilities
           
Equity Contracts
   $ (1,789,095    $ (2,492,060    $      $ (4,281,155
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  69

Schedule of Investments  
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Common Stocks
    
Canada — 2.8%
            
TELUS Corp.
    882,602      $ 17,032,785  
    
 
 
 
China — 2.3%
            
Budweiser Brewing Co. APAC Ltd.
(a)
    2,344,500        7,328,897  
Yum China Holdings, Inc.
(b)
    114,085        6,234,745  
    
 
 
 
       13,563,642  
Denmark — 4.2%
            
Novo Nordisk A/S, Class B
    182,254        24,752,930  
    
 
 
 
France — 17.0%
            
Air Liquide SA
    85,428        12,125,247  
EssilorLuxottica SA
    62,452        11,299,625  
Kering SA
    37,422        19,045,084  
LVMH Moet Hennessy Louis Vuitton SE
    28,655        20,852,024  
Sanofi
    203,467        19,619,617  
Schneider Electric SE
    126,724        17,796,432  
    
 
 
 
       100,738,029  
Germany — 1.6%
            
MTU Aero Engines AG
    45,121        9,707,114  
    
 
 
 
India — 3.2%
            
HDFC Bank Ltd.
    921,648        18,076,789  
Jasper Infotech Private Ltd., Series I, (Acquired 01/25/22,
Cost: $3,948,600)
(c)(d)
    848,000        757,183  
    
 
 
 
       18,833,972  
Indonesia — 2.0%
            
Bank Rakyat Indonesia Persero Tbk PT
    37,156,800        11,780,567  
    
 
 
 
Japan — 3.3%
            
Daiichi Sankyo Co. Ltd.
    266,200        8,568,097  
KDDI Corp.
    360,400        10,929,810  
    
 
 
 
       19,497,907  
Mexico — 2.7%
            
Wal-Mart de Mexico SAB de CV
    4,549,212        16,012,647  
    
 
 
 
Netherlands — 3.9%
            
Koninklijke KPN NV
    4,569,967        14,145,209  
Shell PLC
    312,459        8,860,509  
    
 
 
 
       23,005,718  
Singapore — 4.5%
            
DBS Group Holdings Ltd.
    477,400        12,083,759  
United Overseas Bank Ltd.
    653,100        14,959,801  
    
 
 
 
       27,043,560  
Spain — 5.3%
            
Bankinter SA
    1,956,309        13,106,355  
Industria de Diseno Textil SA
    689,012        18,300,872  
    
 
 
 
       31,407,227  
Sweden — 3.0%
            
Epiroc AB, Class A
    979,807        17,841,409  
    
 
 
 
Switzerland — 4.7%
            
Lonza Group AG, Registered Shares
    32,717        16,059,970  
Zurich Insurance Group AG
    25,565        12,222,044  
    
 
 
 
       28,282,014  
Security
 
Shares
    
Value
 
Taiwan — 5.5%
            
MediaTek, Inc.
    659,000      $ 13,324,271  
Taiwan Semiconductor Manufacturing Co. Ltd.
    1,319,000        19,156,442  
    
 
 
 
       32,480,713  
United Kingdom — 23.8%
            
AstraZeneca PLC
    129,697        17,550,514  
Diageo PLC
    510,690        22,353,849  
Ferguson PLC
    159,157        19,981,176  
Prudential PLC
    1,589,131        21,668,258  
Reckitt Benckiser Group PLC
    341,909        23,699,873  
RELX PLC
    757,901        20,994,651  
Taylor Wimpey PLC
    12,189,366        14,928,291  
    
 
 
 
       141,176,612  
United States
(b)(e)
— 9.1%
            
Baker Hughes Co.
    380,276        11,229,550  
Estee Lauder Cos., Inc., Class A
    40,863        10,138,519  
Otis Worldwide Corp.
    237,987        18,636,762  
Visa, Inc., Class A
    66,582        13,833,077  
    
 
 
 
       53,837,908  
    
 
 
 
Total Long-Term Investments — 98.9%
(Cost: $533,942,385)
 
     586,994,754  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 1.0%
            
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(f)(g)
    5,622,321        5,622,321  
    
 
 
 
Total Short-Term Securities — 1.0%
(Cost: $5,622,321)
       5,622,321  
    
 
 
 
Total Investments Before Options Written — 99.9%
(Cost: $539,564,706)
 
     592,617,075  
    
 
 
 
Options Written — (0.8)%
            
(Premiums Received: $(5,783,243))
       (4,476,797
    
 
 
 
Total Investments, Net of Options Written — 99.1%
(Cost: $533,781,463)
 
     588,140,278  
Other Assets Less Liabilities — 0.9%
         5,331,097  
    
 
 
 
Net Assets — 100.0%
         $ 593,471,375  
    
 
 
 
 
(a)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(b)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(c)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(d)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $757,183, representing 0.1% of its net assets as of period end, and an original cost of $3,948,600.
(e)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(f)
 
Affiliate of the Trust.
(g)
 
Annualized 7-day yield as of period end.
 
 
70
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $ 5,586,240     $ 36,081
(a)
 
  $     $     $     $ 5,622,321       5,622,321     $ 86,543     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call                                                   
Visa, Inc., Class A
     3          01/06/23        USD     220.00        USD     62        $ (27
Baker Hughes Co.
     612          01/10/23        USD     31.05        USD     1,807          (15,339
Otis Worldwide Corp.
     155          01/10/23        USD     79.25        USD     1,214          (13,536
Visa, Inc., Class A
     119          01/10/23        USD     216.00        USD     2,472          (11,275
Visa, Inc., Class A
     19          01/13/23        USD     215.00        USD     395          (2,812
Visa, Inc., Class A
     19          01/13/23        USD     220.00        USD     395          (1,159
Baker Hughes Co.
     185          01/20/23        USD     32.00        USD     546          (5,088
Baker Hughes Co.
     534          01/20/23        USD     29.00        USD     1,577          (76,095
Estee Lauder Cos., Inc., Class A
     43          01/20/23        USD     220.00        USD     1,067          (126,850
Estee Lauder Cos., Inc., Class A
     15          01/20/23        USD     240.00        USD     372          (19,950
Otis Worldwide Corp.
     452          01/20/23        USD     75.00        USD     3,540          (180,800
Otis Worldwide Corp.
     116          01/20/23        USD     80.00        USD     908          (11,600
TELUS Corp.
     1,999          01/20/23        CAD     29.00        CAD     5,223          (2,215
Visa, Inc., Class A
     37          01/20/23        USD     215.00        USD     769          (7,955
Yum China Holdings, Inc.
     257          01/20/23        USD     55.00        USD     1,405          (46,902
Visa, Inc., Class A
     65          01/27/23        USD     210.00        USD     1,350          (40,462
Estee Lauder Cos., Inc., Class A
     136          01/30/23        USD     231.50        USD     3,374            (292,822
Otis Worldwide Corp.
     115          02/17/23        USD     80.00        USD     901          (27,313
Otis Worldwide Corp.
     232          02/17/23        USD     82.50        USD     1,817          (32,480
TELUS Corp.
     1,116          02/17/23        CAD     29.00        CAD     2,916          (4,945
Visa, Inc., Class A
     37          02/17/23        USD     220.00        USD     769          (15,170
Yum China Holdings, Inc.
     257          02/17/23        USD     57.50        USD     1,405          (52,685
TELUS Corp.
     1,739          03/17/23        CAD     29.00        CAD     4,544          (10,275
                          
 
 
 
                           $  (997,755
                          
 
 
 
OTC Options Written
 
 
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
 
 
Call
                
AstraZeneca PLC
   Goldman Sachs International     16,100       01/05/23       GBP       110.75       GBP       1,806     $ (38,909
DBS Group Holdings Ltd.
   UBS AG     121,000       01/05/23       SGD       35.60       SGD       4,104       (197
Epiroc AB, Class A
   Morgan Stanley & Co. International PLC     1,400       01/05/23       SEK       192.46       SEK       266       (201
Ferguson PLC
   UBS AG     39,100       01/05/23       GBP       102.57       GBP       4,082         (121,524
MediaTek, Inc.
   Citibank N.A.     10,000       01/05/23       TWD       780.03       TWD       6,250        
Reckitt Benckiser Group PLC
   JPMorgan Chase Bank N.A.     43,900       01/05/23       GBP       60.02       GBP       2,526       (817
United Overseas Bank Ltd.
   UBS AG     75,000       01/05/23       SGD       30.50       SGD       2,303       (23,462
Wal-Mart de Mexico SAB de CV
   Citibank N.A.     1,200,900       01/05/23       MXN       75.28       MXN       82,370       (7
Budweiser Brewing Co. APAC Ltd.
   Citibank N.A.     527,000       01/06/23       HKD       19.48       HKD       12,938       (341,503
Daiichi Sankyo Co. Ltd.
   Bank of America N.A.     76,200       01/10/23       JPY       4,840.50       JPY       323,850       (4,139
Epiroc AB, Class A
   UBS AG     87,500       01/10/23       SEK       192.78       SEK       16,612       (18,979
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
   Goldman Sachs International     195,000       01/10/23       TWD       426.15       TWD       87,458       (148,108
Diageo PLC
   UBS AG     39,800       01/11/23       GBP       38.47       GBP       1,453       (1,254
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  71

Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
    
 
OTC Options Written (continued)
 
 
 
Description
  
Counterparty
  
Number of
Contracts
    
Expiration
Date
    
Exercise Price
    
Notional
Amount (000)
    
Value
 
 
 
Call (continued)
                     
Ferguson PLC
   Royal Bank of Canada      20,200        01/11/23        GBP       96.77        GBP       2,109      $ (194,233
Koninklijke KPN NV
   UBS AG      1,075,900        01/11/23        EUR       2.95        EUR       3,109        (19,890
Novo Nisk, Class B
   Goldman Sachs International      65,000        01/11/23        DKK       906.10        DKK       60,970        (343,317
Prudential PLC
   Goldman Sachs International      169,900        01/11/23        GBP       10.48        GBP       1,916        (174,219
Sanofi
   Goldman Sachs International      42,300        01/11/23        EUR       89.95        EUR       3,800        (56,892
Shell PLC
   Morgan Stanley & Co. International PLC      70,000        01/11/23        EUR       28.23        EUR       1,854        (3,669
Taylor Wimpey PLC
   Merrill Lynch International      850,000        01/11/23        GBP       1.05        GBP       864        (17,788
Zurich Insurance Group AG
   Goldman Sachs International      5,300        01/11/23        CHF       456.52        CHF       2,344        (4,029
Bankinter SA
   UBS AG      144,700        01/13/23        EUR       6.58        EUR       907        (4,791
Epiroc AB, Class A
   Goldman Sachs International      54,700        01/13/23        SEK       199.20        SEK       10,385        (5,365
Industria de Diseno Textil SA
   Morgan Stanley & Co. International PLC      121,600        01/13/23        EUR       25.68        EUR       3,022        (18,903
KDDI Corp.
   Societe Generale      58,700        01/13/23        JPY       4,200.47        JPY       233,743        (3,458
Lonza Group AG, Registered Shares
   Goldman Sachs International      7,300        01/13/23        CHF       538.26        CHF       3,308        (215
RELX PLC
   Merrill Lynch International      101,000        01/13/23        EUR       27.49        EUR       2,610        (1,845
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
   Goldman Sachs International      36,000        01/13/23        TWD       510.64        TWD       16,146        (18
United Overseas Bank Ltd.
   Morgan Stanley & Co. International PLC      156,600        01/13/23        SGD       30.71        SGD       4,808        (47,989
Epiroc AB, Class A
   Goldman Sachs International      108,800        01/17/23        SEK       198.58        SEK       20,656        (15,703
KDDI Corp.
   BNP Paribas SA      139,500        01/17/23        JPY       4,108.47        JPY       555,489        (24,266
Kering SA
   Barclays Bank PLC      6,500        01/17/23        EUR       543.50        EUR       3,091        (1,079
RELX PLC
   Goldman Sachs International      71,700        01/17/23        EUR       27.67        EUR       1,853        (1,817
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
   BNP Paribas SA      64,000        01/17/23        TWD       498.75        TWD       28,704        (411
Zurich Insurance Group AG
   Barclays Bank PLC      6,300        01/17/23        CHF       459.92        CHF       2,786        (6,646
Bankinter SA
   Morgan Stanley & Co. International PLC      540,100        01/18/23        EUR       6.56        EUR       3,385        (28,595
Epiroc AB, Class A
   Goldman Sachs International      50,600        01/18/23        SEK       203.90        SEK       9,606        (3,600
Essilorluxottica SA
   Goldman Sachs International      42,100        01/18/23        EUR       182.65        EUR       7,123        (18,906
RELX PLC
   Royal Bank of Canada      85,500        01/18/23        EUR       27.49        EUR       2,209        (3,208
Shell PLC
   Morgan Stanley & Co. International PLC      70,000        01/18/23        EUR       28.23        EUR       1,854        (8,233
Taylor Wimpey PLC
   Merrill Lynch International      850,000        01/18/23        GBP       1.05        GBP       864        (25,464
Epiroc AB, Class A
   Royal Bank of Canada      50,600        01/25/23        SEK       203.90        SEK       9,606        (6,621
Ferguson PLC
   Morgan Stanley & Co. International PLC      12,400        01/25/23        GBP       109.28        GBP       1,295        (15,359
Industria de Diseno Textil SA
   Morgan Stanley & Co. International PLC      84,735        01/25/23        EUR       25.26        EUR       2,106        (40,962
Koninklijke KPN NV
   Goldman Sachs International      980,600        01/25/23        EUR       3.00        EUR       2,834        (31,711
MTU Aero Engines AG
   Morgan Stanley & Co. International PLC      25,300        01/25/23        EUR       211.95        EUR       5,116        (41,223
Schneider Electric SE
   Goldman Sachs International      22,900        01/25/23        EUR       144.57        EUR       2,993        (4,990
Taylor Wimpey PLC
   Merrill Lynch International      850,000        01/25/23        GBP       1.05        GBP       864        (32,195
Air Liquide SA
   Morgan Stanley & Co. International PLC      27,300        01/27/23        EUR       146.47        EUR       3,615        (3,744
Budweiser Brewing Co. APAC Ltd.
   Citibank N.A.      527,000        01/27/23        HKD       19.66        HKD       12,938        (363,658
Prudential PLC
   Goldman Sachs International      169,200        01/27/23        GBP       11.30        GBP       1,908        (80,603
Sanofi
   Goldman Sachs International      52,200        01/27/23        EUR       89.66        EUR       4,690          (122,230
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
   BNP Paribas SA      30,000        01/30/23     
 
TWD
 
    521.09        TWD       13,455        (171
Diageo PLC
   Goldman Sachs International      69,500        01/31/23        GBP       37.54        GBP       2,537        (37,116
Industria de Diseno Textil SA
   Goldman Sachs International      103,735        01/31/23        EUR       25.28        EUR       2,578        (58,111
Reckitt Benckiser Group PLC
   UBS AG      75,700        01/31/23        GBP       59.02        GBP       4,356        (70,794
RELX PLC
   JPMorgan Chase Bank N.A.      82,900        01/31/23        EUR       26.97        EUR       2,142        (18,154
Taiwan Semiconductor Manufacturing Co. Ltd., ADR
   Goldman Sachs International      136,000        01/31/23        TWD       480.37        TWD       60,996        (13,074
United Overseas Bank Ltd.
   Morgan Stanley & Co. International PLC      74,000        01/31/23        SGD       31.66        SGD       2,272        (12,956
Wal-Mart de Mexico SAB de CV
   Morgan Stanley & Co. International PLC      579,000        01/31/23        MXN       70.27        MXN       39,714        (46,181
Taylor Wimpey PLC
   Merrill Lynch International      850,000        02/01/23        GBP       1.07        GBP       864        (28,403
AstraZeneca PLC
   Morgan Stanley & Co. International PLC      42,300        02/02/23        GBP       114.69        GBP       4,745        (87,185
Daiichi Sankyo Co. Ltd.
   UBS AG      43,600        02/02/23        JPY       4,518.52        JPY       185,300        (19,715
Diageo PLC
   Morgan Stanley & Co. International PLC      69,500        02/02/23        GBP       37.74        GBP       2,537        (34,637
Lonza Group AG, Registered Shares
   UBS AG      7,400        02/02/23        CHF       456.40        CHF       3,353        (118,286
Novo Nisk, Class B
   Goldman Sachs International      2,200        02/02/23        DKK       952.75        DKK       2,064        (7,209
Prudential PLC
   Goldman Sachs International      183,300        02/02/23        GBP       11.36        GBP       2,067        (92,848
Schneider Electric SE
   Goldman Sachs International      21,500        02/02/23        EUR       137.93        EUR       2,810        (33,064
Taylor Wimpey PLC
   UBS AG      1,100,000        02/02/23        GBP       1.06        GBP       1,118        (43,991
Air Liquide SA
   Morgan Stanley & Co. International PLC      22,000        02/08/23        EUR       143.69        EUR       2,913        (10,651
DBS Group Holdings Ltd.
   JPMorgan Chase Bank N.A.      93,900        02/08/23        SGD       35.54        SGD       3,185        (14,613
 
 
72
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
    
 
OTC Options Written (continued)
 
 
 
Description
  
Counterparty
  
Number of
Contracts
    
Expiration
Date
    
Exercise Price
    
Notional
Amount (000)
    
Value
 
 
 
Call (continued)
                     
Epiroc AB, Class A
   Goldman Sachs International      87,400        02/08/23        SEK       210.08        SEK       16,593      $ (14,556
Kering SA
   Goldman Sachs International      6,500        02/08/23        EUR       545.69        EUR       3,091        (11,071
LVMH Moet Hennessy Louis Vuitton SE
   Goldman Sachs International      10,100        02/08/23        EUR       545.69        EUR       6,867        (124,802
MediaTek, Inc.
   JPMorgan Chase Bank N.A.      220,000        02/08/23        TWD       753.90        TWD       137,500        (1,613
Novo Nisk, Class B
   JPMorgan Chase Bank N.A.      14,900        02/08/23        DKK       975.00        DKK       13,976        (38,704
Prudential PLC
   Goldman Sachs International      49,600        02/08/23        GBP       11.44        GBP       559        (25,852
Taylor Wimpey PLC
   Morgan Stanley & Co. International PLC      985,200        02/08/23        GBP       1.07        GBP       1,001        (38,340
                     
 
 
 
                      $ (3,479,042
                     
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
 
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
 
 
Options Written
   $ N/A      $ N/A      $ 2,774,158      $ (1,467,712      $(4,476,797)  
 
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
 
 
    
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
 
 
Liabilities — Derivative Financial Instruments
                    
Options written
                    
Options written at value
   $      $      $  4,476,797      $      $      $      $  4,476,797  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
 
 
    
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
 
 
Net Realized Gain (Loss) from:
                    
Options purchased
(a)
   $      $      $ (12,871,852)      $      $      $      $ (12,871,852
Options written
                   11,872,703                             11,872,703  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ (999,149)      $      $      $      $ (999,149
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options written
   $      $      $ 3,532,841      $      $      $      $ 3,532,841  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
 
 
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 5,052,583  
 
 
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  73

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
    
 
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
    
Liabilities
 
Derivative Financial Instruments
     
Options
   $      $ 4,476,797  
  
 
 
    
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
            4,476,797  
  
 
 
    
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
            (997,755
  
 
 
    
 
 
 
Total derivative assets and liabilities subject to an MNA
   $      $ 3,479,042  
  
 
 
    
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to

an MNA by
Counterparty
 
 
 

 
 
  
 

Derivatives
Available

for Offset
 
 

 
  
 

Non-Cash
Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
  
 


Net Amount

of Derivative
Liabilities
 

 
(b)
 
Bank of America N.A.
   $ 4,139      $      $ (4,139    $      $  
Barclays Bank PLC
     7,725                             7,725  
BNP Paribas SA
     24,848                             24,848  
Citibank N.A.
     705,168               (705,168              
Goldman Sachs International
     1,468,335               (1,468,335              
JPMorgan Chase Bank N.A.
     73,901               (73,901              
Merrill Lynch International
     105,695                             105,695  
Morgan Stanley & Co. International PLC
     438,828               (223,828      (215,000       
Royal Bank of Canada
     204,062               (204,062              
Societe Generale
     3,458                             3,458  
UBS AG
     442,883               (442,883              
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 3,479,042      $      $     (3,122,316)      $ (215,000    $ 141,726  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Investments
           
Long-Term Investments
           
Common Stocks
           
Canada
   $ 17,032,785      $      $                 —      $ 17,032,785  
China
     6,234,745        7,328,897               13,563,642  
Denmark
            24,752,930               24,752,930  
France
              100,738,029                 100,738,029  
Germany
            9,707,114               9,707,114  
India
            18,076,789        757,183        18,833,972  
Indonesia
            11,780,567               11,780,567  
Japan
            19,497,907               19,497,907  
Mexico
       16,012,647                      16,012,647  
Netherlands
            23,005,718               23,005,718  
Singapore
            27,043,560               27,043,560  
Spain
            31,407,227               31,407,227  
Sweden
            17,841,409               17,841,409  
Switzerland
            28,282,014               28,282,014  
Taiwan
            32,480,713               32,480,713  
 
 
74
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Enhanced International Dividend Trust (BGY)
    
 
Fair Value Hierarchy as of Period End (continued)
 
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Common Stocks (continued)
           
United Kingdom
   $      $ 141,176,612      $      $ 141,176,612  
United States
     53,837,908                      53,837,908  
Short-Term Securities
           
Money Market Funds
     5,622,321                      5,622,321  
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ 98,740,406      $ 493,119,486      $ 757,183      $ 592,617,075  
  
 
 
    
 
 
    
 
 
    
 
 
 
Derivative Financial Instruments
(a)
           
Liabilities
           
Equity Contracts
   $ (664,783    $ (3,812,014    $      $ (4,476,797
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  75

Schedule of Investments
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Common Stocks
   
Biotechnology — 21.0%
           
AbbVie, Inc.
    107,973     $ 17,449,517  
Affinivax, Inc., (Acquired 08/18/22, Cost: $0)
(a)(b)
    6,331       81,797  
Alkermes PLC
(c)
    22,001       574,886  
Alnylam Pharmaceuticals, Inc.
(c)
    15,553       3,696,170  
Amgen, Inc.
(d)
    69,758       18,321,241  
Apellis Pharmaceuticals, Inc.
(c)
    11,780       609,144  
Arcutis Biotherapeutics, Inc.
(c)
    42,854       634,239  
Argenx SE, ADR
(c)
    7,121       2,697,648  
Biogen, Inc.
(c)
    26,702       7,394,318  
BioMarin Pharmaceutical, Inc.
(c)
    30,495       3,155,928  
BioNTech SE, ADR
    10,000       1,502,200  
Blueprint Medicines Corp.
(c)
    14,055       615,750  
Cellarity, Inc., (Acquired 01/15/21,
Cost: $265,002)
(a)(b)
    44,167       174,901  
Cerevel Therapeutics Holdings, Inc.
(c)
    16,785       529,399  
Decibel Therapeutics, Inc.
(c)(e)
    46,884       96,112  
Design Therapeutics, Inc.
(c)
    13,967       143,301  
Enanta Pharmaceuticals, Inc.
(c)
    3,150       146,538  
Exact Sciences Corp.
(c)
    26,711       1,322,462  
Genmab A/S
(c)
    2,498       1,056,141  
Genmab A/S, ADR
(c)
    16,911       716,688  
Gilead Sciences, Inc.
    168,017       14,424,259  
Horizon Therapeutics PLC
(c)
    7,410       843,258  
Imago Biosciences, Inc.
(c)
    47,824       1,719,273  
Immuneering Corp., Class A
(c)(e)
    14,456       70,112  
Immunocore Holdings PLC, ADR
(c)
    9,668       551,753  
Incyte Corp.
(c)
    26,918       2,162,054  
Ionis Pharmaceuticals, Inc.
(c)
    18,640       704,033  
Karuna Therapeutics, Inc.
(c)
    3,635       714,277  
Krystal Biotech, Inc.
(c)
    3,135       248,355  
Legend Biotech Corp., ADR
(c)
    14,146       706,168  
Mirati Therapeutics, Inc.
(c)
    4,450       201,629  
Moderna, Inc.
(c)
    41,978       7,540,088  
Monte Rosa Therapeutics, Inc.
(c)
    28,575       217,456  
MoonLake Immunotherapeutics
(c)
    11,715       123,008  
Neurocrine Biosciences, Inc.
(c)
    23,254       2,777,458  
Nuvalent, Inc., Class A
(c)
    11,178       332,881  
PMV Pharmaceuticals, Inc.
(c)
    17,490       152,163  
Prime Medicine, Inc.
(e)
    22,929       426,021  
Prometheus Biosciences, Inc.
(c)
    6,920       761,200  
Prothena Corp. PLC
(c)
    8,734       526,223  
PTC Therapeutics, Inc.
(c)
    8,450       322,536  
Regeneron Pharmaceuticals, Inc.
(c)
    10,697       7,717,779  
Revolution Medicines, Inc.
(c)
    18,874       449,579  
Rhythm Pharmaceuticals, Inc.
(c)
    48,130       1,401,546  
Rocket Pharmaceuticals, Inc.
(c)
    17,213       336,858  
Sage Therapeutics, Inc.
(c)
    21,680       826,875  
Sarepta Therapeutics, Inc.
(c)
    18,688       2,421,591  
Seagen, Inc.
(c)
    20,872       2,682,261  
Sigilon Therapeutics, Inc.
(c)
    19,555       6,844  
Tenaya Therapeutics, Inc.
(c)
    25,502       51,259  
TScan Therapeutics, Inc.
(c)
    29,940       48,802  
Ultragenyx Pharmaceutical, Inc.
(c)
    6,140       284,466  
Vertex Pharmaceuticals, Inc.
(c)
    45,850       13,240,563  
   
 
 
 
      125,911,008  
Diversified Financial Services — 0.0%
           
Health Sciences Acquisitions Corp.
(c)
    13,696       136,823  
   
 
 
 
Health Care Equipment & Supplies — 19.4%
           
Abbott Laboratories
(d)
    165,757       18,198,461  
Security
 
Shares
    
Value
 
Health Care Equipment & Supplies (continued)
        
Abiomed, Inc.
(a)
    14,359      $ 14,646  
Alcon, Inc.
    79,014        5,416,410  
Align Technology, Inc.
(c)
    3,960        835,164  
Bausch & Lomb Corp.
(c)(e)
    75,830        1,176,123  
Baxter International, Inc.
    71,467        3,642,673  
Boston Scientific Corp.
(c)
    422,762        19,561,198  
Cooper Cos., Inc.
    10,901        3,604,634  
Dexcom, Inc.
(c)
    52,400        5,933,776  
Edwards Lifesciences Corp.
(c)
    39,026        2,911,730  
Glaukos Corp.
(c)
    4,880        213,158  
Insulet Corp.
(c)
    8,685        2,556,777  
Intuitive Surgical, Inc.
(c)
    47,294        12,549,463  
iRhythm Technologies, Inc.
(c)
    2,280        213,568  
Masimo Corp.
(c)
    8,435        1,247,958  
Medtronic PLC
    128,480        9,985,466  
Nevro Corp.
(c)
    36,067        1,428,253  
Novocure Ltd.
(c)
    10,555        774,209  
Omnicell, Inc.
(c)
    6,425        323,948  
Penumbra, Inc.
(c)
    21,510        4,785,115  
ResMed, Inc.
    17,159        3,571,303  
STERIS PLC
    4,935        911,445  
Stryker Corp.
    60,410        14,769,641  
Zimmer Biomet Holdings, Inc.
    14,617        1,863,667  
    
 
 
 
        116,488,786  
Health Care Providers & Services — 20.5%
        
Agiliti, Inc.
(c)
    40,496        660,490  
Amedisys, Inc.
(c)
    22,677        1,894,437  
AmerisourceBergen Corp.
    55,773        9,242,144  
Centene Corp.
(c)
    36,831        3,020,510  
Cigna Corp.
    44,169        14,634,956  
Elevance Health, Inc.
(d)
    35,882        18,406,389  
Encompass Health Corp.
    43,989        2,630,982  
Guardant Health, Inc.
(c)
    11,675        317,560  
HCA Healthcare, Inc.
    8,085        1,940,077  
LHC Group, Inc.
(c)
    20,224        3,270,019  
McKesson Corp.
    24,550        9,209,196  
Quest Diagnostics, Inc.
    41,129        6,434,221  
UnitedHealth Group, Inc.
(d)
    97,235        51,552,052  
    
 
 
 
       123,213,033  
Life Sciences Tools & Services — 11.4%
        
10X Genomics, Inc., Class A
(c)
    10,520        383,349  
Agilent Technologies, Inc.
    62,776        9,394,428  
Avantor, Inc.
(c)
    78,897        1,663,938  
Danaher Corp.
    67,989        18,045,640  
Icon PLC
(c)
    8,210        1,594,792  
IQVIA Holdings, Inc.
(c)
    24,543        5,028,615  
Mettler-Toledo International, Inc.
(c)
    1,055        1,524,950  
Nautilus Biotechnology, Inc.
(c)
    16,560        29,808  
QIAGEN NV
(c)
    31,011        1,546,519  
Rapid Micro Biosystems, Inc., Class A
(c)(e)
    20,561        23,234  
Thermo Fisher Scientific, Inc.
(f)
    42,868        23,606,979  
Waters Corp.
(c)
    10,760        3,686,161  
West Pharmaceutical Services, Inc.
    7,775        1,829,846  
    
 
 
 
       68,358,259  
Pharmaceuticals — 23.6%
            
Arvinas, Inc.
(c)
    11,035        377,507  
AstraZeneca PLC
    63,946        8,653,131  
AstraZeneca PLC, ADR
    24,607        1,668,355  
Bristol-Myers Squibb Co.
    39,106        2,813,677  
Catalent, Inc.
(c)
    20,045        902,226  
 
 
76
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Pharmaceuticals (continued)
            
Daiichi Sankyo Co. Ltd.
    114,400      $ 3,682,157  
Eli Lilly & Co.
    91,436        33,450,946  
Johnson & Johnson
(d)
    179,664        31,737,646  
Merck & Co., Inc.
(d)
    226,786        25,161,907  
Pfizer, Inc.
(d)
    337,176        17,276,898  
Roche Holding AG
    6,561        2,061,711  
Sanofi
    24,587        2,370,839  
Zoetis, Inc.
    77,984        11,428,555  
    
 
 
 
       141,585,555  
    
 
 
 
Total Common Stocks — 95.9%
    (Cost: $390,083,055)
     575,693,464  
    
 
 
 
    
Benefical
Interest (000)
         
Other Interests
(g)
    
Pharmaceuticals — 0.0%
 
Afferent Pharmaceuticals, Inc.
(a)(b)(g)
  $ 190        144,522  
    
 
 
 
Total Other Interests — 0.0%
    (Cost: $ — )
     144,522  
    
 
 
 
    
Shares
         
Preferred Securities
    
Preferred Stocks — 0.7%
(a)(b)
 
Biotechnology — 0.1%
 
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20,
Cost: $224,200)
    190,000        60,800  
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800)
    21,100        531,720  
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $260,568)
    106,790        259,500  
    
 
 
 
       852,020  
Health Care Equipment & Supplies — 0.3%
 
Exo Imaging, Inc., Series C, (Acquired 06/24/21,
Cost: $595,999)
    101,741        300,136  
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)
    367,395        1,039,728  
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759)
    4,243,029        338,554  
Swift Health Systems, Inc., Series D, (Acquired 08/27/21,
Cost: $286,998)
    92,580        163,866  
    
 
 
 
       1,842,284  
Pharmaceuticals — 0.1%
 
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000)
    30,616        364,024  
    
 
 
 
Software — 0.2%
 
Carbon Health Technologies, Inc., (Acquired 07/09/21,
    
    Cost: $907,000)
    907        909,839  
    
 
 
 
       3,968,167  
    
 
 
 
Total Preferred Securities — 0.7%
    (Cost: $5,011,325)
     3,968,167  
    
 
 
 
Security
 
Shares
   
Value
 
Warrants
   
Health Care Providers & Services — 0.0%
 
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price USD 11.50)
(c)
    4,201     $ 1,786  
   
 
 
 
Pharmaceuticals — 0.0%
 
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)
(c)
    4,050       585  
   
 
 
 
Total Warrants — 0.0%
    (Cost: $14,030)
    2,371  
   
 
 
 
Total Long-Term Investments — 96.6%
    (Cost: $395,108,410)
    579,808,524  
   
 
 
 
Short-Term Securities
   
Money Market Funds — 4.0%
 
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(h)(i)
    23,195,315       23,195,315  
SL Liquidity Series, LLC, Money Market
Series, 4.49%
(h)(i)(j)
    676,047       675,980  
   
 
 
 
Total Short-Term Securities — 4.0%
    (Cost: $23,871,030)
    23,871,295  
   
 
 
 
Total Investments Before Options Written — 100.6%
    (Cost: $418,979,440)
    603,679,819  
   
 
 
 
Options Written — (0.7)%
    (Premiums Received: $(6,502,317))
    (4,323,328)  
   
 
 
 
Total Investments, Net of Options Written — 99.9%
    (Cost: $412,477,123)
    599,356,491  
Other Assets Less Liabilities — 0.1%
    840,422  
   
 
 
 
Net Assets — 100.0%
    $  600,196,913  
   
 
 
 
 
(a)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(b)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,369,387, representing 0.7% of its net assets as of period end, and an original cost of $5,276,327.
(c)
 
Non-income producing security.
(d)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(e)
 
All or a portion of this security is on loan.
(f)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(g)
 
Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
(h)
 
Affiliate of the Trust.
(i)
 
Annualized 7-day yield as of period end.
(j)
 
All or a portion of this security was purchased with the cash collateral from loaned securities.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  77

Schedule of Investments 
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $  27,581,316     $     $  (4,386,001)
(
a)
 
  $     $     $ 23,195,315       23,195,315     $ 432,499     $  
SL Liquidity Series, LLC, Money Market Series
    211,489         464,567
(a)
 
    —         (349     273       675,980       676,047       29,546
(b)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ (349   $ 273     $  23,871,295       $  462,045     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
 
(b)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call                                                   
Abbott Laboratories
     246          01/06/23        USD     107.00        USD     2,701        $ (79,950)  
AbbVie, Inc.
     105          01/06/23        USD     160.00        USD     1,697          (28,927)  
AmerisourceBergen Corp.
     161          01/06/23        USD     175.00        USD     2,668          (1,610)  
Bristol-Myers Squibb Co.
     148          01/06/23        USD     79.00        USD     1,065          (444)  
Centene Corp.
     79          01/06/23        USD     89.00        USD     648          (790)  
Cigna Corp.
     48          01/06/23        USD     325.00        USD     1,590          (38,880)  
Danaher Corp.
     140          01/06/23        USD     275.00        USD     3,716          (11,200)  
Elevance Health, Inc.
     33          01/06/23        USD     520.00        USD     1,693          (10,230)  
Exact Sciences Corp.
     58          01/06/23        USD     52.00        USD     287          (3,045)  
Gilead Sciences, Inc.
     295          01/06/23        USD     87.00        USD     2,533          (12,832)  
Intuitive Surgical, Inc.
     31          01/06/23        USD     270.00        USD     823          (6,975)  
Johnson & Johnson
     165          01/06/23        USD     180.00        USD     2,915          (6,023)  
McKesson Corp.
     22          01/06/23        USD     380.00        USD     825          (6,545)  
Medtronic PLC
     103          01/06/23        USD     80.00        USD     801          (2,060)  
Moderna, Inc.
     21          01/06/23        USD     215.00        USD     377          (273)  
Sarepta Therapeutics, Inc.
     3          01/06/23        USD     127.00        USD     39          (953)  
Thermo Fisher Scientific, Inc.
     81          01/06/23        USD     570.00        USD     4,461          (12,555)  
Vertex Pharmaceuticals, Inc.
     70          01/06/23        USD     320.00        USD     2,021          (700)  
Abbott Laboratories
     85          01/13/23        USD     106.00        USD     933          (38,887)  
Align Technology, Inc.
     15          01/13/23        USD     210.00        USD     316          (13,650)  
Alkermes PLC
     19          01/13/23        USD     25.60        USD     50          (2,174)  
AmerisourceBergen Corp.
     4          01/13/23        USD     175.00        USD     66          (480)  
Baxter International, Inc.
     164          01/13/23        USD     55.00        USD     836          (2,050)  
Cigna Corp.
     111          01/13/23        USD     335.00        USD     3,678          (49,950)  
Edwards Lifesciences Corp.
     42          01/13/23        USD     74.00        USD     313          (9,765)  
Eli Lilly & Co.
     138          01/13/23        USD     375.00        USD     5,049          (50,853)  
Gilead Sciences, Inc.
     182          01/13/23        USD     90.00        USD     1,562          (4,641)  
Johnson & Johnson
     187          01/13/23        USD     180.00        USD     3,303          (18,793)  
McKesson Corp.
     32          01/13/23        USD     390.00        USD     1,200          (6,640)  
Medtronic PLC
     217          01/13/23        USD     79.00        USD     1,687          (22,351)  
Merck & Co., Inc.
     151          01/13/23        USD     110.00        USD     1,675          (37,372)  
Merck & Co., Inc.
     243          01/13/23        USD     111.00        USD     2,696            (45,562)  
Moderna, Inc.
     23          01/13/23        USD     210.00        USD     413          (2,335)  
Pfizer, Inc.
     374          01/13/23        USD     52.00        USD     1,916          (23,375)  
Regeneron Pharmaceuticals, Inc.
     14          01/13/23        USD     760.00        USD     1,010          (5,320)  
Sarepta Therapeutics, Inc.
     59          01/13/23        USD     130.00        USD     765          (25,370)  
UnitedHealth Group, Inc.
     95          01/13/23        USD     555.00        USD     5,037          (20,567)  
Vertex Pharmaceuticals, Inc.
     25          01/13/23        USD     325.00        USD     722          (9,750)  
10X Genomics, Inc., Class A
     16          01/20/23        USD     50.00        USD     58          (880)  
10X Genomics, Inc., Class A
     6          01/20/23        USD     40.00        USD     22          (780)  
Abbott Laboratories
     128          01/20/23        USD     109.00        USD     1,405          (35,648)  
 
 
78
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
AbbVie, Inc.
     104          01/20/23        USD     160.00        USD     1,681        $ (41,600
Agilent Technologies, Inc.
     43          01/20/23        USD     140.00        USD     643          (47,515
Alcon, Inc.
     118          01/20/23        USD     70.00        USD     809          (12,980
Alkermes PLC
     22          01/20/23        USD     24.00        USD     57          (5,500
Alnylam Pharmaceuticals, Inc.
     43          01/20/23        USD     220.00        USD     1,022          (95,890
Amedisys, Inc.
     41          01/20/23        USD     100.00        USD     343          (4,510
AmerisourceBergen Corp.
     23          01/20/23        USD     160.00        USD     381          (17,825
Amgen, Inc.
     66          01/20/23        USD     295.00        USD     1,733          (1,221
Arcutis Biotherapeutics, Inc.
     55          01/20/23        USD     20.00        USD     81          (825
Argenx SE, ADR
     27          01/20/23        USD     400.00        USD     1,023          (15,525)  
Arvinas, Inc.
     15          01/20/23        USD     50.00        USD     51          (4,500
AstraZeneca PLC, ADR
     93          01/20/23        USD     65.00        USD     631          (32,317
Avantor, Inc.
     149          01/20/23        USD     22.50        USD     314          (4,098
Baxter International, Inc.
     107          01/20/23        USD     57.50        USD     545          (1,070
Biogen, Inc.
     100          01/20/23        USD     305.00        USD     2,769          (27,750
BioMarin Pharmaceutical, Inc.
     63          01/20/23        USD     90.00        USD     652          (84,420
Blueprint Medicines Corp.
     26          01/20/23        USD     50.00        USD     114          (7,800
Boston Scientific Corp.
     127          01/20/23        USD     45.00        USD     588          (24,130
Boston Scientific Corp.
     306          01/20/23        USD     48.00        USD     1,416          (11,475
Catalent, Inc.
     58          01/20/23        USD     50.00        USD     261          (4,930
Cerevel Therapeutics Holdings, Inc.
     31          01/20/23        USD     35.00        USD     98          (2,248
Cooper Cos., Inc.
     25          01/20/23        USD     320.00        USD     827          (43,250
Danaher Corp.
     118          01/20/23        USD     270.00        USD     3,132          (63,720
Design Therapeutics, Inc.
     33          01/20/23        USD     17.50        USD     34          (1,320
Dexcom, Inc.
     100          01/20/23        USD     120.00        USD     1,132          (22,750
Edwards Lifesciences Corp.
     53          01/20/23        USD     75.00        USD     395            (11,395
Edwards Lifesciences Corp.
     53          01/20/23        USD     76.00        USD     395          (8,745
Elevance Health, Inc.
     69          01/20/23        USD     550.00        USD     3,539          (11,385
Eli Lilly & Co.
     105          01/20/23        USD     370.00        USD     3,841          (77,700
Gilead Sciences, Inc.
     38          01/20/23        USD     90.00        USD     326          (1,520
Glaukos Corp.
     9          01/20/23        USD     55.00        USD     39          (675
HCA Healthcare, Inc.
     30          01/20/23        USD     240.00        USD     720          (19,200
Incyte Corp.
     102          01/20/23        USD     80.00        USD     819          (20,910
Insulet Corp.
     13          01/20/23        USD     320.00        USD     383          (1,820
Intuitive Surgical, Inc.
     125          01/20/23        USD     270.00        USD     3,317          (86,250
Ionis Pharmaceuticals, Inc.
     41          01/20/23        USD     40.00        USD     155          (2,050
IQVIA Holdings, Inc.
     30          01/20/23        USD     230.00        USD     615          (1,275
iRhythm Technologies, Inc.
     4          01/20/23        USD     120.51        USD     37          (94
Karuna Therapeutics, Inc.
     13          01/20/23        USD     270.00        USD     255          (2,860
Legend Biotech Corp., ADR
     27          01/20/23        USD     60.00        USD     135          (1,148
Masimo Corp.
     16          01/20/23        USD     150.00        USD     237          (6,640
McKesson Corp.
     39          01/20/23        USD     390.00        USD     1,463          (13,942
Medtronic PLC
     103          01/20/23        USD     80.00        USD     801          (9,682
Mettler-Toledo International, Inc.
     4          01/20/23        USD     1,550.00        USD     578          (3,500
Moderna, Inc.
     72          01/20/23        USD     190.00        USD     1,293          (41,040
Moderna, Inc.
     22          01/20/23        USD     220.00        USD     395          (1,760
Neurocrine Biosciences, Inc.
     44          01/20/23        USD     120.00        USD     526          (13,970
Nevro Corp.
     16          01/20/23        USD     50.00        USD     63          (480
Nevro Corp.
     31          01/20/23        USD     45.00        USD     123          (2,170
Novocure Ltd.
     20          01/20/23        USD     105.00        USD     147          (21,700
Novocure Ltd.
     20          01/20/23        USD     120.00        USD     147          (16,200
Omnicell, Inc.
     12          01/20/23        USD     55.00        USD     61          (1,170
Penumbra, Inc.
     20          01/20/23        USD     210.00        USD     445          (36,200
Penumbra, Inc.
     61          01/20/23        USD     240.00        USD     1,357          (26,230
Pfizer, Inc.
     427          01/20/23        USD     50.00        USD     2,188          (85,186
Prometheus Biosciences, Inc.
     13          01/20/23        USD     130.00        USD     143          (1,268
Prothena Corp. PLC
     33          01/20/23        USD     75.00        USD     199          (2,393
PTC Therapeutics, Inc.
     32          01/20/23        USD     41.00        USD     122          (4,480
QIAGEN NV
     17          01/20/23        USD     50.00        USD     85          (1,955
Quest Diagnostics, Inc.
     155          01/20/23        USD     155.00        USD     2,425          (61,225
Regeneron Pharmaceuticals, Inc.
     11          01/20/23        USD     750.00        USD     794          (11,715
ResMed, Inc.
     39          01/20/23        USD     230.00        USD     812          (15,600
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  79

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Revolution Medicines, Inc.
     35          01/20/23        USD     24.30        USD     83        $ (3,886
Rhythm Pharmaceuticals, Inc.
     32          01/20/23        USD     35.00        USD     93          (1,520
Rhythm Pharmaceuticals, Inc.
     67          01/20/23        USD     30.00        USD     195          (11,893
Sage Therapeutics, Inc.
     62          01/20/23        USD     42.50        USD     236          (2,325
Sarepta Therapeutics, Inc.
     6          01/20/23        USD     125.00        USD     78          (4,680
Seagen, Inc.
     39          01/20/23        USD     145.00        USD     501          (9,263
Stryker Corp.
     215          01/20/23        USD     240.00        USD     5,257            (201,025
Thermo Fisher Scientific, Inc.
     81          01/20/23        USD     570.00        USD     4,461          (59,535
UnitedHealth Group, Inc.
     65          01/20/23        USD     540.00        USD     3,446          (53,137
Vertex Pharmaceuticals, Inc.
     40          01/20/23        USD     305.00        USD     1,155          (7,300
West Pharmaceutical Services, Inc.
     5          01/20/23        USD     266.00        USD     118          (494
Zoetis, Inc.
     166          01/20/23        USD     155.00        USD     2,433          (18,260
AmerisourceBergen Corp.
     23          01/27/23        USD     170.00        USD     381          (6,555
Amgen, Inc.
     70          01/27/23        USD     275.00        USD     1,838          (12,145
Centene Corp.
     133          01/27/23        USD     85.00        USD     1,091          (16,292
Cigna Corp.
     8          01/27/23        USD     340.00        USD     265          (4,080
Elevance Health, Inc.
     34          01/27/23        USD     505.00        USD     1,744          (73,270
Eli Lilly & Co.
     104          01/27/23        USD     370.00        USD     3,805          (89,960
Medtronic PLC
     65          01/27/23        USD     78.00        USD     505          (13,487
Merck & Co., Inc.
     207          01/27/23        USD     112.00        USD     2,297          (44,298
Merck & Co., Inc.
     260          01/27/23        USD     110.00        USD     2,885          (83,200
Moderna, Inc.
     21          01/27/23        USD     225.00        USD     377          (2,342
Pfizer, Inc.
     427          01/27/23        USD     55.00        USD     2,188          (8,327
Regeneron Pharmaceuticals, Inc.
     15          01/27/23        USD     760.00        USD     1,082          (15,600
UnitedHealth Group, Inc.
     209          01/27/23        USD     540.00        USD     11,081          (209,000
Agilent Technologies, Inc.
     110          02/03/23        USD     156.00        USD     1,646          (34,532
Johnson & Johnson
     165          02/03/23        USD     180.00        USD     2,915          (44,962
Alkermes PLC
     20          02/06/23        USD     25.00        USD     52          (4,455
Insulet Corp.
     6          02/13/23        USD     308.00        USD     177          (6,263
10X Genomics, Inc., Class A
     17          02/17/23        USD     40.00        USD     62          (5,143
Abbott Laboratories
     170          02/17/23        USD     115.00        USD     1,866          (32,640
AbbVie, Inc.
     201          02/17/23        USD     165.00        USD     3,248          (80,902
Agilent Technologies, Inc.
     94          02/17/23        USD     165.00        USD     1,407          (16,920
Alcon, Inc.
     66          02/17/23        USD     72.50        USD     452          (9,570
Alkermes PLC
     22          02/17/23        USD     26.00        USD     57          (4,400
Alnylam Pharmaceuticals, Inc.
     16          02/17/23        USD     250.00        USD     380          (20,480
Amgen, Inc.
     129          02/17/23        USD     280.00        USD     3,388          (36,507
Arvinas, Inc.
     26          02/17/23        USD     45.00        USD     89          (2,210
Avantor, Inc.
     150          02/17/23        USD     22.50        USD     316          (10,500
Bausch & Lomb Corp.
     80          02/17/23        USD     15.00        USD     124          (9,800
Biogen, Inc.
     11          02/17/23        USD     310.00        USD     305          (5,280
BioMarin Pharmaceutical, Inc.
     52          02/17/23        USD     110.00        USD     538          (13,000
Boston Scientific Corp.
     866          02/17/23        USD     44.00        USD     4,007          (298,770
Boston Scientific Corp.
     306          02/17/23        USD     48.00        USD     1,416          (35,955
Cerevel Therapeutics Holdings, Inc.
     32          02/17/23        USD     30.00        USD     101          (12,160
Cooper Cos., Inc.
     16          02/17/23        USD     350.00        USD     529          (11,920
Dexcom, Inc.
     100          02/17/23        USD     116.50        USD     1,132          (65,351
Encompass Health Corp.
     84          02/17/23        USD     60.00        USD     502          (22,470
Encompass Health Corp.
     83          02/17/23        USD     58.00        USD     496          (31,427
Gilead Sciences, Inc.
     123          02/17/23        USD     87.50        USD     1,056          (32,841
Glaukos Corp.
     9          02/17/23        USD     45.00        USD     39          (2,903
Horizon Therapeutics PLC
     10          02/17/23        USD     80.00        USD     114          (34,350
Icon PLC
     31          02/17/23        USD     210.00        USD     602          (14,105
Immunocore Holdings PLC, ADR
     37          02/17/23        USD     60.00        USD     211          (20,165
Insulet Corp.
     14          02/17/23        USD     320.00        USD     412          (6,965
Intuitive Surgical, Inc.
     23          02/17/23        USD     270.00        USD     610          (31,165
IQVIA Holdings, Inc.
     63          02/17/23        USD     214.25        USD     1,291          (41,757
iRhythm Technologies, Inc.
     4          02/17/23        USD     110.00        USD     37          (1,380
Johnson & Johnson
     165          02/17/23        USD     180.00        USD     2,915          (57,750
Legend Biotech Corp., ADR
     26          02/17/23        USD     60.00        USD     130          (2,860
Masimo Corp.
     16          02/17/23        USD     155.00        USD     237          (10,000
Neurocrine Biosciences, Inc.
     44          02/17/23        USD     120.00        USD     526          (30,140
 
 
80
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Nevro Corp.
     90          02/17/23        USD     40.00        USD     356        $ (31,500
Omnicell, Inc.
     12          02/17/23        USD     50.00        USD     61          (6,480
Pfizer, Inc.
     53          02/17/23        USD     52.50        USD     272          (7,049
Prometheus Biosciences, Inc.
     13          02/17/23        USD     130.00        USD     143          (5,460
QIAGEN NV
     94          02/17/23        USD     50.00        USD     469          (19,035
ResMed, Inc.
     33          02/17/23        USD     220.00        USD     687          (18,810
Revolution Medicines, Inc.
     18          02/17/23        USD     30.00        USD     43          (2,070
Rhythm Pharmaceuticals, Inc.
     83          02/17/23        USD     30.00        USD     242          (26,560
Sage Therapeutics, Inc.
     20          02/17/23        USD     45.00        USD     76          (1,400
Sarepta Therapeutics, Inc.
     3          02/17/23        USD     130.00        USD     39          (2,580
Seagen, Inc.
     40          02/17/23        USD     145.00        USD     514          (11,500
Stryker Corp.
     14          02/17/23        USD     251.14        USD     342          (11,285
Ultragenyx Pharmaceutical, Inc.
     23          02/17/23        USD     45.00        USD     107          (12,190
Vertex Pharmaceuticals, Inc.
     39          02/17/23        USD     310.00        USD     1,126          (24,375
Waters Corp.
     40          02/17/23        USD     350.00        USD     1,370          (55,800
West Pharmaceutical Services, Inc.
     10          02/17/23        USD     260.00        USD     235          (5,850
Zimmer Biomet Holdings, Inc.
     55          02/17/23        USD     129.50        USD     701          (24,296
Zoetis, Inc.
     130          02/17/23        USD     160.00        USD     1,905          (24,700
Revolution Medicines, Inc.
     18          03/17/23        USD     30.00        USD     43          (3,960
                          
 
 
 
                           $  (4,204,659
                          
 
 
 
OTC Options Written
 
 
 
Description
 
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
 
 
Call
               
Daiichi Sankyo Co. Ltd.
  UBS AG     22,500       01/05/23       JPY       4,912.95       JPY       95,625     $ (273
Bausch & Lomb Corp.
  Citibank N.A.     7,300       01/11/23       USD       15.36       USD       113       (4,580
Daiichi Sankyo Co. Ltd.
  BNP Paribas SA     10,500       01/11/23       JPY       4,717.44       JPY       44,625       (1,419
Genmab A/S
  JPMorgan Chase Bank N.A.     900       01/11/23       DKK       3,275.40       DKK       2,647       (146
Sanofi
  Goldman Sachs International     4,700       01/11/23       EUR       89.95       EUR       422       (6,321
Roche Holding AG
  UBS AG     2,000       01/13/23       CHF       314.10       CHF       581       (114
Roche Holding AG
  Barclays Bank PLC     1,200       01/17/23       CHF       308.64       CHF       349       (302
Bausch & Lomb Corp.
  Morgan Stanley & Co. International PLC     5,500       01/20/23       USD       15.80       USD       85       (3,667
Ionis Pharmaceuticals, Inc.
  JPMorgan Chase Bank N.A.     2,900       01/23/23       USD       48.30       USD       110       (428
Daiichi Sankyo Co. Ltd.
  Goldman Sachs International     10,400       01/25/23       JPY       4,544.39       JPY       44,200       (3,108
Sanofi
  Goldman Sachs International     4,700       01/27/23       EUR       89.66       EUR       422       (11,005
Genmab A/S, ADR
  Citibank N.A.     6,400       01/30/23       USD       43.15       USD       271       (13,065
West Pharmaceutical Services, Inc.
  JPMorgan Chase Bank N.A.     400       01/30/23       USD       251.58       USD       94       (2,332
AstraZeneca PLC
  Morgan Stanley & Co. International PLC     3,600       02/02/23       GBP       114.69       GBP       404       (7,420
Alcon, Inc.
  Morgan Stanley & Co. International PLC     11,600       02/03/23       USD       67.45       USD       795       (37,856
AstraZeneca PLC
  Morgan Stanley & Co. International PLC     20,700       02/08/23       GBP       118.56       GBP       2,322       (26,633
               
 
 
 
                $   (118,669
               
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
 
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
 
 
Options Written
   $  N/A      $  N/A      $ 2,767,997      $ (589,008    $  (4,323,328)  
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  81

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
 
 
   
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
 
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $  4,323,328     $     $     $     $  4,323,328  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
 
 
   
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
 
 
Net Realized Gain (Loss) from:
             
Options purchased
(a)
  $     $     $ (575,962   $     $     $     $ (575,962
Options written
                4,201,095                         4,201,095  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $     $     $ 3,625,133     $     $     $     $  3,625,133  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
             
Options written
  $     $     $  5,913,956     $     $     $     $  5,913,956  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
 
 
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 5,279,903  
 
 
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
 
 
    
Assets
    
Liabilities 
 
 
 
Derivative Financial Instruments
     
Options
   $      $ 4,323,328  
  
 
 
    
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
            4,323,328  
  
 
 
    
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
            (4,204,659
  
 
 
    
 
 
 
Total derivative assets and liabilities subject to an MNA
   $      $ 118,669  
  
 
 
    
 
 
 
 
 
82
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust (BME)
    
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    
 

Derivatives
Available
for Offset
 
 
 
    
 

Non-Cash
Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
    
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 302        $        $      $        $ 302  
BNP Paribas SA
     1,419                                   1,419  
Citibank N.A.
     17,645                                   17,645  
Goldman Sachs International
     20,434                                   20,434  
JPMorgan Chase Bank N.A.
     2,906                   (2,906                
Morgan Stanley & Co. International PLC
     75,576                                   75,576  
UBS AG
     387                                   387  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
   $ 118,669        $        $     (2,906)      $        $ 115,763  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total 
 
 
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Biotechnology
   $ 124,598,169        $ 1,056,141        $ 256,698        $ 125,911,008  
Diversified Financial Services
     136,823                            136,823  
Health Care Equipment & Supplies
     116,474,140                   14,646          116,488,786  
Health Care Providers & Services
     123,213,033                            123,213,033  
Life Sciences Tools & Services
     68,358,259                            68,358,259  
Pharmaceuticals
     124,817,717          16,767,838                   141,585,555  
Other Interests
                       144,522          144,522  
Preferred Securities
                 
Preferred Stocks
                       3,968,167          3,968,167  
Warrants
     2,371                            2,371  
Short-Term Securities
                 
Money Market Funds
     23,195,315                            23,195,315  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $  580,795,827        $   17,823,979        $   4,384,033          603,003,839  
  
 
 
      
 
 
      
 
 
      
 
 
 
Investments Valued at NAV
(a)
                    675,980  
                 
 
 
 
                  $  603,679,819  
                 
 
 
 
Derivative Financial Instruments
(b)
                 
Liabilities
                 
Equity Contracts
   $ (3,978,645      $ (344,683      $        $ (4,323,328
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
 
(b)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  83

Schedule of Investments
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
(Percentages shown are based on Net Assets)
 
 
Security
 
Shares
   
Value
 
Common Stocks
 
Biotechnology — 37.7%
 
Abbisko Cayman Ltd., (Acquired 10/29/21, Cost: $14,841,983)
(a)
    10,378,250     $       4,236,223  
Acumen Pharmaceuticals, Inc.
(b)
    833,448       4,500,619  
Affinivax, Inc., (Acquired 08/18/22,
Cost: $0)
(a)(c)
    183,164       2,366,479  
Alkermes PLC
(b)
    1,163,110       30,392,064  
Alnylam Pharmaceuticals, Inc.
(b)(d)
    177,747       42,241,575  
Annexon, Inc.
(b)
    237,835       1,229,607  
Apellis Pharmaceuticals, Inc.
(b)
    80,955       4,186,183  
Arcus Biosciences, Inc.
(b)
    84,495       1,747,357  
Arcutis Biotherapeutics, Inc.
(b)
    511,332       7,567,714  
Argenx SE, ADR
(b)
    54,934       20,810,647  
Arrowhead Pharmaceuticals, Inc.
(b)
    81,025       3,286,374  
Biogen, Inc.
(b)
    36,740       10,174,041  
Biohaven Ltd.
(b)
    99,155       1,376,271  
BioMarin Pharmaceutical, Inc.
(b)
    365,103       37,784,509  
Biomea Fusion, Inc.
(b)
    95,454       804,677  
BioNTech SE, ADR
    61,590       9,252,050  
Blueprint Medicines Corp.
(b)
    210,780       9,234,272  
Cellarity, Inc., (Acquired 01/15/21, Cost: $14,584,998)
(a)(c)
    2,430,833       9,626,099  
Cerevel Therapeutics Holdings, Inc.
(b)
    266,656       8,410,330  
Connect Biopharma Holdings Ltd.
(b)
    1,125,262       976,502  
CRISPR Therapeutics AG
(b)
    94,915       3,858,295  
Day One Biopharmaceuticals, Inc.
(b)
    200,635       4,317,665  
Decibel Therapeutics, Inc.
(b)(e)
    793,527       1,626,730  
Design Therapeutics, Inc.
(b)(f)
    446,731       4,583,460  
Enanta Pharmaceuticals, Inc.
(b)
    20,508       954,032  
EQRx, Inc.
(b)
    220,265       541,852  
Everest Medicines Ltd.
    3,113,667       6,884,950  
Exact Sciences Corp.
(b)
    239,870       11,875,964  
Exelixis, Inc.
(b)
    599,520       9,616,301  
FibroGen, Inc.
(b)
    136,080       2,180,002  
Galapagos NV, ADR
(b)
    74,410       3,302,316  
Genmab A/S
(b)
    34,827       14,724,674  
Genmab A/S, ADR
(b)
    114,086       4,834,965  
Gilead Sciences, Inc.
    254,765       21,871,575  
Gracell Biotechnologies, Inc., ADR
(b)
    340,846       783,946  
Halozyme Therapeutics, Inc.
(b)
    502,750       28,606,475  
Horizon Therapeutics PLC
(b)
    75,466       8,588,031  
Imago Biosciences, Inc.
(b)
    1,120,866       40,295,133  
Immuneering Corp., Class A
(b)(e)
    696,696       3,378,976  
Immunocore Holdings PLC, ADR
(b)
    59,868       3,416,667  
Immunocore Holdings PLC
    321,900       18,370,833  
ImmunoGen, Inc.
(b)
    497,785       2,469,014  
Incyte Corp.
(b)
    331,720       26,643,750  
Ionis Pharmaceuticals, Inc.
(b)
    468,285       17,687,124  
Karuna Therapeutics, Inc.
(b)
    46,950       9,225,675  
Keros Therapeutics, Inc.
(b)
    200,607       9,633,148  
Kinnate Biopharma, Inc.
(b)
    295,538       1,802,782  
Kronos Bio, Inc.
(b)
    284,272       460,521  
Krystal Biotech, Inc.
(b)
    26,937       2,133,949  
Legend Biotech Corp., ADR
(b)
    195,632       9,765,949  
LianBio, Series A, ADR
(b)
    615,188       1,008,908  
Mirati Therapeutics, Inc.
(b)
    46,905       2,125,266  
Moderna, Inc.
(b)
    108,100       19,416,922  
Monte Rosa Therapeutics, Inc.
(b)
    764,573       5,818,401  
MoonLake Immunotherapeutics
(b)(e)
    216,150       2,269,575  
Neurocrine Biosciences, Inc.
(b)
    268,575       32,078,598  
Nuvalent, Inc., Class A
(b)
    158,475       4,719,385  
Security
 
Shares
   
Value
 
Biotechnology (continued)
 
Omega Therapeutics, Inc.
(b)
    161,767     $          923,690  
PMV Pharmaceuticals, Inc.
(b)
    305,830       2,660,721  
Prime Medicine, Inc.
(e)
    412,139       7,657,543  
Prometheus Biosciences, Inc.
(b)
    83,554       9,190,940  
Prothena Corp. PLC
(b)
    126,646       7,630,421  
PTC Therapeutics, Inc.
(b)
    79,210       3,023,446  
Revolution Medicines, Inc.
(b)
    377,632       8,995,194  
Rhythm Pharmaceuticals, Inc.
(b)
    683,675       19,908,616  
Rocket Pharmaceuticals, Inc.
(b)
    177,632       3,476,258  
Sage Therapeutics, Inc.
(b)
    272,895       10,408,215  
Sarepta Therapeutics, Inc.
(b)(d)
    282,889       36,656,757  
Seagen, Inc.
(b)(d)(g)
    79,130       10,168,996  
Sigilon Therapeutics, Inc.
(b)
    564,538       197,588  
Tenaya Therapeutics, Inc.
(b)
    165,729       333,115  
TScan Therapeutics, Inc.
(b)
    855,317       1,394,167  
Twist Bioscience Corp.
(b)
    204,550       4,870,335  
Ultragenyx Pharmaceutical, Inc.
(b)
    99,375       4,604,044  
United Therapeutics Corp.
(b)(d)
    55,704       15,490,725  
Vaxcyte, Inc.
(b)
    60,290       2,890,905  
Vertex Pharmaceuticals, Inc.
(b)(g)
    235,570       68,027,905  
Viridian Therapeutics, Inc.
(b)
    120,615       3,523,164  
   
 
 
 
      774,108,147  
Diversified Financial Services
(b)
— 0.8%
           
DA32 Life Science Tech Acquisition Corp.,
Class A
(f)
    1,496,819       14,818,508  
Health Sciences Acquisitions Corp.
    233,344       2,331,107  
   
 
 
 
          17,149,615  
Electronic Equipment, Instruments & Components — 0.1%
 
908 Devices, Inc.
(b)(f)
    274,084       2,088,520  
   
 
 
 
Health Care Equipment & Supplies — 24.2%
 
Abiomed, Inc.
(c)
    98,636       100,609  
Alcon, Inc.
    736,189       50,465,756  
Align Technology, Inc.
(b)
    36,710       7,742,139  
Bausch & Lomb Corp.
(b)(e)
    523,547       8,120,214  
Boston Scientific Corp.
(b)
    455,830       21,091,254  
ConvaTec Group PLC
(h)
    4,411,215       12,354,350  
Cooper Cos., Inc.
    101,760       33,648,979  
Dexcom, Inc.
(b)
    361,853       40,976,234  
Glaukos Corp.
(b)
    55,300       2,415,504  
Globus Medical, Inc., Class A
(b)
    104,070       7,729,279  
Hologic, Inc.
(b)(d)
    233,820       17,492,074  
Insulet Corp.
(b)
    127,880       37,646,593  
Intuitive Surgical, Inc.
(b)
    116,128       30,814,565  
iRhythm Technologies, Inc.
(b)
    59,920       5,612,706  
Masimo Corp.
(b)
    106,515       15,758,894  
Nevro Corp.
(b)(d)
    376,430       14,906,628  
Novocure Ltd.
(b)
    127,530       9,354,325  
Nyxoah SA
(b)(e)
    648,041       3,084,675  
Omnicell, Inc.
(b)
    140,725       7,095,355  
Penumbra, Inc.
(b)
    175,178       38,970,098  
Pulmonx Corp.
(b)
    335,566       2,828,821  
ResMed, Inc.
(d)
    167,296       34,819,316  
Shockwave Medical, Inc.
(b)
    53,670       11,035,089  
SI-BONE, Inc.
(b)
    204,910       2,786,776  
Silk Road Medical, Inc.
(b)
    204,932       10,830,656  
STAAR Surgical Co.
(b)
    73,525       3,568,904  
STERIS PLC
    136,740       25,254,511  
Stryker Corp.
    127,940       31,280,051  
Tandem Diabetes Care, Inc.
(b)(d)
    238,345       10,713,608  
   
 
 
 
      498,497,963  
 
 
84
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
(Percentages shown are based on Net Assets)
 
    
Security
 
Shares
   
Value
 
Health Care Providers & Services — 5.1%
 
Amedisys, Inc.
(b)
    164,226     $      13,719,440  
AmerisourceBergen Corp.
    193,455       32,057,428  
Chemed Corp.
    10,662       5,442,205  
Encompass Health Corp.
(d)
    279,008       16,687,469  
Guardant Health, Inc.
(b)
    181,915       4,948,088  
Kindstar Globalgene Technology, Inc.
(b)(h)
    4,092,500       1,496,119  
LHC Group, Inc.
(b)(d)
    138,534       22,399,562  
R1 RCM, Inc.
(b)
    690,615       7,562,234  
   
 
 
 
      104,312,545  
Health Care Technology — 0.0%
 
Sophia Genetics SA
(b)
    291,485       600,459  
   
 
 
 
Life Sciences Tools & Services — 14.7%
 
10X Genomics, Inc., Class A
(b)
    231,905       8,450,618  
Agilent Technologies, Inc.
    209,600       31,366,640  
Avantor, Inc.
(b)(d)
    560,319       11,817,128  
Bio-Techne Corp.
    136,220       11,289,914  
Bruker Corp.
    207,802       14,203,267  
Cytek Biosciences, Inc.
(b)
    840,842       8,584,997  
Danaher Corp.
    57,370       15,227,145  
Gerresheimer AG
    243,305       16,275,977  
IQVIA Holdings, Inc.
(b)
    127,062       26,033,733  
Mettler-Toledo International, Inc.
(b)(d)
    21,545       31,142,220  
QIAGEN NV
(b)
    645,525       32,192,332  
Rapid Micro Biosystems, Inc., Class A
(b)
    549,778       621,249  
Thermo Fisher Scientific, Inc.
    29,690       16,349,986  
Waters Corp.
(b)
    109,980       37,676,948  
West Pharmaceutical Services, Inc.
    134,085       31,556,905  
Wuxi Biologics Cayman, Inc.
(b)(h)
    1,233,303       9,340,920  
   
 
 
 
      302,129,979  
Pharmaceuticals — 6.5%
 
Antengene Corp. Ltd.
    5,019,274       3,304,265  
Arvinas, Inc.
(b)
    193,095       6,605,780  
AstraZeneca PLC, ADR
    245,200       16,624,560  
Catalent, Inc.
(b)
    347,125       15,624,096  
Daiichi Sankyo Co. Ltd.
    1,462,400       47,069,816  
Nuvation Bio, Inc.
(b)
    200,496       384,952  
Reata Pharmaceuticals, Inc., Class A
(b)
    40,405       1,534,986  
UCB SA
    344,377       27,134,651  
Zoetis, Inc.
(d)
    101,710       14,905,601  
   
 
 
 
      133,188,707  
   
 
 
 
Total Common Stocks — 89.1%
(Cost: $1,884,600,649)
 
    1,832,075,935  
   
 
 
 
Security
 
Benefical
Interest (000)
   
Value
 
Other Interests
 
Biotechnology — 0.2%
 
Vividion Therapeutics, Inc.
(a)(c)(i)
  $ 3,810     $        4,076,191  
   
 
 
 
Total Other Interests — 0.2%
(Cost: $ — )
 
    4,076,191  
   
 
 
 
    
Shares
        
Preferred Securities
 
Preferred Stocks — 7.7%
(a)(c)
 
Biotechnology — 2.7%
 
Amunix Pharmaceuticals, Inc., Series B, (Acquired 02/08/22, Cost: $0)
    5,657,068       3,620,523  
Bright Peak Therapeutics AG, Series B, (Acquired 05/14/21, Cost: $8,000,004)
    2,048,132       4,260,115  
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $4,543,847)
    3,850,718       1,232,230  
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $13,498,156)
    482,077       12,148,340  
Mirvie, Inc., Series B, (Acquired 10/15/21, Cost: $6,250,000)
    2,793,833       5,894,988  
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $9,549,916)
    3,913,900       9,510,777  
NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996)
    1,394,189       6,050,780  
Numab Therapeutics AG, Series C, (Acquired 05/07/21, Cost: $7,770,441)
    815,851       7,173,383  
OnKure, Inc., Series B, (Acquired 03/03/21, Cost: $4,500,001)
    1,628,488       4,852,894  
   
 
 
 
      54,744,030  
Health Care Equipment & Supplies — 1.3%
 
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $13,225,003)
    2,257,597       6,659,911  
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $6,929,998)
    2,379,480       6,733,929  
Quanta Dialysis Technologies Ltd.,
Series D, (Acquired 06/18/21,
Cost: $14,071,890)
    115,766,240       9,237,070  
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $6,441,930)
    2,078,042       3,678,134  
   
 
 
 
      26,309,044  
Health Care Providers & Services — 1.6%
 
Adicon Holdings Ltd., (Acquired 12/22/20, Cost: $17,840,000)
    10,696,226       22,889,923  
Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986)
    382,775       11,280,379  
   
 
 
 
      34,170,302  
Pharmaceuticals — 0.6%
 
Insitro, Inc.
   
Series B, (Acquired 05/21/20,
Cost: $4,999,999)
    802,478       9,541,464  
Series C, (Acquired 03/10/21,
Cost: $3,600,018)
    196,818       2,340,166  
   
 
 
 
      11,881,630  
 
 
S
C
H
E
D
U
L
E
   
O
F   
I
N
V
E
S
T
M
E
N
T
S
  85

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Semiconductors & Semiconductor Equipment — 0.7%
 
PsiQuantum Corp., Series D, (Acquired 05/21/21,
Cost: $14,999,996)
    571,947      $       14,533,173  
    
 
 
 
Software — 0.8%
 
Carbon Health Technologies, Inc., (Acquired 07/09/21,
Cost: $17,100,000)
    17,100        17,153,523  
    
 
 
 
       158,791,702  
    
 
 
 
Total Preferred Securities — 7.7%
(Cost: $171,321,181)
 
     158,791,702  
    
 
 
 
Warrants
 
Health Care Providers & Services — 0.0%
 
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price
USD 11.50)
(b)
    63,808        27,118  
    
 
 
 
Pharmaceuticals — 0.0%
 
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)
(b)
    68,880        9,953  
    
 
 
 
Total Warrants — 0.0%
(Cost: $227,725)
 
     37,071  
    
 
 
 
Total Long-Term Investments — 97.0%
(Cost: $2,056,149,555)
 
     1,994,980,899  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 4.1%
            
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(f)(j)
    83,001,707        83,001,707  
SL Liquidity Series, LLC, Money Market Series, 4.49%
(f)(j)(k)
    1,828,233        1,828,050  
    
 
 
 
Total Short-Term Securities — 4.1%
(Cost: $84,829,558)
 
     84,829,757  
    
 
 
 
Total Investments Before Options Written — 101.1%
 
(Cost: $2,140,979,113)
 
     2,079,810,656  
    
 
 
 
Options Written — (0.9)%
(Premiums Received: $(20,871,623))
 
     (18,495,960
    
 
 
 
Total Investments, Net of Options Written — 100.2%
 
(Cost: $2,120,107,490)
 
     2,061,314,696  
Liabilities in Excess of Other Assets — (0.2)%
 
     (4,895,976
    
 
 
 
Net Assets — 100.0%
 
   $  2,056,418,720  
    
 
 
 
 
(a)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $179,096,694, representing 8.7% of its net assets as of period end, and an original cost of $200,748,162.
(b)
 
Non-income producing security.
(c)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(d)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(e)
 
All or a portion of this security is on loan.
(f)
 
Affiliate of the Trust.
(g)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(h)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(i)
 
Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
(j)
 
Annualized 7-day yield as of period end.
(k)
 
All or a portion of this security was purchased with the cash collateral from loaned securities.
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
 
 
86
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds,
T-Fund, Institutional Class
  $ 61,616,484     $ 21,385,223
(a)
 
  $     $     $     $ 83,001,707       83,001,707     $ 904,054     $  
DA32 Life Science Tech Acquisition Corp., Class A
    14,683,795                         134,713       14,818,508       1,496,819              
Eucrates Biomedical Acquisition Corp.
(b)
    8,761,132             (9,040,612     485,043       (205,563     N/A       N/A              
SL Liquidity Series, LLC, Money Market Series
    4,939,518             (3,110,643 )
(a)
 
    (1,162     337       1,828,050       1,828,233       321,733
(c)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ 483,881     $ (70,513   $ 99,648,265       $ 1,225,787     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
 
(b)
 
As of period end, the entity is no longer an affiliate.
 
 
(c)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period End
Forward Foreign Currency Exchange Contracts
 
 
 
Currency Purchased
      
Currency Sold
    
Counterparty
  
Settlement Date
      
Unrealized
Appreciation
(Depreciation)
 
 
 
AUD
     34,753,850          USD        22,994,537      Goldman Sachs International      03/15/23        $ 734,424  
DKK
     223,287,150          USD        30,856,536      BNP Paribas SA      03/15/23          1,458,879  
EUR
     30,956,300          USD        31,785,000      BNP Paribas SA      03/15/23          1,511,092  
GBP
     4,842,100          USD        5,678,815      BNP Paribas SA      03/15/23          185,224  
JPY
     2,040,830,600          USD        14,621,225      BNP Paribas SA      03/15/23          1,074,936  
                     
 
 
 
                      $ 4,964,555  
                     
 
 
 
Exchange-Traded Options Written
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call                                                   
AmerisourceBergen Corp.
     295          01/06/23        USD     175.00        USD     4,888        $       (2,950)  
Danaher Corp.
     100          01/06/23        USD     275.00        USD     2,654          (8,000)  
Exact Sciences Corp.
     502          01/06/23        USD     52.00        USD     2,485          (26,355)  
Intuitive Surgical, Inc.
     76          01/06/23        USD     270.00        USD     2,017          (17,100)  
Moderna, Inc.
     80          01/06/23        USD     215.00        USD     1,437          (1,040)  
Sarepta Therapeutics, Inc.
     199          01/06/23        USD     127.00        USD     2,579          (63,182)  
Tandem Diabetes Care, Inc.
     132          01/06/23        USD     43.00        USD     593          (31,680)  
Thermo Fisher Scientific, Inc.
     47          01/06/23        USD     570.00        USD     2,588          (7,285)  
Vertex Pharmaceuticals, Inc.
     222          01/06/23        USD     320.00        USD     6,411          (2,220)  
Align Technology, Inc.
     57          01/13/23        USD     210.00        USD     1,202          (51,870)  
Alkermes PLC
     885          01/13/23        USD     25.60        USD     2,313          (101,244)  
AmerisourceBergen Corp.
     162          01/13/23        USD     175.00        USD     2,685          (19,440)  
CRISPR Therapeutics AG
     300          01/13/23        USD     59.00        USD     1,220          (22,500)  
Moderna, Inc.
     92          01/13/23        USD     210.00        USD     1,653          (9,338)  
Sarepta Therapeutics, Inc.
     103          01/13/23        USD     130.00        USD     1,335          (44,290)  
Vertex Pharmaceuticals, Inc.
     180          01/13/23        USD     325.00        USD     5,198          (70,200)  
10X Genomics, Inc., Class A
     144          01/20/23        USD     50.00        USD     525          (7,920)  
10X Genomics, Inc., Class A
     149          01/20/23        USD     40.00        USD     543          (19,370)  
908 Devices, Inc.
     400          01/20/23        USD     12.50        USD     305          (4,000)  
Agilent Technologies, Inc.
     284          01/20/23        USD     140.00        USD     4,250          (313,820)  
Alcon, Inc.
     1,175          01/20/23        USD     70.00        USD     8,055          (129,250)  
Align Technology, Inc.
     60          01/20/23        USD     240.00        USD     1,265          (10,350)  
Alkermes PLC
     976          01/20/23        USD     24.00        USD     2,550          (244,000)  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  87

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Alnylam Pharmaceuticals, Inc.
     463          01/20/23        USD     220.00        USD     11,003        $   (1,032,490
Amedisys, Inc.
     263          01/20/23        USD     100.00        USD     2,197          (28,930
AmerisourceBergen Corp.
     81          01/20/23        USD     160.00        USD     1,342          (62,775
Arcutis Biotherapeutics, Inc.
     545          01/20/23        USD     20.00        USD     807          (8,175
Argenx SE, ADR
     182          01/20/23        USD     400.00        USD     6,895          (104,650
Arrowhead Pharmaceuticals, Inc.
     129          01/20/23        USD     35.00        USD     523          (79,980
Arvinas, Inc.
     126          01/20/23        USD     50.00        USD     431          (37,800
AstraZeneca PLC, ADR
     620          01/20/23        USD     65.00        USD     4,204          (215,450
AstraZeneca PLC, ADR
     164          01/20/23        USD     70.00        USD     1,112          (9,840
Avantor, Inc.
     897          01/20/23        USD     22.50        USD     1,892          (24,668
Biogen, Inc.
     120          01/20/23        USD     305.00        USD     3,323          (33,300
BioMarin Pharmaceutical, Inc.
     587          01/20/23        USD     90.00        USD     6,075          (786,580
Bio-Techne Corp.
     28          01/20/23        USD     90.00        USD     232          (5,460
Blueprint Medicines Corp.
     334          01/20/23        USD     50.00        USD     1,463          (100,200
Boston Scientific Corp.
     418          01/20/23        USD     45.00        USD     1,934          (79,420
Boston Scientific Corp.
     520          01/20/23        USD     48.00        USD     2,406          (19,500
Bruker Corp.
     332          01/20/23        USD     67.50        USD     2,269          (97,940
Catalent, Inc.
     388          01/20/23        USD     50.00        USD     1,746          (32,980
Cerevel Therapeutics Holdings, Inc.
     455          01/20/23        USD     35.00        USD     1,435          (32,988
Chemed Corp.
     34          01/20/23        USD     510.00        USD     1,735          (37,060
Cooper Cos., Inc.
     235          01/20/23        USD     320.00        USD     7,771          (406,550
Danaher Corp.
     83          01/20/23        USD     270.00        USD     2,203          (44,820
Day One Biopharmaceuticals, Inc.
     340          01/20/23        USD     25.00        USD     732          (96,900
Day One Biopharmaceuticals, Inc.
     300          01/20/23        USD     22.50        USD     646          (78,000
Design Therapeutics, Inc.
     627          01/20/23        USD     17.50        USD     643          (25,080
Dexcom, Inc.
     580          01/20/23        USD     120.00        USD     6,568          (131,950
Exact Sciences Corp.
     265          01/20/23        USD     47.50        USD     1,312          (115,275
Exelixis, Inc.
     1,439          01/20/23        USD     18.00        USD     2,308          (35,975
Galapagos NV, ADR
     238          01/20/23        USD     40.00        USD     1,056          (108,290
Gilead Sciences, Inc.
     408          01/20/23        USD     90.00        USD     3,503          (16,320
Glaukos Corp.
     88          01/20/23        USD     55.00        USD     384          (6,600
Globus Medical, Inc., Class A
     166          01/20/23        USD     70.00        USD     1,233          (94,620
Halozyme Therapeutics, Inc.
     377          01/20/23        USD     55.00        USD     2,145          (128,180
Hologic, Inc.
     374          01/20/23        USD     80.00        USD     2,798          (19,635
Incyte Corp.
     646          01/20/23        USD     80.00        USD     5,189          (132,430
Insulet Corp.
     117          01/20/23        USD     320.00        USD     3,444          (16,380
Intuitive Surgical, Inc.
     151          01/20/23        USD     270.00        USD     4,007          (104,190
Ionis Pharmaceuticals, Inc.
     750          01/20/23        USD     40.00        USD     2,833          (37,500
IQVIA Holdings, Inc.
     174          01/20/23        USD     230.00        USD     3,565          (7,395
iRhythm Technologies, Inc.
     95          01/20/23        USD     120.51        USD     890          (2,239
Karuna Therapeutics, Inc.
     150          01/20/23        USD     270.00        USD     2,948          (33,000
Keros Therapeutics, Inc.
     320          01/20/23        USD     55.00        USD     1,537          (160,000
Krystal Biotech, Inc.
     50          01/20/23        USD     90.00        USD     396          (11,250
Legend Biotech Corp., ADR
     313          01/20/23        USD     60.00        USD     1,562          (13,303
Masimo Corp.
     170          01/20/23        USD     150.00        USD     2,515          (70,550
Mettler-Toledo International, Inc.
     68          01/20/23        USD     1,550.00        USD     9,829          (59,500
Moderna, Inc.
     92          01/20/23        USD     220.00        USD     1,653          (7,360
Neurocrine Biosciences, Inc.
     469          01/20/23        USD     120.00        USD     5,602          (148,907
Nevro Corp.
     163          01/20/23        USD     50.00        USD     645          (4,890
Nevro Corp.
     328          01/20/23        USD     45.00        USD     1,299          (22,960
Novocure Ltd.
     204          01/20/23        USD     105.00        USD     1,496          (221,340
Novocure Ltd.
     204          01/20/23        USD     120.00        USD     1,496          (165,240
Omnicell, Inc.
     225          01/20/23        USD     55.00        USD     1,134          (21,938
Penumbra, Inc.
     110          01/20/23        USD     210.00        USD     2,447          (199,100
Penumbra, Inc.
     450          01/20/23        USD     240.00        USD     10,011          (193,500
Prometheus Biosciences, Inc.
     92          01/20/23        USD     85.00        USD     1,012          (234,600
Prothena Corp. PLC
     405          01/20/23        USD     75.00        USD     2,440          (29,363
PTC Therapeutics, Inc.
     253          01/20/23        USD     41.00        USD     966          (35,420
QIAGEN NV
     799          01/20/23        USD     50.00        USD     3,985          (91,885
R1 RCM, Inc.
     1,104          01/20/23        USD     12.50        USD     1,209          (27,600
ResMed, Inc.
     315          01/20/23        USD     230.00        USD     6,556          (126,000
Revolution Medicines, Inc.
     604          01/20/23        USD     24.30        USD     1,439          (67,058
 
 
88
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Rhythm Pharmaceuticals, Inc.
     583          01/20/23        USD     35.00        USD     1,698        $       (27,693
Rhythm Pharmaceuticals, Inc.
     673          01/20/23        USD     30.00        USD     1,960          (119,457
Sage Therapeutics, Inc.
     424          01/20/23        USD     42.50        USD     1,617          (15,900
Sarepta Therapeutics, Inc.
     404          01/20/23        USD     125.00        USD     5,235          (315,120
Seagen, Inc.
     126          01/20/23        USD     145.00        USD     1,619          (29,925
Shockwave Medical, Inc.
     80          01/20/23        USD     280.00        USD     1,645          (8,000
Shockwave Medical, Inc.
     91          01/20/23        USD     250.00        USD     1,871          (14,560
Silk Road Medical, Inc.
     300          01/20/23        USD     55.00        USD     1,586          (54,000
STAAR Surgical Co.
     117          01/20/23        USD     75.00        USD     568          (8,775
STERIS PLC
     135          01/20/23        USD     200.00        USD     2,493          (45,900
STERIS PLC
     135          01/20/23        USD     195.00        USD     2,493          (36,450
STERIS PLC
     166          01/20/23        USD     210.00        USD     3,066          (29,880
Stryker Corp.
     1          01/20/23        USD     240.00        USD     24          (935
Stryker Corp.
     106          01/20/23        USD     250.00        USD     2,592          (42,400
Stryker Corp.
     98          01/20/23        USD     260.00        USD     2,396          (13,965
Tandem Diabetes Care, Inc.
     165          01/20/23        USD     45.00        USD     742          (38,362
Thermo Fisher Scientific, Inc.
     48          01/20/23        USD     570.00        USD     2,643          (35,280
Twist Bioscience Corp.
     654          01/20/23        USD     35.00        USD     1,557          (16,350
United Therapeutics Corp.
     94          01/20/23        USD     260.00        USD     2,614          (195,050
Vaxcyte, Inc.
     192          01/20/23        USD     50.00        USD     921          (49,440
Vertex Pharmaceuticals, Inc.
     175          01/20/23        USD     305.00        USD     5,054          (31,938
Viridian Therapeutics, Inc.
     342          01/20/23        USD     25.00        USD     999          (152,190
Waters Corp.
     157          01/20/23        USD     330.00        USD     5,379          (274,750
West Pharmaceutical Services, Inc.
     62          01/20/23        USD     266.00        USD     1,459          (6,121
Zoetis, Inc.
     306          01/20/23        USD     155.00        USD     4,484          (33,660
AmerisourceBergen Corp.
     81          01/27/23        USD     170.00        USD     1,342          (23,085
Moderna, Inc.
     81          01/27/23        USD     225.00        USD     1,455          (9,032
Halozyme Therapeutics, Inc.
     452          01/30/23        USD     54.05        USD     2,572          (210,195
Agilent Technologies, Inc.
     207          02/03/23        USD     156.00        USD     3,098          (64,983
Alkermes PLC
     884          02/06/23        USD     25.00        USD     2,310          (196,905
Incyte Corp.
     415          02/10/23        USD     83.00        USD     3,333          (74,586
Insulet Corp.
     117          02/13/23        USD     308.00        USD     3,444          (122,122
10X Genomics, Inc., Class A
     448          02/17/23        USD     40.00        USD     1,633          (135,520
908 Devices, Inc.
     477          02/17/23        USD     9.01        USD     363          (22,634
Agilent Technologies, Inc.
     208          02/17/23        USD     165.00        USD     3,113          (37,440
Alcon, Inc.
     714          02/17/23        USD     72.50        USD     4,894          (103,530
Alkermes PLC
     976          02/17/23        USD     26.00        USD     2,550          (195,200
Alnylam Pharmaceuticals, Inc.
     105          02/17/23        USD     250.00        USD     2,495          (134,400
Arrowhead Pharmaceuticals, Inc.
     129          02/17/23        USD     35.00        USD     523          (105,780
Arvinas, Inc.
     491          02/17/23        USD     45.00        USD     1,680          (41,735
Avantor, Inc.
     896          02/17/23        USD     22.50        USD     1,890          (62,720
Bausch & Lomb Corp.
     458          02/17/23        USD     15.00        USD     710          (56,105
Biogen, Inc.
     100          02/17/23        USD     310.00        USD     2,769          (48,000
BioMarin Pharmaceutical, Inc.
     581          02/17/23        USD     110.00        USD     6,013          (145,250
Boston Scientific Corp.
     520          02/17/23        USD     48.00        USD     2,406          (61,100
Bruker Corp.
     332          02/17/23        USD     67.50        USD     2,269          (151,060
Cerevel Therapeutics Holdings, Inc.
     398          02/17/23        USD     30.00        USD     1,255          (151,240
Cooper Cos., Inc.
     90          02/17/23        USD     350.00        USD     2,976          (67,050
Dexcom, Inc.
     580          02/17/23        USD     116.50        USD     6,568          (379,036
Encompass Health Corp.
     585          02/17/23        USD     60.00        USD     3,499          (156,487
Encompass Health Corp.
     307          02/17/23        USD     58.00        USD     1,836          (116,244
Exelixis, Inc.
     479          02/17/23        USD     17.00        USD     768          (32,333
Gilead Sciences, Inc.
     407          02/17/23        USD     87.50        USD     3,494          (108,669
Glaukos Corp.
     88          02/17/23        USD     45.00        USD     384          (28,380
Hologic, Inc.
     374          02/17/23        USD     76.09        USD     2,798          (98,919
Horizon Therapeutics PLC
     290          02/17/23        USD     80.00        USD     3,300          (996,150
Immunocore Holdings PLC, ADR
     193          02/17/23        USD     60.00        USD     1,101          (105,185
Insulet Corp.
     175          02/17/23        USD     320.00        USD     5,152          (87,062
Intuitive Surgical, Inc.
     144          02/17/23        USD     270.00        USD     3,821          (195,120
IQVIA Holdings, Inc.
     232          02/17/23        USD     214.25        USD     4,753          (153,771
iRhythm Technologies, Inc.
     96          02/17/23        USD     110.00        USD     899          (33,120
Keros Therapeutics, Inc.
     321          02/17/23        USD     55.00        USD     1,541          (88,275
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  89

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Exchange-Traded Options Written (continued)
 
 
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
 
 
Call (continued)                                                   
Legend Biotech Corp., ADR
     314          02/17/23        USD     60.00        USD     1,567        $ (34,540
Masimo Corp.
     170          02/17/23        USD     155.00        USD     2,515          (106,250
Neurocrine Biosciences, Inc.
     390          02/17/23        USD     120.00        USD     4,658          (267,150
Nevro Corp.
     713          02/17/23        USD     40.00        USD     2,823          (249,550
Omnicell, Inc.
     225          02/17/23        USD     50.00        USD     1,134          (121,500
Prometheus Biosciences, Inc.
     175          02/17/23        USD     130.00        USD     1,925          (73,500
QIAGEN NV
     1,266          02/17/23        USD     50.00        USD     6,314          (256,365
R1 RCM, Inc.
     1,104          02/17/23        USD     12.50        USD     1,209          (69,000
ResMed, Inc.
     220          02/17/23        USD     220.00        USD     4,579          (125,400
Revolution Medicines, Inc.
     302          02/17/23        USD     30.00        USD     719          (34,730
Rhythm Pharmaceuticals, Inc.
     931          02/17/23        USD     30.00        USD     2,711          (297,920
Sage Therapeutics, Inc.
     449          02/17/23        USD     45.00        USD     1,712          (31,430
Sarepta Therapeutics, Inc.
     199          02/17/23        USD     130.00        USD     2,579          (171,140
Seagen, Inc.
     127          02/17/23        USD     145.00        USD     1,632          (36,513
Silk Road Medical, Inc.
     355          02/17/23        USD     60.00        USD     1,876          (84,312
Stryker Corp.
     106          02/17/23        USD     251.14        USD     2,592          (85,443
Stryker Corp.
     98          02/17/23        USD     250.94        USD     2,396          (79,770
Tandem Diabetes Care, Inc.
     165          02/17/23        USD     45.00        USD     742          (60,225
Ultragenyx Pharmaceutical, Inc.
     317          02/17/23        USD     45.00        USD     1,469          (168,010
United Therapeutics Corp.
     84          02/17/23        USD     280.00        USD     2,336          (95,340
Vertex Pharmaceuticals, Inc.
     176          02/17/23        USD     310.00        USD     5,083          (110,000
Viridian Therapeutics, Inc.
     43          02/17/23        USD     30.00        USD     126          (18,060
Waters Corp.
     194          02/17/23        USD     350.00        USD     6,646          (270,630
West Pharmaceutical Services, Inc.
     62          02/17/23        USD     260.00        USD     1,459          (36,270
Zoetis, Inc.
     19          02/17/23        USD     160.00        USD     278          (3,610
Halozyme Therapeutics, Inc.
     402          03/17/23        USD     60.00        USD     2,287          (147,735
Revolution Medicines, Inc.
     302          03/17/23        USD     30.00        USD     719          (66,440
                          
 
 
 
                           $ (17,086,040
                          
 
 
 
OTC Options Written
 
 
 
Description
 
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
 
 
Call
               
Daiichi Sankyo Co. Ltd.
  UBS AG     344,000       01/05/23       JPY       4,912.95       JPY       1,462,000     $ (4,168
Pulmonx Corp.
  Citibank N.A.     78,000       01/05/23       USD       6.31       USD       658       (165,675
Bausch & Lomb Corp.
  Citibank N.A.     43,300       01/11/23       USD       15.36       USD       672       (27,165
ConvaTec Group PLC
  JPMorgan Chase Bank N.A.     490,000       01/11/23       GBP       2.38       GBP       1,140       (17,736
Daiichi Sankyo Co. Ltd.
  BNP Paribas SA     62,000       01/11/23       JPY       4,717.44       JPY       263,500       (8,379
Genmab A/S
  JPMorgan Chase Bank N.A.     9,200       01/11/23       DKK       3,275.40       DKK       27,057       (1,493
UCB SA
  JPMorgan Chase Bank N.A.     55,200       01/11/23       EUR       79.07       EUR       4,061       (4,520
Gerresheimer AG
  JPMorgan Chase Bank N.A.     27,800       01/13/23       EUR       71.43       EUR       1,746       (641
Wuxi Biologics Cayman, Inc.
  Citibank N.A.     394,000       01/13/23       HKD       54.02       HKD       23,581       (330,324
ConvaTec Group PLC
  Morgan Stanley & Co. International PLC     411,500       01/17/23       GBP       2.36       GBP       957       (23,606
Bausch & Lomb Corp.
  Morgan Stanley & Co. International PLC     32,500       01/20/23       USD       15.80       USD       504       (21,666
Ionis Pharmaceuticals, Inc.
  JPMorgan Chase Bank N.A.     74,800       01/23/23       USD       48.30       USD       2,825       (11,028
Daiichi Sankyo Co. Ltd.
  Goldman Sachs International     62,000       01/25/23       JPY       4,544.39       JPY       263,500       (18,530
Gerresheimer AG
  Goldman Sachs International     20,000       01/27/23       EUR       68.83       EUR       1,256       (7,280
Bio-Techne Corp.
  Bank of America N.A.     20,400       01/30/23       USD       85.47       USD       1,691       (49,096
Genmab A/S, ADR
  Citibank N.A.     36,500       01/30/23       USD       43.15       USD       1,547       (74,511
West Pharmaceutical Services, Inc.
  JPMorgan Chase Bank N.A.     23,000       01/30/23       USD       251.58       USD       5,413       (134,086
Genmab A/S
  Goldman Sachs International     1,900       01/31/23       DKK       3,136.29       DKK       5,588       (8,913
UCB SA
  Goldman Sachs International     55,000       01/31/23       EUR       76.49       EUR       4,046       (64,319
Alcon, Inc.
  Morgan Stanley & Co. International PLC     46,600       02/03/23       USD       67.45       USD       3,194       (152,076
ConvaTec Group PLC
  JPMorgan Chase Bank N.A.     510,000       02/08/23       GBP       2.49       GBP       1,186       (24,095
Gerresheimer AG
  Goldman Sachs International     28,000       02/08/23       EUR       65.30       EUR       1,758       (45,262
Halozyme Therapeutics, Inc.
  Citibank N.A.     37,700       02/13/23       USD       57.65       USD       2,145       (118,414
Globus Medical, Inc., Class A
  Barclays Bank PLC     16,700       02/27/23       USD       72.00       USD       1,240       (96,937
               
 
 
 
                $ (1,409,920
               
 
 
 
 
 
90
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
Options Written
   $ N/A      $ N/A      $ 7,107,599      $ (4,731,936    $ (18,495,960)  
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Assets — Derivative Financial Instruments
                    
Forward foreign currency exchange contracts
                    
Unrealized appreciation on forward foreign currency exchange contracts
   $      $      $      $ 4,964,555      $      $      $ 4,964,555  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities — Derivative Financial Instruments
                    
Options written
Options written at value
   $      $      $ 18,495,960      $      $      $      $ 18,495,960  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options purchased
   $      $      $ (5,710,386    $      $      $      $ (5,710,386
Options written
                   39,793,747                             39,793,747  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ 34,083,361      $      $      $      $ 34,083,361  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Forward foreign currency exchange contracts
   $      $      $      $ 4,964,555      $      $      $ 4,964,555  
Options written
                   4,045,807                             4,045,807  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ 4,045,807      $ 4,964,555      $      $      $ 9,010,362  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Forward foreign currency exchange contracts:
  
 
 
 
Average amounts sold — in USD
   $ 26,484,028  
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 19,273,533  
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
    
Liabilities
 
Derivative Financial Instruments
     
Forward foreign currency exchange contracts
   $ 4,964,555      $  
Options
            18,495,960  
  
 
 
    
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
     4,964,555        18,495,960  
  
 
 
    
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
            (17,086,040
  
 
 
    
 
 
 
Total derivative assets and liabilities subject to an MNA
   $ 4,964,555      $ 1,409,920  
  
 
 
    
 
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  91

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
The following table presents the Trust’s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:
 
Counterparty
  
 

Derivative

Assets
Subject to
an MNA by
Counterparty
 

 
 
 
 
  
 

Derivatives

Available
for Offset
 

 
(a)
 
  
 

Non-Cash

Collateral
Received
 

 
 
  
 

Cash

Collateral
Received
 

 
 
  
 

Net Amount

of Derivative
Assets
 

 
(b)(c)
 
BNP Paribas SA
   $ 4,230,131      $ (8,379    $      $      $ 4,221,752  
Goldman Sachs International
     734,424        (144,304                    590,120  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 4,964,555      $ (152,683    $      $      $ 4,811,872  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
Counterparty
  
 

Derivative

Liabilities
Subject to
an MNA by
Counterparty
 

 
 
 
 
  
 

Derivatives

Available
for Offset
 

 
(a)
 
  
 

Non-Cash

Collateral
Pledged
 

 
(d)
 
  
 

Cash

Collateral
Pledged
 

 
 
  
 

Net Amount

of Derivative
Liabilities
 

 
(e)
 
Bank of America N.A.
   $ 49,096      $      $      $      $ 49,096  
Barclays Bank PLC
     96,937                             96,937  
BNP Paribas SA
     8,379        (8,379                     
Citibank N.A.
     716,089               (696,089      (20,000       
Goldman Sachs International
     144,304        (144,304                     
JPMorgan Chase Bank N.A.
     193,599               (193,599              
Morgan Stanley & Co. International PLC
     197,348               (181,348      (16,000       
UBS AG
     4,168               (4,168              
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 1,409,920      $ (152,683    $     (1,075,204    $ (36,000    $ 146,033  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
The amount of derivatives available for offset is limited to the amount of derivative asset and/or liabilities that are subject to an MNA.
 
 
(b)
 
Net amount may also include forward foreign currency exchange contracts that are not required to be collateralized.
 
 
(c)
 
Net amount represents the net amount receivable from the counterparty in the event of default.
 
 
(d)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(e)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Investments
           
Long-Term Investments
           
Common Stocks
           
Biotechnology
   $ 736,269,722      $ 25,845,847      $ 11,992,578      $ 774,108,147  
Diversified Financial Services
     17,149,615                      17,149,615  
Electronic Equipment, Instruments & Components
     2,088,520                      2,088,520  
Health Care Equipment & Supplies
     486,043,004        12,354,350        100,609        498,497,963  
Health Care Providers & Services
     102,816,426        1,496,119               104,312,545  
Health Care Technology
     600,459                      600,459  
Life Sciences Tools & Services
     276,513,082        25,616,897               302,129,979  
Pharmaceuticals
     55,679,975        77,508,732               133,188,707  
Other Interests
                   4,076,191        4,076,191  
Preferred Securities
           
Preferred Stocks
                   158,791,702        158,791,702  
Warrants
     37,071                      37,071  
 
 
92
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
Fair Value Hierarchy as of Period End (continued)
 
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Short-Term Securities
           
Money Market Funds
   $ 83,001,707      $      $      $ 83,001,707  
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ 1,760,199,581      $ 142,821,945      $ 174,961,080        2,077,982,606  
  
 
 
    
 
 
    
 
 
    
 
 
 
Investments Valued at NAV
(a)
              1,828,050  
           
 
 
 
            $ 2,079,810,656  
           
 
 
 
Derivative Financial Instruments
(b)
           
Assets
           
Foreign Currency Exchange Contracts
   $      $ 4,964,555      $      $ 4,964,555  
Liabilities
           
Equity Contracts
     (15,304,770      (3,191,190)               (18,495,960
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ (15,304,770    $ 1,773,365      $      $ (13,531,405
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
 
(b)
 
Derivative financial instruments are forward foreign currency exchange contracts and options written. Forward foreign currency exchange contracts are valued at the unrealized appreciation (depreciation) on the instrument and options written are shown at value.
 
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
 
     
Common
Stocks
    
Other
Interests
    
Preferred
Stocks
    
Total
 
Assets
           
Opening balance, as of December 31, 2021
   $      $ 4,000,000      $ 232,701,012      $ 236,701,012  
Transfers into Level 3
                           
Transfers out of Level 3
                           
Other
(a)
     13,126,498               (13,126,498       
Accrued discounts/premiums
                           
Net realized gain (loss)
                   24,462,564        24,462,564  
Net change in unrealized appreciation (depreciation)
(b)(c)
     (1,133,920      76,191        (48,761,387      (49,819,116
Purchases
     100,609               3,764,615        3,865,224  
Sales
                   (40,248,604      (40,248,604
  
 
 
    
 
 
    
 
 
    
 
 
 
Closing balance, as of December 31, 2022
   $   12,093,187      $   4,076,191      $   158,791,702      $   174,961,080  
  
 
 
    
 
 
    
 
 
    
 
 
 
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022
(c)
   $   (1,133,920    $   76,191      $ (31,596,090    $ (32,653,819
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.
 
 
(b)
 
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.
 
 
(c)
 
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022 is generally due to investments no longer held or categorized as Level 3 at period end.
 
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon unadjusted third-party pricing information in the amount of $100,609. A significant change in third party information could result in a significantly lower or higher value of such Level 3 financial instruments.
 
 
  
 
Value
 
  
 

Valuation

Approach
 

 
  
 

Unobservable

Inputs
 

 
  
 

Range of

Unobservable
Inputs
Utilized
 

 
 
(a)
 
  
 

Weighted

Average of
Unobservable
Inputs Based
on Fair Value
 

 
 
 
 
Assets
              
Common Stocks
(b)
   $     11,992,578        Income       
Discount Rate
       5%         
        Market       
Volatility
       70%         
          
Time to Exit
       2.0 years         
          
Market Adjustment Multiple
       1.00x         
Preferred Stocks
(c)
     158,791,702        Market       
Revenue Multiple
       1.50x - 7.25x        4.09x  
          
EBITDA Multiple
       10.00x         
          
Volatility
       50% -91%        66%  
          
Time to Exit
      
1.0 - 4.0 years
       2.4 years  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  93

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Health Sciences Trust II (BMEZ)
    
 
 
 
  
 
Value
 
  
 

Valuation

Approach
 

 
  
Unobservable

Inputs
  
 

Range of

Unobservable
Inputs
Utilized
 

 
 
(a)
 
  
 

Weighted

Average of
Unobservable
Inputs Based
on Fair Value
 

 
 
 
 
        
Market Adjustment Multiple
     0.45x - 1.00x        0.86x  
        Income     
Discount Rate
     5%         
Other Interests
(d)
   $ 4,076,191        Income     
Discount Rate
     6%         
  
 
 
             
  
$
    174,860,471
 
           
  
 
 
             
 
 
(a)
 
A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.
 
 
(b)
 
For the period end December 31, 2022, the valuation technique for investments classified as Common Stock amounting to $2,366,479 changed to a discounted cash flow approach. The investments were previously valued utilizing a market adjustment approach. The change was due to consideration of the information that was available at the time the investments were valued.
 
 
(c)
 
For the period end December 31, 2022, the valuation technique for investments classified as Preferred Stock amounting to $3,620,523 changed to a discounted cash flow approach. The investments were previously valued utilizing a market adjustment approach. The change was due to consideration of the information that was available at the time the investments were valued.
 
 
(d)
 
For the period end December 31, 2022, the valuation technique for investments classified as Other Interests amounting to $4,076,191 changed to a discounted cash flow approach. The investments were previously valued utilizing a recent transaction. The change was due to consideration of the information that was available at the time the investments were valued.
 
See notes to financial statements.
 
 
94
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
December 31, 2022
 
 
  
BlackRock Innovation and Growth Trust (BIGZ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Common Stocks
   
Aerospace & Defense — 6.0%
 
Axon Enterprise, Inc.
(a)(b)
    473,566     $ 78,578,806  
HEICO Corp.
    281,673       43,276,240  
   
 
 
 
      121,855,046  
Air Freight & Logistics — 1.1%
       
GXO Logistics, Inc.
(b)
    529,641       22,610,374  
   
 
 
 
Auto Components — 2.2%
           
Fox Factory Holding Corp.
(b)
    493,110       44,986,425  
   
 
 
 
Biotechnology — 2.1%
           
Halozyme Therapeutics, Inc.
(b)
    759,381       43,208,779  
   
 
 
 
Building Products — 0.7%
           
AZEK Co., Inc.
(b)
    725,567       14,743,521  
   
 
 
 
Capital Markets — 3.6%
           
TPG, Inc.
    708,658       19,721,952  
Tradeweb Markets, Inc., Class A
(c)
    804,964       52,266,313  
   
 
 
 
      71,988,265  
Diversified Consumer Services — 3.0%
           
Duolingo, Inc.
(b)
    382,916       27,236,815  
Ideal Image, Class A, (Acquired 05/05/21, Cost: $50,000,000)
(d)(e)
    6,224       33,627,984  
   
 
 
 
      60,864,799  
Entertainment — 1.2%
           
Kahoot! ASA
(b)
    12,223,339       24,393,559  
   
 
 
 
Equity Real Estate Investment Trusts (REITs) — 0.4%
 
Innovative Industrial Properties, Inc.
    33,866       3,432,319  
Rexford Industrial Realty, Inc.
    88,153       4,816,680  
   
 
 
 
      8,248,999  
Food Products — 0.3%
           
Freshpet, Inc.
(b)
    90,230       4,761,437  
   
 
 
 
Health Care Equipment & Supplies
(b)
— 2.5%
 
Figs, Inc., Class A
    2,000,216       13,461,454  
Inmode Ltd.
    407,065       14,532,220  
Insulet Corp.
    78,734       23,178,502  
   
 
 
 
      51,172,176  
Health Care Technology
(b)
— 3.0%
           
Certara, Inc.
    520,099       8,357,991  
Doximity, Inc., Class A
    1,251,172       41,989,332  
Phreesia, Inc.
(a)
    282,730       9,149,143  
   
 
 
 
      59,496,466  
Hotels, Restaurants & Leisure — 5.4%
           
Evolution AB
(f)
    417,935       40,708,703  
Penn Entertainment, Inc.
(b)
    369,706       10,980,268  
Planet Fitness, Inc., Class A
(b)(c)
    738,209       58,170,869  
   
 
 
 
      109,859,840  
Interactive Media & Services — 2.0%
           
Match Group, Inc.
(b)
    984,751       40,857,319  
   
 
 
 
Internet & Direct Marketing Retail
(b)
— 2.4%
           
Etsy, Inc.
    284,635       34,093,580  
Fiverr International Ltd.
    518,976       15,122,961  
   
 
 
 
      49,216,541  
Security
 
Shares
   
Value
 
IT Services — 3.7%
           
DigitalOcean Holdings, Inc.
(b)
    529,706     $ 13,491,612  
Globant SA
(b)
    221,257       37,206,577  
Salt Pay Co. Ltd., Series C, (Acquired 11/16/21, Cost: $49,999,974)
(d)(e)
    25,742       24,234,291  
   
 
 
 
      74,932,480  
Life Sciences Tools & Services — 9.0%
           
10X Genomics, Inc., Class A
(b)(c)
    133,858       4,877,786  
Azenta, Inc.
    611,504       35,601,763  
Bio-Techne Corp.
(a)(c)
    511,337       42,379,611  
Charles River Laboratories International,
Inc.
(b)
    139,286       30,350,419  
Olink Holding AB, ADR
(b)(g)
    276,359       7,013,991  
Repligen Corp.
(b)
    188,038       31,836,714  
West Pharmaceutical Services, Inc.
    130,655       30,749,654  
   
 
 
 
      182,809,938  
Machinery — 1.6%
           
Chart Industries, Inc.
(b)
    273,333       31,496,162  
   
 
 
 
Road & Rail — 2.0%
           
Saia, Inc.
(b)
    188,175       39,456,534  
   
 
 
 
Semiconductors & Semiconductor Equipment — 9.7%
 
Ambarella, Inc.
(b)
    385,947       31,736,422  
Entegris, Inc.
(c)
    776,659       50,941,064  
Lattice Semiconductor Corp.
(b)
    610,160       39,587,181  
Monolithic Power Systems, Inc.
(a)(c)
    133,547       47,223,554  
SolarEdge Technologies, Inc.
(b)
    95,685       27,104,690  
   
 
 
 
      196,592,911  
Software — 15.1%
           
Bill.com Holdings, Inc.
(b)
    396,344       43,185,642  
Confluent, Inc., Class A
(b)
    1,634,976       36,361,866  
Five9, Inc.
(b)
    863,340       58,586,252  
Gitlab, Inc., Class A
(b)
    678,865       30,847,626  
Grammarly, Inc., (Acquired 11/17/21,
Cost: $26,250,012)
(d)(e)
    1,001,454       16,794,384  
HubSpot, Inc.
(b)
    96,554       27,916,658  
Patreon, Inc., (Acquired 08/19/21,
Cost: $11,732,736)
(d)(e)
    208,333       5,295,825  
Paylocity Holding Corp.
(a)(b)(c)
    226,757       44,049,815  
SiteMinder Ltd.
(b)
    10,336,222       21,428,087  
Snorkel AI, Inc., (Acquired 06/30/21,
Cost: $2,999,997)
(d)(e)
    199,738       1,422,135  
Snyk Ltd., (Acquired 09/02/21,
Cost: $25,961,537)
(d)(e)
    1,809,860       20,795,291  
   
 
 
 
      306,683,581  
   
 
 
 
Total Common Stocks — 77.0%
(Cost: $2,088,809,694)
 
    1,560,235,152  
   
 
 
 
Preferred Securities
   
Preferred Stocks — 23.3%
(d)(e)
 
Aerospace & Defense — 1.8%
           
Relativity Space, Inc., Series E, (Acquired 05/27/21, Cost: $50,000,009)
    2,189,612       36,062,910  
   
 
 
 
Banks — 0.7%
           
Varo Money, Inc., Series E, (Acquired 08/27/21, Cost: $40,000,001)
    4,316,904       14,073,107  
   
 
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  95

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Capital Markets — 2.4%
            
The Production Board LLC, Series A3, (Acquired 06/04/21, Cost: $50,000,001)
    16,666,667      $   47,666,668  
    
 
 
 
Entertainment — 0.6%
            
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $17,999,912)
    32,690        12,934,125  
    
 
 
 
Food Products — 1.0%
            
Motif Food Works, Inc., Series B, (Acquired 06/08/21, Cost: $39,999,986)
    1,972,240        21,063,523  
    
 
 
 
Hotels, Restaurants & Leisure — 1.2%
            
Dapper Labs, Inc., Series 7, (Acquired 07/20/21, Cost: $29,999,946)
    191,067        6,209,678  
Underdog Sports, Inc., Series B, (Acquired 01/11/22, Cost: $14,999,974)
    291,061        17,722,704  
    
 
 
 
       23,932,382  
Internet Software & Services — 1.2%
            
Via Transportation, Inc., Series G, (Acquired 11/05/21, Cost: $24,999,974)
    549,357        24,528,790  
    
 
 
 
IT Services — 1.0%
            
Open Space Labs, Inc., Series D, (Acquired 01/31/22, Cost: $15,000,003)
    1,687,916        13,840,911  
Wagestream Holdings Ltd., Series C, (Acquired 02/11/22, Cost: $10,024,684)
    762,746        5,449,740  
    
 
 
 
       19,290,651  
Leisure Products — 1.8%
            
Under Canvas, Inc., Class A, (Acquired 08/19/21, Cost: $49,999,982)
    2,172,486        36,323,966  
    
 
 
 
Semiconductors & Semiconductor Equipment — 2.3%
 
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $39,999,990)
    1,525,192        38,755,129  
Rivos, Inc., Series A, (Acquired 12/03/21, Cost: $7,996,292)
    2,997,684        7,134,488  
    
 
 
 
       45,889,617  
Software — 7.4%
            
Anchor Labs, Inc., Series D, (Acquired 11/24/21, Cost: $9,999,995)
    428,785        2,928,602  
AnyRoad, Inc., Series B, (Acquired 12/07/21, Cost: $14,999,995)
    2,745,894        11,093,412  
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $44,999,983)
    898,024        25,423,059  
Deepgram, Inc., Series B, (Acquired 10/22/21, Cost: $11,999,997)
    2,165,400        11,996,316  
Dragos, Inc., Series D, (Acquired 09/28/21, Cost: $39,999,959)
    900,760        26,554,405  
Genesys Cloud Services, Inc., (Acquired 11/24/21, Cost: $30,000,101)
    4,651,163        20,232,559  
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $8,750,004)
    333,818        5,598,128  
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $23,333,352)
    416,667        10,591,675  
SkySafe, Inc., Series B, (Acquired 12/02/21, Cost: $4,999,999)
    909,438        2,273,595  
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $10,999,994)
    732,373        5,214,496  
Security
 
Shares
    
Value
 
Software (continued)
            
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $24,038,470)
    1,675,797      $ 19,355,455  
Validere Technologies, Inc., Series B, (Acquired 10/21/21,
Cost: $10,000,000)
    4,684,060        8,993,395  
    
 
 
 
       150,255,097  
Specialty Retail — 0.7%
            
Super73, Inc., Series C-1, (Acquired 10/25/22, Cost: $12,000,000)
    1,400,669        14,713,327  
    
 
 
 
Wireless Telecommunication Services — 1.2%
 
Loft Orbital Solutions, Inc., Series B, (Acquired 10/14/21, Cost: $24,999,992)
    1,365,305        24,548,184  
    
 
 
 
       471,282,347  
    
 
 
 
Total Preferred Securities — 23.3%
(Cost: $662,142,595)
 
     471,282,347  
    
 
 
 
Total Long-Term Investments — 100.3%
(Cost: $2,750,952,289)
 
     2,031,517,499  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 1.0%
            
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(h)(i)
    20,778,628        20,778,628  
SL Liquidity Series, LLC, Money Market Series, 4.49%
(h)(i)
    184,619        184,600  
    
 
 
 
Total Short-Term Securities — 1.0%
(Cost: $20,963,228)
 
     20,963,228  
    
 
 
 
Total Investments Before Options Written — 101.3%
(Cost: $2,771,915,517)
 
     2,052,480,727  
    
 
 
 
Options Written — (0.3)%
    (Premiums Received: $(12,213,208))
         (6,641,472)  
    
 
 
 
Total Investments, Net of Options Written — 101.0% (Cost: $2,759,702,309)
 
     2,045,839,255  
Liabilities in Excess of Other Assets — (1.0)%
 
     (19,351,341
    
 
 
 
Net Assets — 100.0%
     $ 2,026,487,914  
    
 
 
 
 
(a)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(b)
 
Non-income producing security.
(c)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(d)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(e)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $573,452,257, representing 28.3% of its net assets as of period end, and an original cost of $829,086,851.
(f)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(g)
 
All or a portion of this security is on loan.
(h)
 
Affiliate of the Trust.
(i)
 
Annualized 7-day yield as of period end.
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
 
 
96
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
908 Devices, Inc.
(a)
  $ 59,749,533     $     $ (32,811,876   $ (71,423,753   $ 44,486,096     $ N/A       N/A     $     $  
BlackRock Liquidity Funds, T-Fund, Institutional Class
    1,836,203       18,942,425
(b)
 
                      20,778,628       20,778,628       587,413        
SL Liquidity Series, LLC, Money Market Series
    5,204,477             (5,019,258 )
(b)
 
    (923     304       184,600       184,619       80,749
(c)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ (71,424,676   $ 44,486,400     $ 20,963,228       $ 668,162     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
As of period end, the entity is no longer an affiliate.
 
 
(b)
 
Represents net amount purchased (sold).
 
 
(c)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call                                                   
Ambarella, Inc.
     119          01/06/23        USD     76.00        USD     979        $ (85,680
Bill.com Holdings, Inc.
     220          01/06/23        USD     135.00        USD     2,397          (1,100
Match Group, Inc.
     270          01/06/23        USD     54.00        USD     1,120          (4,320
Penn Entertainment, Inc.
     351          01/06/23        USD     38.00        USD     1,042          (11,232
Ambarella, Inc.
     122          01/13/23        USD     75.00        USD     1,003          (107,360
10X Genomics, Inc., Class A
     182          01/20/23        USD     50.00        USD     663          (10,010
10X Genomics, Inc., Class A
     11          01/20/23        USD     40.00        USD     40          (1,430
Ambarella, Inc.
     223          01/20/23        USD     77.50        USD     1,834          (175,055
Ambarella, Inc.
     95          01/20/23        USD     82.50        USD     781          (47,025
Axon Enterprise, Inc.
     280          01/20/23        USD     185.00        USD     4,646          (30,100
AZEK Co., Inc.
     543          01/20/23        USD     22.50        USD     1,103          (38,010
Azenta, Inc.
     330          01/20/23        USD     55.00        USD     1,921          (145,200
Bill.com Holdings, Inc.
     138          01/20/23        USD     145.00        USD     1,504          (4,140
Bio-Techne Corp.
     556          01/20/23        USD     90.00        USD     4,608          (108,420
Chart Industries, Inc.
     190          01/20/23        USD     145.00        USD     2,189          (5,225
Confluent, Inc., Class A
     882          01/20/23        USD     30.00        USD     1,962          (11,025
Doximity, Inc., Class A
     880          01/20/23        USD     35.00        USD     2,953          (112,200
Doximity, Inc., Class A
     318          01/20/23        USD     37.50        USD     1,067          (18,285
Duolingo, Inc.
     306          01/20/23        USD     80.00        USD     2,177          (24,480
Entegris, Inc.
     600          01/20/23        USD     82.00        USD     3,935          (4,619
Etsy, Inc.
     120          01/20/23        USD     115.00        USD     1,437          (110,700
Figs, Inc., Class A
     1,700          01/20/23        USD     7.50        USD     1,144          (42,500
Five9, Inc.
     785          01/20/23        USD     65.00        USD     5,327          (408,200
Fiverr International Ltd.
     466          01/20/23        USD     45.00        USD     1,358          (4,660
Fox Factory Holding Corp.
     310          01/20/23        USD     107.55        USD     2,828          (9,556
Freshpet, Inc.
     32          01/20/23        USD     70.00        USD     169          (2,560
Gitlab, Inc., Class A
     509          01/20/23        USD     60.00        USD     2,313          (10,180
GXO Logistics, Inc.
     232          01/20/23        USD     50.00        USD     990          (2,900
Halozyme Therapeutics, Inc.
     484          01/20/23        USD     55.00        USD     2,754          (164,560
HEICO Corp.
     252          01/20/23        USD     165.00        USD     3,872          (11,340
HubSpot, Inc.
     40          01/20/23        USD     340.00        USD     1,157          (10,800
Inmode Ltd.
     387          01/20/23        USD     42.50        USD     1,382          (10,643
Innovative Industrial Properties, Inc.
     90          01/20/23        USD     115.00        USD     912          (6,750
Insulet Corp.
     50          01/20/23        USD     320.00        USD     1,472          (7,000
Lattice Semiconductor Corp.
     367          01/20/23        USD     64.00        USD     2,381          (128,387
Lattice Semiconductor Corp.
     92          01/20/23        USD     74.83        USD     597          (3,482
Lattice Semiconductor Corp.
     19          01/20/23        USD     75.00        USD     123          (808
Monolithic Power Systems, Inc.
     78          01/20/23        USD     433.00        USD     2,758          (7,822
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  97

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
Exchange-Traded Options Written (continued)
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)                                                   
Olink Holding AB, ADR
     326          01/20/23        USD     20.00        USD     827        $ (182,560
Paylocity Holding Corp.
     200          01/20/23        USD     250.00        USD     3,885          (12,000
Phreesia, Inc.
     226          01/20/23        USD     35.00        USD     731          (24,860
Planet Fitness, Inc., Class A
     557          01/20/23        USD     77.50        USD     4,389          (194,950
Repligen Corp.
     300          01/20/23        USD     228.00        USD     5,079          (3,012
Repligen Corp.
     40          01/20/23        USD     190.00        USD     677          (9,000
Rexford Industrial Realty, Inc.
     212          01/20/23        USD     60.00        USD     1,158          (3,710
Saia, Inc.
     130          01/20/23        USD     265.25        USD     2,726          (2,545
SolarEdge Technologies, Inc.
     108          01/20/23        USD     360.00        USD     3,059          (5,130
TPG, Inc.
     566          01/20/23        USD     35.00        USD     1,575          (28,300
Tradeweb Markets, Inc., Class A
     768          01/20/23        USD     65.00        USD     4,987          (78,720
West Pharmaceutical Services, Inc.
     73          01/20/23        USD     266.00        USD     1,718          (7,206
Ambarella, Inc.
     203          01/27/23        USD     83.00        USD     1,669          (110,635
Etsy, Inc.
     135          01/27/23        USD     135.00        USD     1,617          (33,142
Match Group, Inc.
     240          01/27/23        USD     49.00        USD     996          (11,640
Penn Entertainment, Inc.
     240          01/27/23        USD     34.00        USD     713          (9,360
Halozyme Therapeutics, Inc.
     373          01/30/23        USD     54.05        USD     2,122          (173,458
Azenta, Inc.
     288          01/31/23        USD     60.35        USD     1,677          (65,221
Planet Fitness, Inc., Class A
     663          02/01/23        USD     82.50        USD     5,224          (133,437
Azenta, Inc.
     360          02/10/23        USD     62.25        USD     2,096          (78,402
10X Genomics, Inc., Class A
     21          02/17/23        USD     40.00        USD     77          (6,353
Axon Enterprise, Inc.
     570          02/17/23        USD     171.50        USD     9,458          (477,012
AZEK Co., Inc.
     617          02/17/23        USD     21.84        USD     1,254          (58,767
Bill.com Holdings, Inc.
     184          02/17/23        USD     140.00        USD     2,005          (84,640
Charles River Laboratories International, Inc.
     258          02/17/23        USD     240.00        USD     5,622          (123,840
Chart Industries, Inc.
     162          02/17/23        USD     133.00        USD     1,867          (52,918
Confluent, Inc., Class A
     1,733          02/17/23        USD     25.83        USD     3,854          (241,625
DigitalOcean Holdings, Inc.
     850          02/17/23        USD     35.00        USD     2,165          (40,375
Doximity, Inc., Class A
     803          02/17/23        USD     37.50        USD     2,695          (172,645
Duolingo, Inc.
     306          02/17/23        USD     80.00        USD     2,177          (77,265
Entegris, Inc.
     642          02/17/23        USD     80.00        USD     4,211          (65,805
Etsy, Inc.
     200          02/17/23        USD     145.00        USD     2,396          (54,900
Figs, Inc., Class A
     1,500          02/17/23        USD     7.44        USD     1,010          (77,616
Five9, Inc.
     700          02/17/23        USD     75.00        USD     4,750          (197,750
Fiverr International Ltd.
     370          02/17/23        USD     35.00        USD     1,078          (49,025
Fox Factory Holding Corp.
     480          02/17/23        USD     100.00        USD     4,379          (126,000
Freshpet, Inc.
     112          02/17/23        USD     65.00        USD     591          (11,200
Globant SA
     134          02/17/23        USD     185.00        USD     2,253          (95,140
GXO Logistics, Inc.
     232          02/17/23        USD     50.01        USD     990          (21,232
HEICO Corp.
     200          02/17/23        USD     160.00        USD     3,073          (59,500
Inmode Ltd.
     264          02/17/23        USD     42.50        USD     942          (26,400
Insulet Corp.
     75          02/17/23        USD     320.00        USD     2,208          (37,312
Match Group, Inc.
     1,000          02/17/23        USD     47.50        USD     4,149          (172,500
Monolithic Power Systems, Inc.
     113          02/17/23        USD     400.00        USD     3,996          (119,215
Olink Holding AB, ADR
     120          02/17/23        USD     24.00        USD     305          (52,648
Paylocity Holding Corp.
     170          02/17/23        USD     240.00        USD     3,302          (36,125
Phreesia, Inc.
     226          02/17/23        USD     35.00        USD     731          (44,070
Planet Fitness, Inc., Class A
     90          02/17/23        USD     77.50        USD     709          (46,350
Saia, Inc.
     95          02/17/23        USD     250.00        USD     1,992          (33,013
Tradeweb Markets, Inc., Class A
     519          02/17/23        USD     65.00        USD     3,370          (153,105
West Pharmaceutical Services, Inc.
     102          02/17/23        USD     260.00        USD     2,401          (59,670
Halozyme Therapeutics, Inc.
     218          03/17/23        USD     60.00        USD     1,240          (80,115
                          
 
 
 
                           $  (6,009,183
                          
 
 
 
 
 
98
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
OTC Options Written
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call
                
Evolution AB
   Morgan Stanley & Co. International PLC     72,900       01/05/23       SEK       1,043.38       SEK       74,023     $ (41,161
Kahoot! ASA
   Morgan Stanley & Co. International PLC     598,000       01/05/23       NOK       27.10       NOK       11,622       (1
Saia, Inc.
   Citibank N.A.     12,600       01/05/23       USD       245.26       USD       2,642       (3,467
SiteMinder Ltd.
   Goldman Sachs International     15,000       01/05/23       AUD       3.22       AUD       46       (188
Certara, Inc.
   Citibank N.A.     44,200       01/09/23       USD       13.42       USD       710       (120,902
Globant SA
   Goldman Sachs International     22,000       01/11/23       USD       183.36       USD       3,700       (40,156
Kahoot! ASA
   Morgan Stanley & Co. International PLC     520,000       01/13/23       NOK       26.95       NOK       10,106       (88
SiteMinder Ltd.
   UBS AG     42,000       01/13/23       AUD       2.96       AUD       128       (4,524
Kahoot! ASA
   Goldman Sachs International     359,700       01/18/23       NOK       24.53       NOK       6,991       (1,275
Kahoot! ASA
   Goldman Sachs International     253,818       01/25/23       NOK       25.03       NOK       4,933       (1,842
Kahoot! ASA
   Royal Bank of Canada     105,882       01/25/23       NOK       24.68       NOK       2,058       (928
Certara, Inc.
   Citibank N.A.     39,000       01/26/23       USD       19.10       USD       627       (6,251
Bio-Techne Corp.
   Bank of America N.A.     15,100       01/30/23       USD       85.47       USD       1,251       (36,341
Gitlab, Inc., Class A
   BNP Paribas SA     28,900       01/31/23       USD       53.74       USD       1,313       (47,671
Kahoot! ASA
   Goldman Sachs International     118,400       02/01/23       NOK       24.08       NOK       2,301       (2,644
Chart Industries, Inc.
   JPMorgan Chase Bank N.A.     17,000       02/06/23       USD       154.00       USD       1,959       (13,244
Lattice Semiconductor Corp.
   Citibank N.A.     8,800       02/07/23       USD       67.50       USD       571       (29,610
Halozyme Therapeutics, Inc.
   Citibank N.A.     31,100       02/13/23       USD       57.65       USD       1,770       (97,684
Gitlab, Inc., Class A
   BNP Paribas SA     28,900       02/14/23       USD       53.74       USD       1,313       (71,519
Lattice Semiconductor Corp.
   JPMorgan Chase Bank N.A.     56,000       02/24/23       USD       75.00       USD       3,633       (112,793
                
 
 
 
                 $  (632,289
                
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
  
Swap
Premiums
Received
  
Unrealized
Appreciation
  
Unrealized
Depreciation
  
Value
Options Written    $       N/A    $       N/A    $6,566,417    $(994,681)    $(6,641,472)
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Liabilities — Derivative Financial Instruments
 
                 
Options written
                    
Options written at value
   $      $      $   6,641,472      $      $      $      $   6,641,472  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
 
                 
Options purchased
(a)
   $      $      $ (575,065    $      $      $      $ (575,065
Options written
                   46,651,673                             46,651,673  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $   46,076,608      $      $      $      $   46,076,608  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation
(Depreciation) on:
 
              
Options written
   $      $      $ (842,713    $      $      $      $ (842,713
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  99

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Options:
  
 
 
 
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 8,835,552  
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $ 6,641,472  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
              6,641,472  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (6,009,183
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 632,289  
  
 
 
      
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
    
 

Derivatives
Available
for Offset
 
 
 
    
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
    
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Bank of America N.A.
   $ 36,341        $        $      $        $ 36,341  
BNP Paribas SA
     119,190                                   119,190  
Citibank N.A.
     257,914                   (257,914                
Goldman Sachs International
     46,105                   (46,105                
JPMorgan Chase Bank N.A.
     126,037                   (126,037                
Morgan Stanley & Co. International PLC
     41,250                   (41,250                
Royal Bank of Canada
     928                                   928  
UBS AG
     4,524                                   4,524  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
   $ 632,289        $        $   (471,306)      $        $ 160,983  
  
 
 
      
 
 
      
 
 
    
 
 
      
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Aerospace & Defense
   $   121,855,046        $        $        $   121,855,046  
Air Freight & Logistics
     22,610,374                            22,610,374  
Auto Components
     44,986,425                            44,986,425  
Biotechnology
     43,208,779                            43,208,779  
Building Products
     14,743,521                            14,743,521  
Capital Markets
     71,988,265                            71,988,265  
Diversified Consumer Services
     27,236,815                     33,627,984          60,864,799  
Entertainment
                24,393,559                   24,393,559  
 
 
100
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
Fair Value Hierarchy as of Period End (continued)
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Common Stocks (continued)
                 
Equity Real Estate Investment Trusts (REITs)
   $ 8,248,999        $        $        $ 8,248,999  
Food Products
     4,761,437                            4,761,437  
Health Care Equipment & Supplies
     51,172,176                            51,172,176  
Health Care Technology
     59,496,466                            59,496,466  
Hotels, Restaurants & Leisure
     69,151,137          40,708,703                   109,859,840  
Interactive Media & Services
     40,857,319                            40,857,319  
Internet & Direct Marketing Retail
     49,216,541                            49,216,541  
IT Services
     50,698,189                   24,234,291          74,932,480  
Life Sciences Tools & Services
     182,809,938                            182,809,938  
Machinery
     31,496,162                            31,496,162  
Road & Rail
     39,456,534                            39,456,534  
Semiconductors & Semiconductor Equipment
     196,592,911                            196,592,911  
Software
     240,947,859          21,428,087          44,307,635          306,683,581  
Preferred Securities
                 
Preferred Stocks
                       471,282,347          471,282,347  
Short-Term Securities
                 
Money Market Funds
     20,778,628                            20,778,628  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $ 1,392,313,521        $ 86,530,349        $   573,452,257          2,052,296,127  
  
 
 
      
 
 
      
 
 
      
 
 
 
Investments Valued at NAV
(a)
                    184,600  
                 
 
 
 
                  $ 2,052,480,727  
                 
 
 
 
Derivative Financial Instruments
(b)
                 
Liabilities
                 
Equity Contracts
   $ (4,410,218      $ (2,231,254      $        $ (6,641,472
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
 
(b)
 
Derivative financial instruments are options written. Options written are shown at value.
 
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
 
     
Common
Stocks
    
Convertible
Notes
    
Preferred
Stocks
    
Total
 
Assets
           
Opening balance, as of December 31, 2021
   $ 167,039,627      $ 12,000,000      $ 544,568,505      $ 723,608,132  
Transfers into Level 3
                           
Transfers out of Level 3
                           
Accrued discounts/premiums
                           
Net realized gain (loss)
                           
Net change in unrealized appreciation (depreciation)
(a)(b)
     (64,869,717             (170,310,802      (235,180,519
Purchases
                   97,024,644        97,024,644  
Sales
            (12,000,000             (12,000,000
  
 
 
    
 
 
    
 
 
    
 
 
 
Closing balance, as of December 31, 2022
   $ 102,169,910      $      $ 471,282,347      $ 573,452,257  
  
 
 
    
 
 
    
 
 
    
 
 
 
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022
(b)
   $ (64,869,717    $      $ (170,310,802    $ (235,180,519
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.
 
 
(b)
 
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022 is generally due to investments no longer held or categorized as Level 3 at period end.
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  101

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Innovation and Growth Trust (BIGZ)
    
 
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
 
 
  
 
Value
 
  
Valuation
Approach
  
Unobservable
Inputs
  
 


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)
 
  
 



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
Assets
              
Common Stocks
(b)
   $ 102,169,910      Market    Revenue Multiple      7.75x -29.13x        15.71x  
         EBITDA Multiple      18.50x         
         Market Adjustment Multiple      0.50x         
Preferred Stocks
(b)
   $ 471,282,347      Market    Revenue Multiple      1.25x -29.13x        11.34x  
         Time to Exit      2.0 -5.0 years        3.2 years  
         Volatility      50% - 115%        71%  
         Market Adjustment Multiple      0.50x - 1.00x        0.94x  
         Recent Transactions     
(c)
 
        
              
  
 
 
             
   $   573,452,257              
  
 
 
             
 
 
(a)
 
A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.
 
 
(b)
 
The Trust valued certain of its Level 3 Common Stock and Preferred Stock using recent transaction prices as the best approximation of fair value. The value of Level 3 investments obtained using recent prior transaction prices, for which inputs are unobservable, is $11,996,316 as of December 31, 2022.
 
 
(c)
 
For the period end December 31, 2022, the valuation technique for certain investments classified as Preferred Stock used recent prior transaction prices as inputs within the model used for the approximation of fair value.
 
See notes to financial statements.
 
 
102
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    (Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Common Stocks
   
Chemicals — 11.3%
 
Albemarle Corp.
(a)
    24,996     $ 5,420,632  
CF Industries Holdings, Inc.
(a)(b)
    315,036       26,841,067  
FMC Corp.
(a)
    166,497       20,778,826  
Koninklijke DSM NV
    75,079       9,219,293  
Nutrien Ltd.
    525,792       38,398,590  
Sociedad Quimica y Minera de Chile SA, ADR
(a)
    128,668       10,272,853  
   
 
 
 
      110,931,261  
Containers & Packaging — 0.4%
           
Packaging Corp. of America
(a)
    31,594       4,041,189  
   
 
 
 
Food Products — 7.9%
           
Archer-Daniels-Midland Co.
(a)
    267,006       24,791,507  
Bunge Ltd.
(a)
    206,089       20,561,500  
Darling Ingredients, Inc.
(a)(c)
    126,528       7,919,387  
Hofseth International A/S, (Acquired 05/26/21, Cost: $10,198,057)
(d)(e)
    18,993,283       9,267,097  
Kerry Group PLC, Class A
    160,749       14,520,492  
   
 
 
 
      77,059,983  
Machinery
(a)
— 6.0%
           
AGCO Corp.
(b)
    194,970       27,040,398  
Deere & Co.
    74,124       31,781,406  
   
 
 
 
      58,821,804  
Metals & Mining — 35.4%
           
Alcoa Corp.
(a)
    220,423       10,022,634  
Anglo American PLC
    310,379       12,154,402  
ArcelorMittal SA, Registered Shares
(a)
    367,528       9,636,584  
BHP Group Ltd., ADR
(a)
    675,910       41,940,215  
First Quantum Minerals Ltd.
    684,944       14,310,979  
Franco-Nevada Corp.
(a)
    81,091       11,067,300  
Freeport-McMoRan, Inc.
(a)
    675,905       25,684,390  
Glencore PLC
    11,097,285       74,003,840  
Newmont Corp.
(a)
    226,682       10,699,390  
Norsk Hydro ASA
    2,820,457       21,075,481  
Polyus PJSC
(c)(d)
    104,732       14  
Stelco Holdings, Inc.
    439,632       14,380,577  
Teck Resources Ltd., Class B
(a)
    929,606       35,157,699  
Vale SA, ADR
(a)
    2,224,776       37,754,449  
Wheaton Precious Metals Corp.
(a)
    779,179       30,450,315  
   
 
 
 
      348,338,269  
Oil, Gas & Consumable Fuels — 35.2%
           
BP PLC
    6,407,994       36,973,751  
Canadian Natural Resources Ltd.
    380,536       21,131,833  
Cenovus Energy, Inc.
    578,921       11,232,094  
Chevron Corp.
(a)
    128,092       22,991,233  
ConocoPhillips
(a)
    204,461       24,126,398  
Security
 
Shares
   
Value
 
Oil, Gas & Consumable Fuels (continued)
           
Eni SpA
    1,060,959     $ 15,086,265  
EOG Resources, Inc.
(a)
    105,787       13,701,532  
Exxon Mobil Corp.
(a)
    500,048       55,155,295  
Galp Energia SGPS SA
    595,525       8,034,001  
Gazprom PJSC
(d)
    5,430,000       736  
Hess Corp.
(a)
    62,404       8,850,135  
Kinder Morgan, Inc.
(a)
    804,762       14,550,097  
Shell PLC, ADR
(a)
    1,128,773       64,283,622  
TotalEnergies SE
    798,313       50,112,610  
   
 
 
 
      346,229,602  
Paper & Forest Products — 2.1%
           
Precious Woods Holding AG, Registered Shares
(c)
    20,000       216,298  
UPM-Kymmene OYJ
    543,569       20,341,085  
   
 
 
 
      20,557,383  
   
 
 
 
Total Long-Term Investments — 98.3%
(Cost: $782,768,496)
 
    965,979,491  
   
 
 
 
Short-Term Securities
   
Money Market Funds — 2.0%
           
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(f)(g)
    19,404,102       19,404,102  
   
 
 
 
Total Short-Term Securities — 2.0%
(Cost: $19,404,102)
 
    19,404,102  
   
 
 
 
Total Investments Before Options Written — 100.3%
(Cost: $802,172,598)
 
    985,383,593  
   
 
 
 
Options Written — (0.7)%
(Premiums Received: $(10,076,296))
 
    (6,601,706
   
 
 
 
Total Investments, Net of Options Written — 99.6%
(Cost: $792,096,302)
 
    978,781,887  
Other Assets Less Liabilities — 0.4%
 
    4,399,153  
   
 
 
 
Net Assets — 100.0%
    $  983,181,040  
   
 
 
 
 
(a)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(b)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(c)
 
Non-income producing security.
(d)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(e)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $9,267,097, representing 0.9% of its net assets as of period end, and an original cost of $10,198,057.
(f)
 
Affiliate of the Trust.
(g)
 
Annualized 7-day yield as of period end.
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  103

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
 
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
 
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $  16,654,313     $  2,749,789
(a)
 
  $     $     $     $ 19,404,102       19,404,102     $ 352,525     $  
SL Liquidity Series, LLC, Money Market Series
(b)
                (330 )
(a)
 
    330                         952
(c)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ 330     $     $  19,404,102       $   353,477     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
 
(b)
 
As of period end, the entity is no longer held.
 
 
(c)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period
End Exchange-Traded Options Written
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call                                                   
Alcoa Corp.
     396          01/06/23        USD     54.00        USD     1,801        $ (1,188
ArcelorMittal SA, Registered Shares
     284          01/06/23        USD     28.00        USD     745          (994
Archer-Daniels-Midland Co.
     230          01/06/23        USD     98.00        USD     2,136          (1,150
Chevron Corp.
     216          01/06/23        USD     180.00        USD     3,877          (50,976
ConocoPhillips
     146          01/06/23        USD     132.00        USD     1,723          (1,168
Deere & Co.
     86          01/06/23        USD     450.00        USD     3,687          (5,203
Exxon Mobil Corp.
     155          01/06/23        USD     113.00        USD     1,710          (9,068
Hess Corp.
     95          01/06/23        USD     148.00        USD     1,347          (7,363
Kinder Morgan, Inc.
     492          01/06/23        USD     19.00        USD     890          (738
Newmont Corp.
     843          01/06/23        USD     50.00        USD     3,979          (8,852
Teck Resources Ltd., Class B
     785          01/06/23        USD     36.00        USD     2,969          (164,850
Vale SA, ADR
     1,048          01/06/23        USD     17.50        USD     1,778          (12,576
Alcoa Corp.
     143          01/13/23        USD     54.00        USD     650          (2,145
ArcelorMittal SA, Registered Shares
     530          01/13/23        USD     29.00        USD     1,390          (3,445
Archer-Daniels-Midland Co.
     225          01/13/23        USD     95.00        USD     2,089          (21,938
Chevron Corp.
     417          01/13/23        USD     185.00        USD     7,485          (75,268
ConocoPhillips
     365          01/13/23        USD     129.00        USD     4,307          (14,965
Deere & Co.
     46          01/13/23        USD     445.00        USD     1,972          (14,651
EOG Resources, Inc.
     108          01/13/23        USD     139.50        USD     1,399          (7,560
Exxon Mobil Corp.
     123          01/13/23        USD     109.00        USD     1,357          (40,897
Freeport-McMoRan, Inc.
     800          01/13/23        USD     41.00        USD     3,040          (28,000
Hess Corp.
     95          01/13/23        USD     148.00        USD     1,347          (18,525
Kinder Morgan, Inc.
     1,243          01/13/23        USD     18.50        USD     2,247          (22,374
Teck Resources Ltd., Class B
     764          01/13/23        USD     38.65        USD     2,889          (71,915
Vale SA, ADR
     1,624          01/13/23        USD     18.00        USD     2,756          (26,796
Wheaton Precious Metals Corp.
     913          01/13/23        USD     41.00        USD     3,568          (31,955
AGCO Corp.
     228          01/20/23        USD     130.00        USD     3,162          (223,440
Albemarle Corp.
     15          01/20/23        USD     290.00        USD     325          (525
Albemarle Corp.
     78          01/20/23        USD     270.00        USD     1,692          (1,560
Alcoa Corp.
     281          01/20/23        USD     50.00        USD     1,278          (34,844
ArcelorMittal SA, Registered Shares
     553          01/20/23        USD     25.00        USD     1,450          (95,116
Archer-Daniels-Midland Co.
     115          01/20/23        USD     95.00        USD     1,068          (15,238
BHP Group Ltd., ADR
     550          01/20/23        USD     57.50        USD     3,413          (286,000
BHP Group Ltd., ADR
     230          01/20/23        USD     67.50        USD     1,427          (5,175
Bunge Ltd.
     197          01/20/23        USD     100.00        USD     1,965          (55,160
Canadian Natural Resources Ltd.
     760          01/20/23        CAD     80.00        CAD     5,714          (30,030
Cenovus Energy, Inc.
     1,532          01/20/23        CAD     31.00        CAD     4,025          (5,092
ConocoPhillips
     27          01/20/23        USD     120.00        USD     319          (8,708
Darling Ingredients, Inc.
     268          01/20/23        USD     90.00        USD     1,677          (20,100
 
 
104
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    
 
Exchange-Traded Options Written (continued)
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)                                                   
Deere & Co.
     86          01/20/23        USD     420.00        USD     3,687        $ (143,190
EOG Resources, Inc.
     143          01/20/23        USD     132.20        USD     1,852          (45,760
Exxon Mobil Corp.
     798          01/20/23        USD     115.00        USD     8,802          (94,962
FMC Corp.
     268          01/20/23        USD     130.00        USD     3,345          (28,140
Franco-Nevada Corp.
     189          01/20/23        USD     140.00        USD     2,579          (49,140
Franco-Nevada Corp.
     112          01/20/23        USD     155.00        USD     1,529          (3,920
Freeport-McMoRan, Inc.
     163          01/20/23        USD     35.00        USD     619          (57,865
Packaging Corp. of America
     117          01/20/23        USD     135.00        USD     1,497          (15,503
Shell PLC, ADR
     1,108          01/20/23        USD     57.50        USD     6,310          (127,420
Sociedad Quimica y Minera de Chile SA, ADR
     28          01/20/23        USD     125.00        USD     224          (560
Sociedad Quimica y Minera de Chile SA, ADR
     101          01/20/23        USD     105.00        USD     806          (1,515
Stelco Holdings, Inc.
     847          01/20/23        CAD     42.00        CAD     3,751          (217,380
Teck Resources Ltd., Class B
     589          01/20/23        USD     37.00        USD     2,228          (117,800
Vale SA, ADR
     1,083          01/20/23        USD     18.00        USD     1,838          (27,616
Wheaton Precious Metals Corp.
     390          01/20/23        USD     39.00        USD     1,524          (52,650
Wheaton Precious Metals Corp.
     523          01/20/23        USD     41.00        USD     2,044          (28,765
Archer-Daniels-Midland Co.
     211          01/27/23        USD     95.00        USD     1,959          (45,892
ConocoPhillips
     222          01/27/23        USD     121.00        USD     2,620          (79,920
Deere & Co.
     57          01/27/23        USD     440.00        USD     2,444          (47,595
EOG Resources, Inc.
     142          01/27/23        USD     135.50        USD     1,839          (40,115
Exxon Mobil Corp.
     784          01/27/23        USD     111.00        USD     8,648          (260,680
Freeport-McMoRan, Inc.
     682          01/27/23        USD     44.00        USD     2,592          (23,529
Kinder Morgan, Inc.
     1,259          01/27/23        USD     18.00        USD     2,276          (76,169
Teck Resources Ltd., Class B
     534          01/27/23        USD     39.00        USD     2,020          (71,289
Vale SA, ADR
     1,353          01/27/23        USD     18.00        USD     2,296          (50,061
Wheaton Precious Metals Corp.
     800          01/27/23        USD     42.00        USD     3,126          (38,000
Vale SA, ADR
     965          02/03/23        USD     17.50        USD     1,638          (62,242
Wheaton Precious Metals Corp.
     273          02/03/23        USD     44.00        USD     1,067          (8,190
Vale SA, ADR
     965          02/10/23        USD     17.51        USD     1,638          (73,989
AGCO Corp.
     250          02/17/23        USD     135.00        USD     3,467          (250,000
Archer-Daniels-Midland Co.
     212          02/17/23        USD     97.50        USD     1,968          (44,520
BHP Group Ltd., ADR
     342          02/17/23        USD     65.00        USD     2,122          (61,560
BHP Group Ltd., ADR
     614          02/17/23        USD     67.50        USD     3,810          (62,935
Bunge Ltd.
     569          02/17/23        USD     105.00        USD     5,677          (160,742
Canadian Natural Resources Ltd.
     167          02/17/23        CAD     86.00        CAD     1,256          (6,845
Cenovus Energy, Inc.
     411          02/17/23        CAD     29.00        CAD     1,080          (22,766
Darling Ingredients, Inc.
     204          02/17/23        USD     66.00        USD     1,277          (51,395
FMC Corp.
     351          02/17/23        USD     130.00        USD     4,380          (122,850
Freeport-McMoRan, Inc.
     870          02/17/23        USD     38.00        USD     3,306          (238,815
Hess Corp.
     42          02/17/23        USD     150.00        USD     596          (24,360
Shell PLC, ADR
     804          02/17/23        USD     60.00        USD     4,579          (92,460
Sociedad Quimica y Minera de Chile SA, ADR
     349          02/17/23        USD     99.00        USD     2,786          (32,613
Stelco Holdings, Inc.
     796          02/17/23        CAD     44.00        CAD     3,525          (214,579
Teck Resources Ltd., Class B
     787          02/17/23        USD     40.00        USD     2,976          (131,035
Vale SA, ADR
     1,241          02/17/23        USD     17.00        USD     2,106          (131,546
Canadian Natural Resources Ltd.
     489          03/17/23        CAD     80.00        CAD     3,677          (103,109
Cenovus Energy, Inc.
     211          03/17/23        CAD     27.00        CAD     554          (29,686
                          
 
 
 
                           $  (5,097,221
                          
 
 
 
OTC Options Written
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call
                
Anglo American PLC
   Morgan Stanley & Co. International PLC     26,900       01/05/23       GBP       32.68       GBP       871     $ (14,363
Eni SpA
   Morgan Stanley & Co. International PLC     335,100       01/05/23       EUR       14.57       EUR       4,452       (398
Norsk Hydro ASA
   Morgan Stanley & Co. International PLC     378,810       01/05/23       NOK       73.90       NOK       27,774       (34,228
Shell PLC, ADR
   Barclays Bank PLC     115,700       01/05/23       USD       58.93       USD       6,589       (13,340
Shell PLC, ADR
   JPMorgan Chase Bank N.A.     110,700       01/05/23       USD       56.33       USD       6,304       (130,315
BP PLC
   Morgan Stanley & Co. International PLC     1,043,800       01/10/23       GBP       5.10       GBP       4,957       (5,843
Norsk Hydro ASA
   Morgan Stanley & Co. International PLC     195,700       01/10/23       NOK       73.59       NOK       14,349       (28,632
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  105

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    
 
OTC Options Written (continued)
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call (continued)
                
Norsk Hydro ASA
   Royal Bank of Canada     126,000       01/10/23       NOK       76.82       NOK       9,238     $ (4,938
TotalEnergies SE
   Royal Bank of Canada     59,818       01/11/23       EUR       60.77       EUR       3,508       (17,901
Galp Energia SGPS SA
   Goldman Sachs International     110,800       01/17/23       EUR       12.21       EUR       1,397       (70,650
Koninklijke DSM NV
   Morgan Stanley & Co. International PLC     20,500       01/17/23       EUR       124.33       EUR       2,343       (4,303
TotalEnergies SE
   Morgan Stanley & Co. International PLC     105,000       01/17/23       EUR       58.51       EUR       6,158       (144,883
Norsk Hydro ASA
   Morgan Stanley & Co. International PLC     349,000       01/18/23       NOK       76.73       NOK       25,589       (26,989
Kerry Group PLC
   Morgan Stanley & Co. International PLC     59,800       01/27/23       EUR       91.39       EUR       5,038       (29,947
BHP Group Ltd., ADR
   JPMorgan Chase Bank N.A.     77,900       01/30/23       USD       63.93       USD       4,834       (121,901
AGCO Corp.
   Goldman Sachs International     25,000       01/31/23       USD       131.84       USD       3,467       (260,843
Eni SpA
   Goldman Sachs International     59,700       01/31/23       EUR       13.59       EUR       793       (18,097
Galp Energia SGPS SA
   Goldman Sachs International     110,800       02/01/23       EUR       12.21       EUR       1,397       (84,654
BP PLC
   Morgan Stanley & Co. International PLC     1,400,000       02/02/23       GBP       4.92       GBP       6,649       (162,821
Koninklijke DSM NV
   Morgan Stanley & Co. International PLC     7,500       02/02/23       EUR       122.23       EUR       857       (9,900
TotalEnergies SE
   Goldman Sachs International     135,608       02/02/23       EUR       60.76       EUR       7,953       (123,519
UPM Kymmene OYJ
   Morgan Stanley & Co. International PLC     120,000       02/02/23       EUR       37.28       EUR       4,192       (32,793
Anglo American PLC
   JPMorgan Chase Bank N.A.     88,700       02/08/23       GBP       32.89       GBP       2,871       (143,884
UPM Kymmene OYJ
   UBS AG     82,300       02/08/23       EUR       37.94       EUR       2,875       (19,343
                
 
 
 
                 $ (1,504,485
                
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
Options Written
   $ N/A      $ N/A      $ 4,498,058      $ (1,023,468    $ (6,601,706)  
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
     
Commodity
Contracts
    
Credit
  Contracts
    
Equity
Contracts
    
Foreign
Currency
  Exchange
Contracts
    
Interest
Rate
  Contracts
    
Other
  Contracts
    
Total
 
Liabilities — Derivative Financial Instruments
 
                 
Options written
                    
Options written at value
   $      $     —      $   6,601,706      $     —      $     —      $     —      $ 6,601,706  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options purchased
(a)
   $      $      $ (4,824,362    $      $      $      $ (4,824,362
Options written
                   (36,914,355                           (36,914,355
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $  (41,738,717)      $      $      $      $  (41,738,717
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options purchased
(b)
   $      $      $ 1,311      $      $      $      $ 1,311  
Options written
                   4,849,639                             4,849,639  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ 4,850,950      $      $      $      $ 4,850,950  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
 
(b)
 
Options purchased are included in net change in unrealized appreciation (depreciation) on investments — unaffiliated.
 
 
 
106
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
Options:
  
 
 
 
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 7,213,553  
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $ 6,601,706  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
              6,601,706  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (5,097,221
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 1,504,485  
  
 
 
      
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
  
 

Derivatives
Available
for Offset
 
 
 
  
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
  
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 13,340      $      $      $      $ 13,340  
Goldman Sachs International
     557,763               (557,763              
JPMorgan Chase Bank N.A.
     396,100               (366,100      (30,000       
Morgan Stanley & Co. International PLC
     495,100               (495,100              
Royal Bank of Canada
     22,839                             22,839  
UBS AG
     19,343                             19,343  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 1,504,485      $      $ (1,418,963)      $ (30,000    $ 55,522  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Chemicals
   $ 101,711,968        $ 9,219,293        $        $ 110,931,261  
Containers & Packaging
     4,041,189                            4,041,189  
Food Products
     53,272,394          14,520,492          9,267,097          77,059,983  
Machinery
     58,821,804                            58,821,804  
Metals & Mining
     241,104,532          107,233,723          14          348,338,269  
Oil, Gas & Consumable Fuels
     236,022,239          110,206,627          736          346,229,602  
Paper & Forest Products
              20,557,383                   20,557,383  
Short-Term Securities
                 
Money Market Funds
     19,404,102                            19,404,102  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $ 714,378,228        $ 261,737,518        $   9,267,847        $ 985,383,593  
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  107

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Resources & Commodities Strategy Trust (BCX)
    
 
Fair Value Hierarchy as of Period End (continued)
 
 
 
    
Level 1
      
Level 2
      
Level 3
      
Total
 
 
 
Derivative Financial Instruments
(a)
                 
Liabilities
                 
Equity Contracts
   $   (4,867,309)        $   (1,734,397)        $           —        $   (6,601,706
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
 
 
 
    
Common
Stocks
 
 
 
Assets
  
Opening balance, as of December 31, 2021
   $ 9,834,654  
Transfers into Level 3
      
Transfers out of Level 3
      
Accrued discounts/premiums
      
Net realized gain (loss)
  
Net change in unrealized appreciation (depreciation)
(a)(b)
     (38,407,944
Purchases
     37,841,138  
Sales
      
  
 
 
 
Closing balance, as of December 31, 2022
   $ 9,267,847  
  
 
 
 
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022
(b)
   $ (38,407,944
  
 
 
 
 
 
(a)
 
Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.
 
 
(b)
 
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022 is generally due to investments no longer held or categorized as Level 3 at period end.
 
See notes to financial statements.
 
 
108
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Common Stocks
 
Automobiles — 1.3%
 
Tesla, Inc.
(a)(b)
       100,796     $    12,416,051  
   
 
 
 
Banks — 0.5%
 
Klarna Holdings AB, (Acquired 08/07/19,
Cost: $7,971,978)
(c)(d)
    26,430       4,842,243  
   
 
 
 
Capital Markets — 0.9%
 
S&P Global, Inc.
(a)
    24,719       8,279,382  
   
 
 
 
Communications Equipment — 0.5%
 
Motorola Solutions, Inc.
(a)
    20,355       5,245,687  
   
 
 
 
Diversified Consumer Services — 0.3%
 
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $1,524,948)
(c)(d)
    997       2,393,479  
   
 
 
 
Electrical Equipment — 0.4%
 
Sungrow Power Supply Co. Ltd., Class A
    221,100       3,563,698  
   
 
 
 
Electronic Equipment, Instruments & Components — 2.4%
 
CDW Corp.
(a)
    44,250       7,902,165  
Flex Ltd.
(a)(b)
    227,810       4,888,803  
Samsung SDI Co. Ltd.
(b)
    22,188       10,418,206  
   
 
 
 
      23,209,174  
Entertainment
(a)
— 1.8%
 
Electronic Arts, Inc.
    31,150       3,805,907  
Netflix, Inc.
(b)
    22,221       6,552,529  
Spotify Technology SA
(b)
    38,793       3,062,707  
Take-Two Interactive Software, Inc.
(b)
    39,170       4,078,772  
   
 
 
 
      17,499,915  
Equity Real Estate Investment Trusts (REITs) — 0.4%
 
SBA Communications Corp.
(a)
    14,781       4,143,262  
   
 
 
 
Hotels, Restaurants & Leisure — 0.9%
 
Trip.com Group Ltd.
(b)
    260,650       8,989,713  
   
 
 
 
Interactive Media & Services — 3.1%
 
Alphabet, Inc., Class A
(a)(b)
    171,511       15,132,416  
Meta Platforms, Inc., Class A
(a)(b)
    41,030       4,937,550  
Tencent Holdings Ltd.
    111,100       4,710,680  
ZoomInfo Technologies, Inc., CLass A
(a)(b)
    170,230       5,125,625  
   
 
 
 
      29,906,271  
Internet & Direct Marketing Retail — 2.8%
 
Alibaba Group Holding Ltd., ADR
(a)(b)
    57,983       5,107,723  
Amazon.com, Inc.
(a)(b)
    136,031       11,426,604  
Jasper Infotech Private Ltd., Series I, (Acquired 08/31/18, Cost: $1,998,435)
(c)(d)
    168,640       150,579  
MercadoLibre, Inc.
(a)(b)
    12,034       10,183,652  
   
 
 
 
      26,868,558  
IT Services — 15.0%
 
Adyen NV
(b)(e)
    6,728       9,340,139  
Automatic Data Processing, Inc.
(a)
    25,500       6,090,930  
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $7,999,945)
(c)(d)
    94,117       3,718,563  
Block, Inc.
(a)(b)
    85,377       5,365,091  
GMO Payment Gateway, Inc.
    67,300       5,565,639  
Mastercard, Inc., Class A
(a)
    95,659       33,263,504  
MongoDB, Inc.
(a)(b)
    34,742       6,838,615  
Okta, Inc.
(a)(b)
    66,245       4,526,521  
PayPal Holdings, Inc.
(a)(b)
    91,693       6,530,375  
Security
 
Shares
   
Value
 
IT Services (continued)
 
Salt Pay Co. Ltd., Series C, (Acquired 12/17/21, Cost: $24,999,987)
(c)(d)
    12,871     $ 12,117,146  
Snowflake, Inc., Class A
(a)(b)
    13,175       1,891,139  
TRAX Ltd., (Acquired 09/12/19,
Cost: $4,000,012)
(c)(d)
    106,667       2,686,942  
TRAX Ltd., Series D, (Acquired 02/18/21,
Cost: $1,999,989)
(c)(d)
    38,361       966,314  
Twilio, Inc., Class A
(a)(b)
    71,823       3,516,454  
Visa, Inc., Class A
(a)
    130,798       27,174,592  
Voltron Data, Inc., Series A, (Acquired 01/18/22, Cost: $10,000,000)
(c)(d)
    6,201,935       7,504,341  
Wise PLC, Class A
(b)
    1,036,641       7,023,016  
   
 
 
 
      144,119,321  
Professional Services — 0.3%
 
Planet Labs PBC
    548,200       2,674,772  
   
 
 
 
Road & Rail — 1.6%
           
Ant Group Co., Ltd., Series C, (Acquired 05/18/18, Cost: $6,492,862)
(c)(d)
    1,703,548       4,275,906  
Full Truck Alliance Co. Ltd., ADR
(a)(b)
    624,074       4,992,592  
Uber Technologies, Inc.
(a)(b)
    232,966       5,761,249  
   
 
 
 
      15,029,747  
Semiconductors & Semiconductor Equipment — 17.7%
 
Advanced Micro Devices, Inc.
(a)(b)
    137,476       8,904,320  
Alphawave IP Group PLC
(b)
    2,327,484       2,870,088  
Analog Devices, Inc.
(a)
    29,134       4,778,850  
ASM International NV
    29,379       7,454,463  
ASML Holding NV
    42,974       23,431,644  
Broadcom, Inc.
(a)
    25,330       14,162,763  
Credo Technology Group Holding Ltd.
(a)(b)
    879,796       11,710,085  
First Solar, Inc.
(a)(b)
    23,707       3,551,071  
Global Foundries, Inc.
(a)(b)(f)
    83,946       4,523,850  
Lam Research Corp.
(a)
    22,982       9,659,335  
Marvell Technology, Inc.
(a)
    192,929       7,146,090  
Micron Technology, Inc.
(a)
    150,469       7,520,441  
Monolithic Power Systems, Inc.
(a)
    23,555       8,329,284  
NVIDIA Corp.
(a)
    63,235       9,241,163  
Qualcomm, Inc.
(a)
    65,936       7,249,004  
Soitec SA
(b)
    96,789       15,886,596  
STMicroelectronics NV
    214,912       7,637,118  
Wolfspeed, Inc.
(a)(b)
    236,466       16,325,613  
   
 
 
 
      170,381,778  
Software — 22.0%
 
Adobe, Inc.
(a)(b)
    15,974       5,375,730  
Alteryx, Inc., Class A
(a)(b)
    78,203       3,962,546  
ANSYS, Inc.
(a)(b)
    37,677       9,102,387  
Aspen Technology, Inc.
(a)(b)
    35,939       7,381,870  
Atlassian Corp., Class A
(a)(b)
    37,595       4,837,725  
Cadence Design Systems, Inc.
(a)(b)
    109,188       17,539,960  
Constellation Software, Inc.
    3,620       5,651,798  
Crowdstrike Holdings, Inc., Class A
(a)(b)
    33,034       3,478,150  
Dassault Systemes SE
    144,641       5,201,240  
Databricks, Inc., (Acquired 07/24/20,
Cost: $960,476)
(c)(d)
    59,997       3,070,646  
DataRobot, Inc., (Acquired 03/01/21,
Cost: $583,275)
(c)(d)
    38,789       202,091  
DocuSign, Inc.
(a)(b)
    71,854       3,982,149  
Gitlab, Inc., Class A
(a)(b)
    125,370       5,696,813  
Grammarly, Inc., (Acquired 11/17/21,
Cost: $18,749,975)
(c)(d)
    715,323       11,995,967  
Intuit, Inc.
(a)
    23,704       9,226,071  
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  109

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Software (continued)
 
Microsoft Corp.
(a)
    262,904     $ 63,049,637  
Oracle Corp.
(a)
    167,689       13,706,899  
Patreon, Inc., (Acquired 08/19/21,
Cost: $3,352,226)
(c)(d)
.
    59,524       1,513,100  
Salesforce, Inc.
(a)(b)
    29,317       3,887,141  
ServiceNow, Inc.
(a)(b)
    17,141       6,655,336  
SiteMinder Ltd.
(b)
    1,904,282       3,947,779  
Snorkel AI, Inc., (Acquired 06/30/21,
Cost: $997,636)
(c)(d)
    66,422       472,925  
Snyk Ltd., (Acquired 09/02/21,
Cost: $5,192,307)
(c)(d)
    361,972       4,159,058  
Splunk, Inc.
(a)(b)
    53,087       4,570,260  
Unity Software, Inc.
(a)(b)
    114,284       3,267,379  
Xero Ltd.
(b)
    120,170       5,730,166  
Zscaler, Inc.
(a)(b)
    32,603       3,648,276  
   
 
 
 
      211,313,099  
Technology Hardware, Storage & Peripherals
(a)
— 7.2%
 
Apple, Inc.
    491,130       63,812,521  
Dell Technologies, Inc., Class C
    124,617       5,012,096  
   
 
 
 
      68,824,617  
   
 
 
 
Total Common Stocks — 79.1%
(Cost: $566,123,998)
 
     759,700,767  
   
 
 
 
    
Par
(000)
        
Convertible Notes
 
Software — 0.2%
 
Wyre, Inc., (Acquired: 12/14/21,
Cost: $8,000,000), 0.00%
(c)(d)
  $ 80       1,920,000  
   
 
 
 
Total Convertible Notes — 0.2%
(Cost: $8,000,000)
 
    1,920,000  
   
 
 
 
    
Shares
        
Preferred Securities
 
Preferred Stocks — 20.4%
(c)(d)
 
Chemicals — 1.1%
 
Solugen, Inc., Series C, (Acquired 09/02/21, Cost: $9,999,977)
    269,284       10,959,859  
   
 
 
 
Diversified Consumer Services — 0.3%
 
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $3,052,975)
    1,054       2,530,318  
   
 
 
 
Diversified Financial Services — 0.8%
 
Trumid Holdings LLC, Class L, (Acquired 09/15/21, Cost: $9,999,695), 07/16/22
(g)
    11,420       7,660,537  
   
 
 
 
Entertainment — 0.5%
 
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $7,000,088)
    12,713       5,030,026  
   
 
 
 
Food & Staples Retailing — 1.6%
 
Grubmarket, Inc., Series E, (Acquired 10/18/21, Cost: $6,999,994)
    709,724       15,670,706  
   
 
 
 
Security
 
Shares
   
Value
 
Food Products — 1.0%
 
Farmer’s Business Network, Inc.
   
Series F, (Acquired 07/31/20, Cost: $2,999,886)
    90,750     $ 4,229,857  
Series G, (Acquired 09/15/21, Cost: $6,999,963)
    112,616       5,249,032  
   
 
 
 
      9,478,889  
Interactive Media & Services — 1.5%
 
ByteDance Ltd., Series
E-1,
(Acquired 11/11/20, Cost: $9,650,746)
    88,075          14,515,369  
   
 
 
 
IT Services — 1.9%
 
Deep Instinct Ltd., Series
D-2,
(Acquired 03/19/21, Cost: $2,999,391)
    493,493       3,390,297  
Trumid Holdings LLC
(g)
   
Class J-A,
(Acquired 07/24/20,
Cost: $2,499,716)
    5,038       3,379,490  
Class J-B,
(Acquired 07/24/20,
Cost: $1,499,830)
    5,038       3,379,490  
Voltron Data, Inc., Seed Shares, (Acquired 07/14/21, Cost: $5,000,000)
    9,090,909       7,545,454  
   
 
 
 
      17,694,731  
Road & Rail — 0.5%
 
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $5,482,937)
    275       4,258,179  
   
 
 
 
Semiconductors & Semiconductor Equipment — 4.3%
 
PsiQuantum Corp.
   
Series C, (Acquired 09/09/19,
Cost: $3,200,234)
    690,003       14,214,062  
Series D, (Acquired 05/21/21,
Cost: $5,000,025)
    190,650       4,844,416  
Rivos, Inc., Series A, (Acquired 12/03/21,
Cost: $12,003,705)
    4,500,000       10,710,000  
SambaNova Systems, Inc., Series C, (Acquired 02/20/20, Cost: $9,972,125)
    187,300       11,891,677  
   
 
 
 
      41,660,155  
Software — 6.9%
 
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $29,999,955)
    598,682       16,948,687  
Databricks, Inc.
   
Series F, (Acquired 10/22/19,
Cost: $3,999,999)
    279,405       14,299,948  
Series G, (Acquired 02/01/21,
Cost: $4,500,001)
    76,113       3,895,463  
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $2,999,996)
    228,276       1,449,553  
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $6,249,992)
    238,441       3,998,656  
MNTN Digital, Inc., Series D, (Acquired 11/05/21, Cost: $24,999,980)
    1,088,598       10,450,541  
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $6,666,632)
    119,047       3,026,175  
Prosimo, Inc., Series B, (Acquired 11/04/21, Cost: $4,999,998)
    2,515,811       4,075,614  
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $4,999,985)
    332,896       2,370,220  
Snyk Ltd., Series F, (Acquired 09/02/21,
Cost: $4,807,688)
    335,159       3,871,086  
 
 
110
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
   
Value
 
Software (continued)
 
Unqork, Inc.
   
Series B, (Acquired 09/19/19,
Cost: $3,198,416)
    281,080     $ 1,751,128  
Series C, (Acquired 09/18/20,
Cost: $1,303,260)
    47,600       371,756  
   
 
 
 
      66,508,827  
   
 
 
 
      195,967,596  
   
 
 
 
Total Preferred Securities — 20.4%
(Cost: $203,087,189)
 
    195,967,596  
   
 
 
 
Warrants
 
IT Services — 0.0%
 
TRAX Ltd., (Acquired 09/12/19, Cost: $0), (Issued 09/23/19, Exercisable 07/12/23, 1 Share for 1 Warrant, Expires 09/15/23, Strike Price USD 46.88)
(b)(c)(d)
    17,065       16,212  
   
 
 
 
Total Warrants — 0.0%
(Cost: $ — )
 
    16,212  
   
 
 
 
Total Long-Term Investments — 99.7%
(Cost: $777,211,187)
 
    957,604,575  
   
 
 
 
Short-Term Securities
 
Money Market Funds — 0.7%
 
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(h)(i)
    5,779,501       5,779,501  
SL Liquidity Series, LLC, Money Market Series, 4.49%
(h)(i)(j)
    825,108       825,025  
   
 
 
 
Total Short-Term Securities — 0.7%
(Cost: $6,604,446)
 
    6,604,526  
   
 
 
 
Total Investments Before Options Written — 100.4%
(Cost: $783,815,633)
 
    964,209,101  
   
 
 
 
Options Written — (0.5)%
(Premiums Received: $(11,681,013))
 
    (4,275,777
   
 
 
 
Total Investments, Net of Options Written — 99.9%
(Cost: $772,134,620)
 
    959,933,324  
Other Assets Less Liabilities — 0.1%
 
    769,877  
   
 
 
 
Net Assets — 100.0%
 
  $ 960,703,201  
   
 
 
 
 
(a)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(b)
 
Non-income producing security.
(c)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
(d)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $257,973,108, representing 26.9% of its net assets as of period end, and an original cost of $307,911,240.
(e)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(f)
 
All or a portion of this security is on loan.
(g)
 
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.
(h)
 
Affiliate of the Trust.
(i)
 
Annualized 7-day yield as of period end.
(j)
 
All or a portion of this security was purchased with the cash collateral from loaned securities.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  111

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $ 42,574,872     $     $ (36,795,371 )
(a)
 
  $     $     $ 5,779,501       5,779,501     $ 325,571     $  
SL Liquidity Series, LLC, Money Market Series
    840,396             (15,244 )
(a)
 
    (207     80       825,025       825,108       41,308
(b)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ (207   $ 80     $ 6,604,526       $ 366,879     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
 
(b)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call
                                
Adobe, Inc.
     22          01/06/23          USD          350.00          USD          740        $        (3,421
Advanced Micro Devices, Inc.
     251          01/06/23          USD          81.00          USD          1,626          (502
Alibaba Group Holding Ltd., ADR
     98          01/06/23          USD          99.00          USD          863          (1,225
Alphabet, Inc., Class A
     55          01/06/23          USD          99.00          USD          485          (138
Amazon.com, Inc.
     37          01/06/23          USD          96.00          USD          311          (111
Analog Devices, Inc.
     21          01/06/23          USD          175.00          USD          344          (263
Apple, Inc.
     157          01/06/23          USD          157.50          USD          2,040          (157
Atlassian Corp., Class A
     33          01/06/23          USD          135.00          USD          425          (5,857
Atlassian Corp., Class A
     32          01/06/23          USD          150.00          USD          412          (720
Block, Inc.
     139          01/06/23          USD          80.00          USD          873          (209
Broadcom, Inc.
     26          01/06/23          USD          535.00          USD          1,454          (69,420
Electronic Arts, Inc.
     70          01/06/23          USD          135.00          USD          855          (980
First Solar, Inc.
     23          01/06/23          USD          172.50          USD          345          (265
Intuit, Inc.
     90          01/06/23          USD          415.00          USD          3,503          (9,000
Lam Research Corp.
     20          01/06/23          USD          510.00          USD          841          (100
Mastercard, Inc., Class A
     86          01/06/23          USD          350.00          USD          2,990          (31,175
MercadoLibre, Inc.
     12          01/06/23          USD          995.00          USD          1,015          (3,600
Micron Technology, Inc.
     237          01/06/23          USD          58.00          USD          1,185          (356
Microsoft Corp.
     443          01/06/23          USD          260.00          USD          10,624          (3,987
MongoDB, Inc.
     28          01/06/23          USD          175.00          USD          551          (63,700
MongoDB, Inc.
     15          01/06/23          USD          210.00          USD          295          (3,300
Netflix, Inc.
     21          01/06/23          USD          310.00          USD          619          (3,633
Netflix, Inc.
     16          01/06/23          USD          315.00          USD          472          (1,688
NVIDIA Corp.
     138          01/06/23          USD          165.00          USD          2,017          (2,622
Oracle Corp.
     360          01/06/23          USD          83.00          USD          2,943          (16,380
PayPal Holdings, Inc.
     166          01/06/23          USD          87.00          USD          1,182          (249
Qualcomm, Inc.
     161          01/06/23          USD          133.00          USD          1,770          (322
S&P Global, Inc.
     50          01/06/23          USD          360.00          USD          1,675          (4,250
ServiceNow, Inc.
     16          01/06/23          USD          430.00          USD          621          (440
Snowflake, Inc., Class A
     35          01/06/23          USD          155.00          USD          502          (3,238
Splunk, Inc.
     59          01/06/23          USD          100.00          USD          508          (266
Spotify Technology SA
     68          01/06/23          USD          85.00          USD          537          (2,380
Tesla, Inc.
     97          01/06/23          USD          205.00          USD          1,195          (97
Twilio, Inc., Class A
     24          01/06/23          USD          53.00          USD          118          (996
Unity Software, Inc.
     149          01/06/23          USD          37.00          USD          426          (745
Visa, Inc., Class A
     102          01/06/23          USD          220.00          USD          2,119          (918
Zscaler, Inc.
     30          01/06/23          USD          130.00          USD          336          (270
Wolfspeed, Inc.
     250          01/12/23          USD          100.50          USD          1,726          (107
Adobe, Inc.
     19          01/13/23          USD          350.00          USD          639          (8,930
Advanced Micro Devices, Inc.
     242          01/13/23          USD          73.00          USD          1,567          (10,043
Alibaba Group Holding Ltd., ADR
     98          01/13/23          USD          99.00          USD          863          (6,958
 
 
112
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Exchange-Traded Options Written (continued)
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)
                                
Alphabet, Inc., Class A
     54          01/13/23          USD          100.00          USD          476        $ (513
Amazon.com, Inc.
     38          01/13/23          USD          98.00          USD          319          (494
Analog Devices, Inc.
     76          01/13/23          USD          172.50          USD          1,247          (9,310
Apple, Inc.
     255          01/13/23          USD          148.00          USD          3,313          (2,678
Atlassian Corp., Class A
     32          01/13/23          USD          140.00          USD          412          (8,240
Atlassian Corp., Class A
     33          01/13/23          USD          150.00          USD          425          (3,382
Automatic Data Processing, Inc.
     102          01/13/23          USD          265.00          USD          2,436          (2,295
Crowdstrike Holdings, Inc., Class A
     69          01/13/23          USD          135.00          USD          727          (518
DocuSign, Inc.
     149          01/13/23          USD          63.00          USD          826          (8,344
Intuit, Inc.
     18          01/13/23          USD          430.00          USD          701          (2,700
Mastercard, Inc., Class A
     161          01/13/23          USD          350.00          USD          5,598             (107,870
MercadoLibre, Inc.
     19          01/13/23          USD          1,000.00          USD          1,608          (6,365
Micron Technology, Inc.
     155          01/13/23          USD          59.00          USD          775          (930
Microsoft Corp.
     173          01/13/23          USD          250.00          USD          4,149          (36,849
MongoDB, Inc.
     15          01/13/23          USD          190.00          USD          295          (21,900
MongoDB, Inc.
     15          01/13/23          USD          210.00          USD          295          (8,250
Netflix, Inc.
     17          01/13/23          USD          340.00          USD          501          (1,522
Netflix, Inc.
     16          01/13/23          USD          320.00          USD          472          (4,584
Okta, Inc.
     70          01/13/23          USD          75.00          USD          478          (7,805
S&P Global, Inc.
     11          01/13/23          USD          335.00          USD          368          (8,360
Salesforce, Inc.
     107          01/13/23          USD          150.00          USD          1,419          (2,461
ServiceNow, Inc.
     12          01/13/23          USD          440.00          USD          466          (1,530
Spotify Technology SA
     51          01/13/23          USD          86.00          USD          403          (5,227
Take-Two Interactive Software, Inc.
     11          01/13/23          USD          106.00          USD          115          (2,387
Tesla, Inc.
     113          01/13/23          USD          190.00          USD          1,392          (1,243
Uber Technologies, Inc.
     1,048          01/13/23          USD          29.00          USD          2,592          (7,336
Unity Software, Inc.
     200          01/13/23          USD          43.00          USD          572          (2,600
Zscaler, Inc.
     39          01/13/23          USD          145.00          USD          436          (507
Zscaler, Inc.
     39          01/13/23          USD          135.00          USD          436          (1,112
Adobe, Inc.
     30          01/20/23          USD          345.00          USD          1,010          (24,375
Advanced Micro Devices, Inc.
     146          01/20/23          USD          72.50          USD          946          (10,950
Alphabet, Inc., Class A
     55          01/20/23          USD          100.00          USD          485          (1,073
Alphabet, Inc., Class A
     52          01/20/23          USD          92.00          USD          459          (7,254
Alteryx, Inc., Class A
     175          01/20/23          USD          55.00          USD          887          (17,937
Amazon.com, Inc.
     189          01/20/23          USD          107.50          USD          1,588          (1,323
ANSYS, Inc.
     89          01/20/23          USD          260.00          USD          2,150          (14,240
Apple, Inc.
     168          01/20/23          USD          160.00          USD          2,183          (588
Aspen Technology, Inc.
     83          01/20/23          USD          270.00          USD          1,705          (39,840
Atlassian Corp., Class A
     52          01/20/23          USD          160.00          USD          669          (4,030
Automatic Data Processing, Inc.
     12          01/20/23          USD          252.50          USD          287          (1,380
Block, Inc.
     114          01/20/23          USD          70.00          USD          716          (16,644
Cadence Design Systems, Inc.
     270          01/20/23          USD          185.00          USD          4,337          (10,125
CDW Corp.
     87          01/20/23          USD          190.00          USD          1,554          (6,307
Credo Technology Group Holding Ltd.
     1,123          01/20/23          USD          15.00          USD          1,495          (19,652
Credo Technology Group Holding Ltd.
     248          01/20/23          USD          17.50          USD          330          (4,960
Crowdstrike Holdings, Inc., Class A
     63          01/20/23          USD          130.00          USD          663          (1,859
Dell Technologies, Inc., Class C
     549          01/20/23          USD          45.00          USD          2,208          (3,843
DocuSign, Inc.
     150          01/20/23          USD          65.00          USD          831          (8,475
Electronic Arts, Inc.
     35          01/20/23          USD          140.00          USD          428          (263
Electronic Arts, Inc.
     35          01/20/23          USD          135.00          USD          428          (665
First Solar, Inc.
     36          01/20/23          USD          165.00          USD          539          (7,920
Flex Ltd.
     450          01/20/23          USD          23.00          USD          966          (10,125
Flex Ltd.
     555          01/20/23          USD          24.00          USD          1,191          (8,325
Full Truck Alliance Co. Ltd., ADR
     800          01/20/23          USD          10.00          USD          640          (14,000
Gitlab, Inc., Class A
     528          01/20/23          USD          45.00          USD          2,399          (176,880
Global Foundries, Inc.
     509          01/20/23          USD          65.00          USD          2,743          (6,362
Intuit, Inc.
     26          01/20/23          USD          400.00          USD          1,012          (26,520
Lam Research Corp.
     31          01/20/23          USD          515.00          USD          1,303          (2,015
Marvell Technology, Inc.
     140          01/20/23          USD          47.00          USD          519          (910
Marvell Technology, Inc.
     370          01/20/23          USD          45.00          USD          1,370          (4,810
Mastercard, Inc., Class A
     182          01/20/23          USD          360.00          USD          6,329          (74,620
Microsoft Corp.
     173          01/20/23          USD          240.00          USD          4,149          (124,560
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  113

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Exchange-Traded Options Written (continued)
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)
                                
Microsoft Corp.
     132          01/20/23          USD          260.00          USD          3,166        $ (12,804
MongoDB, Inc.
     68          01/20/23          USD          175.00          USD          1,339             (180,880
Monolithic Power Systems, Inc.
     41          01/20/23          USD          433.00          USD          1,450          (4,112
Motorola Solutions, Inc.
     49          01/20/23          USD          270.00          USD          1,263          (7,595
Motorola Solutions, Inc.
     40          01/20/23          USD          280.00          USD          1,031          (1,400
Netflix, Inc.
     37          01/20/23          USD          300.00          USD          1,091          (67,525
NVIDIA Corp.
     90          01/20/23          USD          160.00          USD          1,315          (24,075
Oracle Corp.
     197          01/20/23          USD          85.00          USD          1,610          (12,805
PayPal Holdings, Inc.
     148          01/20/23          USD          87.50          USD          1,054          (2,590
S&P Global, Inc.
     50          01/20/23          USD          360.00          USD          1,675          (7,375
ServiceNow, Inc.
     50          01/20/23          USD          410.00          USD          1,941          (39,250
Splunk, Inc.
     58          01/20/23          USD          100.00          USD          499          (3,306
Spotify Technology SA
     55          01/20/23          USD          80.00          USD          434          (20,350
Take-Two Interactive Software, Inc.
     72          01/20/23          USD          130.00          USD          750          (936
Tesla, Inc.
     117          01/20/23          USD          223.33          USD          1,441          (1,053
Twilio, Inc., Class A
     105          01/20/23          USD          65.00          USD          514          (1,890
Unity Software, Inc.
     89          01/20/23          USD          35.00          USD          254          (3,693
Visa, Inc., Class A
     98          01/20/23          USD          215.00          USD          2,036          (21,070
Wolfspeed, Inc.
     233          01/20/23          USD          105.00          USD          1,609          (1,165
ZoomInfo Technologies, Inc., CLass A
     530          01/20/23          USD          35.00          USD          1,596          (11,925
Zscaler, Inc.
     39          01/20/23          USD          150.00          USD          436          (644
Zscaler, Inc.
     39          01/20/23          USD          135.00          USD          436          (2,262
Alphabet, Inc., Class A
     82          01/27/23          USD          99.00          USD          723          (3,526
Alphabet, Inc., Class A
     140          01/27/23          USD          94.00          USD          1,235          (16,940
Amazon.com, Inc.
     75          01/27/23          USD          93.00          USD          630          (7,725
Analog Devices, Inc.
     39          01/27/23          USD          170.00          USD          640          (13,065
Apple, Inc.
     357          01/27/23          USD          152.50          USD          4,639          (6,961
Apple, Inc.
     112          01/27/23          USD          142.00          USD          1,455          (12,824
Block, Inc.
     145          01/27/23          USD          74.00          USD          911          (16,457
Broadcom, Inc.
     57          01/27/23          USD          575.00          USD          3,187          (70,965
Broadcom, Inc.
     28          01/27/23          USD          560.00          USD          1,566          (54,600
Crowdstrike Holdings, Inc., Class A
     65          01/27/23          USD          130.00          USD          684          (3,282
First Solar, Inc.
     44          01/27/23          USD          170.00          USD          659          (9,570
Lam Research Corp.
     58          01/27/23          USD          470.00          USD          2,438          (39,440
MercadoLibre, Inc.
     22          01/27/23          USD          895.00          USD          1,862          (67,320
Meta Platforms, Inc., Class A
     99          01/27/23          USD          124.00          USD          1,191          (49,500
Micron Technology, Inc.
     174          01/27/23          USD          59.00          USD          870          (3,393
NVIDIA Corp.
     66          01/27/23          USD          165.00          USD          965          (16,401
Okta, Inc.
     44          01/27/23          USD          72.00          USD          301          (13,464
Okta, Inc.
     250          01/27/23          USD          67.00          USD          1,708          (135,000
PayPal Holdings, Inc.
     136          01/27/23          USD          76.00          USD          969          (24,072
Qualcomm, Inc.
     69          01/27/23          USD          120.00          USD          759          (9,556
Salesforce, Inc.
     24          01/27/23          USD          144.00          USD          318          (4,056
Splunk, Inc.
     116          01/27/23          USD          95.00          USD          999          (19,778
Take-Two Interactive Software, Inc.
     93          01/27/23          USD          104.00          USD          968          (41,385
Tesla, Inc.
     37          01/27/23          USD          170.00          USD          456          (4,884
Twilio, Inc., Class A
     88          01/27/23          USD          56.00          USD          431          (11,176
Visa, Inc., Class A
     157          01/27/23          USD          210.00          USD          3,262          (97,732
CDW Corp.
     121          02/02/23          USD          187.00          USD          2,161          (30,590
Amazon.com, Inc.
     278          02/03/23          USD          88.00          USD          2,335          (102,860
Apple, Inc.
     168          02/03/23          USD          140.00          USD          2,183          (38,724
Credo Technology Group Holding Ltd.
     600          02/03/23          USD          15.00          USD          799          (17,726
Snowflake, Inc., Class A
     24          02/03/23          USD          160.00          USD          344          (12,240
Wolfspeed, Inc.
     239          02/03/23          USD          96.00          USD          1,650          (8,435
MongoDB, Inc.
     15          02/10/23          USD          225.00          USD          295          (12,375
Alphabet, Inc., Class A
     343          02/17/23          USD          100.00          USD          3,026          (43,389
ANSYS, Inc.
     86          02/17/23          USD          260.00          USD          2,078          (46,010
Apple, Inc.
     161          02/17/23          USD          155.00          USD          2,092          (9,982
Apple, Inc.
     340          02/17/23          USD          145.00          USD          4,418          (65,790
Cadence Design Systems, Inc.
     221          02/17/23          USD          170.00          USD          3,550          (108,290
Credo Technology Group Holding Ltd.
     515          02/17/23          USD          17.50          USD          685          (5,150
Credo Technology Group Holding Ltd.
     950          02/17/23          USD          15.00          USD          1,264          (42,750
 
 
114
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Exchange-Traded Options Written (continued)
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)
                                
Crowdstrike Holdings, Inc., Class A
     93          02/17/23          USD          125.00          USD          979        $ (21,204
Marvell Technology, Inc.
     370          02/17/23          USD          45.00          USD          1,370          (22,570
Monolithic Power Systems, Inc.
     68          02/17/23          USD          400.00          USD          2,405          (71,740
Oracle Corp.
     197          02/17/23          USD          85.00          USD          1,610          (33,785
SBA Communications Corp.
     66          02/17/23          USD          290.00          USD          1,850          (55,110
ServiceNow, Inc.
     20          02/17/23          USD          430.00          USD          777          (25,000
Tesla, Inc.
     89          02/17/23          USD          205.00          USD          1,096          (7,698
Twilio, Inc., Class A
     105          02/17/23          USD          55.00          USD          514          (39,112
Unity Software, Inc.
     190          02/17/23          USD          40.00          USD          543          (17,290
Visa, Inc., Class A
     227          02/17/23          USD          220.00          USD          4,716          (93,070
Wolfspeed, Inc.
     361          02/17/23          USD          92.75          USD          2,492          (37,873
Zscaler, Inc.
     117          02/17/23          USD          140.00          USD          1,309          (21,703
                                
 
 
 
                                 $  (3,355,403
                                
 
 
 
OTC Options Written
 
Description
 
Counterparty
 
Number of
Contracts
   
Expiration
Date
 
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call
               
Aspen Technology, Inc.
  Barclays Bank PLC     8,200     01/05/23     USD       247.99       USD       1,684     $ (2
Credo Technology Group Holding Ltd.
  Citibank N.A.     78,600     01/05/23     USD       15.07       USD       1,046       (766
SiteMinder Ltd.
  Goldman Sachs International     18,000     01/05/23     AUD       3.22       AUD       55       (226
Soitec SA
  Goldman Sachs International     21,000     01/05/23     EUR       167.02       EUR       3,210       (670
STMicroelectronics NV
  Goldman Sachs International     36,000     01/05/23     EUR       38.91       EUR       1,188       (1
Wise PLC, Class A
  JPMorgan Chase Bank N.A.     100,000     01/05/23     GBP       6.30       GBP       563       (2,164
Xero Ltd.
  UBS AG     50,000     01/05/23     AUD       73.53       AUD       3,514       (24,557
Wise PLC, Class A
  Morgan Stanley & Co. International PLC     130,000     01/10/23     GBP       7.48       GBP       732       (130
ASM International NV
  Goldman Sachs International     13,200     01/13/23     EUR       262.43       EUR       3,111       (12,496
Dassault Systèmes SE
  Goldman Sachs International     65,000     01/13/23     EUR       37.55       EUR       2,177       (481
GMO Payment Gateway, Inc.
  BNP Paribas SA     8,200     01/13/23     JPY       13,114.50       JPY       89,544       (551
SiteMinder Ltd.
  UBS AG     23,000     01/13/23     AUD       2.96       AUD       70       (2,478
Soitec SA
  Goldman Sachs International     7,000     01/13/23     EUR       162.27       EUR       1,070       (6,158
Soitec SA
  JPMorgan Chase Bank N.A.     2,050     01/13/23     EUR       163.49       EUR       313       (1,435
STMicroelectronics NV
  Goldman Sachs International     45,000     01/13/23     EUR       34.33       EUR       1,485       (15,921
Soitec SA
  Barclays Bank PLC     7,000     01/17/23     EUR       166.42       EUR       1,070       (4,441
Wise PLC, Class A
  Morgan Stanley & Co. International PLC     130,000     01/17/23     GBP       7.48       GBP       732       (957
Soitec SA
  Goldman Sachs International     1,800     01/18/23     EUR       164.14       EUR       275       (1,805
GMO Payment Gateway, Inc.
  UBS AG     13,800     01/25/23     JPY       13,064.70       JPY       150,696       (4,937
Soitec SA
  Goldman Sachs International     1,800     01/27/23     EUR       166.95       EUR       275       (2,397
ASML Holding NV
  Goldman Sachs International     19,500     01/31/23     EUR       556.50       EUR       9,824       (131,692
Gitlab, Inc., Class A
  BNP Paribas SA     36,200     01/31/23     USD       53.74       USD       1,645       (59,712
Samsung SDI Co. Ltd.
  JPMorgan Chase Bank N.A.     10,600     01/31/23     KRW       748,360.00       KRW       6,264,600       (2,772
STMicroelectronics NV
  UBS AG     18,300     01/31/23     EUR       36.28       EUR       604       (5,756
Sungrow Power Supply Co. Ltd., Class A
  JPMorgan Chase Bank N.A.     94,000     01/31/23     CNY       104.20       CNY       10,559       (158,553
Trip.com Group Ltd.
  Morgan Stanley & Co. International PLC     101,000     01/31/23     HKD       278.04       HKD       27,634       (160,555
Adyen NV
  Goldman Sachs International     3,100     02/02/23     EUR       1,399.71       EUR       3,994       (96,351
GMO Payment Gateway, Inc.
  UBS AG     8,200     02/02/23     JPY       11,518.10       JPY       89,544       (23,484
Trip.com Group Ltd.
  Citibank N.A.     15,100     02/02/23     HKD       285.18       HKD       4,131       (22,547
Soitec SA
  Morgan Stanley & Co. International PLC     3,900     02/08/23     EUR       177.08       EUR       596       (3,895
Wise PLC, Class A
  JPMorgan Chase Bank N.A.     105,000     02/08/23     GBP       6.97       GBP       591       (10,045
Xero Ltd.
  Morgan Stanley & Co. International PLC     7,700     02/08/23     AUD       80.33       AUD       541       (8,740
Gitlab, Inc., Class A
  BNP Paribas SA     36,200     02/14/23     USD       53.74       USD       1,645       (89,585
ZoomInfo Technologies, Inc., CLass A
  JPMorgan Chase Bank N.A.     46,100     02/14/23     USD       33.17       USD       1,388       (64,114
               
 
 
 
                $   (920,374
               
 
 
 
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  115

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
 
Description
  
Swap
Premiums
Paid
      
Swap
Premiums
Received
      
Unrealized
Appreciation
      
Unrealized
Depreciation
      
Value 
 
Options Written
   $ N/A        $ N/A         $ 7,856,096          $ (450,860      $  (4,275,777
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
 
               
    
Commodity
Contracts
   
Credit
  Contracts
   
Equity
Contracts
   
Foreign
Currency
  Exchange
Contracts
   
Interest
Rate
  Contracts
   
Other
  Contracts
   
Total
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $   4,275,777      $     $     $     $  4,275,777   
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
 
    
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total 
 
Net Realized Gain (Loss) from:
             
Options purchased
(a)
  $     $     $ (5,157,003   $     $     $     $ (5,157,003
Options written
                56,941,702                         56,941,702  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $     $     $ 51,784,699     $     $     $     $ 51,784,699  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
             
Options written
  $     $     $ 1,620,333     $     $     $     $ 1,620,333  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
 
 
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 7,489,051  
 
 
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $  4,275,777  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities
              4,275,777  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (3,355,403
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 920,374  
  
 
 
      
 
 
 
 
 
116
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
           
Counterparty
  
 



Derivative
Liabilities
Subject to
an MNA by
  Counterparty
 
 

 
 
  
 

    Derivatives
Available
for Offset
 
 
 
  
 

      Non-Cash

Collateral
Pledged
 
 
 
  
 

Cash
      Collateral
Pledged
 
 
(a)
 
  
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Barclays Bank PLC
   $ 4,443      $      $      $      $ 4,443  
BNP Paribas SA
     149,848                             149,848  
Citibank N.A.
     23,313                             23,313  
Goldman Sachs International
     268,198                      (170,000      98,198  
JPMorgan Chase Bank N.A.
     239,083                      (239,083       
Morgan Stanley & Co. International PLC
     174,277                      (120,000      54,277  
UBS AG
     61,212                      (61,212       
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 920,374      $      $      $ (590,295    $ 330,079  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.
 
         
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Investments
           
Long-Term Investments
           
Common Stocks
           
Automobiles
   $ 12,416,051      $      $      $ 12,416,051  
Banks
                   4,842,243        4,842,243  
Capital Markets
     8,279,382                      8,279,382  
Communications Equipment
     5,245,687                      5,245,687  
Diversified Consumer Services
                   2,393,479        2,393,479  
Electrical Equipment
            3,563,698               3,563,698  
Electronic Equipment, Instruments & Components
     12,790,968        10,418,206               23,209,174  
Entertainment
     17,499,915                      17,499,915  
Equity Real Estate Investment Trusts (REITs)
     4,143,262                      4,143,262  
Hotels, Restaurants & Leisure
            8,989,713               8,989,713  
Interactive Media & Services
     25,195,591        4,710,680               29,906,271  
Internet & Direct Marketing Retail
     26,717,979               150,579        26,868,558  
IT Services
     95,197,221        21,928,794        26,993,306        144,119,321  
Professional Services
            2,674,772               2,674,772  
Road & Rail
     10,753,841               4,275,906        15,029,747  
Semiconductors & Semiconductor Equipment
     115,971,957        54,409,821               170,381,778  
Software
     175,020,127        14,879,185        21,413,787        211,313,099  
Technology Hardware, Storage & Peripherals
     68,824,617                      68,824,617  
Convertible Notes
                   1,920,000        1,920,000  
Preferred Securities
           
Preferred Stocks
                   195,967,596        195,967,596  
Warrants
                   16,212        16,212  
Short-Term Securities
           
Money Market Funds
     5,779,501                      5,779,501  
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ 583,836,099      $ 121,574,869      $ 257,973,108        963,384,076  
  
 
 
    
 
 
    
 
 
    
 
 
 
Investments Valued at NAV
(a)
              825,025  
           
 
 
 
            $ 964,209,101  
           
 
 
 
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  117

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
Fair Value Hierarchy as of Period End (continued)
 
         
     
Level 1
    
Level 2
    
        Level 3
    
Total
 
Derivative Financial Instruments
(b)
           
Liabilities
           
Equity Contracts
   $   (3,256,560)      $   (1,019,217)      $      $   (4,275,777
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
 
(b)
 
Derivative financial instruments are options written. Options written are shown at value.
 
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
 
    
Common
Stocks
   
Convertible
Notes
   
Preferred
Stocks
   
Unfunded
SPAC
PIPE
Commitments
   
Warrants
   
Total
 
Assets
           
Opening balance, as of December 31, 2021
  $ 119,431,663     $ 8,000,000     $ 240,189,562     $
(a)
 
  $ 117,749     $ 367,738,974  
Transfers into Level 3
                                   
Transfers out of Level 3
                                   
Accrued discounts/premiums
                                   
Net realized gain (loss)
                168,816                   168,816  
Net change in unrealized appreciation (depreciation)
(b)(c)
    (69,362,363     (6,080,000     (68,468,210           (101,537     (144,012,110
Purchases
    11,998,435             29,999,956                   41,998,391  
Sales
    (1,998,435           (5,922,528                 (7,920,963
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Closing balance, as of December 31, 2022
  $ 60,069,300     $ 1,920,000     $ 195,967,596     $     $ 16,212     $ 257,973,108  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022
(c)
  $ (71,108,091   $ (6,080,000   $ (65,497,011   $     $ (101,537   $ (142,786,639
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Rounds to less than $1.
 
 
(b)
 
Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.
 
 
(c)
 
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022 is generally due to investments no longer held or categorized as Level 3 at period end.
 
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
 
           
 
  
 
Value
 
    
Valuation
Approach
    
Unobservable
Inputs
  
 

Range of
Unobservable
Inputs
Utilized
 
 
 
(a)
 
  
 



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
Assets
                  
Common Stocks
   $ 60,069,300        Market     
Revenue Multiple
    
2.50x - 29.13x
       10.38x  
            
Volatility
    
70% - 75%
       75%  
            
Time to Exit
    
3.0 - 4.0 years
       4.0 years  
            
Exit Multiple
     9.50x         
            
Market Adjustment Multiple
     0.50x         
        Income     
Discount
     16%         
Convertible Notes
     1,920,000        Income     
Discount
     21%         
            
Volatility
     80%         
        Market     
Revenue Multiple
     4.89x         
Preferred Stocks
     195,967,596        Market     
Revenue Multiple
    
3.25x - 29.13x
       14.07x  
            
Volatility
    
50% - 75%
       62%  
            
Time to Exit
    
3.0 - 5.0 years
     4.1 years  
            
Market Adjustment Multiple
    
0.50x - 1.00x
       0.93x  
            
Gross Profit Multiple
     11.89x         
            
Recent Transactions
    
(b)
 
        
 
 
118
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust (BST)
    
 
           
 
  
 
Value
 
    
Valuation
Approach
    
Unobservable
Inputs
  
 

Range of
Unobservable
Inputs
Utilized
 
 
 
(a)
 
  
 



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
Warrants
     16,212        Market     
Revenue Multiple
     7.00x         
            
Volatility
     39%         
            
Time to Exit
     1.5 years         
  
 
 
                 
   $ 257,973,108                  
  
 
 
                 
 
 
(a)
 
A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.
 
 
(b)
 
For the period end December 31, 2022, the valuation technique for certain investments classified as Preferred Stock used recent prior transaction prices as inputs within the model used for the approximation of fair value.
 
See notes to financial statements.
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  119

Consolidated Schedule of Investments
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Common Stocks
    
Automobiles — 1.5%
 
Tesla, Inc.
(a)
    185,296      $     22,824,761  
    
 
 
 
Banks — 1.0%
 
Klarna Holdings AB, (Acquired 08/07/19, Cost: $23,354,997)
(b)(c)
    86,839        15,909,783  
    
 
 
 
Diversified Consumer Services — 0.7%
 
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $7,113,729)
(b)(c)
    4,651        11,165,570  
    
 
 
 
Electrical Equipment — 1.6%
 
Array Technologies, Inc.
(a)
    266,710        5,155,504  
Sungrow Power Supply Co. Ltd., Class A
    523,600        8,439,405  
Suzhou Maxwell Technologies Co. Ltd., Class A
    99,668        5,916,828  
Yantai Zhenghai Magnetic Material Co. Ltd., Class A
(a)
    2,591,011        4,679,461  
    
 
 
 
       24,191,198  
Electronic Equipment, Instruments & Components — 4.5%
 
Delta Electronics, Inc.
    898,000        8,324,448  
E Ink Holdings, Inc.
    1,298,000        6,797,253  
Jabil, Inc.
    308,161        21,016,580  
Samsung SDI Co. Ltd.
(a)
    55,754        26,178,866  
Xiamen Faratronic Co. Ltd., Class A
    239,377        5,523,282  
    
 
 
 
       67,840,429  
Entertainment — 3.0%
 
Bilibili, Inc., ADR
(a)
    342,852        8,122,164  
CTS Eventim AG & Co. KGaA
(a)
    135,310        8,589,330  
Electronic Arts, Inc.
    51,789        6,327,580  
Spotify Technology SA
(a)
    77,350        6,106,782  
Take-Two Interactive Software, Inc.
(a)
    153,468        15,980,623  
    
 
 
 
       45,126,479  
Hotels, Restaurants & Leisure — 1.7%
 
Trip.com Group Ltd., ADR
(a)(d)
    731,410        25,160,504  
    
 
 
 
Household Durables — 0.4%
 
TCL Technology Group Corp., Class A
    11,070,900        5,932,007  
    
 
 
 
Interactive Media & Services
(a)
— 1.8%
 
Kanzhun Ltd., ADR
    381,361        7,768,324  
Pinterest, Inc., Class A
    415,285        10,083,120  
ZoomInfo Technologies, Inc., CLass A
    300,339        9,043,207  
    
 
 
 
       26,894,651  
Internet & Direct Marketing Retail
(a)
— 2.1%
 
Coupang, Inc.
    634,423        9,332,362  
MercadoLibre, Inc.
    19,580        16,569,379  
Xometry, Inc., Class A
    195,559        6,302,867  
    
 
 
 
       32,204,608  
IT Services — 11.2%
 
Adyen NV
(a)(e)
    16,164        22,439,656  
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $34,000,000)
(b)(c)
    400,000        15,804,000  
AvidXchange Holdings, Inc.
(a)
    1,115,450        11,087,573  
Block, Inc.
(a)(d)
    143,115        8,993,347  
Cloudflare, Inc., Class A
(a)
    158,086        7,147,068  
Endava PLC, ADR
(a)
    152,105        11,636,033  
GMO Payment Gateway, Inc.
    162,000        13,397,229  
Grid Dynamics Holdings, Inc.
(a)
    699,155        7,844,519  
Locaweb Servicos de Internet SA
(a)(e)
    6,904,011        9,188,957  
MongoDB, Inc.
(a)
    68,590        13,501,256  
Okta, Inc.
(a)
    119,167        8,142,681  
Security
 
Shares
    
Value
 
IT Services (continued)
 
Shift4 Payments, Inc., Class A
(a)
    239,409      $ 13,390,145  
TRAX Ltd., (Acquired 09/12/19,
Cost: $10,999,988)
(b)(c)
    293,333        7,389,058  
TRAX Ltd., Series D, (Acquired 02/18/21, Cost: $9,999,998)
(b)(c)
    191,806        4,831,593  
Twilio, Inc., Class A
(a)
    116,960        5,726,362  
Wise PLC, Class A
(a)
    1,608,578        10,897,764  
    
 
 
 
           171,417,241  
Life Sciences Tools & Services — 0.5%
 
IQVIA Holdings, Inc.
(a)
    39,417        8,076,149  
    
 
 
 
Machinery — 0.6%
            
Shenzhen Inovance Technology Co. Ltd., Class A
    941,700        9,438,229  
    
 
 
 
Media — 1.3%
            
Informa PLC
    2,706,045        20,186,453  
    
 
 
 
Professional Services — 1.0%
 
Wolters Kluwer NV
    147,785        15,463,515  
    
 
 
 
Road & Rail — 0.7%
 
Full Truck Alliance Co. Ltd., ADR
(a)
    1,230,077        9,840,616  
    
 
 
 
Semiconductors & Semiconductor Equipment — 20.1%
 
Alphawave IP Group PLC
(a)
    4,346,392        5,359,663  
Ambarella, Inc.
(a)
    87,401        7,186,984  
ASM International NV
    70,536        17,897,410  
BE Semiconductor Industries NV
    193,870        11,814,610  
CNEX Labs, Inc., (Acquired 12/14/21,
Cost: $5,699,998)
(b)(c)
    1,161,804        3,194,961  
Credo Technology Group Holding
Ltd.
(a)
    3,296,992        43,882,965  
First Solar, Inc.
(a)
    44,526        6,669,550  
Lasertec Corp.
    189,400        30,923,449  
Lattice Semiconductor Corp.
(a)
    382,189        24,796,422  
MACOM Technology Solutions Holdings, Inc., Class H
(a)
    152,718        9,618,180  
Marvell Technology, Inc.
(d)
    448,510        16,612,810  
Monolithic Power Systems, Inc.
    65,404        23,127,508  
Nordic Semiconductor ASA
(a)
    267,825        4,489,334  
Qorvo, Inc.
(a)
    89,966        8,154,518  
Rambus, Inc.
(a)
    233,809        8,375,038  
SK Hynix, Inc.
    180,204        10,751,691  
Soitec SA
(a)
    195,102        32,023,337  
StarPower Semiconductor Ltd., Class A
    198,314        9,423,105  
Wolfspeed, Inc.
(a)(d)
    466,553        32,210,819  
    
 
 
 
       306,512,354  
Software — 16.1%
 
Altium Ltd.
    762,952        18,123,640  
Aspen Technology, Inc.
(a)
    81,943        16,831,092  
Atlassian Corp., Class A
(a)
    65,383        8,413,485  
Confluent, Inc., Class A
(a)
    187,397        4,167,709  
Databricks, Inc., (Acquired 07/24/20,
Cost: $5,501,686)
(b)(c)
    343,659        17,588,468  
DataRobot, Inc., (Acquired 03/01/21,
Cost: $1,384,813)
(b)(c)
    92,093        479,805  
Freee KK
(a)
    452,800        10,047,317  
Gitlab, Inc., Class A
(a)
    316,185        14,367,446  
Glodon Co. Ltd., Class A
    1,107,983        9,578,166  
Kinaxis, Inc.
(a)
    48,780        5,472,799  
Palo Alto Networks, Inc.
(a)
    105,737        14,754,541  
Rapid7, Inc.
(a)
    194,980        6,625,420  
RingCentral, Inc., Class A
(a)
    161,080        5,702,232  
 
 
120
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Software (continued)
            
SiteMinder Ltd.
(a)
    5,037,902      $   10,444,106  
Snorkel AI, Inc., (Acquired 10/13/20,
Cost: $2,017,593)
(b)(c)
    500,250        3,561,780  
Snyk Ltd., (Acquired 11/02/20,
Cost: $9,287,400)
(b)(c)
.
    1,267,643        14,565,218  
Splunk, Inc.
(a)
    83,595        7,196,694  
Synopsys, Inc.
(a)(d)
    127,564        40,729,910  
Tenable Holdings, Inc.
(a)
    103,791        3,959,627  
Tuya, Inc., ADR
(a)
    265,084        506,310  
Unity Software, Inc.
(a)
    237,004        6,775,944  
Varonis Systems, Inc.
(a)
    284,811        6,818,375  
Xero Ltd.
(a)
    246,056        11,732,892  
Zscaler, Inc.
(a)(d)
    67,334        7,534,675  
    
 
 
 
       245,977,651  
Technology Hardware, Storage & Peripherals — 2.3%
 
Logitech International SA, Registered Shares
    164,045        10,211,801  
Pure Storage, Inc., Class A
(a)
    931,063        24,915,246  
    
 
 
 
       35,127,047  
    
 
 
 
Total Common Stocks — 72.1%
(Cost: $1,032,685,485)
 
     1,099,289,245  
    
 
 
 
Preferred Securities
    
Preferred Stocks — 27.1%
(b)(c)
 
Communications Equipment — 0.7%
 
Astranis Space Technologies Corp., Series C, (Acquired 03/19/21,
Cost: $17,000,010)
    775,515        10,818,434  
    
 
 
 
Diversified Consumer Services — 0.8%
 
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $14,251,080)
    4,920        11,811,353  
    
 
 
 
Diversified Financial Services — 0.1%
 
Snorkel Al, Inc., Series B, (Acquired 10/13/20, Cost: $999,996)
    247,943        1,765,354  
    
 
 
 
Food & Staples Retailing — 2.5%
 
GrubMarket, Inc. , Series D, (Acquired 07/23/20, Cost: $8,000,001)
    1,762,969        38,926,355  
    
 
 
 
Food Products — 1.1%
 
Farmer’s Business Network, Inc., Series F, (Acquired 07/31/20, Cost: $11,961,002)
    361,834        16,865,083  
    
 
 
 
Interactive Media & Services — 3.7%
 
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $33,777,337)
    308,260        50,803,379  
    
 
 
 
ResearchGate GmbH, Series D, (Acquired 09/24/20, Cost: $6,999,988)
    424,688        5,852,201  
    
 
 
 
       56,655,580  
IT Services — 2.7%
 
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $12,000,008)
    1,974,374        13,563,950  
Trumid Holdings LLC
(f)
    
Class J-A, (Acquired 07/24/20,
Cost: $9,999,857)
    20,154        13,519,303  
Class J-B, (Acquired 07/24/20,
Cost: $5,999,914)
    20,154        13,519,303  
    
 
 
 
       40,602,556  
Road & Rail — 0.9%
            
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $16,947,253)
    850        13,161,644  
    
 
 
 
Security
 
Shares
    
Value
 
Semiconductors & Semiconductor Equipment — 6.9%
 
Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost: $7,000,000)
    1,018,908      $ 224,160  
PsiQuantum Corp.
    
Series C, (Acquired 09/09/19,
Cost: $9,101,310)
    1,962,335        40,424,101  
Series D, (Acquired 05/21/21,
Cost: $19,999,969)
    762,595        19,377,539  
SambaNova Systems, Inc.
    
Series C, (Acquired 02/20/20,
Cost: $33,904,161)
    636,800        40,430,432  
Series D, (Acquired 04/09/21,
Cost: $6,999,979)
    73,670        4,677,308  
    
 
 
 
       105,133,540  
Software — 7.7%
            
Databricks, Inc.
    
Series F, (Acquired 10/22/19,
Cost: $13,200,019)
    922,038        47,189,905  
Series G, (Acquired 02/01/21,
Cost: $18,500,004)
    312,909        16,014,683  
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $11,499,999)
    875,059        5,556,625  
Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978)
    190,705        12,794,398  
Snyk Ltd. , (Acquired 11/02/20,
Cost: $13,212,590)
    2,663,936        30,608,625  
Unqork, Inc.
    
Series B, (Acquired 09/19/19,
Cost: $6,801,016)
    597,680        3,723,546  
Series C, (Acquired 09/18/20,
Cost: $7,994,787)
    292,000        2,280,520  
    
 
 
 
       118,168,302  
    
 
 
 
       413,908,201  
    
 
 
 
Total Preferred Securities — 27.1%
(Cost: $300,150,258)
 
     413,908,201  
    
 
 
 
Warrants
    
IT Services — 0.0%
            
TRAX Ltd., (Acquired 09/12/19, Cost: $0), (Issued 09/23/19, Exercisable 07/12/23, 1 Share for 1 Warrant, Expires 09/15/23, Strike Price USD 46.88)
(a)(b)(c)
    46,928        44,581  
    
 
 
 
Total Warrants — 0.0%
(Cost: $ — )
 
     44,581  
    
 
 
 
Total Long-Term Investments — 99.2%
(Cost: $1,332,835,743)
 
     1,513,242,027  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 1.4%
    
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(g)(h)
    20,683,361        20,683,361  
    
 
 
 
Total Short-Term Securities — 1.4%
(Cost: $20,683,361)
 
     20,683,361  
    
 
 
 
Total Investments Before Options Written — 100.6% (Cost: $1,353,519,104)
 
     1,533,925,388  
    
 
 
 
Options Written — (0.6)%
(Premiums Received: $(18,258,347))
 
     (8,555,152
    
 
 
 
Total Investments, Net of Options Written — 100.0% (Cost: $1,335,260,757)
 
     1,525,370,236  
Liabilities in Excess of Other Assets — 0.0%
 
     (712,599
    
 
 
 
Net Assets — 100.0%
 
   $ 1,524,657,637  
    
 
 
 
 
(a)
 
Non-income producing security.
(b)
 
Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  121

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
(c)
 
Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $508,443,018, representing 33.4% of its net assets as of period end, and an original cost of $409,510,460.
(d)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(e)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(f)
 
All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.
(g)
Affiliate of the Trust.
(h)
 
Annualized 7-day yield as of period end.
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
Affiliated Issuer
 
Value at
12/31/21
   
Purchases
at Cost
   
Proceeds
from Sales
   
Net
Realized
Gain (Loss)
   
Change in
Unrealized
Appreciation
(Depreciation)
   
Value at
12/31/22
   
Shares
Held at
12/31/22
   
Income
   
Capital Gain
Distributions
from
Underlying
Funds
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
  $ 46,915,934     $     $ (26,232,573 )
(a)
 
  $     $     $ 20,683,361       20,683,361     $ 496,490     $  
SL Liquidity Series, LLC, Money Market Series
(b)
    1,949,219             (1,949,963 )
(a)
 
    744                         196,790
(c)
 
     
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
        $ 744     $     $ 20,683,361       $ 693,280     $  
       
 
 
   
 
 
   
 
 
     
 
 
   
 
 
 
 
 
(a)
 
Represents net amount purchased (sold). (b) As of period end, the entity is no longer held.
 
(c)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
Description
  
Number of
Contracts
    
Expiration
Date
    
Exercise Price
    
Notional
Amount (000)
    
Value
 
Call
                    
Ambarella, Inc.
     136        01/06/23        USD        76.00        USD        1,118      $ (97,920
Atlassian Corp., Class A
     49        01/06/23        USD        135.00        USD        631        (8,698
Atlassian Corp., Class A
     50        01/06/23        USD        150.00        USD        643        (1,125
Block, Inc.
     172        01/06/23        USD        80.00        USD        1,081        (258
Electronic Arts, Inc.
     96        01/06/23        USD        135.00        USD        1,173        (1,344
First Solar, Inc.
     8        01/06/23        USD        172.50        USD        120        (92
MercadoLibre, Inc.
     17        01/06/23        USD        995.00        USD        1,439        (5,100
MongoDB, Inc.
     50        01/06/23        USD        175.00        USD        984        (113,750
MongoDB, Inc.
     35        01/06/23        USD        210.00        USD        689        (7,700
Palo Alto Networks, Inc.
     146        01/06/23        USD        185.00        USD        2,037        (730
Pinterest, Inc., Class A
     1,045        01/06/23        USD        27.50        USD        2,537        (3,658
Splunk, Inc.
     156        01/06/23        USD        100.00        USD        1,343        (702
Spotify Technology SA
     87        01/06/23        USD        85.00        USD        687        (3,045
Tesla, Inc.
     175        01/06/23        USD        205.00        USD        2,156        (175
Twilio, Inc., Class A
     44        01/06/23        USD        53.00        USD        215        (1,826
Unity Software, Inc.
     331        01/06/23        USD        37.00        USD        946        (1,655
Zscaler, Inc.
     79        01/06/23        USD        130.00        USD        884        (711
Wolfspeed, Inc.
     390        01/12/23        USD        100.50        USD        2,693        (167
Ambarella, Inc.
     125        01/13/23        USD        75.00        USD        1,028        (110,000
Atlassian Corp., Class A
     50        01/13/23        USD        140.00        USD        643        (12,875
Atlassian Corp., Class A
     49        01/13/23        USD        150.00        USD        631        (5,023
Bilibili, Inc., ADR
     620        01/13/23        USD        30.00        USD        1,469        (22,010
Coupang, Inc.
     1,086        01/13/23        USD        20.00        USD        1,598        (1,086
MercadoLibre, Inc.
     33        01/13/23        USD        1,000.00        USD        2,793        (11,055
 
 
122
 
2 0 2 2
  B
L
A
C
K
R
O
C
K  
A
N
N
U
A
L  
R
E
P
O
R
T  T
O  
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
Exchange-Traded Options Written (continued)
 
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)
                          
MongoDB, Inc.
     35          01/13/23        USD     190.00        USD     689        $ (51,100)  
MongoDB, Inc.
     35          01/13/23        USD     210.00        USD     689          (19,250)  
Okta, Inc.
     74          01/13/23        USD     75.00        USD     506          (8,251)  
Palo Alto Networks, Inc.
     171          01/13/23        USD     175.00        USD     2,386          (2,565)  
Pinterest, Inc., Class A
     590          01/13/23        USD     26.00        USD     1,433          (24,780)  
Spotify Technology SA
     109          01/13/23        USD     86.00        USD     861          (11,172)  
Take-Two Interactive Software, Inc.
     198          01/13/23        USD     106.00        USD     2,062          (42,966)  
Tesla, Inc.
     122          01/13/23        USD     190.00        USD     1,503          (1,342)  
Unity Software, Inc.
     300          01/13/23        USD     43.00        USD     858          (3,900)  
Zscaler, Inc.
     94          01/13/23        USD     145.00        USD     1,052          (1,222)  
Zscaler, Inc.
     94          01/13/23        USD     135.00        USD     1,052          (2,679)  
Ambarella, Inc.
     78          01/20/23        USD     82.50        USD     641          (38,610)  
Array Technologies, Inc.
     304          01/20/23        USD     25.00        USD     588          (3,800)  
Aspen Technology, Inc.
     168          01/20/23        USD     270.00        USD     3,451          (80,640)  
Atlassian Corp., Class A
     77          01/20/23        USD     160.00        USD     991          (5,968)  
Bilibili, Inc., ADR
     620          01/20/23        USD     30.00        USD     1,469          (35,960)  
Block, Inc.
     175          01/20/23        USD     70.00        USD     1,100          (25,550)  
Cloudflare, Inc., Class A
     450          01/20/23        USD     55.00        USD     2,034          (25,200)  
Confluent, Inc., Class A
     830          01/20/23        USD     30.00        USD     1,846          (10,375)  
Coupang, Inc.
     690          01/20/23        USD     22.50        USD     1,015          (1,725)  
Credo Technology Group Holding Ltd.
     4,026          01/20/23        USD     15.00        USD     5,359          (70,455)  
Credo Technology Group Holding Ltd.
     890          01/20/23        USD     17.50        USD     1,185          (17,800)  
Electronic Arts, Inc.
     48          01/20/23        USD     140.00        USD     586          (360)  
Electronic Arts, Inc.
     48          01/20/23        USD     135.00        USD     586          (912)  
Endava PLC, ADR
     230          01/20/23        USD     75.00        USD     1,760          (88,550)  
First Solar, Inc.
     81          01/20/23        USD     165.00        USD     1,213          (17,820)  
Full Truck Alliance Co. Ltd., ADR
     1,912          01/20/23        USD     10.00        USD     1,530          (33,460)  
Gitlab, Inc., Class A
     1,334          01/20/23        USD     45.00        USD     6,062          (446,890)  
Grid Dynamics Holdings, Inc.
     300          01/20/23        USD     12.50        USD     337          (5,250)  
Grid Dynamics Holdings, Inc.
     878          01/20/23        USD     13.62        USD     985          (8,338)  
IQVIA Holdings, Inc.
     89          01/20/23        USD     230.00        USD     1,824          (3,783)  
Jabil, Inc.
     794          01/20/23        USD     70.00        USD     5,415          (99,250)  
Kanzhun Ltd., ADR
     756          01/20/23        USD     25.00        USD     1,540          (20,790)  
Lattice Semiconductor Corp.
     333          01/20/23        USD     64.00        USD     2,161          (116,493)  
Lattice Semiconductor Corp.
     201          01/20/23        USD     74.83        USD     1,304          (7,608)  
Lattice Semiconductor Corp.
     371          01/20/23        USD     75.00        USD     2,407          (15,767)  
Logitech International SA, Registered Shares
     168          01/20/23        USD     65.00        USD     1,046          (16,380)  
MACOM Technology Solutions Holdings, Inc., Class H
     380          01/20/23        USD     70.00        USD     2,393          (26,600)  
Marvell Technology, Inc.
     905          01/20/23        USD     45.00        USD     3,352          (11,765)  
MongoDB, Inc.
     84          01/20/23        USD     175.00        USD     1,653          (223,440)  
Monolithic Power Systems, Inc.
     136          01/20/23        USD     433.00        USD     4,809          (13,639)  
Okta, Inc.
     55          01/20/23        USD     75.00        USD     376          (8,718)  
Palo Alto Networks, Inc.
     190          01/20/23        USD     170.00        USD     2,651          (1,425)  
Pure Storage, Inc., Class A
     1,544          01/20/23        USD     35.00        USD     4,132          (7,720)  
Qorvo, Inc.
     143          01/20/23        USD     97.50        USD     1,296          (15,730)  
Rambus, Inc.
     480          01/20/23        USD     39.00        USD     1,719          (24,000)  
Shift4 Payments, Inc., Class A
     384          01/20/23        USD     55.00        USD     2,148          (151,680)  
Splunk, Inc.
     156          01/20/23        USD     100.00        USD     1,343          (8,892)  
Spotify Technology SA
     113          01/20/23        USD     80.00        USD     892          (41,810)  
Synopsys, Inc.
     190          01/20/23        USD     340.00        USD     6,067          (52,725)  
Take-Two Interactive Software, Inc.
     208          01/20/23        USD     130.00        USD     2,166          (2,704)  
Tesla, Inc.
     185          01/20/23        USD     223.33        USD     2,279          (1,665)  
Trip.com Group Ltd., ADR
     1,400          01/20/23        USD     30.00        USD     4,816          (672,000)  
Trip.com Group Ltd., ADR
     1,491          01/20/23        USD     37.00        USD     5,129          (115,552)  
Twilio, Inc., Class A
     105          01/20/23        USD     65.00        USD     514          (1,890)  
Unity Software, Inc.
     223          01/20/23        USD     35.00        USD     638          (9,254)  
Varonis Systems, Inc.
     380          01/20/23        USD     25.00        USD     910          (34,200)  
Wolfspeed, Inc.
     467          01/20/23        USD     105.00        USD     3,224          (2,335)  
Xometry, Inc., Class A
     380          01/20/23        USD     50.00        USD     1,225          (34,200)  
ZoomInfo Technologies, Inc., CLass A
     610          01/20/23        USD     35.00        USD     1,837          (13,725)  
Zscaler, Inc.
     94          01/20/23        USD     150.00        USD     1,052          (1,551)  
Zscaler, Inc.
     94          01/20/23        USD     135.00        USD     1,052          (5,452)  
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  123

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
Exchange-Traded Options Written (continued)
 
Description
  
Number of
Contracts
    
Expiration
Date
    
Exercise Price
    
Notional
Amount (000)
    
Value
 
Call (continued)
                    
Ambarella, Inc.
     25        01/27/23        USD        83.00        USD        206      $ (13,625
Block, Inc.
     255        01/27/23        USD        74.00        USD        1,602        (28,942
Cloudflare, Inc., Class A
     340        01/27/23        USD        53.00        USD        1,537        (41,310
First Solar, Inc.
     81        01/27/23        USD        170.00        USD        1,213        (17,617
MercadoLibre, Inc.
     27        01/27/23        USD        895.00        USD        2,285        (82,620
Okta, Inc.
     48        01/27/23        USD        72.00        USD        328        (14,688
Okta, Inc.
     418        01/27/23        USD        67.00        USD        2,856        (225,720
Splunk, Inc.
     22        01/27/23        USD        95.00        USD        189        (3,751
Take-Two Interactive Software, Inc.
     207        01/27/23        USD        104.00        USD        2,155        (92,115
Tesla, Inc.
     75        01/27/23        USD        170.00        USD        924        (9,900
Twilio, Inc., Class A
     212        01/27/23        USD        56.00        USD        1,038        (26,924
Coupang, Inc.
     760        02/03/23        USD        17.00        USD        1,118        (23,180
Credo Technology Group Holding Ltd.
     2,000        02/03/23        USD        15.00        USD        2,662        (59,086
Wolfspeed, Inc.
     371        02/03/23        USD        96.00        USD        2,561        (13,094
MongoDB, Inc.
     35        02/10/23        USD        225.00        USD        689        (28,875
Array Technologies, Inc.
     152        02/17/23        USD        25.00        USD        294        (8,360
Confluent, Inc., Class A
     142        02/17/23        USD        25.83        USD        316        (19,798
Credo Technology Group Holding Ltd.
     1,844        02/17/23        USD        17.50        USD        2,454        (18,440
Credo Technology Group Holding Ltd.
     2,850        02/17/23        USD        15.00        USD        3,793        (128,250
Endava PLC, ADR
     175        02/17/23        USD        85.00        USD        1,339        (45,500
Full Truck Alliance Co. Ltd., ADR
     1,912        02/17/23        USD        10.10        USD        1,530        (42,466
Grid Dynamics Holdings, Inc.
     878        02/17/23        USD        13.62        USD        985        (29,949
IQVIA Holdings, Inc.
     68        02/17/23        USD        214.25        USD        1,393        (45,071
Jabil, Inc.
     438        02/17/23        USD        75.00        USD        2,987        (36,135
Kanzhun Ltd., ADR
     920        02/17/23        USD        25.00        USD        1,874        (78,200
Lattice Semiconductor Corp.
     201        02/17/23        USD        80.00        USD        1,304        (34,170
Logitech International SA, Registered Shares
     450        02/17/23        USD        62.00        USD        2,801        (169,371
MACOM Technology Solutions Holdings, Inc., Class H
     260        02/17/23        USD        70.00        USD        1,637        (52,650
Marvell Technology, Inc.
     905        02/17/23        USD        45.00        USD        3,352        (55,205
Monolithic Power Systems, Inc.
     130        02/17/23        USD        400.00        USD        4,597        (137,150
Pure Storage, Inc., Class A
     2,180        02/17/23        USD        31.00        USD        5,834        (81,750
Rambus, Inc.
     455        02/17/23        USD        39.00        USD        1,630        (39,812
Shift4 Payments, Inc., Class A
     813        02/17/23        USD        55.00        USD        4,547        (483,735
Tenable Holdings, Inc.
     210        02/17/23        USD        40.00        USD        801        (53,550
Tesla, Inc.
     185        02/17/23        USD        205.00        USD        2,279        (16,002
Twilio, Inc., Class A
     105        02/17/23        USD        55.00        USD        514        (39,112
Unity Software, Inc.
     331        02/17/23        USD        40.00        USD        946        (30,121
Wolfspeed, Inc.
     669        02/17/23        USD        92.75        USD        4,619        (70,185
Xometry, Inc., Class A
     400        02/17/23        USD        45.00        USD        1,289        (84,000
Zscaler, Inc.
     164        02/17/23        USD        140.00        USD        1,835        (30,422
Endava PLC, ADR
     176        03/17/23        USD        85.01        USD        1,346        (69,083
                    
 
 
 
                     $ (5,840,272
                    
 
 
 
OTC Options Written
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call
                
Altium Ltd.
   Morgan Stanley & Co. International PLC     54,000       01/05/23       AUD       39.57       AUD       1,894     $ (83)  
ASM International NV
   Goldman Sachs International     28,200       01/05/23       EUR       271.59       EUR       6,645       (583)  
Aspen Technology, Inc.
   Barclays Bank PLC     16,900       01/05/23       USD       247.99       USD       3,471       (5)  
BE Semiconductor Industries NV
   JPMorgan Chase Bank N.A.     59,800       01/05/23       EUR       64.00       EUR       3,382       (592)  
Credo Technology Group Holding Ltd.
   Citibank N.A.     281,800       01/05/23       USD       15.07       USD       3,751       (2,745)  
SiteMinder Ltd.
   Goldman Sachs International     150,000       01/05/23       AUD       3.22       AUD       456       (1,885)  
Soitec SA
   Goldman Sachs International     29,000       01/05/23       EUR       167.02       EUR       4,433       (926)  
Wise PLC, Class A
   JPMorgan Chase Bank N.A.     200,000       01/05/23       GBP       6.30       GBP       1,126       (4,328)  
Xero Ltd.
   UBS AG     90,000       01/05/23       AUD       73.53       AUD       6,324       (44,202)  
Grid Dynamics Holdings, Inc.
   BNP Paribas SA     91,300       01/09/23       USD       14.40       USD       1,024       (138)  
Wise PLC, Class A
   Morgan Stanley & Co. International PLC     137,000       01/10/23       GBP       7.48       GBP       771       (137)  
E Ink Holdings, Inc.
   UBS AG     422,000       01/11/23       TWD       193.67       TWD       67,942       (4,026)  
Altium Ltd    
   Goldman Sachs International     60,000       01/13/23       AUD       37.80       AUD       2,105       (8,233)  
 
 
124
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
OTC Options Written (continued)
 
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call (continued)
                
CTS Eventim AG & Co. KGaA
   Goldman Sachs International     20,100       01/13/23       EUR       58.61       EUR       1,198     $ (40,576)  
E Ink Holdings, Inc.
   Goldman Sachs International     20,000       01/13/23       TWD       174.82       TWD       3,220       (1,689)  
Freee KK
   BNP Paribas SA     93,600       01/13/23       JPY       3,323.25       JPY       274,061       (19,971)  
GMO Payment Gateway, Inc.
   BNP Paribas SA     23,600       01/13/23       JPY       13,114.50       JPY       257,712       (1,587)  
Informa PLC
   UBS AG     411,900       01/13/23       GBP       5.75       GBP       2,552       (233,003)  
Lasertec Corp.
   Citibank N.A.     78,800       01/13/23       JPY       24,857.00       JPY       1,713,506       (96,878)  
Nordic Semiconductor ASA
   Morgan Stanley & Co. International PLC     42,600       01/13/23       NOK       184.79       NOK       6,982       (2,152)  
SiteMinder Ltd.
   UBS AG     51,000       01/13/23       AUD       2.96       AUD       155       (5,494)  
Soitec SA
   Goldman Sachs International     9,000       01/13/23       EUR       162.27       EUR       1,376       (7,917)  
Soitec SA
   JPMorgan Chase Bank N.A.     8,300       01/13/23       EUR       163.49       EUR       1,269       (5,811)  
Altium Ltd.
   UBS AG     54,000       01/17/23       AUD       40.00       AUD       1,894       (3,002)  
Delta Electronics, Inc.
   Citibank N.A.     40,000       01/17/23       TWD       305.77       TWD       11,460       (1,519)  
E Ink Holdings, Inc.
   Morgan Stanley & Co. International PLC     134,000       01/17/23       TWD       201.91       TWD       21,574       (1,592)  
Glodon Co., Ltd., Class A
   UBS AG     240,000       01/17/23       CNY       59.52       CNY       14,388       (84,137)  
SK Hynix, Inc.
   Morgan Stanley & Co. International PLC     57,900       01/17/23       KRW       83,276.82       KRW       4,342,500       (6,881)  
Soitec SA
   Barclays Bank PLC     7,000       01/17/23       EUR       166.43       EUR       1,070       (4,441)  
Suzhou Maxwell Technologies Co. Ltd., Class A
   UBS AG     7,500       01/17/23       CNY       479.03       CNY       3,103       (899)  
Wise PLC, Class A
   Morgan Stanley & Co. International PLC     137,000       01/17/23       GBP       7.48       GBP       771       (1,009)  
CTS Eventim AG & Co. KGaA
   UBS AG     17,000       01/18/23       EUR       61.53       EUR       1,013       (13,089)  
Freee KK
   Bank of America N.A.     93,100       01/18/23       JPY       3,515.40       JPY       272,597       (14,612)  
Nordic Semiconductor ASA
   JPMorgan Chase Bank N.A.     42,700       01/18/23       NOK       190.97       NOK       6,999       (2,127)  
Soitec SA
   Goldman Sachs International     9,200       01/18/23       EUR       164.14       EUR       1,406       (9,224)  
BE Semiconductor Industries NV
   Goldman Sachs International     20,800       01/25/23       EUR       66.85       EUR       1,176       (4,679)  
CTS Eventim AG & Co. KGaA
   UBS AG     17,000       01/25/23       EUR       61.53       EUR       1,013       (19,239)  
GMO Payment Gateway, Inc.
   UBS AG     17,600       01/25/23       JPY       13,064.70       JPY       192,192       (6,296)  
Altium Ltd.
   JPMorgan Chase Bank N.A.     63,000       01/27/23       AUD       40.54       AUD       2,210       (7,424)  
Soitec SA
   Goldman Sachs International     9,200       01/27/23       EUR       166.95       EUR       1,406       (12,250)  
Array Technologies, Inc.
   UBS AG     54,800       01/31/23       USD       23.25       USD       1,059       (29,009)  
Gitlab, Inc., Class A
   BNP Paribas SA     91,000       01/31/23       USD       53.74       USD       4,135       (150,104)  
Qorvo, Inc.
   Citibank N.A.     21,600       01/31/23       USD       103.00       USD       1,958       (21,201)  
Samsung SDI Co. Ltd.
   JPMorgan Chase Bank N.A.     27,900       01/31/23       KRW       748,360.00       KRW       16,488,900       (7,296)  
Shenzhen Inovance Technology Co. Ltd., Class A
   Morgan Stanley & Co. International PLC     364,700       01/31/23       CNY       73.54       CNY       25,467       (60,099)  
Sungrow Power Supply Co. Ltd., Class A
   JPMorgan Chase Bank N.A.     205,600       01/31/23       CNY       104.20       CNY       23,095       (346,792)  
Suzhou Maxwell Technologies Co. Ltd., Class A
   Morgan Stanley & Co. International PLC     32,300       01/31/23       CNY       444.58       CNY       13,366       (39,843)  
Synopsys, Inc.
   Barclays Bank PLC     32,500       01/31/23       USD       336.66       USD       10,377       (214,569)  
Wolters Kluwer N.V
   Goldman Sachs International     44,300       01/31/23       EUR       103.85       EUR       4,331       (19,339)  
Altium Ltd.
   UBS AG     37,100       02/01/23       AUD       38.54       AUD       1,301       (13,608)  
Adyen NV.
   Goldman Sachs International     6,703       02/02/23       EUR       1,399.71       EUR       8,636       (208,335)  
Delta Electronics, Inc.
   Goldman Sachs International     293,000       02/02/23       TWD       298.12       TWD       83,945       (44,633)  
Glodon Co., Ltd., Class A
   UBS AG     165,000       02/02/23       CNY       59.30       CNY       9,892       (46,066)  
GMO Payment Gateway, Inc.
   UBS AG     23,600       02/02/23       JPY       11,518.10       JPY       257,712       (67,588)  
Xiamen Faratronic Co. Ltd., Class A
   UBS AG     95,800       02/02/23       CNY       161.87       CNY       15,389       (53,077)  
Endava PLC, ADR
   Goldman Sachs International     23,000       02/06/23       USD       78.10       USD       1,760       (101,622)  
Lattice Semiconductor Corp.
   Citibank N.A.     42,200       02/07/23       USD       67.50       USD       2,738       (141,991)  
Altium Ltd.
   UBS AG     37,100       02/08/23       AUD       38.30       AUD       1,301       (18,444)  
Informa PLC
   UBS AG     400,000       02/08/23       GBP       6.47       GBP       2,478       (55,655)  
Nordic Semiconductor ASA
   JPMorgan Chase Bank N.A.     21,900       02/08/23       NOK       191.10       NOK       3,589       (4,582)  
Soitec SA
   Morgan Stanley & Co. International PLC     7,100       02/08/23       EUR       177.08       EUR       1,085       (7,092)  
Wise PLC, Class A
   JPMorgan Chase Bank N.A.     150,000       02/08/23       GBP       6.97       GBP       844       (14,350)  
Xero Ltd.
   Morgan Stanley & Co. International PLC     12,300       02/08/23       AUD       80.33       AUD       864       (13,961)  
Gitlab, Inc., Class A
   BNP Paribas SA     91,000       02/14/23       USD       53.74       USD       4,135       (225,199)  
ZoomInfo Technologies, Inc., CLass A
   JPMorgan Chase Bank N.A.     97,100       02/14/23       USD       33.17       USD       2,924       (135,044)  
                
 
 
 
                 $  (2,714,880)  
                
 
 
 
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  125

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
 
 
 
Description
  
Swap
Premiums
Paid
    
Swap
Premiums
Received
    
Unrealized
Appreciation
    
Unrealized
Depreciation
    
Value
 
 
 
Options Written
   $ N/A      $ N/A      $ 11,143,376      $ (1,440,181    $ (8,555,152)  
 
 
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
 
               
    
Commodity
Contracts
   
Credit
  Contracts
   
Equity
Contracts
   
Foreign
Currency
  Exchange
Contracts
   
Interest
Rate
  Contracts
   
Other
  Contracts
   
Total
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $ 8,555,152     $     $     $     $ 8,555,152  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
 
 
 
   
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
 
 
Net Realized Gain (Loss) from:
             
Options purchased
(a)
  $     $     $ (12,338,594   $     $     $     $ (12,338,594
Options written
                100,510,091                         100,510,091  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $     $     $ 88,171,497     $     $     $     $ 88,171,497  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
             
Options written
  $     $     $ 2,676,552     $     $     $     $ 2,676,552  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
 
 
Options:
  
Average value of option contracts purchased
   $
(a)
 
Average value of option contracts written
   $ 15,801,272     
 
 
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
 
 
    
Assets
      
Liabilities
 
 
 
Derivative Financial Instruments
       
Options
   $        $ 8,555,152  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities
              8,555,152  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (5,840,272
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 2,714,880  
  
 
 
      
 
 
 
 
 
126
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
           
Counterparty
  
 



Derivative
Liabilities
Subject to

an MNA by
Counterparty
 
 
 

 
 
  
 

Derivatives
Available

for Offset
 
 

 
  
 

Non-Cash
Collateral
Pledged
 
 
 
  
 

Cash
Collateral
Pledged
 
 
(a)
 
  
 

Net Amount
of Derivative
Liabilities
 
 
(b)
 
Bank of America N.A
   $ 14,612      $      $      $ (14,612    $  
Barclays Bank PLC
     219,015                             219,015  
BNP Paribas SA
     396,999                      (340,000      56,999  
Citibank N.A
     264,334                      (264,334       
Goldman Sachs International
     461,891                      (310,000      151,891  
JPMorgan Chase Bank N.A
     528,346                      (528,346       
Morgan Stanley & Co. International PLC
     132,849                      (132,849       
UBS AG
     696,834                      (696,834       
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 2,714,880      $      $      $     (2,286,975)      $ 427,905  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.
 
         
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets
           
Investments
           
Long-Term Investments
           
Common Stocks
           
Automobiles
   $ 22,824,761      $      $      $ 22,824,761  
Banks
                   15,909,783        15,909,783  
Diversified Consumer Services
                   11,165,570        11,165,570  
Electrical Equipment
     5,155,504        19,035,694               24,191,198  
Electronic Equipment, Instruments & Components
     21,016,580        46,823,849               67,840,429  
Entertainment
     36,537,149        8,589,330               45,126,479  
Hotels, Restaurants & Leisure
     25,160,504                      25,160,504  
Household Durables
            5,932,007               5,932,007  
Interactive Media & Services
     26,894,651                      26,894,651  
Internet & Direct Marketing Retail
     32,204,608                      32,204,608  
IT Services
     87,468,984        55,923,606        28,024,651        171,417,241  
Life Sciences Tools & Services
     8,076,149                      8,076,149  
Machinery
            9,438,229               9,438,229  
Media
            20,186,453               20,186,453  
Professional Services
            15,463,515               15,463,515  
Road & Rail
     9,840,616                      9,840,616  
Semiconductors & Semiconductor Equipment
     185,994,457        117,322,936        3,194,961        306,512,354  
Software
     149,856,259        59,926,121        36,195,271        245,977,651  
Technology Hardware, Storage & Peripherals
     35,127,047                      35,127,047  
Preferred Securities
           
Preferred Stocks
                   413,908,201        413,908,201  
Warrants
                   44,581        44,581  
Short-Term Securities
           
Money Market Funds
     20,683,361                      20,683,361  
  
 
 
    
 
 
    
 
 
    
 
 
 
   $ 666,840,630      $ 358,641,740      $ 508,443,018      $ 1,533,925,388  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
C
O
N
S
O
L
I
D
A
T
E
D   
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  127

Consolidated Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Science and Technology Trust II (BSTZ)
    
 
Fair Value Hierarchy as of Period End (continued)
 
         
     
Level 1
    
Level 2
    
Level 3
    
Total
 
Derivative Financial Instruments
(a)
           
Liabilities
           
Equity Contracts
   $     (5,175,924    $     (3,379,228    $             —      $     (8,555,152
  
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Derivative financial instruments are options written. Options written are shown at value.
 
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
 
 
 
   
Common
Stocks
   
Preferred
Stocks
   
Warrants
   
Total
 
 
 
Assets
       
Opening balance, as of December 31, 2021
  $  246,829,600     $ 565,071,190     $ 323,803     $ 812,224,593  
Transfers into Level 3
                       
Transfers out of Level 3
                       
Accrued discounts/premiums
                       
Net realized gain (loss)
          591,104             591,104  
Net change in unrealized appreciation (depreciation)
(a)(b)
    (152,339,364     (128,322,271     (279,222     (280,940,857
Purchases
                       
Sales
          (23,431,822           (23,431,822
 
 
 
   
 
 
   
 
 
   
 
 
 
Closing balance, as of December 31, 2022
  $ 94,490,236     $ 413,908,201     $ 44,581     $ 508,443,018  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022
(b)
  $ (152,339,364   $ (116,437,486   $ (279,222   $ (269,056,072
 
 
 
   
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.
 
 
(b)
 
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2022 is generally due to investments no longer held or categorized as Level 3 at period end.
 
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
 
           
 
  
 
Value
 
    
Valuation
Approach
    
 

Unobservable

Inputs
 

 
  
 


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)
 
  
 



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
Assets
                  
Common Stocks
   $ 94,490,236        Market        Revenue Multiple       
1.80x -29.13x
        13.01x  
               Volatility        60% - 70%        61%  
               Time to Exit        1.0 -3.0 years        1.3 years  
               Market Adjustment Multiple        0.50x         
Preferred Stocks
     413,908,201        Market        Revenue Multiple       
0.50x -29.13x
     14.84x  
               Time to Exit        3.0 -4.0 years        3.9 years  
               Volatility        32% - 70%        52%  
               Market Adjustment Multiple        0.50x - 1.00x        0.99x  
              
Gross Profit Multiple
       11.89x         
              
Recent Transactions
       (b)         
Warrants
     44,581        Market        Revenue Multiple        7.00x         
               Volatility        39%         
               Time to Exit        1.5 years         
  
 
 
                 
  
$
508,443,018
 
               
  
 
 
                 
 
 
(a)
 
A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.
 
 
(b)
 
For the period end December 31, 2022, the valuation technique for certain investments classified as Preferred Stock used recent prior transaction prices as inputs within the model used for the approximation of fair value.
 
See notes to financial statements.
 
 
128
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
(Percentages shown are based on Net Assets)
 
Security
 
Shares
    
Value
 
Common Stocks
    
Building Products — 5.9%
 
Johnson Controls International PLC
(a)
    205,259      $   13,136,576  
Kingspan Group PLC
    117,665        6,370,839  
Trane Technologies PLC
(a)
    58,800        9,883,692  
    
 
 
 
           29,391,107  
Chemicals — 3.9%
 
Air Liquide SA
    52,768        7,489,641  
LG Chem Ltd.
    9,550        4,560,405  
Linde PLC
(b)
    22,278        7,261,761  
    
 
 
 
           19,311,807  
Commercial Services & Supplies
(a)
— 5.2%
 
Waste Connections, Inc.
    77,400        10,260,144  
Waste Management, Inc.
(c)
    98,000        15,374,240  
    
 
 
 
           25,634,384  
Construction & Engineering — 4.9%
 
MasTec, Inc.
(a)(b)
    33,600        2,867,088  
Quanta Services, Inc.
(a)
    48,960        6,976,800  
Vinci SA
    148,150        14,768,610  
    
 
 
 
           24,612,498  
Electric Utilities — 29.3%
 
American Electric Power Co., Inc.
(a)
    157,000        14,907,150  
Duke Energy Corp.
(a)
    123,618        12,731,418  
Edison International
    121,700        7,742,554  
EDP - Energias de Portugal SA
    1,738,550        8,666,333  
Enel SpA
    3,823,125        20,561,308  
Exelon Corp.
(a)
    252,658        10,922,405  
FirstEnergy Corp.
(a)
    87,550        3,671,847  
Iberdrola SA
    957,702        11,179,723  
Neoenergia SA
(b)
    741,450        2,177,057  
NextEra Energy, Inc.
(a)(c)
    491,530        41,091,908  
Orsted A/S
(d)
    71,450        6,459,482  
Xcel Energy, Inc.
(a)
    87,390        6,126,913  
    
 
 
 
           146,238,098  
Electrical Equipment — 6.6%
 
Eaton Corp. PLC
(a)
    33,790        5,303,340  
ITM Power PLC
(b)(e)
    598,850        665,355  
Prysmian SpA
    108,550        4,033,230  
Schneider Electric SE
    43,182        6,064,246  
Sunrun, Inc.
(b)
    82,300        1,976,846  
Vestas Wind Systems A/S
    504,321        14,711,369  
    
 
 
 
           32,754,386  
Electronic Equipment, Instruments & Components — 0.9%
 
Samsung SDI Co. Ltd.
(b)
    9,600        4,507,607  
    
 
 
 
Independent Power and Renewable Electricity Producers — 9.4%
 
AES Corp.
(a)
    327,790        9,427,241  
China Longyuan Power Group Corp. Ltd., Class H
    3,472,000        4,220,524  
EDP Renovaveis SA
    436,256        9,613,134  
Orron Energy AB
    951,750        2,057,079  
RWE AG
    445,395        19,689,883  
Sunnova Energy International, Inc.
(b)
    102,950        1,854,129  
    
 
 
 
           46,861,990  
Machinery — 5.2%
 
Atlas Copco AB, B Shares
    1,064,300        11,355,709  
Ingersoll Rand, Inc.
(a)
    182,400        9,530,400  
Spirax-Sarco Engineering PLC
    39,850        5,090,060  
    
 
 
 
           25,976,169  
Security
 
Shares
    
Value
 
Multi-Utilities — 11.6%
 
CMS Energy Corp.
(a)
    130,410      $ 8,258,865  
Dominion Energy, Inc.
(a)(c)
    171,748        10,531,587  
National Grid PLC
    898,474        10,763,137  
Public Service Enterprise Group, Inc.
(a)
    209,742        12,850,892  
Sempra Energy
(a)(c)
    99,000        15,299,460  
    
 
 
 
           57,703,941  
Oil, Gas & Consumable Fuels — 10.1%
 
Cheniere Energy, Inc.
(a)
    51,950        7,790,422  
Enterprise Products Partners LP
(a)
    205,113        4,947,326  
Kinder Morgan, Inc.
(a)
    740,450        13,387,336  
TC Energy Corp.
    261,550        10,427,230  
Williams Cos., Inc.
(a)(c)
    421,205        13,857,644  
    
 
 
 
           50,409,958  
Semiconductors & Semiconductor Equipment — 5.3%
 
Analog Devices, Inc.
(a)
    24,374        3,998,067  
ASML Holding NV
    10,850        5,915,980  
Canadian Solar, Inc.
(b)
    82,140        2,538,126  
First Solar, Inc.
(a)(b)
    38,634        5,786,987  
Infineon Technologies AG
(b)
    154,300        4,689,468  
STMicroelectronics NV
    100,200        3,560,710  
    
 
 
 
           26,489,338  
    
 
 
 
Total Long-Term Investments — 98.3%
(Cost: $349,887,670)
 
     489,891,283  
    
 
 
 
Short-Term Securities
    
Money Market Funds — 2.2%
            
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.03%
(f)(g)
    11,042,199        11,042,199  
SL Liquidity Series, LLC, Money Market Series, 4.49%
(f)(g)
    225,202        225,179  
    
 
 
 
Total Short-Term Securities — 2.2%
(Cost: $11,267,256)
 
     11,267,378  
    
 
 
 
Total Investments Before Options Written — 100.5%
(Cost: $361,154,926)
 
     501,158,661  
    
 
 
 
Options Written — (0.6)%
(Premiums Received: $(4,592,709))
 
     (3,071,338
    
 
 
 
Total Investments, Net of Options Written — 99.9%
(Cost: $356,562,217)
 
     498,087,323  
Other Assets Less Liabilities — 0.1%
 
     305,643  
    
 
 
 
Net Assets — 100.0%
     $ 498,392,966  
    
 
 
 
 
(a)
 
All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
(b)
 
Non-income producing security.
(c)
 
All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
(d)
 
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
(e)
 
All or a portion of this security is on loan.
(f)
 
Affiliate of the Trust.
(g)
 
Annualized 7-day yield as of period end.
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  129

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
 
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
 
                   
Affiliated Issuer
  
Value at
12/31/21
    
Purchases
at Cost
    
Proceeds
  from Sales
    
Net
Realized
Gain (Loss)
    
Change in
Unrealized
Appreciation
(Depreciation)
    
Value at
12/31/22
    
Shares
Held at
12/31/22
    
Income
    
Capital Gain
Distributions
from
Underlying
Funds
 
BlackRock Liquidity Funds, T-Fund, Institutional Class
   $  7,380,748      $  3,661,451
(a)
 
   $      $      $      $ 11,042,199        11,042,199      $ 204,577      $  
SL Liquidity Series, LLC, Money Market Series
            224,970
(a)
 
            87        122        225,179        225,202        9,618
(b)
 
      
           
 
 
    
 
 
    
 
 
       
 
 
    
 
 
 
            $ 87      $ 122      $ 11,267,378         $ 214,195      $  
           
 
 
    
 
 
    
 
 
       
 
 
    
 
 
 
 
 
(a)
 
Represents net amount purchased (sold).
 
 
(b)
 
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
 
           
Description
  
Number of
Contracts
    
Expiration
Date
    
Exercise Price
    
Notional
Amount (000)
    
Value
 
Call
                    
Analog Devices, Inc.
     24        01/06/23        USD        175.00        USD        394      $ (300)  
Enterprise Products Partners LP
     18        01/06/23        USD        25.00        USD        43        (36)  
First Solar, Inc.
     80        01/06/23        USD        172.50        USD        1,198        (920)  
Kinder Morgan, Inc.
     481        01/06/23        USD        19.00        USD        870        (722)  
Waste Management, Inc.
     168        01/06/23        USD        165.00        USD        2,636        (4,200)  
Williams Cos., Inc.
     111        01/06/23        USD        34.00        USD        365        (1,110)  
Williams Cos., Inc.
     501        01/06/23        USD        35.00        USD        1,648        (5,010)  
Analog Devices, Inc.
     38        01/13/23        USD        172.50        USD        623        (4,655)  
Enterprise Products Partners LP
     198        01/13/23        USD        24.50        USD        478        (4,752)  
Kinder Morgan, Inc.
     1,055        01/13/23        USD        18.50        USD        1,907        (18,990)  
Williams Cos., Inc.
     112        01/13/23        USD        34.00        USD        368        (2,800)  
Williams Cos., Inc.
     501        01/13/23        USD        35.00        USD        1,648        (3,758)  
AES Corp.
     730        01/20/23        USD        29.00        USD        2,099        (49,275)  
American Electric Power Co., Inc.
     509        01/20/23        USD        95.00        USD        4,833        (99,255)  
Cheniere Energy, Inc.
     37        01/20/23        USD        175.00        USD        555        (925)  
CMS Energy Corp.
     265        01/20/23        USD        60.00        USD        1,678        (99,375)  
CMS Energy Corp.
     191        01/20/23        USD        62.40        USD        1,210        (37,996)  
Dominion Energy, Inc.
     601        01/20/23        USD        62.50        USD        3,685        (55,592)  
Duke Energy Corp.
     213        01/20/23        USD        97.50        USD        2,194        (125,670)  
Eaton Corporation PLC
     63        01/20/23        USD        155.00        USD        989        (31,185)  
Enterprise Products Partners LP
     18        01/20/23        USD        25.00        USD        43        (270)  
Enterprise Products Partners LP
     71        01/20/23        USD        24.00        USD        171        (4,083)  
Exelon Corp.
     265        01/20/23        USD        40.00        USD        1,146        (91,425)  
First Solar, Inc.
     55        01/20/23        USD        165.00        USD        824        (12,100)  
FirstEnergy Corp.
     150        01/20/23        USD        39.00        USD        629        (48,000)  
Ingersoll Rand, Inc.
     283        01/20/23        USD        55.00        USD        1,479        (13,443)  
Johnson Controls International PLC
     202        01/20/23        USD        67.50        USD        1,293        (8,585)  
Johnson Controls International PLC
     151        01/20/23        USD        70.00        USD        966        (2,643)  
MasTec, Inc.
     117        01/20/23        USD        100.00        USD        998        (2,925)  
NextEra Energy, Inc.
     627        01/20/23        USD        85.00        USD        5,242        (89,347)  
Public Service Enterprise Group, Inc.
     218        01/20/23        USD        57.79        USD        1,336        (83,194)  
Quanta Services, Inc.
     116        01/20/23        USD        155.00        USD        1,653        (7,830)  
Sempra Energy
     173        01/20/23        USD        160.00        USD        2,674        (22,490)  
TC Energy Corp.
     457        01/20/23        CAD        58.00        CAD        2,467        (2,531)  
Trane Technologies PLC
     109        01/20/23        USD        180.00        USD        1,832        (16,895)  
Trane Technologies PLC
     30        01/20/23        USD        175.00        USD        504        (5,100)  
 
 
130
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
    
 
Exchange-Traded Options Written (continued)
 
           
Description
  
Number of
Contracts
      
Expiration
Date
      
Exercise Price
      
Notional
Amount (000)
      
Value
 
Call (continued)                                                   
Waste Connections, Inc.
     212          01/20/23        USD     145.00        USD     2,810        $ (62,540
Waste Management, Inc.
     175          01/20/23        USD     162.50        USD     2,745          (14,438
Williams Cos., Inc.
     249          01/20/23        USD     34.00        USD     819          (9,960
Xcel Energy, Inc.
     153          01/20/23        USD     68.35        USD     1,073          (42,190
Analog Devices, Inc.
     23          01/27/23        USD     170.00        USD     377          (7,705
Edison International
     425          01/27/23        USD     65.55        USD     2,704          (35,931
Enterprise Products Partners LP
     198          01/27/23        USD     24.50        USD     478          (8,019
Kinder Morgan, Inc.
     1,055          01/27/23        USD     18.00        USD     1,907          (63,827
Exelon Corp.
     279          02/01/23        USD     40.00        USD     1,206          (102,639
Enterprise Products Partners LP
     214          02/03/23        USD     24.29        USD     516          (10,992
Public Service Enterprise Group, Inc.
     217          02/06/23        USD     59.00        USD     1,330          (70,522
AES Corp.
     420          02/17/23        USD     29.00        USD     1,208          (46,200
American Electric Power Co., Inc.
     40          02/17/23        USD     100.00        USD     380          (4,300
Cheniere Energy, Inc.
     144          02/17/23        USD     173.07        USD     2,159          (23,830
Duke Energy Corp.
     219          02/17/23        USD     103.50        USD     2,255          (65,214
Eaton Corporation PLC
     55          02/17/23        USD     167.09        USD     863          (15,943
Exelon Corp.
     340          02/17/23        USD     44.33        USD     1,470          (37,661
FirstEnergy Corp.
     156          02/17/23        USD     42.00        USD     654          (21,060
Johnson Controls International PLC
     365          02/17/23        USD     67.50        USD     2,336          (53,837
NextEra Energy, Inc.
     1,166          02/17/23        USD     90.00        USD     9,748          (134,090
Public Service Enterprise Group, Inc.
     299          02/17/23        USD     60.00        USD     1,832          (89,700
Quanta Services, Inc.
     55          02/17/23        USD     155.00        USD     784          (14,025
Sempra Energy
     173          02/17/23        USD     165.00        USD     2,674          (28,112
TC Energy Corp.
     457          02/17/23        CAD     58.00        CAD     2,467          (14,682
Trane Technologies PLC
     66          02/17/23        USD     177.23        USD     1,109          (22,812
Waste Connections, Inc.
     58          02/17/23        USD     140.00        USD     769          (8,990
                          
 
 
 
                           $  (1,966,606
                          
 
 
 
OTC Options Written
 
             
Description
  
Counterparty
  
Number of
Contracts
    
Expiration
Date
   
Exercise Price
    
Notional
Amount (000)
    
Value
 
                 
Call
                    
Atlas Copco AB, B Shares
   Morgan Stanley & Co. International PLC      111,700        01/05/23       SEK       117.40        SEK       12,410      $ (1,819
China Longyuan Power Group Corp. Ltd.,
Class H
   Citibank N.A.      550,000        01/05/23       HKD       10.53        HKD       5,247        (2,418
LG Chem Ltd.
   Bank of America N.A.      4,200        01/05/23       KRW       742,000.00        KRW       2,520,000         
Linde PLC
   Morgan Stanley & Co. International PLC      3,500        01/05/23       EUR       328.36        EUR       1,069        (40
Neoenergia SA
   Morgan Stanley & Co. International PLC      249,000        01/05/23       BRL       16.03        BRL       3,847        (1,606
Orsted A/S
   Morgan Stanley & Co. International PLC      14,800        01/05/23       DKK       662.78        DKK       9,343        (6,000
RWE AG
   Morgan Stanley & Co. International PLC      41,000        01/05/23       EUR       42.24        EUR       1,705        (10,489
Spirax-Sarco Engineering PLC
   Morgan Stanley & Co. International PLC      13,500        01/05/23       GBP       116.30        GBP       1,433        (186
STMicroelectronics NV
   Goldman Sachs International      35,000        01/05/23       EUR       38.20        EUR       1,155        (2
Vinci SA
   Goldman Sachs International      2,900        01/05/23       EUR       98.43        EUR       271        (23
Kingspan Group PLC
   Morgan Stanley & Co. International PLC      20,600        01/10/23       EUR       53.12        EUR       1,042        (8,096
Vestas Wind Systems A/S
   Merrill Lynch International      88,000        01/10/23       DKK       169.60        DKK       17,785        (420,205
EDP Renovaveis SA
   Merrill Lynch International      42,000        01/11/23       EUR       22.60        EUR       864        (1,281
Enel SpA
   Goldman Sachs International      682,800        01/11/23       EUR       5.21        EUR       3,434        (14,947
Iberdrola SA
   Merrill Lynch International      95,100        01/11/23       EUR       10.76        EUR       1,039        (13,540
Infineon Technologies AG
   Royal Bank of Canada      19,200        01/11/23       EUR       33.10        EUR       546        (109
Xcel Energy, Inc.
   Bank of America N.A.      15,800        01/11/23       USD       68.67        USD       1,108        (33,734
EDP-Energias de Portugal SA
   Goldman Sachs International      200,000        01/13/23       EUR       4.78        EUR       931        (8,078
National Grid PLC
   Goldman Sachs International      129,400        01/13/23       GBP       10.73        GBP       1,291        (152
RWE AG
   UBS AG      94,300        01/13/23       EUR       42.78        EUR       3,922        (29,794
Atlas Copco AB, B Shares
   Goldman Sachs International      282,000        01/17/23       SEK       121.39        SEK       31,330        (10,482
EDP Renovaveis SA
   Goldman Sachs International      29,600        01/17/23       EUR       22.03        EUR       609        (4,445
EDP Renovaveis SA
   Morgan Stanley & Co. International PLC      81,000        01/18/23       EUR       22.59        EUR       1,667        (6,737
Infineon Technologies AG
   Merrill Lynch International      25,000        01/18/23       EUR       33.02        EUR       711        (735
ITM Power PLC
   Goldman Sachs International      209,500        01/18/23       GBP       1.04        GBP       192        (8,125
National Grid PLC
   UBS AG      185,100        01/18/23       GBP       10.29        GBP       1,846        (10,099
EDP-Energias de Portugal SA
   Barclays Bank PLC      164,700        01/25/23       EUR       4.75        EUR       767        (13,422
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  131

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
    
 
OTC Options Written (continued)
 
             
Description
  
Counterparty
 
Number of
Contracts
   
Expiration
Date
   
Exercise Price
   
Notional
Amount (000)
   
Value
 
Call (continued)
                
Iberdrola SA
   Morgan Stanley & Co. International PLC     240,100       01/25/23       EUR       10.94       EUR       2,624     $ (29,917
Orron Energy AB
   Goldman Sachs International     69,200       01/25/23       SEK       26.51       SEK       1,554       (1,770
Schneider Electric SE
   Goldman Sachs International     8,200       01/25/23       EUR       144.57       EUR       1,072       (1,787
Air Liquide SA
   Morgan Stanley & Co. International PLC     18,400       01/27/23       EUR       146.47       EUR       2,436       (2,523
ASML Holding NV
   Goldman Sachs International     3,100       01/31/23       EUR       556.50       EUR       1,562       (20,936
Linde PLC
   Goldman Sachs International     4,200       01/31/23       EUR       317.24       EUR       1,283       (15,497
Orron Energy AB
   Goldman Sachs International     264,000       01/31/23       SEK       22.44       SEK       5,929       (34,802
RWE AG
   Goldman Sachs International     20,600       01/31/23       EUR       43.16       EUR       857       (12,632
Samsung SDI Co. Ltd.
   JPMorgan Chase Bank N.A.     3,400       01/31/23       KRW       748,360.00       KRW       2,009,400       (889
EDP-Energias de Portugal SA
   Morgan Stanley & Co. International PLC     243,700       02/02/23       EUR       4.82       EUR       1,135       (18,149
Enel SpA
   Goldman Sachs International     708,600       02/02/23       EUR       5.27       EUR       3,564       (11,347
Infineon Technologies AG
   Goldman Sachs International     9,900       02/02/23       EUR       30.72       EUR       281       (4,434
Orsted A/S
   Morgan Stanley & Co. International PLC     5,800       02/02/23       DKK       659.92       DKK       3,662       (15,898
Schneider Electric SE
   Goldman Sachs International     7,000       02/02/23       EUR       137.93       EUR       915       (10,765
Vestas Wind Systems A/S
   Morgan Stanley & Co. International PLC     88,500       02/02/23       DKK       203.45       DKK       17,886       (160,267
China Longyuan Power Group Corp. Ltd., Class H
   JPMorgan Chase Bank N.A.     545,000       02/08/23       HKD       9.55       HKD       5,199       (52,128
Kingspan Group PLC
   Goldman Sachs International     20,600       02/08/23       EUR       56.18       EUR       1,042       (13,491
Prysmian SpA
   Morgan Stanley & Co. International PLC     38,000       02/08/23       EUR       37.02       EUR       1,317       (15,015
Vinci SA
   Morgan Stanley & Co. International PLC     44,900       02/08/23       EUR       99.30       EUR       4,189       (23,945
Ingersoll Rand, Inc.
   Citibank N.A.     36,000       02/13/23       USD       54.30       USD       1,881       (51,976
                
 
 
 
                 $  (1,104,732
                
 
 
 
Balances Reported in the Statements of Assets and Liabilities for Options Written
 
           
Description
  
Swap
Premiums
Paid
      
Swap
Premiums
Received
      
Unrealized
Appreciation
      
Unrealized
Depreciation
      
Value
 
Options Written
   $ N/A        $ N/A        $ 2,354,918        $ (833,547)        $ (3,071,338)  
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
 
               
    
Commodity
Contracts
   
Credit
Contracts
   
Equity
Contracts
   
Foreign
Currency
Exchange
Contracts
   
Interest
Rate
Contracts
   
Other
Contracts
   
Total
 
Liabilities — Derivative Financial Instruments
             
Options written
             
Options written at value
  $     $     $ 3,071,338     $     $     $     $   3,071,338  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
For the period ended December 31, 2022, the effect of derivative financial instruments in the Statements of Operations was as follows:
 
               
     
Commodity
Contracts
    
Credit
Contracts
    
Equity
Contracts
    
Foreign
Currency
Exchange
Contracts
    
Interest
Rate
Contracts
    
Other
Contracts
    
Total
 
Net Realized Gain (Loss) from:
                    
Options purchased
(a)
   $      $      $ (6,148,502    $      $      $      $ (6,148,502
Options written
                   2,970,321                             2,970,321  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $      $      $ (3,178,181    $      $      $      $ (3,178,181
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Change in Unrealized Appreciation (Depreciation) on:
                    
Options written
   $      $      $ 2,726,906      $      $      $      $ 2,726,906  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Options purchased are included in net realized gain (loss) from investments — unaffiliated.
 
 
 
132
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
    
 
Average Quarterly Balances of Outstanding Derivative Financial Instruments
 
   
Options:
 
Average value of option contracts purchased
  $
(a)
 
Average value of option contracts written
  $ 3,923,401  
 
 
(a)
 
Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.
 
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
 
     
     
Assets
      
Liabilities
 
Derivative Financial Instruments
       
Options
   $        $ 3,071,338  
  
 
 
      
 
 
 
Total derivative assets and liabilities in the Statements of Assets and Liabilities
              3,071,338  
  
 
 
      
 
 
 
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)
              (1,966,606
  
 
 
      
 
 
 
Total derivative assets and liabilities subject to an MNA
   $        $ 1,104,732  
  
 
 
      
 
 
 
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:
 
           
Counterparty
  
 


Derivative

Liabilities
Subject to
an MNA by
Counterparty
 

 
 
 
 
  
 

Derivatives
Available
for Offset
 
 
 
  
 

Non-Cash

Collateral
Pledged
 
 
(a)
 
  
 

Cash
Collateral
Pledged
 
 
 
  
 


Net Amount

of Derivative
Liabilities
 

 
(b)
 
Bank of America N.A.
   $ 33,734      $      $      $      $ 33,734  
Barclays Bank PLC
     13,422               (13,422              
Citibank N.A.
     54,394                             54,394  
Goldman Sachs International
     173,715                      (160,000      13,715  
JPMorgan Chase Bank N.A.
     53,017               (53,017              
Merrill Lynch International
     435,761               (435,761              
Morgan Stanley & Co. International PLC
     300,687               (300,687              
Royal Bank of Canada
     109                             109  
UBS AG
     39,893               (6,393      (33,500       
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 1,104,732      $      $     (809,280)      $     (193,500)      $ 101,952  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
(a)
 
Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.
 
 
(b)
 
Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
 
         
     
Level 1
      
Level 2
      
Level 3
      
Total
 
Assets
                 
Investments
                 
Long-Term Investments
                 
Common Stocks
                 
Building Products
   $   23,020,268        $ 6,370,839        $           —        $ 29,391,107  
Chemicals
              19,311,807                   19,311,807  
Commercial Services & Supplies
     25,634,384                            25,634,384  
Construction & Engineering
     9,843,888          14,768,610                   24,612,498  
Electric Utilities
     97,194,195          49,043,903                   146,238,098  
Electrical Equipment
     7,280,186          25,474,200                   32,754,386  
Electronic Equipment, Instruments & Components
              4,507,607                   4,507,607  
 
 
S
C
H
E
D
U
L
E   O
F   
I
N
V
E
S
T
M
E
N
T
S
  133

Schedule of Investments  
(continued)
December 31, 2022
  
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
    
 
Fair Value Hierarchy as of Period End (continued)
 
         
     
Level 1
      
Level 2
      
Level 3
      
Total
 
Common Stocks (continued)
                 
Independent Power and Renewable Electricity Producers
   $ 11,281,370        $ 35,580,620        $        $ 46,861,990  
Machinery
     9,530,400          16,445,769                   25,976,169  
Multi-Utilities
     46,940,804          10,763,137                   57,703,941  
Oil, Gas & Consumable Fuels
     50,409,958                            50,409,958  
Semiconductors & Semiconductor Equipment
     12,323,180          14,166,158                   26,489,338  
Short-Term Securities
                 
Money Market Funds
     11,042,199                            11,042,199  
  
 
 
      
 
 
      
 
 
      
 
 
 
   $ 304,500,832        $ 196,432,650        $          500,933,482  
  
 
 
      
 
 
      
 
 
      
 
 
 
Investments Valued at NAV
(a)
                    225,179  
                 
 
 
 
                  $   501,158,661  
                 
 
 
 
Derivative Financial Instruments
(b)
                 
Liabilities
                 
Equity Contracts
   $ (1,417,682      $ (1,653,656      $             —        $ (3,071,338
  
 
 
      
 
 
      
 
 
      
 
 
 
 
 
(a)
 
Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
 
(b)
 
Derivative financial instruments are options written. Options written are shown at value.
 
See notes to financial statements.
 
 
134
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Assets and Liabilities  
December 31, 2022
 
      BGR     CII      BDJ
(a)
     BOE  
ASSETS
          
Investments, at value — unaffiliated
(b)
   $ 393,791,742     $ 770,187,379      $ 1,563,253,442      $ 681,294,894  
Investments, at value — affiliated
(c)
     7,695,475       14,661,156        76,042,437        6,643,752  
Cash
                  128,711         
Cash pledged as collateral for exchange-traded options written
                         4,880,000  
Foreign currency, at value
(d)
     58,425              942        73,552  
Receivables:
          
Investments sold
                  4,432,718         
Dividends — unaffiliated
     720,616       556,822        2,369,831        1,681,024  
Dividends — affiliated
     23,851       86,533        322,754        26,699  
  
 
 
   
 
 
    
 
 
    
 
 
 
Total assets
     402,290,109       785,491,890        1,646,550,835        694,599,921  
  
 
 
   
 
 
    
 
 
    
 
 
 
LIABILITIES
          
Bank overdraft
     83,281       24,238                
Options written, at value
(e)
     2,475,779       7,689,724        13,840,189        4,281,155  
Payables:
          
Investments purchased
                         21  
Accounting services fees
     14,686       15,658        30,678        19,009  
Capital shares redeemed
     259,837                     332,399  
Custodian fees
     16,041       7,954        52,687        41,109  
Income dividend distributions
     91,573       2,099,324               135,865  
Investment advisory fees
     327,765       578,544        1,134,205        488,109  
Trustees’ and Officer’s fees
     406,775       228,435        910,967        646,826  
Other accrued expenses
     28,480       51,339        40,722        28,807  
Professional fees
     70,792       102,413        172,587        131,501  
Transfer agent fees
     22,516       27,189        60,425        31,235  
Other liabilities
                  666,808         
  
 
 
   
 
 
    
 
 
    
 
 
 
Total liabilities
     3,797,525       10,824,818        16,909,268        6,136,036  
  
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS
   $ 398,492,584     $ 774,667,072      $ 1,629,641,567      $ 688,463,885  
  
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS CONSIST OF
          
Paid-in capital
(f)(g)(h)
   $ 525,444,447     $ 561,558,505      $ 1,312,911,822      $ 696,104,439  
Accumulated earnings (loss)
     (126,951,863     213,108,567        316,729,745        (7,640,554
  
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS
   $ 398,492,584     $ 774,667,072      $ 1,629,641,567      $ 688,463,885  
  
 
 
   
 
 
    
 
 
    
 
 
 
Net asset value
(f)(g)(h)
   $ 14.21     $ 17.55      $ 8.74      $ 10.97  
  
 
 
   
 
 
    
 
 
    
 
 
 
(a)
  Consolidated Statement of Assets and Liabilities.
          
(b)
  Investments, at cost — unaffiliated
   $ 255,848,980     $ 579,756,295      $ 1,347,790,184      $ 647,598,133  
(c)  
Investments, at cost — affiliated
   $ 7,695,475     $ 14,661,156      $ 76,042,437      $ 6,643,752  
(d)
  Foreign currency, at cost
   $ 58,416     $      $ 1,073      $ 73,402  
(e)
  Premiums received
   $ 4,901,028     $ 13,089,762      $ 21,781,553      $ 7,666,872  
(f)  
Shares outstanding
     28,052,743       44,132,101        186,416,092        62,739,814  
(g)
  Shares authorized
     Unlimited       200 million        Unlimited        Unlimited  
(h)
  Par value
   $ 0.001     $ 0.10      $ 0.001      $ 0.001  
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  135

 
Statements of Assets and Liabilities 
 (continued)
December 31, 2022
 
     BGY      BME     BMEZ     BIGZ  
ASSETS
        
Investments, at value — unaffiliated
(a)(b)
  $ 586,994,754      $ 579,808,524     $ 1,980,162,391     $ 2,031,517,499  
Investments, at value — affiliated
(c)
    5,622,321        23,871,295       99,648,265       20,963,228  
Cash pledged:
        
Collateral — exchange-traded options written
    5,611,000                     
Collateral — OTC derivatives
    215,000              36,000        
Foreign currency, at value
(d)
    582,896        3,118       115       335  
Receivables:
        
Investments sold
           1,767,716
(e)
 
          3,951,773  
Securities lending income — affiliated
           4,456       41,826       7,588  
Dividends — unaffiliated
    1,287,381        524,290       795,323       207,997  
Dividends — affiliated
    15,872        72,051       173,155       17,561  
Unrealized appreciation on forward foreign currency exchange contracts
                 4,964,555        
Deferred offering costs
           78,174              
 
 
 
    
 
 
   
 
 
   
 
 
 
Total assets
    600,329,224        606,129,624       2,085,821,630       2,056,665,981  
 
 
 
    
 
 
   
 
 
   
 
 
 
LIABILITIES
        
Bank overdraft
           2,920       95,313        
Collateral on securities loaned
           675,895       1,829,994       184,600  
Options written, at value
(f)
    4,476,797        4,323,328       18,495,960       6,641,472  
Payables:
        
Investments purchased
    869,786        233,198       363,210       15,319,909  
Accounting services fees
    15,658        9,014       75,138       79,600  
Capital shares redeemed
                 3,119,297       2,586,997  
Custodian fees
    42,921        16,741       118,346       28,112  
Deferred foreign capital gain tax
    72,727                     
Income dividend distributions
    162,648              2,537,359       2,398,238  
Investment advisory fees
    508,409        511,348       2,210,943       2,208,435  
Offering costs
           497              
Trustees’ and Officer’s fees
    548,110        23,337       142,641       112,018  
Other accrued expenses
    28,865        38,539       195,311       334,700  
Professional fees
    104,086        75,675       166,873       205,198  
Transfer agent fees
    27,842        22,219       52,525       78,788  
 
 
 
    
 
 
   
 
 
   
 
 
 
Total liabilities
    6,857,849        5,932,711       29,402,910       30,178,067  
 
 
 
    
 
 
   
 
 
   
 
 
 
NET ASSETS
  $ 593,471,375      $ 600,196,913     $ 2,056,418,720     $ 2,026,487,914  
 
 
 
    
 
 
   
 
 
   
 
 
 
NET ASSETS CONSIST OF
        
Paid-in capital
(g)(h)(i)
  $ 577,012,028      $ 424,300,067     $ 2,177,742,368     $ 4,251,072,029  
Accumulated earnings (loss)
    16,459,347        175,896,846       (121,323,648     (2,224,584,115
 
 
 
    
 
 
   
 
 
   
 
 
 
NET ASSETS
  $ 593,471,375      $ 600,196,913     $ 2,056,418,720     $ 2,026,487,914  
 
 
 
    
 
 
   
 
 
   
 
 
 
Net asset value
(g)(h)(i)
  $ 5.78      $ 43.30     $ 18.76     $ 8.82  
 
 
 
    
 
 
   
 
 
   
 
 
 
(a)
  Investments, at cost — unaffiliated
  $ 533,942,385      $ 395,108,410     $ 2,041,181,365     $ 2,750,952,289  
(b)
  Securities loaned, at value
  $      $ 658,422     $ 1,668,909     $ 180,198  
(c)  
Investments, at cost — affiliated
  $ 5,622,321      $ 23,871,030     $ 99,797,748     $ 20,963,228  
(d)
  Foreign currency, at cost
  $ 581,095      $ 3,087     $ 115     $ 343  
(e)
  $866,058 is expected to be collected after 12/31/23.
        
(f)  
Premiums received
  $ 5,783,243      $ 6,502,317     $ 20,871,623     $ 12,213,208  
(g)
  Shares outstanding
    102,745,640        13,860,528       109,597,089       229,666,091  
(h)
  Shares authorized
    Unlimited        Unlimited       Unlimited       Unlimited  
(i)  
Par value
  $ 0.001      $ 0.001     $ 0.001     $ 0.001  
See notes to financial statements.
 
 
136
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Assets and Liabilities 
 (continued)
December 31, 2022
 
     BCX     BST
(a)
     BSTZ
(a)
     BUI  
ASSETS
         
Investments, at value — unaffiliated
(b)(c)
  $ 965,979,491     $ 957,604,575      $ 1,513,242,027      $ 489,891,283  
Investments, at value — affiliated
(d)
    19,404,102       6,604,526        20,683,361        11,267,378  
Cash
                 49,275        2,843  
Cash pledged as collateral for OTC derivatives
    30,000       1,040,000        3,050,000        193,500  
Foreign currency, at value
(e)
    39,403       95,178        1,329,554         
Receivables:
         
Investments sold
    5,077,119       1,060,634        2,644,594         
Securities lending income — affiliated
          1,274               2,132  
Dividends — unaffiliated
    1,601,974       373,716        245,928        1,006,579  
Dividends — affiliated
    77,744       33,862        58,513        38,755  
Due from broker
          1,520,000        3,670,000         
Deferred offering costs
          205,375               103,337  
Other assets
                 680,607         
 
 
 
   
 
 
    
 
 
    
 
 
 
Total assets
    992,209,833       968,539,140        1,545,653,859        502,505,807  
 
 
 
   
 
 
    
 
 
    
 
 
 
LIABILITIES
         
Bank overdraft
    117,583       88,084                
Collateral on securities loaned
          824,856               225,051  
Options written, at value
(f)
    6,601,706       4,275,777        8,555,152        3,071,338  
Payables:
         
Investments purchased
    5,541       552,532        2,145,130         
Accounting services fees
    19,685       16,333        67,706        16,333  
Capital shares redeemed
    704,375              1,940,440         
Custodian fees
    26,312       37,451        62,504        26,187  
Deferred capital gain tax
          113,475        3,459,300         
Income dividend distributions
    167,979       575,826        2,324,974        150,324  
Investment advisory fees
    837,685       845,931        1,682,087        428,210  
Offering costs
          129,910                
Trustees’ and Officer’s fees
    253,019       2,986        145,549        446  
Other accrued expenses
    119,339       150,453        183,351        110,489  
Professional fees
    133,204       175,197        375,357        62,998  
Transfer agent fees
    42,365       47,128        54,672        21,465  
 
 
 
   
 
 
    
 
 
    
 
 
 
Total liabilities
    9,028,793       7,835,939        20,996,222        4,112,841  
 
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS
  $ 983,181,040     $ 960,703,201      $ 1,524,657,637      $ 498,392,966  
 
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS CONSIST OF
         
Paid-in capital
(g)(h)(i)
  $ 1,076,105,039     $ 789,748,815      $ 1,372,362,474      $ 383,506,624  
Accumulated earnings (loss)
    (92,923,999     170,954,386        152,295,163        114,886,342  
 
 
 
   
 
 
    
 
 
    
 
 
 
NET ASSETS
  $ 983,181,040     $ 960,703,201      $ 1,524,657,637      $ 498,392,966  
 
 
 
   
 
 
    
 
 
    
 
 
 
Net asset value
(g)(h)(i)
  $ 11.23     $ 29.11      $ 19.53      $ 22.37  
 
 
 
   
 
 
    
 
 
    
 
 
 
(a)
  Consolidated Statement of Assets and Liabilities.
         
(b)
  Investments, at cost — unaffiliated
  $ 782,768,496     $ 777,211,187      $ 1,332,835,743      $ 349,887,670  
(c)  
Securities loaned, at value
  $     $ 808,350      $      $ 203,256  
(d)
  Investments, at cost — affiliated
  $ 19,404,102     $ 6,604,446      $ 20,683,361      $ 11,267,256  
(e)
  Foreign currency, at cost
  $ 39,392     $ 94,341      $ 1,329,482      $  
(f)  
Premiums received
  $ 10,076,296     $ 11,681,013      $ 18,258,347      $ 4,592,709  
(g)
  Shares outstanding
    87,518,484       33,000,007        78,076,748        22,275,455  
(h)
  Shares authorized
    Unlimited       Unlimited        Unlimited        Unlimited  
(i)  
Par value
  $ 0.001     $ 0.001      $ 0.001      $ 0.001  
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  137

 
Statements of Operations 
 
Year Ended December 31, 2022
 
    BGR     CII     BDJ
(a)
    BOE  
 
 
INVESTMENT INCOME
       
Dividends — unaffiliated
  $ 16,734,616     $ 10,149,979     $ 44,652,454     $ 20,156,768  
Dividends — affiliated
    93,963       382,413       1,115,866       98,337  
Securities lending income — affiliated — net
                33        
Other income — unaffiliated
                      5,863  
Foreign taxes withheld
    (845,417     (139,951     (879,809     (1,270,497
Foreign withholding tax claims
                      336,828  
 
 
 
   
 
 
   
 
 
   
 
 
 
Total investment income
    15,983,162       10,392,441       44,888,544       19,327,299  
 
 
 
   
 
 
   
 
 
   
 
 
 
EXPENSES
       
Investment advisory
    4,507,105       7,332,546       14,211,974       7,403,203  
Transfer agent
    66,889       84,635       158,936       92,440  
Professional
    63,055       76,141       177,794       136,391  
Custodian
    51,756       34,621       139,878       121,127  
Accounting services
    44,041       49,002       94,043       59,029  
Printing and postage
    12,153       41,644       37,848       13,134  
Registration
    9,322       14,523       35,681       20,496  
Trustees and Officer
    (51,222     20,960       (49,719     (44,105
Miscellaneous
    38,753       52,835       86,345       64,413  
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses
    4,741,852       7,706,907       14,892,780       7,866,128  
Less:
       
Fees waived and/or reimbursed by the Manager
    (829,729     (11,312     (42,252     (1,299,298
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    3,912,123       7,695,595       14,850,528       6,566,830  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    12,071,039       2,696,846       30,038,016       12,760,469  
 
 
 
   
 
 
   
 
 
   
 
 
 
REALIZED AND UNREALIZED GAIN (LOSS)
       
Net realized gain (loss) from:
       
Investments — unaffiliated
    55,235,038       75,075,636       132,804,361       170,743  
Investments — affiliated
                (3      
Foreign currency transactions
    (2,824           (102,164     (100,543
Options written
    (20,422,274     25,137,981       14,771,308       15,583,351  
Payment by affiliate
                1,577        
 
 
 
   
 
 
   
 
 
   
 
 
 
    34,809,940       100,213,617       147,475,079       15,653,551  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized appreciation (depreciation) on:
       
Investments — unaffiliated
    65,813,352       (217,026,742     (259,950,835     (142,053,982
Foreign currency translations
    (11,115           (41,058     (50,071
Options written
    1,104,316       5,998,603       9,784,869       5,008,021  
 
 
 
   
 
 
   
 
 
   
 
 
 
    66,906,553       (211,028,139     (250,207,024     (137,096,032
 
 
 
   
 
 
   
 
 
   
 
 
 
Net realized and unrealized gain (loss)
    101,716,493       (110,814,522     (102,731,945     (121,442,481
 
 
 
   
 
 
   
 
 
   
 
 
 
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS
  $ 113,787,532     $ (108,117,676)     $ (72,693,929)     $ (108,682,012)  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Statement of Operations.
See notes to financial statements.
 
 
138
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Operations 
 (continued)
Year Ended December 31, 2022
 
    BGY     BME     BMEZ     BIGZ  
 
 
INVESTMENT INCOME
       
Dividends — unaffiliated
  $ 17,994,089     $ 7,351,097     $ 8,219,564     $ 2,823,086  
Dividends — affiliated
    86,543       432,499       904,054       587,413  
Securities lending income — affiliated — net
          29,546       321,733       80,749  
Other income — affiliated
                      59,874  
Foreign taxes withheld
    (1,742,615     (82,026     (251,775     (41,997
Foreign withholding tax claims
    521,921                    
 
 
 
   
 
 
   
 
 
   
 
 
 
Total investment income
    16,859,938       7,731,116       9,193,576       3,509,125  
 
 
 
   
 
 
   
 
 
   
 
 
 
EXPENSES
       
Investment advisory
    6,137,818       5,773,456       28,100,882       32,019,302  
Professional
    149,514       84,456       360,321       971,990  
Custodian
    134,632       44,058       262,427       126,553  
Transfer agent
    84,174       73,452       151,754       170,347  
Accounting services
    49,002       29,041       225,422       242,519  
Registration
    33,714       9,709       76,366       143,713  
Printing and postage
    12,532       13,426       11,926       31,434  
Offering
          85,598              
Trustees and Officer
    (36,676     26,244       104,739       136,717  
Miscellaneous
    54,280       69,632       361,614       955,521  
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses
    6,618,990       6,209,072       29,655,451       34,798,096  
Less:
       
Fees waived and/or reimbursed by the Manager
    (277,885     (17,512     (40,928     (17,488
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    6,341,105       6,191,560       29,614,523       34,780,608  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income (loss)
    10,518,833       1,539,556       (20,420,947     (31,271,483
 
 
 
   
 
 
   
 
 
   
 
 
 
REALIZED AND UNREALIZED GAIN (LOSS)
       
Net realized gain (loss) from:
       
Investments — unaffiliated
    3,131,399       9,471,828       (66,376,065     (1,291,605,168
Investments — affiliated
          (349     483,881       (71,424,676
Foreign currency transactions
    (23,314     3,821       (145,670     5,208  
Options written
    11,872,703       4,201,095       39,793,747       46,651,673  
 
 
 
   
 
 
   
 
 
   
 
 
 
    14,980,788       13,676,395       (26,244,107     (1,316,372,963
 
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized appreciation (depreciation) on:
       
Investments — unaffiliated
    (95,620,378 )
(a)
 
    (47,585,119     (644,970,858     (352,317,460
Investments — affiliated
          273       (70,513     44,486,400  
Forward foreign currency exchange contracts
                4,964,555        
Foreign currency translations
    (67,157     (16,140     (22,190     3,095  
Options written
    3,532,841       5,913,956       4,045,807       (842,713
 
 
 
   
 
 
   
 
 
   
 
 
 
    (92,154,694     (41,687,030     (636,053,199     (308,670,678
 
 
 
   
 
 
   
 
 
   
 
 
 
Net realized and unrealized loss
    (77,173,906     (28,010,635     (662,297,306     (1,625,043,641
 
 
 
   
 
 
   
 
 
   
 
 
 
NET DECREASE IN NET ASSETS RESULTING FROM OPERATIONS
  $ (66,655,073   $ (26,471,079   $ (682,718,253   $ (1,656,315,124
 
 
 
   
 
 
   
 
 
   
 
 
 
(a)
Net of reduction in deferred foreign capital gain tax of
  $ 158,644     $     $     $  
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  139

 
Statements of Operations 
 (continued)
Year Ended December 31, 2022
 
    BCX     BST
(a)
    BSTZ
(a)
    BUI  
 
 
INVESTMENT INCOME
       
Dividends — unaffiliated
  $ 38,003,639     $ 3,859,416     $ 3,048,647     $ 12,482,930  
Dividends — affiliated
    352,525       325,571       496,490       204,577  
Interest — unaffiliated
    32,648                    
Securities lending income — affiliated — net
    952       41,308       196,790       9,618  
Non-cash dividends — unaffiliated
                      752,590  
Foreign taxes withheld
    (2,229,606     (100,270     (273,088     (688,121
Foreign withholding tax claims
    16,193                    
 
 
 
   
 
 
   
 
 
   
 
 
 
Total investment income
    36,176,351       4,126,025       3,468,839       12,761,594  
 
 
 
   
 
 
   
 
 
   
 
 
 
EXPENSES
       
Investment advisory
    9,567,302       12,069,224       25,278,959       5,074,517  
Transfer agent
    122,536       147,760       161,801       70,520  
Professional
    91,540       307,458       386,876       66,431  
Custodian
    87,027       106,132       188,842       75,961  
Accounting services
    59,025       49,002       214,584       49,002  
Registration
    28,055       18,439       26,609       21,398  
Trustees and Officer
    15,882       62,000       96,317       27,429  
Printing and postage
    12,476       15,077       16,658       11,533  
Offering
          177,517             3,295  
Miscellaneous
    83,794       410,385       500,667       73,112  
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses excluding dividend expense
    10,067,637       13,362,994       26,871,313       5,473,198  
Dividends expense — unaffiliated
          51,803              
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses
    10,067,637       13,414,797       26,871,313       5,473,198  
Less:
       
Fees waived and/or reimbursed by the Manager
    (13,661     (16,683     (24,991     (7,348
 
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    10,053,976       13,398,114       26,846,322       5,465,850  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income (loss)
    26,122,375       (9,272,089     (23,377,483     7,295,744  
 
 
 
   
 
 
   
 
 
   
 
 
 
REALIZED AND UNREALIZED GAIN (LOSS)
       
Net realized gain (loss) from:
       
Investments — unaffiliated
    202,085,395       (5,496,390     16,559,151       4,559,420  
Investments — affiliated
    330       (207     744       87  
Foreign currency transactions
    (209,486     (86,899     (256,938     (104,574
Options written
    (36,914,355     56,941,702       100,510,091       2,970,321  
Payment by affiliate
          21,599              
 
 
 
   
 
 
   
 
 
   
 
 
 
    164,961,884       51,379,805       116,813,048       7,425,254  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized appreciation (depreciation) on:
       
Investments — unaffiliated
    (58,393,369     (698,498,339 )
(b)
 
    (1,432,164,711 )
(b)
 
    (61,954,416
Investments — affiliated
          80             122  
Foreign currency translations
    (29,774     (103     (6,119     (21,429
Options written
    4,849,639       1,620,333       2,676,552       2,726,906  
 
 
 
   
 
 
   
 
 
   
 
 
 
    (53,573,504     (696,878,029     (1,429,494,278     (59,248,817
 
 
 
   
 
 
   
 
 
   
 
 
 
Net realized and unrealized gain (loss)
    111,388,380       (645,498,224     (1,312,681,230     (51,823,563
 
 
 
   
 
 
   
 
 
   
 
 
 
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS
  $  137,510,755     $ (654,770,313   $ (1,336,058,713   $ (44,527,819
 
 
 
   
 
 
   
 
 
   
 
 
 
(a)
Consolidated Statement of Operations.
       
(b)
Net of reduction in deferred capital gain tax of
  $     $ 1,327,759     $ 2,010,922     $  
See notes to financial statements.
 
 
140
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Changes in Net Assets
 
    BGR     CII  
 
 
 
   
 
 
 
    Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/22
    Year Ended
12/31/21
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment income
  $ 12,071,039     $ 8,259,703     $ 2,696,846     $ 1,953,464  
Net realized gain (loss)
    34,809,940       (18,995,472     100,213,617       70,684,499  
Net change in unrealized appreciation (depreciation)
    66,906,553       99,469,573       (211,028,139     107,574,675  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets resulting from operations
    113,787,532       88,733,804       (108,117,676     180,212,638  
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(a)
       
From net investment income and net realized gain
    (11,890,970     (8,262,936     (92,693,757     (48,643,844
Return of capital
    (4,610,793     (4,835,876            
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (16,501,763     (13,098,812     (92,693,757     (48,643,844
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Reinvestment of distributions
                      236,509  
Redemption of shares resulting from share repurchase program (including transaction costs)
    (12,296,655                  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    (12,296,655                 236,509  
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    84,989,114       75,634,992       (200,811,433     131,805,303  
Beginning of year
    313,503,470       237,868,478       975,478,505       843,673,202  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of year
  $ 398,492,584     $ 313,503,470     $ 774,667,072     $ 975,478,505  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  141

 
Statements of Changes in Net Assets 
(continued)
 
    BDJ     BOE  
 
 
 
   
 
 
 
   
Year Ended
12/31/22
(a)
 
 
   
Year Ended
12/31/21
 
 
   
Year Ended
12/31/22
 
 
   
Year Ended
12/31/21
 
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment income
  $ 30,038,016     $ 27,412,185     $ 12,760,469     $ 12,147,742  
Net realized gain
    147,475,079       226,450,882       15,653,551       64,174,290  
Net change in unrealized appreciation (depreciation)
    (250,207,024     71,456,248       (137,096,032     43,778,131  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets resulting from operations
    (72,693,929     325,319,315       (108,682,012     120,100,163  
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(b)
       
From net investment income and net realized gain
    (204,152,869     (161,603,504     (38,142,002     (48,404,308
Return of capital
                (9,962,064      
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (204,152,869     (161,603,504     (48,104,066     (48,404,308
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Reinvestment of distributions
    3,650,249                    
Redemption of shares resulting from share repurchase program (including transaction costs)
                (12,470,648     (205,246
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    3,650,249             (12,470,648     (205,246
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    (273,196,549     163,715,811       (169,256,726     71,490,609  
Beginning of year
    1,902,838,116       1,739,122,305       857,720,611       786,230,002  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of year
  $ 1,629,641,567     $ 1,902,838,116     $ 688,463,885     $ 857,720,611  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Statement of Changes in Net Assets.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
142
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Changes in Net Assets 
(continued)
 
    BGY     BME  
 
 
 
   
 
 
 
    Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/22
    Year Ended
12/31/21
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment income
  $ 10,518,833     $ 9,366,746     $ 1,539,556     $ 41,823  
Net realized gain
    14,980,788       45,489,816       13,676,395       46,771,259  
Net change in unrealized appreciation (depreciation)
    (92,154,694     19,983,472       (41,687,030     12,306,248  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets resulting from operations
    (66,655,073     74,840,034       (26,471,079     59,119,330  
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(a)
       
From net investment income and net realized gain
    (20,170,266     (30,180,220     (32,998,527     (30,764,942
Return of capital
    (21,930,456     (12,098,701     (1,403,564      
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (42,100,722     (42,278,921     (34,402,091     (30,764,942
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Net proceeds from the issuance of shares
                33,618,939       49,710,285  
Reinvestment of distributions
                1,676,333       1,760,978  
Redemption of shares resulting from share repurchase program (including transaction costs)
    (7,282,700                  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    (7,282,700           35,295,272       51,471,263  
 
 
 
   
 
 
   
 
 
   
 
 
 
Capital contribution from affiliate
                      12,661  
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    (116,038,495)       32,561,113       (25,577,898     79,838,312  
Beginning of year
    709,509,870       676,948,757       625,774,811       545,936,499  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of year
  $ 593,471,375     $ 709,509,870     $ 600,196,913     $ 625,774,811  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  143

 
Statements of Changes in Net Assets 
(continued)
 
    BMEZ     BIGZ  
 
 
 
   
 
 
 
   
Year Ended
12/31/22
 
 
   
Year Ended
12/31/21
 
 
   
Year Ended
12/31/22
 
 
   
Period from
03/29/21
to 12/31/21
 
(a)
 
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment loss
  $ (20,420,947   $ (36,221,355   $ (31,271,483   $ (35,735,376
Net realized gain (loss)
    (26,244,107     370,126,396       (1,316,372,963     (199,723,871
Net change in unrealized appreciation (depreciation)
    (636,053,199     (621,751,428     (308,670,678     (405,188,632
 
 
 
   
 
 
   
 
 
   
 
 
 
Net decrease in net assets resulting from operations
    (682,718,253     (287,846,387     (1,656,315,124     (640,647,879
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(b)
       
From net realized gain
    (183,050,144     (192,905,388            
Return of capital
    (11,869,565           (233,929,900     (170,149,458
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (194,919,709     (192,905,388     (233,929,900     (170,149,458
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Net proceeds from the issuance of shares
                      4,861,848,440  
Reinvestment of distributions
                      4,569,561  
Redemption of shares resulting from share repurchase program (including transaction costs)
    (47,829,587           (64,919,571     (74,068,155
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    (47,829,587           (64,919,571     4,792,349,846  
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    (925,467,549     (480,751,775     (1,955,164,595)       3,981,552,509  
Beginning of period
    2,981,886,269       3,462,638,044       3,981,652,509       100,000  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of period
  $ 2,056,418,720     $ 2,981,886,269     $ 2,026,487,914     $ 3,981,652,509  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Commencement of operations.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
144
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Changes in Net Assets 
(continued)
 
    BCX     BST
(a)
 
 
 
 
   
 
 
 
    Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/22
    Year Ended
12/31/21
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment income (loss)
  $ 26,122,375     $ 25,955,087     $ (9,272,089   $ (12,070,576
Net realized gain
    164,961,884       56,049,452       51,379,805       148,321,617  
Net change in unrealized appreciation (depreciation)
    (53,573,504     115,553,664       (696,878,029     (287,749
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets resulting from operations
    137,510,755       197,558,203       (654,770,313     135,963,292  
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(b)
       
From net investment income and net realized gain
    (26,024,883     (33,607,537     (69,684,200     (126,451,369
Return of capital
    (22,531,891     (8,784,140     (27,306,002      
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (48,556,774     (42,391,677     (96,990,202     (126,451,369
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Net proceeds from the issuance of shares
                28,525,537       12,814,651  
Proceeds from rights offering (Note 10)
                      359,278,213  
Reinvestment of distributions
                2,771,741       2,217,548  
Redemption of shares resulting from share repurchase program (including transaction costs)
    (7,554,830                  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    (7,554,830           31,297,278       374,310,412  
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    81,399,151       155,166,526       (720,463,237     383,822,335  
Beginning of year
    901,781,889       746,615,363       1,681,166,438       1,297,344,103  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of year
  $ 983,181,040     $ 901,781,889     $ 960,703,201     $ 1,681,166,438  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Statement of Changes in Net Assets.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  145

 
Statements of Changes in Net Assets 
(continued)
 
    BSTZ
(a)
    BUI  
 
 
 
   
 
 
 
    Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/22
    Year Ended
12/31/21
 
 
 
INCREASE (DECREASE) IN NET ASSETS
       
OPERATIONS
       
Net investment income (loss)
  $ (23,377,483   $ (40,100,308   $ 7,295,744     $ 4,908,839  
Net realized gain
    116,813,048       258,715,033       7,425,254       10,994,095  
Net change in unrealized appreciation (depreciation)
    (1,429,494,278)       29,935,008       (59,248,817     53,132,360  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets resulting from operations
    (1,336,058,713     248,549,733       (44,527,819     69,035,294  
 
 
 
   
 
 
   
 
 
   
 
 
 
DISTRIBUTIONS TO SHAREHOLDERS
(b)
       
From net investment income and net realized gain
    (70,402,537     (240,726,364     (18,983,124     (20,325,579
Return of capital
    (110,549,120           (13,135,583     (9,081,858
 
 
 
   
 
 
   
 
 
   
 
 
 
Decrease in net assets resulting from distributions to shareholders
    (180,951,657     (240,726,364     (32,118,707     (29,407,437
 
 
 
   
 
 
   
 
 
   
 
 
 
CAPITAL SHARE TRANSACTIONS
       
Net proceeds from the issuance of shares
                14,467,890       74,073,395  
Reinvestment of distributions
          17,394,255       766,909       1,577,468  
Redemption of shares resulting from a repurchase offer
    (7,293,625                  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in net assets derived from capital share transactions
    (7,293,625     17,394,255       15,234,799       75,650,863  
 
 
 
   
 
 
   
 
 
   
 
 
 
NET ASSETS
       
Total increase (decrease) in net assets
    (1,524,303,995     25,217,624       (61,411,727     115,278,720  
Beginning of year
    3,048,961,632       3,023,744,008       559,804,693       444,525,973  
 
 
 
   
 
 
   
 
 
   
 
 
 
End of year
  $ 1,524,657,637     $ 3,048,961,632     $ 498,392,966     $ 559,804,693  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Statement of Changes in Net Assets.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
See notes to financial statements.
 
 
146
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Cash Flows
Year Ended December 31, 2022
 
    BGR     CII     BDJ     BOE  
 
 
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
       
Net increase (decrease) in net assets resulting from operations
  $ 113,787,532     $  (108,117,676   $ (72,693,929   $  (108,682,012
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:
       
Proceeds from sales of long-term investments
    325,309,434       342,647,461       1,588,893,057       365,651,353  
Purchases of long-term investments
     (285,311,271     (277,914,860      (1,417,153,439     (337,559,113
Net proceeds from sales (purchases) of short-term securities
    (4,970,196     (4,363,404     (13,780,425     4,618,842  
Premiums paid on closing options written
    (61,922,808     (77,490,845     (179,902,060     (47,018,389
Premiums received from options written
    43,153,217       104,976,111       194,345,118       62,090,628  
Net realized gain on investments and options written
    (34,468,218     (100,210,858     (147,546,256     (15,741,524
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations
    (66,917,668     211,028,139       250,165,966       137,057,509  
(Increase) Decrease in Assets
       
Receivables
       
Dividends — affiliated
    (23,833     (86,492     (322,428     (26,637
Dividends — unaffiliated
    (121,746     (81,628     (157,587     (126,579
Increase (Decrease) in Liabilities
       
Payables
       
Accounting services fees
    3,685       3,388       7,178       4,248  
Custodian fees
    6,540       1,152       7,980       14,400  
Investment advisory fees
    70,686       (111,989     (147,434     (99,308
Trustees’ and Officer’s fees
    (200,419     (79,245     (398,560     (251,989
Other accrued expenses
    1,826       26,681       (13,743     (17,935
Professional fees
    1,807       (2,769     (23,838     4,168  
Transfer agent fees
    10,927       13,529       26,720       13,315  
Other liabilities
                666,808        
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash provided by operating activities
    28,409,495       90,236,695       201,973,128       59,930,977  
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
       
Cash dividends paid to shareholders
    (16,468,172     (90,594,433     (202,441,343     (48,110,253
Net payments on redemption of capital shares including change in redemptions payable
    (12,036,818                 (12,138,249
Increase in bank overdraft
    83,281       24,238              
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash used for financing activities
    (28,421,709     (90,570,195     (202,441,343     (60,248,502
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
       
Cash impact from foreign exchange fluctuations
    (280           (64     152  
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH AND FOREIGN CURRENCY
       
Net decrease in restricted and unrestricted cash and foreign currency
    (12,494     (333,500     (468,279     (317,373
Restricted and unrestricted cash and foreign currency at beginning of year
    70,919       333,500       597,932       5,270,925  
 
 
 
   
 
 
   
 
 
   
 
 
 
Restricted and unrestricted cash and foreign currency at end of year
  $ 58,425     $     $ 129,653     $ 4,953,552  
 
 
 
   
 
 
   
 
 
   
 
 
 
NON-CASH FINANCING ACTIVITIES
       
Reinvestment of distributions
  $     $     $ 3,650,249     $  
 
 
 
   
 
 
   
 
 
   
 
 
 
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
       
Cash
  $     $     $ 128,711     $  
Cash pledged
       
Collateral — exchange-traded options written
                      4,880,000  
Foreign currency at value
    58,425             942       73,552  
 
 
 
   
 
 
   
 
 
   
 
 
 
  $ 58,425     $     $ 129,653     $ 4,953,552  
 
 
 
   
 
 
   
 
 
   
 
 
 
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  147

 
Statements of Cash Flows 
(continued)
Year Ended December 31, 2022
 
    BGY     BME     BMEZ     BIGZ  
 
 
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
       
Net decrease in net assets resulting from operations
  $ (66,655,073   $ (26,471,079   $ (682,718,253)     $ (1,656,315,124)  
Adjustments to reconcile net decrease in net assets resulting from operations to net cash provided by (used for)operating activities:
       
Proceeds from sales of long-term investments
    290,508,247       232,461,355       1,658,616,242       1,380,127,625  
Purchases of long-term investments
     (261,291,269      (244,080,755     (1,414,494,960     (1,059,753,342
Net proceeds from sales (purchases) of short-term securities
    (36,081     3,921,434       (18,274,580     (13,923,166
Premiums paid on closing options written
    (36,202,301     (41,916,239     (103,989,745     (50,101,160
Premiums received from options written
    47,715,959       46,833,298       143,401,073       91,745,469  
Net realized (gain) loss on investments and options written
    (14,991,894     (13,637,992     26,939,166       1,316,367,701  
Net unrealized depreciation on investments, options written and foreign currency translations
    92,246,181       41,690,851       636,031,009       308,673,773  
(Increase) Decrease in Assets
       
Receivables
       
Dividends — affiliated
    (15,831     (71,906     (173,002     (17,539
Dividends — unaffiliated
    251,231       (84,643     (36,143     251,719  
From the Manager
          12,661              
Securities lending income — affiliated
          (2,998     (25,260     (5,194
Prepaid expenses
                48,373       89,817  
Deferred offering costs
          13,327              
Increase (Decrease) in Liabilities
       
Collateral on securities loaned
          464,323       (3,110,643     (5,021,875
Payables
       
Accounting services fees
    3,388       1,760       (28,088     (60,507
Custodian fees
    12,865       (4,104     29,004       (42,550
Deferred foreign capital gain tax
    (158,644                  
Federal income tax
          (12,114            
Investment advisory fees
    (20,731     (4,704     (887,725     (2,064,804
Trustees’ and Officer’s fees
    (214,002     (8,340     12,803       52,423  
Other accrued expenses
    (23,021     3,802       (4,981     287,791  
Professional fees
    (4,106     6,259       132,176       193,717  
Transfer agent fees
    11,536       11,759       31,863       (3,348
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash provided by (used for) operating activities
    51,136,454       (874,045     241,498,329       310,481,426  
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
       
Cash dividends paid to shareholders
    (42,100,118     (32,725,758     (197,003,104     (235,846,053
Payments for offering costs
          (19,930            
Net payments on redemption of capital shares including change in redemptions payable
    (7,282,700           (44,710,290     (74,526,346
Increase (decrease) in bank overdraft
          2,920       95,313       (139,778
Proceeds from issuance of capital shares
          33,618,939              
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash provided by (used for) for financing activities
    (49,382,818     876,171        (241,618,081      (310,512,177
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
       
Cash impact from foreign exchange fluctuations
    1,428       32       (16     (15
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH AND FOREIGN CURRENCY
       
Net increase (decrease) in restricted and unrestricted cash and foreign currency
    1,755,064       2,158       (119,768     (30,766
Restricted and unrestricted cash and foreign currency at beginning of year
    4,653,832       960       155,883       31,101  
 
 
 
   
 
 
   
 
 
   
 
 
 
Restricted and unrestricted cash and foreign currency at end of year
  $ 6,408,896     $ 3,118     $ 36,115     $ 335  
 
 
 
   
 
 
   
 
 
   
 
 
 
NON-CASH FINANCING ACTIVITIES
       
Reinvestment of distributions
  $     $ 1,676,333     $     $  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
 
148
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Cash Flows 
(continued)
Year Ended December 31, 2022
 
    BGY      BME      BMEZ      BIGZ  
 
 
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
          
Cash pledged
          
Collateral — exchange-traded options written
  $ 5,611,000      $      $      $  
Collateral — OTC derivatives
    215,000               36,000         
Foreign currency at value
    582,896        3,118        115        335  
 
 
 
    
 
 
    
 
 
    
 
 
 
  $     6,408,896      $         3,118      $       36,115      $           335  
 
 
 
    
 
 
    
 
 
    
 
 
 
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  149

 
Statements of Cash Flows 
(continued)
Year Ended December 31, 2022
 
     BCX     BST     BSTZ     BUI  
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
       
Net increase (decrease) in net assets resulting from operations
  $ 137,510,755     $ (654,770,313   $ (1,336,058,713   $ (44,527,819
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:
       
Proceeds from sales of long-term investments
    947,656,977       469,415,143       1,050,212,721       198,497,244  
Purchases of long-term investments
    (881,345,749     (480,827,332     (961,507,982     (189,027,519
Net proceeds from sales (purchases) of short-term securities
    (2,749,789     36,810,615       28,182,535       (3,886,421
Premiums paid on closing options written
    (119,211,767     (47,749,812     (74,369,503     (31,236,142
Premiums received from options written
    84,537,503       100,970,392       166,158,579       34,411,517  
Net realized gain on investments and options written
    (164,842,854     (50,486,558     (114,048,861     (7,771,710
Net unrealized depreciation on investments, options written and foreign currency translations
    53,543,730       698,205,891       1,431,499,081       59,227,388  
(Increase) Decrease in Assets
       
Receivables
       
Dividends — affiliated
    (77,679     (33,575     (58,065     (38,723
Dividends — unaffiliated
    97,368       (188,226     (25,565     (76,389
Securities lending income — affiliated
          40,659       6,433       (2,132
Prepaid expenses
          5,213              
Other assets
                (680,607      
Deferred offering costs
          (27,858           (87,669
Increase (Decrease) in Liabilities
       
Collateral on securities loaned
          (16,919     (1,949,206     225,051  
Payables
       
Accounting services fees
    4,919       4,063       (34,615     4,063  
Custodian fees
    8,411       (6,009     (5,210     10,119  
Deferred capital gain tax
          (1,327,759     (2,010,922      
Investment advisory fees
    93,885       (528,662     (1,575,846     (33,701
Trustees’ and Officer’s fees
    (107,553     (4,267     9,209       (1,624
Other accrued expenses
    (12,835     67,662       (135,190     25,291  
Professional fees
    13,283       91,843       167,252       (1,720
Transfer agent fees
    26,097       30,556       33,360       12,603  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash provided by operating activities
    55,144,702       69,674,747       183,808,885       15,721,707  
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
       
Cash dividends paid to shareholders
    (48,513,774     (97,668,781     (178,626,683     (31,201,474
Payments for offering costs
          125,910             (27,388
Net payments on redemption of capital shares including change in redemptions payable
    (6,850,455           (5,353,185      
Increase (decrease) in bank overdraft
    (68,354     88,084              
Proceeds from issuance of capital shares
          28,525,537             15,040,740  
 
 
 
   
 
 
   
 
 
   
 
 
 
Net cash used for financing activities
    (55,432,583     (68,929,250     (183,979,868     (16,188,122
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
       
Cash impact from foreign exchange fluctuations
    (561     865       43        
 
 
 
   
 
 
   
 
 
   
 
 
 
CASH AND FOREIGN CURRENCY
       
Net increase (decrease) in restricted and unrestricted cash and foreign currency
    (288,442     746,362       (170,940     (466,415
Restricted and unrestricted cash and foreign currency at beginning of year
    357,845       1,908,816       8,269,769       662,758  
 
 
 
   
 
 
   
 
 
   
 
 
 
Restricted and unrestricted cash and foreign currency at end of year
  $ 69,403     $ 2,655,178     $ 8,098,829     $ 196,343  
 
 
 
   
 
 
   
 
 
   
 
 
 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
       
Cash paid during the year for interest expense
  $     $ 51,803     $     $  
 
 
 
   
 
 
   
 
 
   
 
 
 
NON-CASH FINANCING ACTIVITIES
       
Reinvestment of distributions
  $     $ 2,771,741     $     $ 766,909  
 
 
 
   
 
 
   
 
 
   
 
 
 
 
 
150
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Statements of Cash Flows 
(continued)
Year Ended December 31, 2022
 
    BCX      BST      BSTZ      BUI  
 
 
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
          
Cash
  $      $      $ 49,275      $ 2,843  
Cash pledged
          
Collateral — OTC derivatives
    30,000        1,040,000        3,050,000        193,500  
Foreign currency at value
    39,403        95,178        1,329,554         
Due from broker
           1,520,000        3,670,000         
 
 
 
    
 
 
    
 
 
    
 
 
 
  $             69,403      $     2,655,178      $       8,098,829      $       196,343  
 
 
 
    
 
 
    
 
 
    
 
 
 
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  151

 
Financial Highlights
(For a share outstanding throughout each period)
 
    BGR  
     Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 10.77     $ 8.17     $ 12.57     $ 11.98     $ 15.79  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
    0.42       0.28       0.32       0.34       0.28  
Net realized and unrealized gain (loss)
    3.60       2.77       (4.06     1.18       (3.16
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    4.02       3.05       (3.74     1.52       (2.88
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
         
From net investment income
    (0.42     (0.28     (0.32     (0.34     (0.27
Return of capital
    (0.16     (0.17     (0.34     (0.59     (0.66
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (0.58     (0.45     (0.66     (0.93     (0.93
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 14.21     $ 10.77     $ 8.17     $ 12.57     $ 11.98  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 12.53     $ 9.48     $ 7.10     $ 11.88     $ 10.45  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(c)
         
Based on net asset value
    38.51     38.36 %
(d)
 
    (29.03 )%      13.74     (18.84 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    38.76     40.14     (34.74 )%      23.23     (21.16 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(e)
         
Total expenses
    1.26     1.33     1.37     1.35     1.29
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    1.04     1.11     1.15     1.16     1.14
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    3.21     2.88     3.77     2.67     1.87
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $ 398,493     $ 313,503     $ 237,868     $ 374,896     $ 357,391  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    76     61     62     24     32
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(d)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(e)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
152
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights
 
(continued)
(For a share outstanding throughout each period)
 
    CII  
     Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 22.10     $ 19.12     $ 17.96     $ 15.28     $ 17.19  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
    0.06       0.04       0.13       0.18       0.17  
Net realized and unrealized gain (loss)
    (2.51     4.04       2.08       3.50       (1.09
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (2.45     4.08       2.21       3.68       (0.92
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
         
From net investment income
    (0.04     (0.04     (0.13     (0.19     (0.17 )
(c)
 
From net realized gain
    (2.06     (1.06     (0.92     (0.44     (0.28 )
(c)
 
Return of capital
                      (0.37     (0.54
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (2.10     (1.10     (1.05     (1.00     (0.99
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 17.55     $ 22.10     $ 19.12     $ 17.96     $ 15.28  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 17.12     $ 22.12     $ 17.40     $ 17.25     $ 14.08  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(d)
         
Based on net asset value
    (10.95 )%      21.97     13.94     25.08     (5.44 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    (13.21 )%      34.15     7.97     30.38     (8.56 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(e)
         
Total expenses
    0.89     0.90     0.91     0.91     0.90
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    0.89     0.90     0.91     0.91     0.90
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    0.31     0.21     0.78     1.08     1.00
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $ 774,667     $ 975,479     $ 843,673     $ 792,638     $ 674,077  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    32     27     46     32     27
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(d)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(e)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  153

 
Financial Highlights
 (continued)
(For a share outstanding throughout each period)
 
    BDJ  
     Year Ended
12/31/22
(a)
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 10.23     $ 9.35     $ 10.03     $ 8.74     $ 9.96  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(b)
    0.16       0.15       0.18       0.18       0.18
(c)
 
Net realized and unrealized gain (loss)
    (0.56     1.60       (0.26     1.86       (0.84
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (0.40     1.75       (0.08     2.04       (0.66
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(d)
         
From net investment income
    (0.04     (0.28     (0.15     (0.08     (0.18 )
(e)
 
From net realized gain
    (1.05     (0.59     (0.45     (0.67     (0.38 )
(e)
 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (1.09     (0.87     (0.60     (0.75     (0.56
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 8.74     $ 10.23     $ 9.35     $ 10.03     $ 8.74  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 9.01     $ 10.08     $ 8.47     $ 9.92     $ 7.77  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(f)
         
Based on net asset value
    (3.71 )%
(g)
 
    19.33     0.77     24.52     (6.59 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    0.74     29.80     (7.70 )%      38.53     (10.39 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(h)
         
Total expenses
    0.84     0.85     0.86     0.87     0.85
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    0.84     0.85     0.86     0.87     0.85
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    1.69     1.44     2.15     1.99     1.85 %
(c)
 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $ 1,629,642     $ 1,902,838     $ 1,739,122     $ 1,881,675     $ 1,638,237  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    81     40     48     40     34
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Financial Highlights.
(b)
 
Based on average shares outstanding.
(c)
 
Net investment income per share and the ratio of net investment income to average net assets includes $0.01 per share and 0.14%, respectively, resulting from a special dividend.
(d)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(e)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(f)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(g)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(h)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
154
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights
 (continued)
(For a share outstanding throughout each period)
 
    BOE  
     Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 13.40     $ 12.28     $ 12.32     $ 11.07     $ 13.22  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
    0.20       0.19       0.26       0.30       0.31  
Net realized and unrealized gain (loss)
    (1.87     1.69       0.46       1.71       (1.61
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (1.67     1.88       0.72       2.01       (1.30
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
         
From net investment income
    (0.19     (0.19     (0.26     (0.31     (0.31 )
(c)
 
From net realized gain
    (0.41     (0.57                 (0.52 )
(c)
 
Return of capital
    (0.16           (0.50     (0.45     (0.02
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (0.76     (0.76     (0.76     (0.76     (0.85
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 10.97     $ 13.40     $ 12.28     $ 12.32     $ 11.07  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 9.56     $ 12.18     $ 10.91     $ 10.99     $ 9.37  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(d)
         
Based on net asset value
    (11.87 )%      16.21     7.65     19.54     (9.63 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    (15.51 )%      18.89     7.22     25.98     (19.16 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(e)
         
Total expenses
    1.06     1.07     1.09     1.12     1.08
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    0.89     0.90     0.92     0.94     0.94
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes
    0.88     0.90     0.92     0.94     0.94
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    1.72     1.46     2.33     2.62     2.52
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $ 688,464     $ 857,721     $ 786,230     $ 807,712     $ 754,602  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    44     65     61     26     28
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(d)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(e)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  155

 
Financial Highlights
 (continued)
(For a share outstanding throughout each period)
 
    BGY  
     Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 6.81     $ 6.49     $ 6.47     $ 5.79     $ 7.06  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
    0.10       0.09       0.12       0.16       0.17
(b)
 
Net realized and unrealized gain (loss)
    (0.72     0.64       0.31       0.93       (1.00
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (0.62     0.73       0.43       1.09       (0.83
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(c)
         
From net investment income
    (0.10     (0.14     (0.13     (0.16     (0.16 )
(d)
 
From net realized gain
    (0.10     (0.15           (0.19     (0.28 )
(d)
 
Return of capital
    (0.21     (0.12     (0.28     (0.06      
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (0.41     (0.41     (0.41     (0.41     (0.44
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 5.78     $ 6.81     $ 6.49     $ 6.47     $ 5.79  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 5.02     $ 6.28     $ 5.87     $ 5.89     $ 4.98  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(e)
         
Based on net asset value
    (8.33 )%      11.92     8.18     20.20     (11.48 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    (13.67 )%      14.11     7.49     27.22     (17.55 )% 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(f)
         
Total expenses
    1.08     1.09     1.10     1.13     1.09
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    1.03     0.99     1.00     1.03     0.99
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes
    1.02     0.99     1.00     1.03     0.99
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    1.71     1.34     1.99     2.57     2.59 %
(b)
 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $ 593,471     $ 709,510     $ 676,949     $ 683,247     $ 623,234  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    41     71     60     28     60
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Net investment income per share and the ratio of net investment income to average net assets includes $0.10 per share and 29%, respectively, resulting from a non-recurring dividend.
(c)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(d)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(e)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(f)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
156
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
    BME  
     Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
  $ 47.96     $ 45.66     $ 41.19     $ 35.87     $ 35.69  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
    0.11             0.01       0.06       0.07  
Net realized and unrealized gain (loss)
    (2.21     4.74       6.86       7.66       2.51  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (2.10     4.74       6.87       7.72       2.58  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
         
From net investment income
    (0.12     (0.00 )
(c)
 
    (0.05     (0.12     (0.07 )
(d)
 
From net realized gain
    (2.34     (2.44     (2.35     (2.28     (2.33 )
(d)
 
Return of capital
    (0.10                        
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
    (2.56     (2.44     (2.40     (2.40     (2.40
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
  $ 43.30     $ 47.96     $ 45.66     $ 41.19     $ 35.87  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
  $ 43.58     $ 48.50     $ 47.59     $ 42.50     $ 36.45  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(e)
         
Based on net asset value
    (4.19 )%      10.66 %
(f)
 
    17.50     22.26     7.26
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
    (4.64 )%      7.37     18.69     24.15     6.57
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(g)
         
Total expenses
    1.08     1.08     1.10     1.09     1.11
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    1.07     1.08     1.10     1.09     1.11
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
    0.27     0.01     0.01     0.16     0.19
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
         
Net assets, end of year (000)
  $  600,197     $  625,775     $  545,936     $  446,773     $  352,675  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    41     49     28     47     37
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Amount is greater than $(0.005) per share.
(d)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(e)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(f)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(g)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  157

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
    BMEZ  
 
   
Year Ended
12/31/22
 
 
   
Year Ended
12/31/21
 
 
   
Period from
01/30/20
to 12/31/20
 
(a)
 
 
       
Net asset value, beginning of period
  $ 26.47     $ 30.73     $ 20.00  
 
 
 
   
 
 
   
 
 
 
Net investment loss
(b)
    (0.18     (0.32     (0.22
Net realized and unrealized gain (loss)
    (5.79     (2.23     11.85  
 
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
    (5.97     (2.55     11.63  
 
 
 
   
 
 
   
 
 
 
Distributions
(c)
     
From net realized gain
    (1.63     (1.71     (0.90
Return of capital
    (0.11            
 
 
 
   
 
 
   
 
 
 
Total distributions
    (1.74     (1.71     (0.90
 
 
 
   
 
 
   
 
 
 
Net asset value, end of period
  $ 18.76     $ 26.47     $ 30.73  
 
 
 
   
 
 
   
 
 
 
Market price, end of period
  $ 15.43     $ 25.36     $ 28.65  
 
 
 
   
 
 
   
 
 
 
Total Return
(d)
     
Based on net asset value
    (21.66 )%      (8.31 )%      59.62 %
(e)(f)
 
 
 
 
   
 
 
   
 
 
 
Based on market price
    (32.75 )%      (5.76 )%      48.82 %
(f)
 
 
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(g)
     
Total expenses
    1.32     1.30     1.29 %
(h)
 
 
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    1.32     1.30     1.28 %
(h)
 
 
 
 
   
 
 
   
 
 
 
Net investment loss
    (0.91 )%      (1.10 )%      (1.00 )%
(h)
 
 
 
 
   
 
 
   
 
 
 
Supplemental Data
     
Net assets, end of period (000)
  $  2,056,419     $  2,981,886     $  3,462,638  
 
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
    63     44     43
 
 
 
   
 
 
   
 
 
 
 
(a)
Commencement of operations.
(b)
 
Based on average shares outstanding.
(c)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(d)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(e)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(f)
 
Not annualized.
(g)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
(h)
 
Annualized.
See notes to financial statements.
 
 
158
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights
 (continued)
(For a share outstanding throughout each period)
 
    BIGZ  
     
Year Ended
12/31/22
 
 
   
Period from
03/29/21
to 12/31/21
 
(a)
 
 
     
Net asset value, beginning of period
  $ 16.72     $ 20.00  
 
 
 
   
 
 
 
Net investment loss
(b)
    (0.13     (0.15
Net realized and unrealized loss
    (6.78     (2.43
 
 
 
   
 
 
 
Net decrease from investment operations
    (6.91     (2.58
 
 
 
   
 
 
 
Distribution from return of capital
(c)
    (0.99     (0.70
 
 
 
   
 
 
 
Net asset value, end of period
  $ 8.82     $ 16.72  
 
 
 
   
 
 
 
Market price, end of period
  $ 6.81     $ 14.54  
 
 
 
   
 
 
 
Total Return
(d)
   
Based on net asset value
    (41.14 )%
(e)
 
    (13.03 )%
(f)
 
 
 
 
   
 
 
 
Based on market price
    (47.74 )%      (24.37 )%
(f)
 
 
 
 
   
 
 
 
Ratios to Average Net Assets
(g)
   
Total expenses
    1.36     1.29 %
(h)
 
 
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
    1.36     1.28 %
(h)
 
 
 
 
   
 
 
 
Net investment loss
    (1.22 )%      (1.02 )%
(h)
 
 
 
 
   
 
 
 
Supplemental Data
   
Net assets, end of period (000)
  $  2,026,488     $  3,981,653  
 
 
 
   
 
 
 
Portfolio turnover rate
    41     55
 
 
 
   
 
 
 
 
(a)
 
Commencement of operations.
(b)
 
Based on average shares outstanding.
(c)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(d)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(e)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(f)
 
Not annualized.
(g)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
(h)
 
Annualized.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  159

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
     BCX  
      Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
   $ 10.21     $ 8.45     $ 9.04     $ 8.44     $ 10.64  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
     0.30       0.29       0.20       0.23       0.22  
Net realized and unrealized gain (loss)
     1.27       1.95       (0.26     0.99       (1.80
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
     1.57       2.24       (0.06     1.22       (1.58
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
          
From net investment income
     (0.29     (0.38     (0.23     (0.23     (0.19
Return of capital
     (0.26     (0.10     (0.30     (0.39     (0.43
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
     (0.55     (0.48     (0.53     (0.62     (0.62
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
   $ 11.23     $ 10.21     $ 8.45     $ 9.04     $ 8.44  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
   $ 9.97     $ 9.35     $ 7.41     $ 8.07     $ 7.06  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(c)
          
Based on net asset value
     16.31     27.20     1.56     15.88     (14.90 )% 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
     12.76     32.83     (0.23 )%      23.67     (22.47 )% 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(d)
          
Total expenses
     1.05     1.07     1.09     1.11     1.08
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
     1.05     1.07     1.09     1.11     1.08
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes
     1.05     1.07     1.09     1.11     1.08
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
     2.73     3.05     2.62     2.56     2.17
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
          
Net assets, end of year (000)
   $  983,181     $  901,782     $  746,615     $  822,754     $  798,282  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
     92     66     78     69     66
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(d)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
160
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
     BST  
      
Year Ended
12/31/22
 
(a)
 
   
Year Ended
12/31/21
 
(a)
 
   
Year Ended
12/31/20
 
(a)
 
   
Year Ended
12/31/19
 
 
   
Year Ended
12/31/18
 
 
           
Net asset value, beginning of year
   $ 52.40     $ 51.94     $ 32.45     $ 26.21     $ 27.73  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment loss
(b)
     (0.29     (0.43     (0.28     (0.17     (0.13
Net realized and unrealized gain (loss)
     (20.00     5.84       21.82       9.92       0.37  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
     (20.29     5.41       21.54       9.75       0.24  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(c)
          
From net realized gain
     (2.16     (4.27     (2.05     (3.51     (1.76 )
(d)
 
Return of capital
     (0.84                        
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
     (3.00     (4.27     (2.05     (3.51     (1.76
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Dilutive effect of rights offer (Note 10)
           (0.68                  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
   $ 29.11     $ 52.40     $ 51.94     $ 32.45     $ 26.21  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
   $ 28.37     $ 49.97     $ 53.30     $ 33.27     $ 27.48  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(e)
          
Based on net asset value
     (39.56 )%
(f)
 
    9.44     68.76 %
(g)
 
    37.82     0.24
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
     (38.23 )%      1.70     68.92     34.77     9.18
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(h)
          
Total expenses
     1.11     1.05     1.09     1.08     1.09
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
     1.11     1.00     0.99     0.92     0.89
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed and excluding dividend expense
     1.10     1.00     0.99     0.92     0.89
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment loss
     (0.77 )%      (0.78 )%      (0.73 )%      (0.52 )%      (0.43 )% 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
          
Net assets, end of year (000)
   $  960,703     $  1,681,166     $  1,297,344     $  742,672     $  587,908  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
     38     31     20     32     53
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Financial Highlights.
(b)
 
Based on average shares outstanding.
(c)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(d)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(e)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(f)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(g)
 
For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (NAV) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020.
(h)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  161

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
     BSTZ  
 
    
Year Ended
12/31/22
 
(a)
 
   
Year Ended
12/31/21
 
(a)
 
   
Year Ended
12/31/20
 
(a)
 
   
Period from
06/27/19
to 12/31/19
 
(b)
 
 
         
Net asset value, beginning of period
   $ 38.82     $ 38.72     $ 20.95     $ 20.00  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net investment loss
(c)
     (0.30     (0.51     (0.30     (0.05
Net realized and unrealized gain (loss)
     (16.69     3.69       19.32       1.50  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
     (16.99     3.18       19.02       1.45  
  
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(d)
        
From net realized gain
     (0.89     (3.08     (1.10      
Return of capital
     (1.41           (0.15     (0.50
  
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
     (2.30     (3.08     (1.25     (0.50
  
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of period
   $ 19.53     $ 38.82     $ 38.72     $ 20.95  
  
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of period
   $ 15.64     $ 38.94     $ 36.38     $ 20.50  
  
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(e)
        
Based on net asset value
     (43.98 )%      8.41     94.60 %
(f)
 
    7.40 %
(g)
 
  
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
     (55.27 )%      15.75     86.85     5.10 %
(g)
 
  
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(h)
        
Total expenses
     1.33     1.31     1.33     1.32 %
(i)
 
  
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
     1.33     1.31     1.33     1.30 %
(i)
 
  
 
 
   
 
 
   
 
 
   
 
 
 
Net investment loss
     (1.16 )%      (1.25 )%      (1.16 )%      (0.48 )%
(i)
 
  
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
        
Net assets, end of period (000)
   $  1,524,658     $  3,048,962     $  3,023,744     $  1,635,966  
  
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
     47     18     45     16
  
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Consolidated Financial Highlights.
(b)
 
Commencement of operations.
(c)
 
Based on average shares outstanding.
(d)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(e)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(f)
 
Includes payment from an affiliate, which had no impact on the Trust’s total return.
(g)
 
Not annualized.
(h)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
(i)
 
Annualized.
See notes to financial statements.
 
 
162
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

 
Financial Highlights 
(continued)
(For a share outstanding throughout each period)
 
     BUI  
      Year Ended
12/31/22
    Year Ended
12/31/21
    Year Ended
12/31/20
    Year Ended
12/31/19
    Year Ended
12/31/18
 
           
Net asset value, beginning of year
   $ 25.86     $ 23.80     $ 22.02     $ 18.77     $ 21.12  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
(a)
     0.33       0.24       0.33       0.37       0.49  
Net realized and unrealized gain (loss)
     (2.37     3.27       2.90       4.33       (1.39
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) from investment operations
     (2.04     3.51       3.23       4.70       (0.90
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Distributions
(b)
          
From net investment income
     (0.30     (0.24     (0.20     (0.24     (0.63 )
(c)
 
From net realized gain
     (0.56     (0.76     (1.08     (1.06     (0.81 )
(c)
 
Return of capital
     (0.59     (0.45     (0.17     (0.15     (0.01
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total distributions
     (1.45     (1.45     (1.45     (1.45     (1.45
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net asset value, end of year
   $ 22.37     $ 25.86     $ 23.80     $ 22.02     $ 18.77  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Market price, end of year
   $ 20.77     $ 26.62     $ 25.04     $ 22.31     $ 19.76  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Return
(d)
          
Based on net asset value
     (7.73 )%      15.13     15.87     25.63     (4.40 )% 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Based on market price
     (16.78 )%      12.65     20.32     20.91     (1.68 )% 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Ratios to Average Net Assets
(e)
          
Total expenses
     1.08     1.08     1.13     1.12     1.12
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses after fees waived and/or reimbursed
     1.08     1.07     1.10     1.10     1.09
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
     1.44     0.97     1.58     1.78     2.46
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Supplemental Data
          
Net assets, end of year (000)
   $  498,393     $  559,805     $  444,526     $  383,337     $  318,933  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Portfolio turnover rate
     36     20     39     39     28
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(a)
 
Based on average shares outstanding.
(b)
 
Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
(c)
 
Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.
(d)
 
Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
(e)
 
Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.
See notes to financial statements.
 
 
F
I
N
A
N
C
I
A
L   
H
I
G
H
L
I
G
H
T
S
  163

Notes to Financial Statements
 
1.
ORGANIZATION
The following are registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as closed-end management investment companies and are referred to herein collectively as the “Trusts”, or individually as a “Trust”:
 
Trust Name
 
Herein Referred To As
  
Organized
  
Diversification
Classification
BlackRock Energy and Resources Trust
  BGR    Delaware    Non-diversified
BlackRock Enhanced Capital and Income Fund, Inc
  CII    Maryland    Diversified
BlackRock Enhanced Equity Dividend Trust
  BDJ    Delaware    Diversified
BlackRock Enhanced Global Dividend Trust
  BOE    Delaware    Diversified
BlackRock Enhanced International Dividend Trust
  BGY    Delaware    Diversified
BlackRock Health Sciences Trust
  BME    Delaware    Diversified
BlackRock Health Sciences Trust II
  BMEZ    Maryland    Non-diversified
BlackRock Innovation and Growth Trust
  BIGZ    Maryland    Non-diversified
BlackRock Resources & Commodities Strategy Trust
  BCX    Delaware    Non-diversified
BlackRock Science and Technology Trust
  BST    Delaware    Diversified
BlackRock Science and Technology Trust II
  BSTZ    Delaware    Non-diversified
BlackRock Utilities, Infrastructure & Power Opportunities Trust
  BUI    Delaware    Diversified
The Boards of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the “Board,” and the trustees thereof are collectively referred to throughout this report as “Trustees”. The Trusts determine and make available for publication the net asset values (“NAVs”) of their Common Shares on a daily basis.
The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the “Manager”) or its affiliates, are included in a complex of funds referred to as the BlackRock Fixed-Income Complex.
Basis of Consolidation:
The accompanying consolidated financial statements of BDJ include the accounts of BDJ Subsidiary, LLC (the “BDJ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BDJ. The BDJ Taxable Subsidiary enables BDJ to hold an investment in a partnership and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BDJ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BDJ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BDJ. BDJ may invest up to 25% of its total assets in the BDJ Taxable Subsidiary. The net assets of the BDJ Taxable Subsidiary as of period end were $11,435,463, which is 0.7% of BDJ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BDJ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BDJ.
The accompanying consolidated financial statements of BST include the accounts of BST Subsidiary, LLC (the “BST Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BST. The BST Taxable Subsidiary enables BST to hold an investment in an operating partnership and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BST Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BST. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BST. Taxes payable or deferred as of December 31, 2022, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BST may invest up to 25% of its total assets in the BST Taxable Subsidiary. The net assets of the BST Taxable Subsidiary as of period end were $14,419,517, which is 1.5% of BST’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BST Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BST.
The accompanying consolidated financial statements of BSTZ include the accounts of BSTZ Subsidiary, LLC (the “BSTZ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BSTZ. The BSTZ Taxable Subsidiary enables BSTZ to hold an investment in an operating partnership and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BSTZ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BSTZ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BSTZ. Taxes payable or deferred as of December 31, 2022, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BSTZ may invest up to 25% of its total assets in the BSTZ Taxable Subsidiary. The net assets of the BSTZ Taxable Subsidiary as of period end were $27,038,606, which is 1.8% of BSTZ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BSTZ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BSTZ.
 
2.
SIGNIFICANT ACCOUNTING POLICIES
The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. Below is a summary of significant accounting policies:
Investment Transactions and Income Recognition:
For financial reporting purposes, investment transactions are recorded on the dates the transactions are executed. Realized gains and losses on investment transactions are determined using the specific identification method. Dividend income and capital gain distributions, if any, are recorded on the ex-dividend dates. Non-cash dividends, if any, are recorded on the ex-dividend dates at fair value. Dividends from foreign securities where the ex-dividend dates may have passed are subsequently recorded when the Trusts are informed of the ex-dividend dates. Under the applicable foreign tax laws, a withholding tax at various
 
 
164
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized daily on an accrual basis.
Foreign Currency Translation:
Each Trust’s books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (“NYSE”). Purchases and sales of investments are recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.
Each Trust does not isolate the effect of fluctuations in foreign exchange rates from the effect of fluctuations in the market prices of investments for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments, but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for U.S. federal income tax purposes.
ForeignTaxes:
The Trusts may be subject to foreign taxes (a portion of which may be reclaimable) on income, stock dividends, capital gains on investments, or certain foreign currency transactions. All foreign taxes are recorded in accordance with the applicable foreign tax regulations and rates that exist in the foreign jurisdictions in which each Trust invests. These foreign taxes, if any, are paid by each Trust and are reflected in its Statements of Operations as follows: foreign taxes withheld at source are presented as a reduction of income, foreign taxes on securities lending income are presented as a reduction of securities lending income, foreign taxes on stock dividends are presented as “Foreign taxes withheld”, and foreign taxes on capital gains from sales of investments and foreign taxes on foreign currency transactions are included in their respective net realized gain (loss) categories. Foreign taxes payable or deferred as of December 31, 2022, if any, are disclosed in the Statements of Assets and Liabilities.
The Trusts file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. The Trusts may record a reclaim receivable based on collectability, which includes factors such as the jurisdiction’s applicable laws, payment history and market convention. The Statements of Operations include tax reclaims recorded as well as professional and other fees, if any, associated with recovery of foreign withholding taxes.
Collateralization:
If required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments.
Distributions:
Distributions paid by the Trusts are recorded on the ex-dividend dates. Subject to the Trusts’ managed distribution plan, the Trusts intend to make monthly cash distributions to shareholders, which may consist of net investment income, and net realized and unrealized gains on investments and/or return of capital.
The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust’s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital. See Income Tax Information note for the tax character of each Trust’s distributions paid during the year.
Deferred Compensation Plan:
Under the Deferred Compensation Plan (the “Plan”) approved by each Trust’s Board, the trustees who are not “interested persons” of the Trusts, as defined in the 1940 Act (“Independent Trustees”), may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain funds in the BlackRock Fixed-Income Complex selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain funds in the BlackRock Fixed-Income Complex.
The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, as applicable. Deferred compensation liabilities, if any, are included in the Trustees’ and Officer’s fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan. Net appreciation (depreciation) in the value of participants’ deferral accounts is allocated among the participating funds in the BlackRock Fixed-Income Complex and reflected as Trustees and Officer expense on the Statements of Operations. The Trustees and Officer expense may be negative as a result of a decrease in value of the deferred accounts.
Indemnifications:
In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust’s maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.
Other:
Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are prorated among those funds on the basis of relative net assets or other appropriate methods.
 
3.
INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS
Investment Valuation Policies:
Each Trust’s investments are valued at fair value (also referred to as “market value” within the financial statements) each day that the Trust is open for business and, for financial reporting purposes, as of the report date. U.S. GAAP defines fair value as the price a fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Board has approved the designation of each Trust’s Manager as the valuation designee for each Trust. Each Trust determines the fair values of its financial instruments using various independent dealers or pricing services under the Manager’s policies. If a security’s market price is not readily available or does not otherwise accurately represent the fair value of the security, the security will be valued in accordance with the Manager’s policies and procedures as reflecting fair value. The Manager has formed a committee (the “Valuation Committee”) to develop pricing policies and procedures and to oversee the pricing function for all financial instruments, with assistance from other BlackRock pricing committees.
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  165

Notes to Financial Statements  
(continued)
 
Fair Value Inputs and Methodologies:
The following methods and inputs are used to establish the fair value of each Trust’s assets and liabilities:
 
   
Equity investments traded on a recognized securities exchange are valued at that day’s official closing price, as applicable, on the exchange where the stock is primarily traded. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price.
 
   
Fixed-income investments for which market quotations are readily available are generally valued using the last available bid price or current market quotations provided by independent dealers or third-party pricing services. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and offers), market data, credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent fair value.
 
   
Investments in open-end U.S. mutual funds (including money market funds) are valued at that day’s published NAV.
 
   
The Trusts value their investment in SL Liquidity Series, LLC, Money Market Series (the “Money Market Series”) at fair value, which is ordinarily based upon their pro rata ownership in the underlying fund’s net assets.
 
   
Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of trading on the NYSE based on that day’s prevailing forward exchange rate for the underlying currencies.
 
   
Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day’s price will be used, unless it is determined that the prior day’s price no longer reflects the fair value of the option. Over-the-counter (“OTC”) options and options on swaps (“swaptions”) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments.
Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Each business day, the Trusts use current market factors supplied by independent pricing services to value certain foreign instruments (“Systematic Fair Value Price”). The Systematic Fair Value Price is designed to value such foreign securities at fair value as of the close of trading on the NYSE, which follows the close of the local markets.
If events (e.g., market volatility, company announcement or a natural disaster) occur that are expected to materially affect the value of such investment, or in the event that application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Valuation Committee in accordance with the Manager’s policies and procedures as reflecting fair value (“Fair Valued Investments”). The fair valuation approaches that may be used by the Valuation Committee include market approach, income approach and cost approach. Valuation techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value. When determining the price for Fair Valued Investments, the Valuation Committee seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm’s-length transaction. Fair value determinations shall be based upon all available factors that the Valuation Committee deems relevant and consistent with the principles of fair value measurement.
For investments in equity or debt issued by privately held companies or funds (“Private Company” or collectively, the “Private Companies”) and other Fair Valued Investments, the fair valuation approaches that are used by the Valuation Committee and third-party pricing services utilized by the Valuation Committee include one or a combination of, but not limited to, the following inputs.
 
   
    
Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services
   
Market approach
 
(i)  recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers;
(ii)   recapitalizations and other transactions across the capital structure; and
(iii)  market multiples of comparable issuers.
 
Income approach
 
(i)  future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks;
(ii)   quoted prices for similar investments or assets in active markets; and
(iii)  other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates.
 
Cost approach
 
(i)  audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private Company;
(ii)   changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company;
(iii)  relevant news and other public sources; and
(iv)  known secondary market transactions in the Private Company’s interests and merger or acquisition activity in companies comparable to the Private Company.
 
Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Enterprise valuation techniques such as an option pricing model (“OPM”), a probability weighted expected return model (“PWERM”), current value method or a hybrid of those techniques are used as deemed appropriate under the circumstances. The use of these valuation techniques involve a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise value of the company among the various parts of its capital structure.
 
 
166
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
The Private Companies are not subject to the public company disclosure, timing, and reporting standards applicable to other investments held by a Trust. Typically, the most recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the value of the investment and the price a Trust could receive upon the sale of the investment.
Fair Value Hierarchy:
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:
 
   
Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access;
 
   
Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and
 
   
Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments).
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities.
As of December 31, 2022, certain investments of BME, BMEZ, BIGZ, BST and BUI were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
 
4.
SECURITIES AND OTHER INVESTMENTS
Preferred Stocks:
Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer’s board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.
Warrants:
Warrants entitle a fund to purchase a specified number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any. If the price of the underlying stock does not rise above the strike price before the warrant expires, the warrant generally expires without any value and a fund will lose any amount it paid for the warrant. Thus, investments in warrants may involve more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.
Commitments:
Commitments are agreements to acquire an investment at a future date (subject to conditions) in connection with a potential public or non-public offering. Such agreements may obligate a fund to make future cash payments. As of December 31, 2022, BDJ had outstanding commitments of $5,564,537. These commitments are not included in the net assets of BDJ as of December 31, 2022.
Securities Lending:
Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.
As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC (“BIM”), if any, is disclosed in the Schedules of Investments. Any non-cash collateral received cannot be sold, re-invested or pledged by the Trust, except in the event of borrower default. The securities on loan, if any, are disclosed in the Trusts’ Schedules of Investments. The market value of any securities on loan and the value of any related collateral are shown separately in the Statements of Assets and Liabilities as a component of investments at value – unaffiliated, and collateral on securities loaned, respectively.
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  167

Notes to Financial Statements  
(continued)
 
Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an “MSLA”), which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty’s bankruptcy or insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties’ obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party’s net payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.
As of period end, the following table is a summary of the Trusts’ securities on loan by counterparty which are subject to offset under an MSLA:
 
Trust Name/Counterparty
  
 
Securities
Loaned at Value
 
 
  
 
Cash Collateral
Received
 
(a)
 
 
 
Non-Cash Collateral
Received, at Fair Value
 
(a)
 
 
 
Net
Amount
 
(b)
 
BME
         
Citigroup Global Markets, Inc.
   $ 124,474      $ (123,435   $     $ 1,039  
Goldman Sachs & Co. LLC
     208,841        (208,841            
National Financial Services LLC
     324,655        (324,487           168  
Toronto-Dominion Bank
     452        (452            
  
 
 
    
 
 
   
 
 
   
 
 
 
   $ 658,422      $ (657,215   $     $ 1,207  
  
 
 
    
 
 
   
 
 
   
 
 
 
BMEZ
         
BNP Paribas SA
   $ 159,788      $ (159,788   $     $  
BofA Securities, Inc.
     133,901        (133,901            
Citigroup Global Markets, Inc.
     73,680        (73,362           318  
Credit Suisse Securities (USA) LLC
     25,704        (25,704            
Goldman Sachs & Co. LLC
     782,874        (782,874            
National Financial Services LLC
     492,962        (492,506           456  
  
 
 
    
 
 
   
 
 
   
 
 
 
   $ 1,668,909      $ (1,668,135   $     $ 774  
  
 
 
    
 
 
   
 
 
   
 
 
 
BIGZ
         
Barclays Capital, Inc.
   $ 25,380      $ (25,380   $     $  
Morgan Stanley
     154,818        (154,818            
  
 
 
    
 
 
   
 
 
   
 
 
 
   $ 180,198      $ (180,198   $     $  
  
 
 
    
 
 
   
 
 
   
 
 
 
BST
         
J.P. Morgan Securities LLC
   $ 808,350      $ (808,350   $     $  
  
 
 
    
 
 
   
 
 
   
 
 
 
BUI
         
BofA Securities, Inc.
   $ 122,727      $ (122,727   $     $  
J.P. Morgan Securities LLC
     80,529        (80,529            
  
 
 
    
 
 
   
 
 
   
 
 
 
   $ 203,256      $ (203,256   $     $  
  
 
 
    
 
 
   
 
 
   
 
 
 
 
 
(a)
 
Collateral received, if any, in excess of the market value of securities on loan is not presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities.
 
 
 
(b)
 
The market value of the loaned securities is determined as of December 31, 2022. Additional collateral is delivered to each Trust on the next business day in accordance with the MSLA. The net amount would be subject to the borrower default indemnity in the event of default by the counterparty.
 
The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM’s indemnity allows for full replacement of the securities loaned to the extent the collateral received does not cover the value on the securities loaned in the event of borrower default. Each Trust could incur a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received. Such losses are borne entirely by the Trusts.
 
5.
DERIVATIVE FINANCIAL INSTRUMENTS
The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.
Forward Foreign Currency Exchange Contracts:
Forward foreign currency exchange contracts are entered into to gain or reduce exposure to foreign currencies (foreign currency exchange rate risk).
A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure to a particular market. The contracts are traded OTC and not on an organized exchange.
 
 
168
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
The contract is marked-to-market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements of Assets and Liabilities. When a contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value at the time it was opened and the value at the time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the value of the referenced foreign currencies, and such value may exceed the amount(s) reflected in the Statements of Assets and Liabilities. Cash amounts pledged for forward foreign currency exchange contracts are considered restricted and are included in cash pledged as collateral for OTC derivatives in the Statements of Assets and Liabilities. A Trust’s risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain netted against any collateral held by the Trust.
Options:
The Trusts may purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.
A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.
Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value –unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically “covered,” meaning that they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, cash is segregated in an amount sufficient to cover the obligation. These amounts, which are considered restricted, are included in cash pledged as collateral for options written in the Statements of Assets and Liabilities.
In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when they otherwise would not, or at a price different from the current market value.
Master Netting Arrangements:
In order to define its contractual rights and to secure rights that will help it mitigate its counterparty risk, a Trust may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or similar agreement with its counterparties. An ISDA Master Agreement is a bilateral agreement between a Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, a Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments’ payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events.
Collateral Requirements:
For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trust and the counterparty.
Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately in the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from the counterparties are not fully collateralized, each Trust bears the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, each Trust bears the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.
For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.
 
6.
INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES
Investment Advisory:
Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts’ investment adviser and an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”), to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust’s portfolio and provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.
For such services, each Trust, except BCX pays the Manager a monthly fee at the following annual rates:
Average weekly value of each Trust’s net assets:
 
    
BGR
   
BDJ
   
BOE
   
BME
 
Investment advisory fees
    1.20     0.80     1.00     1.00
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  169

Notes to Financial Statements  
(continued)
 
Average daily value of each Trust’s net assets:
 
    
CII
   
BGY
   
BUI
 
Investment advisory fees
    0.85     1.00     1.00
Average daily value of each Trust’s managed assets:
 
    
BMEZ
   
BIGZ
   
BST
   
BSTZ
 
Investment advisory fees
    1.25     1.25     1.00     1.25
For such services, BCX pays the Manager a monthly fee of 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the value of the Trust’s interest in the BCX Subsidiary, LLC (the “BCX Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BCX) and the average daily value of the net assets of its subsidiary, which fee is allocated pro rata between the Trust and the BCX Taxable Subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Trust, the value of the Trust’s interest in the BCX Taxable Subsidiary). The BCX Taxable Subsidiary had no net assets or activity during the period ended December 31, 2022.
For purposes of calculating these fees, “net assets” mean the total assets of BGR, CII, BDJ, BOE, BGY, BME, BCX and BUI minus the sum of its accrued liabilities.
For purposes of calculating these fees, “managed assets” are determined as total assets of BMEZ, BIGZ, BST and BSTZ (including any assets attributable to money borrowed for investment purposes) less the sum of its accrued liabilities (other than money borrowed for investment purposes).
With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (“BIL”), an affiliate of the Manager. The Manager pays BIL for services it provides for that portion of each Trust for which BIL acts as sub-adviser, a monthly fee that is equal to a percentage of the investment advisory fees paid by each Trust to the Manager.
The Manager provides investment management and other services to BDJ Taxable Subsidiary, BST Taxable Subsidiary and BSTZ Taxable Subsidiary. The Manager does not receive separate compensation from the BDJ Taxable Subsidiary, BST Taxable Subsidiary or BSTZ Taxable Subsidiary for providing investment management or administrative services. However, BDJ, BST and BSTZ pay the Manager based on the Trust’s net assets, which includes the assets of the BDJ Taxable Subsidiary, BST Taxable Subsidiary and BSTZ Taxable Subsidiary, respectively.
Distribution Fees:
BME, BST and BUI have entered into Distribution Agreements with BlackRock Investments, LLC (“BRIL”), an affiliate of the Manager, to provide for distribution of BME’s, BST’s and BUI’s common shares on a reasonable best efforts basis through an equity shelf offering (a “Shelf Offering”) (the “Distribution Agreement”). Pursuant to the Distribution Agreement, BRIL will receive commissions with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BME’s, BST’s and BUI’s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions retained by BRIL during the year ended December 31, 2022 amounted to $67,961, $57,651 and $29,258 for each of BME, BST and BUI, respectively.
Expense Limitations, Waivers and Reimbursements:
The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a percentage of their average weekly net assets (BGR and BOE) or average daily net assets (BGY), as follows:
 
    
BGR
   
BOE
   
BGY
 
 
    0.220     0.175     0.100
These voluntary waivers may be reduced or discontinued at any time without notice. Effective June 1, 2022, the voluntary waiver agreement between the Manager and BGY was terminated.
For the year ended December 31, 2022, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of Operations, were as follows:
 
Trust Name
 
Fees Waived and/or Reimbursed
by the Manager
 
BGR
  $ 826,303  
BOE
    1,295,560  
BGY
    274,077  
With respect to each Trust, the Manager contractually agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds (the “affiliated money market fund waiver”) through June 30, 2024. The contractual agreement may be terminated upon 90 days’ notice by a majority of the Independent trustees, or by a vote of a majority of the outstanding voting securities of a Trust. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the year ended December 31, 2022, the amounts waived were as follows:
 
Trust Name
 
Fees Waived and/or Reimbursed
by the Manager
 
BGR
  $ 3,426  
CII
    11,312  
BDJ
    42,252  
BOE
    3,738  
BGY
    3,808  
BME
    17,512  
 
 
170
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
Trust Name
 
Fees Waived and/or Reimbursed
by the Manager
 
BMEZ
  $ 40,928  
BIGZ
    17,488  
BCX
    13,661  
BST
    16,683  
BSTZ
    24,991  
BUI
    7,348  
The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each Trust’s assets invested in affiliated equity and fixed-income mutual funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2024. The agreement can be renewed for annual periods thereafter, and may be terminated on 90 days’ notice, each subject to approval by a majority of the Trusts’ Independent Trustees. For the year ended December 31, 2022, there were no fees waived by the Manager pursuant to this arrangement.
Securities Lending:
The U.S. Securities and Exchange Commission (“SEC”) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the “collateral investment expenses”). The cash collateral is invested in a private investment company, Money Market Series, managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the Money Market Series to an annual rate of 0.04%. The investment adviser to the Money Market Series will not charge any advisory fees with respect to shares purchased by the Trusts. The Money Market Series may, under certain circumstances, impose a liquidity fee of up to 2% of the value withdrawn or temporarily restrict withdrawals for up to 10 business days during a 90 day period, in the event that the private investment company’s weekly liquid assets fall below certain thresholds. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments may follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act.
Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent.
Pursuant to the current securities lending agreement, BIM may lend securities only when the difference between the borrower rebate rate and the risk free rate exceeds a certain level (such securities, the “specials only securities”). Each Trust retains 82% of securities lending income (which excludes collateral investment expenses).
In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each Trust, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income (which excludes collateral investment expenses) in an amount equal to 85% of securities lending income.
The share of securities lending income earned by each Trust is shown as securities lending income — affiliated — net in the Statements of Operations. For the year ended December 31, 2022, each Trust paid BIM the following amounts for securities lending agent services:
 
Trust Name
 
Amounts
 
BDJ
  $ 6  
BME
    5,346  
BMEZ
    58,704  
BIGZ
    14,413  
BCX
    168  
BST
    7,868  
BSTZ
    38,051  
BUI
    1,697  
Trustees and Officers:
Certain trustees and/or officers of the Trusts are directors and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts’ Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.
Other Transactions:
During the year ended December 31, 2022, BDJ and BST received a reimbursement of $1,577 and $21,599, respectively, from an affiliate, which is included in payment by affiliate in the Statements of Operations, related to an operating event.
During the year ended December 31, 2022, BIGZ received a reimbursement of $59,874 from an affiliate, which is included in Other income — affiliated in the Statements of Operations, related to an operating event.
The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the year ended December 31, 2022, the purchase and sale transactions and any net realized gains (losses) with affiliated funds in compliance with Rule 17a-7 under the 1940 Act were as follows:
 
 
 
Trust Name
 
Purchases
    
Sales
    
Net Realized
Gain (Loss)
 
 
BOE
  $      $ 5,730,635      $ (144,921
BGY
           11,402,409        (433,728
BCX
    1,461,261                
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  171

Notes to Financial Statements  
(continued)
 
Trust Name
 
Purchases
    
Sales
    
Net Realized
Gain (Loss)
 
BUI
  $ 169,140      $      $  
7. PURCHASES AND SALES
For the year ended December 31, 2022, purchases and sales of investments, excluding short-term securities, were as follows:
 
Trust Name
 
Purchases
    
Sales
 
BGR
  $ 283,806,133      $ 324,962,616  
CII
    277,914,860        342,646,931  
BDJ
    1,403,124,379        1,592,236,088  
BOE
    327,698,168        365,079,012  
BGY
    248,066,755        287,070,630  
BME
    231,241,290        231,504,871  
BMEZ
    1,409,075,306        1,657,788,612  
BIGZ
    1,074,498,186        1,378,149,000  
BCX
    866,452,309        950,743,935  
BST
    467,780,970        460,463,155  
BSTZ
    951,314,518        1,052,857,240  
BUI
    183,314,096        198,190,215  
 
8.
INCOME TAX INFORMATION
It is each Trust’s policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.
Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust’s U.S. federal tax returns generally remains open for a period of three years after they are filed. The statutes of limitations on each Trust’s state and local tax returns may remain open for an additional year depending upon the jurisdiction.
Management has analyzed tax laws and regulations and their application to the Trusts as of December 31, 2022, inclusive of the open tax return years, and does not believe that there are any uncertain tax positions that require recognition of a tax liability in the Trusts’ financial statements.
U.S. GAAP requires that certain components of net assets be adjusted to reflect permanent differences between financial and tax reporting. These reclassifications have no effect on net assets or NAVs per share. As of period end, permanent differences attributable to non-deductible expenses and net operating losses were reclassified to the following accounts:
 
   
Trust Name
 
Paid-in Capital
   
Accumulated
Earnings (Loss)
      
    
 
BDJ
  $ (3,434   $ 3,434          
 
BME
    (97,690     97,690     
 
BMEZ
    (15,954,980     15,954,980     
 
BIGZ
    (37,095,792     37,095,792     
 
BST
    (9,445,376     9,445,376     
 
BSTZ
    (24,681,377     24,681,377     
 
BUI
    (3,295     3,295     
 
The tax character of distributions paid was as follows:
 
   
Trust Name
 
Year Ended
12/31/22
   
Year Ended
12/31/21
      
    
 
BGR
      
 
Ordinary income
  $  11,890,970     $ 8,262,936     
 
Return of capital
    4,610,793       4,835,876          
   
 
 
   
 
 
    
    $ 16,501,763     $  13,098,812     
   
 
 
   
 
 
    
 
CII
      
 
Ordinary income
  $ 21,905,388     $ 2,005,386     
 
Long-term capital gains
    70,788,369       46,638,458     
   
 
 
   
 
 
    
    $ 92,693,757     $ 48,643,844     
   
 
 
   
 
 
    
 
 
172
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
Trust Name
 
Year Ended
12/31/22
    
Year Ended
12/31/21
 
BDJ
    
Ordinary income
  $  25,303,490      $ 58,615,347  
Long-term capital gains
    178,849,379        102,988,157  
 
 
 
    
 
 
 
  $  204,152,869      $  161,603,504  
 
 
 
    
 
 
 
BOE
    
Ordinary income
  $ 16,041,931      $ 48,404,308  
Long-term capital gains
    22,100,071         
Return of capital
    9,962,064         
 
 
 
    
 
 
 
  $ 48,104,066      $ 48,404,308  
 
 
 
    
 
 
 
BGY
    
Ordinary income
  $ 13,622,966      $ 30,180,220  
Long-term capital gains
    6,547,300         
Return of capital
    21,930,456        12,098,701  
 
 
 
    
 
 
 
  $ 42,100,722      $ 42,278,921  
 
 
 
    
 
 
 
BME
    
Ordinary income
  $ 1,635,849      $ 51,302  
Long-term capital gains
    31,362,678        30,713,640  
Return of capital
    1,403,564         
 
 
 
    
 
 
 
  $ 34,402,091      $ 30,764,942  
 
 
 
    
 
 
 
BMEZ
    
Ordinary income
  $ 82,094,690      $ 111,413,529  
Long-term capital gains
    100,955,454        81,491,859  
Return of capital
    11,869,565         
 
 
 
    
 
 
 
  $ 194,919,709      $ 192,905,388  
 
 
 
    
 
 
 
BIGZ
    
Return of capital
  $ 233,929,900      $ 170,149,458  
 
 
 
    
 
 
 
BCX
    
Ordinary income
  $ 26,024,883      $ 33,607,537  
Return of capital
    22,531,891        8,784,140  
 
 
 
    
 
 
 
  $ 48,556,774      $ 42,391,677  
 
 
 
    
 
 
 
BST
    
Long-term capital gains
  $ 69,684,200      $ 126,451,369  
Return of capital
    27,306,002         
 
 
 
    
 
 
 
  $ 96,990,202      $ 126,451,369  
 
 
 
    
 
 
 
BSTZ
    
Long-term capital gains
  $ 70,402,537      $ 240,726,364  
Return of capital
    110,549,120         
 
 
 
    
 
 
 
  $ 180,951,657      $ 240,726,364  
 
 
 
    
 
 
 
BUI
    
Ordinary income
  $ 6,721,779      $ 14,683,563  
Long-term capital gains
    12,261,345        5,642,016  
Return of capital
    13,135,583        9,081,858  
 
 
 
    
 
 
 
  $ 32,118,707      $ 29,407,437  
 
 
 
    
 
 
 
As of December 31, 2022, the tax components of accumulated earnings (loss) were as follows:
 
 
 
Trust Name
 
Undistributed
Ordinary Income
    
Undistributed
Long-Term
Capital Gains
    
Non-Expiring
Capital Loss
Carryforwards
(a)
    
Net Unrealized
Gains (Losses)
(b)
    
Qualified
Late-Year Losses
(c)
    
Total
 
 
BGR
  $      $      $ (239,868,252    $ 112,923,411      $ (7,022    $ (126,951,863
CII
    9,498,319        21,859,831               181,750,417               213,108,567  
BDJ
    23,806,243        90,764,714               202,158,788               316,729,745  
BOE
                         9,641,209        (17,281,763      (7,640,554
BGY
                         22,632,073        (6,172,726      16,459,347  
BME
                         177,920,699        (2,023,853      175,896,846  
BMEZ
                  (37,330,690      (83,992,958             (121,323,648
BIGZ
                  (1,492,285,027      (732,278,996      (20,092      (2,224,584,115
BCX
                  (258,642,241      165,718,242               (92,923,999
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  173

Notes to Financial Statements  
 (continued)
 
Trust Name
 
Undistributed
Ordinary Income
    
Undistributed
Long-Term
Capital Gains
    
Non-Expiring
Capital Loss
Carryforwards
(a)
    
Net Unrealized
Gains (Losses)
(b)
    
Qualified
Late-Year Losses
(c)
   
Total
 
BST
  $      $      $  —      $ 170,987,481      $ (33,095   $ 170,954,386  
BSTZ
                         153,960,952        (1,665,789     152,295,163  
BUI
                         116,984,322        (2,097,980     114,886,342  
 
 
(a)
 
Amounts available to offset future realized capital gains.
 
 
(b)
 
The difference between book-basis and tax-basis net unrealized gains (losses) was attributable primarily to the tax deferral of losses on wash sales and straddles, the realization for tax purposes of unrealized gains (losses) on certain options and foreign currency exchange contracts, the characterization of corporate actions, the realization for tax purposes of unrealized gains on investments in passive foreign investment companies, the deferral of compensation to Trustees and the timing and recognition of partnership income.
 
 
(c)
 
The Trust has elected to defer certain qualified late-year losses and recognize such losses in the next taxable year.
 
During the year ended December 31, 2022, the Trusts listed below utilized the following amounts of their respective capital loss carryforward:
 
Trust Name
 
Amounts
 
BGR
  $ 29,261,865  
BCX
    153,905,560  
As of December 31, 2022, gross unrealized appreciation and depreciation based on cost of investments (including short positions and derivatives, if any) for U.S. federal income tax purposes were as follows:
 
 
 
Trust Name
 
Tax Cost
    
Gross Unrealized
Appreciation
    
Gross Unrealized
Depreciation
   
Net Unrealized
Appreciation
(Depreciation)
 
 
BGR
  $ 280,990,484      $ 130,686,315      $ (7,764,333   $ 122,921,982  
CII
    598,512,194        219,759,042        (28,022,663     191,736,379  
BDJ
    1,422,276,882        273,594,258        (48,807,439     224,786,819  
BOE
    659,952,577        85,441,002        (54,069,216     31,371,786  
BGY
    547,576,930        90,940,423        (44,593,832     46,346,591  
BME
    419,555,387        202,996,911        (16,693,490     186,303,421  
BMEZ
    2,155,695,162        312,492,740        (384,542,704     (72,049,964
BIGZ
    2,785,070,585        65,934,467        (792,952,589     (727,018,122
BCX
    814,773,543        230,508,800        (56,424,160     174,084,640  
BST
    786,028,758        320,437,019        (134,851,440     185,585,579  
BSTZ
    1,356,842,241        361,260,907        (174,474,565     186,786,342  
BUI
    359,972,401        153,604,388        (10,911,963     142,692,425  
 
9.
PRINCIPAL RISKS
In the normal course of business, the Trusts invest in securities or other instruments and may enter into certain transactions, and such activities subject each Trust to various risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability; (iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the Trusts and their investments. BME’s, BST’s and BUI’s prospectuses provide details of the risks to which each Trust is subject.
The Trusts may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of $1.00, which may be subject to redemption gates or liquidity fees under certain circumstances.
Each Trust may invest without limitation in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. A Trust may not be able to readily dispose of such investments at prices that approximate those at which a Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, a Trust may have to sell other investments or engage in borrowing transactions if necessary to raise funds to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting a Trust’s NAV and ability to make dividend distributions. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.
Infectious Illness Risk:
An outbreak of an infectious illness, such as the COVID-19 pandemic, may adversely impact the economies of many nations and the global economy, and may impact individual issuers and capital markets in ways that cannot be foreseen. An infectious illness outbreak may result in, among other things, closed international borders, prolonged quarantines, supply chain disruptions, market volatility or disruptions and other significant economic, social and political impacts.
Valuation Risk:
The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries. A Trust may invest in illiquid investments. An illiquid investment is any investment that a Trust reasonably expects cannot be sold or disposed of in current market conditions in seven calendar days or less without the sale or disposition significantly changing the market value of the investment. A Trust may experience difficulty in selling illiquid investments in a timely manner at the price that it believes the investments are worth. Prices may fluctuate widely over short or extended periods in response to company,
 
 
174
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each Trust’s NAV to experience significant increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a Trust may lose value, regardless of the individual results of the securities and other instruments in which a Trust invests.
The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust’s valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore a Trust’s results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater than expected loss or lesser than expected gain upon the sale of the investment. A Trust’s ability to value its investments may also be impacted by technological issues and/or errors by pricing services or other third-party service providers.
Counterparty Credit Risk:
The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions, including making timely interest and/or principal payments or otherwise honoring its obligations. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trusts’ exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.
A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.
For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent each Trust deposits collateral with its counterparty to a written option.
With exchange-traded options purchased, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default (including the bankruptcy or insolvency).
Concentration Risk:
A diversified portfolio, where this is appropriate and consistent with a fund’s objectives, minimizes the risk that a price change of a particular investment will have a material impact on the NAV of a fund. The investment concentrations within each Trust’s portfolio are disclosed in its Schedule of Investments.
As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:
 
Sectors
 
Trust Name
 
Energy
    BGR, BCX  
Financials
    BDJ
Health Care
    BME, BMEZ  
Information Technology
    BST, BSTZ  
Materials
    BCX  
Utilities
    BUI  
Changes in economic conditions affecting such sectors would have a greater impact on the Trusts and could affect the value, income and/or liquidity of positions in such securities.
Certain Trusts invest a significant portion of their assets in securities within a single or limited number of market sectors. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions affecting such sectors may have a significant impact on the Trust and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Investment percentages in specific sectors are presented in the Schedules of Investments.
Certain Trusts invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions in those countries may have a significant impact on their investment performance and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Unanticipated or sudden political or social developments may cause uncertainty in the markets and as a result adversely affect the Trust’s investments. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the United States. Foreign securities markets may also be more volatile and less liquid than U.S. securities and may be less subject to governmental supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.
Certain Trusts invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts’ investments.
Responses to the financial problems by European governments, central banks and others, including austerity measures and reforms, may not work, may result in social unrest and may limit future growth and economic recovery or have other unintended consequences. Further defaults or restructurings by governments and others of their debt could have additional adverse effects on economies, financial markets and asset valuations around the world. The United Kingdom has withdrawn from the European Union, and one or more other countries may withdraw from the European Union and/or abandon the Euro, the common currency of the European Union. These events and actions have
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  175

Notes to Financial Statements  
(continued)
 
adversely affected, and may in the future adversely affect, the value and exchange rate of the Euro and may continue to significantly affect the economies of every country in Europe, including countries that do not use the Euro and non-European Union member states. The impact of these actions, especially if they occur in a disorderly fashion, is not clear but could be significant and far reaching. In addition, Russia launched a large-scale invasion of Ukraine on February 24, 2022. The extent and duration of the military action, resulting sanctions and resulting future market disruptions in the region are impossible to predict, but could be significant and have a severe adverse effect on the region, including significant negative impacts on the economy and the markets for certain securities and commodities, such as oil and natural gas, as well as other sectors.
LIBOR Transition Risk:
The United Kingdom’s Financial Conduct Authority announced a phase out of the London Interbank Offered Rate (“LIBOR”). Although many LIBOR rates ceased to be published or no longer are representative of the underlying market they seek to measure after December 31, 2021, a selection of widely used USD LIBOR rates will continue to be published through June 2023 in order to assist with the transition. The Trusts may be exposed to financial instruments tied to LIBOR to determine payment obligations, financing terms, hedging strategies or investment value. The transition process away from LIBOR might lead to increased volatility and illiquidity in markets for, and reduce the effectiveness of new hedges placed against instruments whose terms currently include LIBOR. The ultimate effect of the LIBOR transition process on the Trusts is uncertain.
 
10.
CAPITAL SHARE TRANSACTIONS
Each Trust is authorized to issue an unlimited number of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue 200 million Common Shares. The par value for each Trust’s Common Shares is $0.001, except for CII, which is $0.10. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without the approval of Common Shareholders.
BME, BST and BUI have each filed a prospectus with the SEC allowing them to issue an additional 4,000,000, 18,000,000 and 8,000,000 Common Shares, respectively, through an equity Shelf Offering. Under the Shelf Offerings, BME, BST and BUI, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above each Trust’s NAV per Common Share (calculated within 48 hours of pricing). As of period end, 3,404,028, 17,164,641 and 7,826,064 Common Shares, respectively, remain available for issuance under the Shelf Offerings. During the year ended, December 31, 2022, BME, BST and BUI issued 774,304, 835,359 and 590,894 shares, respectively, under the Trust’s respective current Shelf Offering and the Trust’s prior Shelf Offering. See Additional Information — Shelf Offering Program for additional information.
Initial costs incurred by each of BME, BST and BUI in connection with their Shelf Offerings are recorded as “Deferred offering costs” in the Statements of Assets and Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the Shelf Offering period will be charged to expense.
For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:
 
    
Year Ended
 
Trust Name
    12/31/22        12/31/21  
BME
    774,304        1,053,578  
BST
    835,359        242,731  
BUI
    590,894        2,910,832  
For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:
 
    
Year Ended
 
Trust Name
    12/31/22        12/31/21  
CII
           10,701  
BDJ
    412,658         
BME
    38,955        37,877  
BIGZ
           231,136  
BST
    81,277        40,859  
BSTZ
           448,074  
BUI
    32,898        63,066  
The Trusts participate in an open market share repurchase program (the “Repurchase Program”). From December 1, 2021 through November 30, 2022, each Trust may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2021, for each Trust (other than BIGZ, BSTZ and BMEZ) or November 18, 2021 (for BIGZ, BSTZ and BMEZ) subject to certain conditions. From December 1, 2022 through November 30, 2023, each Trust may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2022, subject to certain conditions. The Repurchase Program has an accretive effect as shares are purchased at a discount to the Trust’s NAV. There is no assurance that the Trusts will purchase shares in any particular amounts. For the year ended December 31, 2022, CII, BDJ, BME, BST and BUI did not repurchase any shares.
The total cost of the shares repurchased is reflected in the Trusts’ Statements of Changes in Net Assets. For the periods shown, shares repurchased and cost, including transaction costs, were as follows:
 
    
BGR
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    1,055,728      $ 12,296,655  
 
 
176
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Notes to Financial Statements  
(continued)
 
    
BOE
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    1,285,502      $ 12,470,648  
Year Ended December 31, 2021
    18,558        205,246  
                 
    
BGY
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    1,492,331      $ 7,282,700  
                 
    
BMEZ
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    3,072,736      $ 47,829,587  
                 
    
BIGZ
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    8,519,618      $   64,919,571  
Period Ended December 31, 2021
    5,142,849        74,068,155  
                 
    
BCX
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    797,510      $ 7,554,830  
                 
    
BSTZ
 
    
Shares
    
Amounts
 
Year Ended December 31, 2022
    461,288      $ 7,293,625  
For the year ended December 31, 2022, shares issued and outstanding remained constant for CII. For the year ended December 31, 2021, shares issued and outstanding remained constant for BGR, BDJ, BGY, BMEZ and BCX.
With respect to BST, for the year ended December 31, 2021, shares issued and outstanding increased by 40,859 as a result of dividend reinvestment, 242,731 from the shelf offering and 6,822,923 from the rights issue.
As of December 31, 2022, BlackRock Financial Management, Inc., an affiliate of the Trust, owned 5,000 Shares of BIGZ.
 
11.
SUBSEQUENT EVENTS
Management’s evaluation of the impact of all subsequent events on the Trusts’ financial statements was completed through the date the financial statements were issued and the following items were noted:
The Trusts declared and paid or will pay distributions to Common Shareholders as follows:
 
Trust Name
 
Declaration
Date
    
Record
Date
    
Payable/
Paid Date
    
Dividend Per
Common Share
 
BGR
    01/03/23        01/13/23        01/31/23      $ 0.058500  
    02/01/23        02/15/23        02/28/23        0.058500  
CII
    01/03/23        01/13/23        01/31/23        0.099500  
    02/01/23        02/15/23        02/28/23        0.099500  
BDJ
    01/03/23        01/13/23        01/31/23        0.056200  
    02/01/23        02/15/23        02/28/23        0.056200  
BOE
    01/03/23        01/13/23        01/31/23        0.063000  
    02/01/23        02/15/23        02/28/23        0.063000  
BGY
    01/03/23        01/13/23        01/31/23        0.033800  
    02/01/23        02/15/23        02/28/23        0.033800  
BME
    01/03/23        01/13/23        01/31/23        0.213000  
    02/01/23        02/15/23        02/28/23        0.213000  
BMEZ
    01/03/23        01/13/23        01/31/23        0.145000  
    02/01/23        02/15/23        02/28/23        0.145000  
BIGZ
    01/03/23        01/13/23        01/31/23        0.070000  
    02/01/23        02/15/23        02/28/23        0.070000  
BCX
    01/03/23        01/13/23        01/31/23        0.051800  
    02/01/23        02/15/23        02/28/23        0.051800  
BST
    01/03/23        01/13/23        01/31/23        0.250000  
    02/01/23        02/15/23        02/28/23        0.250000  
BSTZ
    01/03/23        01/13/23        01/31/23        0.192000  
 
 
N
O
T
E
S   T
O   
F
I
N
A
N
C
I
A
L   
S
T
A
T
E
M
E
N
T
S
  177

Notes to Financial Statements  
(continued)
 
Trust Name
 
Declaration
Date
    
Record
Date
    
Payable/
Paid Date
    
Dividend Per
Common Share
 
    02/01/23        02/15/23        02/28/23      $ 0.192000  
BUI
    01/03/23        01/13/23        01/31/23        0.121000  
 
    02/01/23        02/15/23        02/28/23        0.121000  
 
 
178
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Report of Independent Registered Public Accounting Firm
 
To the Shareholders and the Board of Trustees/Directors of BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Trust, BlackRock Health Sciences Trust II, BlackRock Innovation and Growth Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Trust, BlackRock Science and Technology Trust II and BlackRock Utilities, Infrastructure & Power Opportunities Trust:
Opinion on the Financial Statements and Financial Highlights
We have audited the accompanying statements of assets and liabilities of BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Trust, BlackRock Health Sciences Trust II, BlackRock Innovation and Growth Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Trust, BlackRock Science and Technology Trust II and BlackRock Utilities, Infrastructure & Power Opportunities Trust, (the “Funds”), including the schedules of investments, as of December 31, 2022, the related statements of operations and cash flows for the year then ended, the statements of changes in net assets and the financial highlights for the periods indicated in the table below, and the related notes. Such financial statements and financial highlights of BlackRock Science and Technology Trust and BlackRock Science and Technology Trust II are consolidated as of and for the three years in the period ended December 31, 2022. Such financial statements and financial highlights of BlackRock Enhanced Equity Dividend Trust are consolidated as of and for the year ended December 31, 2022. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Funds as of December 31, 2022, and the results of their operations and their cash flows for the year then ended, the statements of changes in their net assets and the financial highlights for the periods indicated in the table below, in conformity with accounting principles generally accepted in the United States of America.
 
Fund
 
Statements of Changes in Net Assets
 
Financial Highlights
BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Trust and BlackRock Utilities, Infrastructure & Power Opportunities Trust
  For each of the two years in the period ended
December 31, 2022
  For each of the five years in the period ended
December 31, 2022
BlackRock Science and Technology Trust II
  For each of the two years in the period ended
December 31, 2022
  For each of the three years in the period ended December 31, 2022 and for the period from June 27, 2019 (commencement of operations) through December 31, 2019
BlackRock Health Sciences Trust II
  For each of the two years in the period ended
December 31, 2022
  For each of the two years in the period ended December 31, 2022 and for the period from January 30, 2020 (commencement of operations) through December 31, 2020
BlackRock Innovation and Growth Trust
  For the year ended December 31, 2022 and for the period from March 29, 2021 (commencement of operations) through December 31, 2021
Basis for Opinion
These financial statements and financial highlights are the responsibility of the Funds’ management. Our responsibility is to express an opinion on the Funds’ financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. The Funds are not required to have, nor were we engaged to perform, an audit of their internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. Our procedures included confirmation of securities owned as of December 31, 2022, by correspondence with custodians or counterparties; when replies were not received, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.
Deloitte & Touche LLP
Boston, Massachusetts
February 23, 2023
We have served as the auditor of one or more BlackRock investment companies since 1992.
 
 
R
E
P
O
R
T   O
F   
I
N
D
E
P
E
N
D
E
N
T   
R
E
G
I
S
T
E
R
E
D   
P
U
B
L
I
C   
A
C
C
O
U
N
T
I
N
G   
F
I
R
M
  179

Important Tax Information  
(unaudited)
  
 
The following amounts, or maximum amounts allowable by law, are hereby designated as qualified dividend income for individuals for the fiscal year ended December 31, 2022:
 
Trust Name
 
Qualified Dividend
Income
 
BGR
  $ 14,460,642  
CII
    9,608,261  
BDJ
    37,257,518  
BOE
    14,210,174  
BGY
    10,371,702  
BME
    6,935,747  
BMEZ
    8,141,212  
BCX
    36,065,761  
BUI
    10,506,658  
The Trusts hereby designate the following amounts, or maximum amounts allowable by law, as capital gain dividends, subject to a long-term capital gains tax rate as noted below, for the fiscal year ended December 31, 2022:
 
Trust Name
 
20% Rate Long-Term

Capital Gain Dividends
 
CII
  $ 70,788,369  
BDJ
    178,849,379  
BOE
    22,100,071  
BGY
    6,547,300  
BME
    31,362,678  
BMEZ
    100,955,454  
BST
    69,684,200  
BSTZ
    70,402,537  
BUI
    12,261,345  
The Trusts intend to pass through to their shareholders the following amounts, or maximum amounts allowable by law, of foreign source income earned and foreign taxes paid for the fiscal year ended December 31, 2022:
 
Trust Name
 
Foreign Source
Income Earned
   
Foreign
Taxes Paid
 
BOE
  $ 7,845,922     $             1,180,080  
BGY
    9,511,491       1,047,586  
BCX
    16,634,913       2,337,154  
The following percentages, or maximum percentages allowable by law, of ordinary income distributions paid during the fiscal year ended December 31, 2022 qualified for the dividends-received deduction for corporate shareholders:
 
Trust Name
 
Dividends-Received

Deduction
 
BGR
    73.04
CII
    25.44  
BDJ
    66.13  
BOE
    39.38  
BGY
    5.82  
BME
    100.00  
BMEZ
    1.98  
BCX
    42.77  
BUI
    90.43  
The Trusts hereby designate the following amounts, or maximum amounts allowable by law, as qualified short-term capital gains eligible for exemption from U.S. withholding tax for nonresident aliens and foreign corporations for the fiscal year ended December 31, 2022:
 
Trust Name
 
Qualified
Short-Term
Capital Gains
 
CII
  $ 20,077,642  
BDJ
    17,421,685  
BOE
    3,670,604  
BGY
    3,176,329  
BMEZ
    82,094,690  
 
 
180
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
 
Recent Changes
The following information is a summary of certain changes since December 31, 2021.This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.
Effective July 25, 2022, BlackRock Enhanced Equity Dividend Trust (BDJ) can invest up to 10% of total assets in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies.
Except as noted above, during each Trust’s most recent fiscal year, there were no material changes in the Trust’s investment objectives or policies that have not been approved by shareholders or in the principal risk factors associated with investment in the Trust.
Investment Objectives and Policies
BlackRock Energy and Resources Trust (BGR)
The Trust’s investment objective is to provide total return through a combination of current income and capital appreciation. The Trust seeks to achieve this objective by investing primarily in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.
Under normal market conditions, the Trust invests at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust will not invest, under normal market conditions, less than 25% of its total assets in securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry without shareholder approval. Companies in the energy and natural resources industry include those companies involved in the exploration, production or distribution of energy or natural resources, such as gas, oil, metals and minerals as well as related transportation companies and equipment manufacturers. These equity securities may include common stocks, preferred shares, convertible securities, warrants, depositary receipts, equity interests in Canadian Royalty Trusts and equity interests in master limited partnerships (“MLPs”). The Trust will not invest more than 25% of its total assets in MLPs. The Trust may invest in companies located anywhere in the world. The Trust expects to invest primarily in companies located in developed countries, but may invest in companies located in emerging markets. Under normal market conditions, the Trust will invest at least 30% of its total assets in at least two countries other than the United States. The Trust may invest in companies of any market capitalization, including small capitalization and mid-capitalization companies. The Trust does not intend to invest directly in commodities.
As part of its strategy, the Trust currently intends to employ an option strategy of writing (selling) covered call options on common stocks. The Trust seeks to produce current income and gains generated from option writing premiums. In addition to its covered call strategy the Trust may, to a lesser extent, pursue an option strategy that includes the sale (writing) of both put options and call options on certain of the common stocks in the Trust’s portfolio.
The Trust may invest up to 20% of its total assets in other U.S. and other non-U.S. investments. These investments may include equity and debt securities of companies not engaged in the energy and natural resources industry. The Trust reserves the right to invest up to 10% of its total assets in non-investment grade debt securities, commonly known as “junk bonds.”
In addition to the option strategies discussed above, the Trust may engage in transactions such as options, futures, swaps, foreign currency transactions including forward foreign currency contracts, currency swaps or options on currency and currency futures and other derivatives transactions for hedging purposes or to enhance total return. The Trust may also engage in short sales of securities.
The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment and the Trust will not be required to sell securities due to subsequent changes in the value of securities it owns.
Application of the Trust’s investment philosophy, from time to time, may cause the Trust to invest a significant portion of its assets in a particular country or region of the world. The Trust anticipates that its investment strategy will cause it to invest in a number of countries throughout the world, but the actual number of countries represented in the Trust’s portfolio will vary over time. The Trust anticipates that application of its investment philosophy currently would cause it to invest in issuers located in 10 countries globally, including the United States. Under normal market conditions, the Trust will invest in the equity securities of issuers in at least three different countries, including the United States, and will invest at least 30% of its total assets at the time of investment in the equity securities of non-United States issuers. However, the Trust may invest in the securities of non-United States issuers without limit.
Leverage:
The Trust may, but does not currently intend to, incur indebtedness or issue preferred shares for investment purposes.
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
The Trust’s investment objective is to provide current income and capital appreciation. The Trust’s investment objective is a fundamental policy and may not be changed without the approval of a majority of the outstanding voting securities of the Trust (as defined in the Investment Company Act of 1940, as amended (the “1940 Act”).
The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. BlackRock Advisors, LLC (the “Manager”) from time to time may vary the percentage of the Trust’s assets invested in any particular type of equity security based on such factors as market and economic conditions, fiscal and monetary policy and the relative security valuation of the various equity asset classes.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  181

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options on indices of securities and sectors of securities. In addition to its option strategy on indices, the Trust may pursue a strategy that includes the writing (selling) of both call and put options on individual common stocks. These option strategies are intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s stockholders. As the Trust writes calls and puts over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.
To the extent the Trust invests in dividend-paying common stocks, the Manager currently intends to emphasize those securities that: (i) are eligible to pay “qualified dividend” income and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers (“Dividends Received Deduction”) pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income included in distributions of a regulated investment company (a “RIC”) to its individual stockholders are generally passed through to such stockholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate stockholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC designates as qualifying for the Dividends Received Deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the Dividends Received Deduction which will, in turn, limit the tax benefit to a corporate stockholder of investing in the Trust. Corporate stockholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals or (ii) the Dividends Received Deduction for corporate stockholders of the Trust.
Investment in the Trust’s common stock offers the individual investor several potential benefits. The Trust offers investors the opportunity to invest in a professionally managed portfolio which contains common stocks and preferred securities of U.S. and foreign issuers. The Manager provides professional management, which includes the extensive securities and credit analysis needed to invest in common stocks, preferred securities and foreign securities. The Trust also relieves the investor of the burdensome administrative details involved in managing a portfolio of such investments. These benefits are at least partially offset by the expenses involved in running an investment company. Such expenses primarily consist of advisory fees and operational costs. The use of leverage also involves certain expenses and risk considerations.
The Trust may engage in various portfolio strategies to seek to increase its return or to hedge its portfolio against movements in interest rates, in currency rates and in the securities markets through the use of derivatives, such as indexed and inverse securities, options, futures, options on futures, total return swaps, short selling and foreign exchange transactions. No assurance can be given that the Trust will employ these strategies or that, if employed, they will be effective.
The Trust may vary its investment objective and policies for temporary defensive purposes during periods in which the Manager believes that conditions in the securities markets or other economic, financial or political conditions warrant and in order to keep the Trust’s cash fully invested, including during the periods which the net proceeds of the offering are being invested. Under such conditions, the Trust may invest up to 100% of its total assets in securities issued or guaranteed by the United States government or its instrumentalities or agencies, certificates of deposit, bankers’ acceptances and other bank obligations, commercial paper rated in the highest category by an established rating service, or other debt securities deemed by the Manager to be consistent with a defensive posture, or may hold its assets in cash.
Leverage:
The Trust does not currently intend to, but may, leverage its portfolio through borrowings, the issuance of debt securities, the issuance of preferred stock or a combination thereof.
BlackRock Enhanced Equity Dividend Trust (BDJ)
The Trust’s primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust’s investment objectives are not fundamental and may be changed by the Board of Trustees without shareholder approval.
The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust uses an option strategy that writes options on approximately 50-60% of its total assets.
Under normal market conditions, the Trust invests at least 80% of its total assets in dividend-paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in such securities or synthetically through the use of derivatives.
To the extent the Trust invests in dividend-paying common stocks, BlackRock Advisors, LLC (the “Manager”) may emphasize those securities that: (i) are eligible to pay “qualified dividend” income, and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income properly reported as being included in distributions of a regulated investment company (a “RIC”) to its individual shareholders are generally passed through to such shareholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate shareholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC reports as qualifying for the dividends received deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the dividends received deduction which will, in turn, limit the tax benefit to a corporate shareholder of investing in the Trust. Corporate shareholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals, or (ii) the dividends received deduction for corporate shareholders of the Trust.
The Trust may invest up to 20% of its total assets in preferred securities.
 
 
182
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may invest up to 10% of its total assets in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies.
The Trust may invest in shares of real estate investment trusts.
The Trust may invest up to 20% of its total assets in non-U.S. securities, which may include securities denominated in U.S. dollars or in foreign currencies or multinational currency units. The Trust may invest in foreign securities of emerging market issuers, but investments in such securities will not comprise more than 10% of its total assets. The Trust will consider a company a U.S. company and not a foreign company if it meets one or more of the following tests: (i) such company was organized in the United States; (ii) such company’s primary business office is in the United States; (iii) the principal trading market for such company’s assets are located in the United States; (iv) 50% or more of such company’s assets are located in the United States; or (v) 50% or more of such issuer’s revenues are derived from the United States.
The Trust may enter into forward currency contracts to purchase or sell foreign currencies for a fixed amount of U.S. dollars or another foreign currency.
The Trust may enter into are interest rate swaps and the purchase or sale of interest rate caps and floors. The Trust expects to enter into these transactions primarily to preserve a return or spread on a particular investment or portion of its portfolio as a duration management technique or to protect against any increase in the price of securities the Trust anticipates purchasing at a later date. The Trust intends to use these transactions for hedging and risk management purposes and not as a speculative investment. The Trust will not sell interest rate caps or floors that it does not own. The Trust will only enter into interest rate swap, cap or floor transactions with counterparties the Investment Advisor believes to be creditworthy at the time they enter into such transactions.
The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of the Trust’s total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may also make short sales “against the box” without respect to such limitations.
Leverage:
The Trust may borrow funds for investment purposes and/or issue debt securities or preferred shares to purchase additional securities. These practices are known as “leverage.” The Trust may borrow from banks and other financial institutions and may also borrow additional funds using such investment techniques as the Manager may from time to time determine. The Trust may borrow in an amount up to 5% of its total assets for temporary or emergency purposes.
The Trust currently does not intend to incur indebtedness or issue preferred shares for investment purposes, except in connection with derivative instruments such as exchange listed and over-the-counter put and call options on securities, financial futures, equity indices, and other financial instruments, purchase and sell futures contracts and options thereon, swaps, forward foreign currency contracts and various interest rate transactions, short sales, repurchase agreements, reverse repurchase agreements, when issued or forward commitment transactions and similar investment strategies.
BlackRock Enhanced Global Dividend Trust (BOE)
The Trust’s investment objective is primarily to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust’s investment objective is not a fundamental policy and may be changed without prior shareholder approval.
The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies located in countries throughout the world and by utilizing an option writing strategy to enhance current gains. BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, from time to time may vary the percentage of the Trust’s assets invested in any particular type of equity security, based on factors such as market and economic conditions, fiscal and monetary policy and the relative security valuation of the various equity asset classes.
The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options on indices of securities and sectors of securities. The Trust intends to write covered put and call options with respect to approximately 30% to 45% of its total assets, although this percentage may vary from time to time with market conditions. In addition to its option strategy on indices, the Trust may pursue a strategy that includes the writing (selling) of both call and put options on individual common stocks. These option strategies are intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders. As the Trust writes calls and puts over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.
Under normal market conditions, the Trust is required to invest at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest directly in such securities or synthetically through the use of derivatives. Equity securities in which the Trust invests include common stocks, preferred stocks, convertible securities, warrants, depositary receipts and equity interests in real estate investment trusts. The Trust may invest in companies located anywhere in the world. The Trust may invest in companies of any size market capitalization, but intends to invest primarily in the securities of large capitalization companies. The Trust may invest in companies conducting initial public offerings. The Trust may invest up to 25% of its total assets in equity securities of issuers in emerging countries. The Trust may invest up to 20% of its total assets in debt securities, including debt securities issued by companies located in emerging markets. The Trust may invest up to 10% of its total assets in non-investment grade debt securities, commonly known as “junk bonds.”
Application of the Trust’s investment philosophy, from time to time, may cause the Trust to invest a significant portion of its assets in a particular country or region of the world. The Trust’s investment strategy causes it to invest in issuers located in a number of countries throughout the world, but the actual number of countries represented in the Trust’s portfolio will vary over time. Under normal market conditions, the Trust invests in the equity securities of issuers in at least three different countries, including the United States. However, the Trust may invest in the securities of non-U.S. issuers without limit.
The Trust may engage in various portfolio strategies to seek to increase its return or to hedge its portfolio against movements in interest rates, in currency rates and in the securities markets through the use of derivatives, such as indexed and inverse securities, options, futures, options on futures, interest rate transactions, including interest rate swaps, total return swaps and credit default swaps and short selling and foreign exchange transactions. Each of these portfolio strategies is described below. No assurance can be given that the Trust will employ these strategies or that, if employed, they will be effective.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  183

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment, and the Trust will not be required to sell securities due to subsequent changes in the value of securities it owns.
To the extent the Trust invests in dividend-paying common stocks, the Advisors currently intend to emphasize those securities that: (i) are eligible to pay “qualified dividend” income and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income included in distributions of a regulated investment company (a “RIC”) to its individual shareholders are generally passed through to such shareholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate shareholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC designates as qualifying for the Dividends Received Deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the Dividends Received Deduction which will, in turn, limit the tax benefit to a corporate shareholder of investing in the Trust. Corporate shareholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals or (ii) the Dividends Received Deduction for corporate shareholders of the Trust.
In selecting investments for the Trust, the Advisors combine fundamental research with a top-down strategy, analyzing 70 sub-industry groups on an ongoing basis. The Advisors seek to identify companies that it believes have the potential to outperform the market. The Advisors’ investment techniques for the Trust include assessing industry structure and dynamics, evaluating growth catalysts on an industry and individual company basis and assessing a company’s valuation relative to the broad market and its respective industry group. The Advisors seek to invest in companies that it believes have sizeable market opportunities, global, regional or local competitive advantages, sound business models and financial strength, proven management teams and compelling relative and absolute valuations.
Leverage:
The Trust may, but does not currently intend to, incur indebtedness or issue preferred shares for investment purposes.
BlackRock Enhanced International Dividend Trust (BGY)
The Trust’s primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. “Current gains” means gains realized from the Trust’s option strategy (described below) pursuant to which the Trust seeks to enhance monthly distributions to investors. The Trust’s investment objectives may be changed without shareholder approval.
The Trust seeks to achieve its objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to enhance current gains. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust may invest up to 20% of its total assets in equity securities of issuers located in the United States. The Trust may invest up to 50% of its total assets in equity securities of issuers located in emerging market countries. Emerging market countries generally include every nation in the world except the United States, Canada, Japan, Australia, New Zealand and most countries in Western Europe. Equity securities in which the Trust anticipates investing include common stocks, preferred stocks, convertible securities, warrants, depositary receipts and equity interests in real estate investment trusts.
Under normal circumstances, the Trust anticipates it will allocate a substantial amount (approximately 40% or more — unless market conditions are not deemed favorable by BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, in which case the Trust would invest at least 30%) — of its total assets in securities of (i) foreign government issuers, (ii) issuers organized or located outside the U.S., (iii) issuers which primarily trade in a market located outside the U.S., or (iv) issuers doing a substantial amount of business outside the U.S., which the Trust considers to be companies that derive at least 50% of their revenue or profits from business outside the U.S. or have at least 50% of their sales or assets outside the U.S. The Trust will allocate its assets among various regions and countries, including the United States (but in no less than three different countries). For temporary defensive purposes, the Trust may deviate very substantially from the allocation described above.
The Trust seeks to generate current dividends and income by investing in equity securities that pay dividends. The Trust will seek income a portion of which is classified as “qualified dividend income,” which is dividend income that is eligible to be taxed at a maximum U.S. federal income tax rate of generally 20%. The lower U.S. federal tax rates generally apply to dividend income from taxable domestic corporations and certain qualified foreign corporations, provided that holding period and other requirements are met by both the Trust and the shareholder.
As part of its investment strategy, the Trust intends to write (sell) covered call and put options on individual common stocks, stock indices and stock sectors. The Trust may utilize over-the-counter options to a significant extent in order to employ its option strategy. This option strategy is intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders. As the Trust writes covered calls over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.
A call option written by the Trust on a security is “covered” if the Trust owns the security underlying the call or has an absolute and immediate right to acquire that security without additional cash consideration (or, if additional cash consideration is required, the Trust’s custodian segregates sufficient cash or other assets determined to be liquid by the Advisors (in accordance with procedures established by the Board of Trustees (the “Board”))) upon conversion or exchange of other securities held by the Trust. A call option is also covered if the Trust holds a call on the same security as the call written where the exercise price of the call held is (i) equal to or less than the exercise price of the call written or (ii) greater than the exercise price of the call written, provided the difference is maintained by the Trust in segregated assets determined to be liquid by the Advisors as described above.
 
 
184
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks  
(continued)
 
Investment Objectives and Policies
(continued)
A put option written by the Trust on a security is “covered” if the Trust segregates assets determined to be liquid by the Advisors (in accordance with procedures established by the Board) equal to the exercise price. A put option is also covered if the Trust holds a put on the same security as the put written where the exercise price of the put held is (i) equal to or greater than the exercise price of the put written or (ii) less than the exercise price of the put written, provided the difference is maintained by the Trust in segregated assets determined to be liquid by the Advisors as described above.
An index- or sector-oriented option is considered “covered” if the Trust maintains with its custodian assets determined to be liquid in an amount equal to the contract value of the applicable basket of securities. An index or sector call option also is covered if the Trust holds a call on the same basket of securities as the call written where the exercise price of the call held is (i) equal to or less than the exercise price of the call written or (ii) greater than the exercise price of the call written, provided the difference is maintained by the Trust in segregated assets determined to be liquid. An index or sector put option also is covered if the Trust holds a put on the same basket of securities as the put written where the exercise price of the put held is (i) equal to or more than the exercise price of the put written or (ii) less than the exercise price of the put written, provided the difference is maintained by the Trust in segregated assets determined to be liquid. Because index and sector options both refer to options on baskets of securities and generally have similar characteristics, we refer to these types of options collectively as “index options.”
The Trust generally intends to write covered put and call options with respect to approximately 30% to 45% of its total assets, although this percentage may vary from time to time with market conditions. As the Trust writes covered calls over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.
The Trust may hold or have exposure to equity securities of issuers of any size, including small and medium capitalization companies, and to issuers in any industry or sector. The Trust will not invest 25% or more of its total assets in securities of issuers in any single industry.
The Trust may invest in the securities of smaller, less seasoned companies. The Trust also may engage in short sales of securities and may lend its portfolio securities to banks or dealers which meet the creditworthiness standards established by the Board.
Although not intended to be a significant element in the Trust’s investment strategy, from time to time the Trust may purchase and sell derivative instruments such as exchange-listed and over-the-counter put and call options on securities, financial futures, equity indices and other financial instruments, purchase and sell financial futures contracts and options thereon, engage in swaps and purchase derivative instruments that combine features of these instruments for hedging and risk management purposes or to enhance total return. The percentage limitations set herein apply at the time of investment, and the Trust will not be required to sell securities because of subsequent changes in market values.
Leverage:
Although the Agreement and Declaration of Trust of the Trust provides that the Board of the Trust may authorize the Trust to issue preferred shares or incur indebtedness, the Trust currently does not intend to issue preferred shares or incur indebtedness for investment purposes.
BlackRock Health Sciences Trust (BME)
The Trust’s investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. Equity derivatives in which the Trust invests as part of this non-fundamental investment policy include purchased and sold (written) call and put options on equity securities of companies in the health sciences and related industries.
The Trust’s investment objective may be changed by the Board of Trustees without prior shareholder approval; however, the Trust will not change its policy of investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry unless it provides shareholders with notice at least 60 days prior to changing this non-fundamental policy, or unless such change was previously approved by shareholders.
Companies in the health sciences industry include health care providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or financial support. Other health sciences industries in which the Trust may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. BlackRock Advisors, LLC (the “Manager”) determines, in its discretion, whether a company is engaged in the health sciences and related industries.
While the Trust will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences industries include companies engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance, improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health.
The Trust will consider a company to be principally engaged in a health sciences or related industry if 50% or more of its revenues are derived from, or 50% or more of its assets are related to, its health sciences business. Although the Trust generally will invest in companies included in the Russell 3000
®
Index, the Trust may invest in equity securities of health sciences companies with any size market capitalization, including small and mid-cap health sciences companies and companies that are not included in the Russell 3000
®
Index.
As part of its investment strategy, the Trust employs an option strategy of writing (selling) covered call options on common stocks in its portfolio, writing other call and put options on individual common stocks and, to a lesser extent, writing call and put options on indices of health sciences securities. The Trust seeks to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. The Trust generally intends to write call and put options with respect to approximately 30% to 50% of its total assets, although this percentage may vary from time to time with market conditions.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  185

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust invests primarily in equity securities, including common stocks, preferred stocks, convertible securities, warrants and depositary receipts, of issuers engaged in the health sciences or related industries and equity interests in real estate investment trusts (“REITs”) that own hospitals. The Trust may invest in companies of any size market capitalization.
The Trust may invest in preferred securities, including preferred securities that may be converted into common stock or other securities of the same or a different issuer. The types of preferred securities in which the Trust may invest include trust preferred securities.
The Trust may invest in convertible securities. A convertible security is a bond, debenture, note, preferred security or other security that may be converted into or exchanged for a prescribed amount of common stock or other equity security of the same or a different issuer within a particular period of time at a specified price or formula.
The Trust may purchase warrants, which are privileges issued by corporations enabling the owners to subscribe to and purchase a specified number of shares of the corporation at a specified price during a specified period of time.
The Trust may invest in sponsored and unsponsored American Depositary Receipts (“ADRs”), European Depositary Receipts (“EDRs”), Global Depositary Receipts (“GDRs”) and other similar global instruments.
The Trust may invest in equity interests of REITs. REITs possess certain risks which differ from an investment in common stocks. REITs are financial vehicles that pool investor’s capital to purchase or finance real estate. REITs may concentrate their investments in specific geographic areas or in specific property types (i.e., hotels, shopping malls, residential complexes and office buildings).
The Trust may invest without limitation in securities of U.S. issuers and non-U.S. issuers located in countries throughout the world, including in developed and emerging markets. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated. For purposes of the Trust, a company is deemed to be a non-U.S. company if it meets the following tests: (i) such company was not organized in the United States; (ii) such company’s primary business office is not in the United States; (iii) the principal trading market for such company’s securities is not located in the United States; (iv) less than 50% of such company’s assets are located in the United States; or (v) 50% or more of such issuer’s revenues are derived from outside the United States.
The Trust may invest up to 20% of its total assets in other investments. These investments may include equity and debt securities of companies not engaged in the health sciences industry. Fixed-income securities in which the Trust may invest include bonds or other debt securities issued by U.S. or foreign (non-U.S.) corporations or other business entities and U.S. Government and agency securities. The Trust has no set policy regarding portfolio maturity or duration of the fixed-income securities it may hold, and such securities may be of any maturity.
The Trust reserves the right to invest up to 10% of its total assets in securities rated, at the time of investment, below investment grade quality, such as those rated “Ba” or below by Moody’s Investors Service, Inc. and “BB” or below by S&P Global Ratings, or securities comparably rated by other rating agencies or in securities determined by the Manager to be of comparable quality. Such securities commonly are referred to as “high yield” or “junk” bonds.
The Trust may invest in registered investment companies in accordance with the Investment Company Act of 1940, as amended (the “1940 Act”). The 1940 Act generally prohibits the Trust from investing more than 5% of its assets in any one other investment company or more than 10% of its assets in all other investment companies.
In addition to the option strategies discussed above, the Trust may engage in strategic transactions to facilitate portfolio management, mitigate risks and generate total return. The Trust may use a variety of other investment management techniques and instruments. The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques. The Trust also may purchase derivative instruments that combine features of these instruments.
In connection with its hedging and other risk management strategies, the Trust may also enter into contracts for the purchase or sale for future delivery (“future contracts”) of securities, aggregates of securities, financial indices, and U.S. Government debt securities or options on the foregoing to hedge the value of its portfolio securities that might result from a change in interest rates or market movements. The Trust may engage in such transactions for bona fide hedging, risk management and other appropriate portfolio management purposes.
The Trust may enter into such transactions without limit for bona fide strategic purposes, including risk management and duration management and other portfolio strategies. The Trust may also engage in transactions in futures contracts or related options for non-strategic purposes to enhance income or gain provided that the Trust will not enter into a futures contract or related option (except for closing transactions) for purposes other than bona fide strategic purposes, or risk management including duration management unless it does so consistent with the rules of the Commodities Futures Trading Commission (the “CFTC”).
The Trust may engage in options and futures transactions on exchanges and options in the over-the-counter (“OTC”) markets.
The Trust intends to enter into options and futures transactions only with banks or dealers the Manager believes to be creditworthy at the time they enter into such transactions.
The CFTC subjects advisers to registered investment companies to regulation by the CFTC if a fund that is advised by the investment adviser either (i) invests, directly or indirectly, more than a prescribed level of its liquidation value in CFTC-regulated futures, options and swaps (“CFTC Derivatives”), or (ii) markets itself as providing investment exposure to such instruments. To the extent the Trust uses CFTC Derivatives, it intends to do so below such prescribed levels and will not market itself as a “commodity pool”
 
 
186
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks  
(continued)
 
Investment Objectives and Policies
(continued)
or a vehicle for trading such instruments. Accordingly, the Manager has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”) pursuant to Rule 4.5 under the CEA. The Manager is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA in respect of the Trust.
In order to enhance income or reduce fluctuations in net asset value, the Trust may sell or purchase call options on securities and indices based upon the prices of futures contracts and debt or equity securities that are traded on U.S. and non-U.S. securities exchanges and on the over-the-counter markets.
As with calls, the Trust may purchase put options on securities (whether or not it holds such securities in its portfolio), indices or future contracts. For the same purposes, the Trust may also sell puts on securities, indices or futures contracts on such securities if the Trust’s contingent obligations on such puts are secured by designating cash or liquid assets on its books and records having a value not less than the exercise price. The Trust will not sell puts if, as a result, more than 50% of the Trust’s assets would be required to be segregated on its books to cover its potential obligation under its hedging and other investment transactions.
The Trust may enter into interest rate swaps and the purchase or sale of interest rate caps and floors. The Trust expects to enter into these transactions primarily to preserve a return or spread on a particular investment or portion of its portfolio as a duration management technique or to protect against any increase in the price of securities the Trust anticipates purchasing at a later date. The Trust may enter into interest rate swaps, caps and floors on either an asset-based or liability-based basis.
The Trust intends to use these transactions for risk management purposes and not as a speculative investment. The Trust will not sell interest rate caps or floors that it does not own. The Trust will only enter into interest rate swap, cap or floor transactions with counterparties the Manager believes to be creditworthy at the time they enter into such transactions.
The Trust may engage in credit derivative transactions. There are two broad categories of credit derivatives: default price risk derivatives and market spread derivatives. Default price risk derivatives are linked to the price of reference securities or loans after a default by the issuer or borrower, respectively. Market spread derivatives are based on the risk that changes in market factors, such as credit spreads, can cause a decline in the value of a security, loan or index. There are three basic transactional forms for credit derivatives: swaps, options and structured instruments.
The Trust may enter into forward currency contracts to purchase or sell foreign currencies for a fixed amount of U.S. dollars or another foreign currency. A forward currency contract involves an obligation to purchase or sell a specific currency at a future date, which may be any fixed number of days (term) from the date of the forward currency contract agreed upon by the parties, at a price set at the time the forward currency contract is entered into. Forward currency contracts are traded directly between currency traders (usually large commercial banks) and their customers.
The Trust may make short sales of securities for risk management, in order to maintain portfolio flexibility or to enhance income or gain. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may also make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale, the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security.
The Trust may invest in illiquid investments. Illiquid investments are subject to legal or contractual restrictions on disposition or lack an established secondary market. The sale of restricted and illiquid investments often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses than does the sale of investments eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted investments may sell at a price lower than similar investments that are not subject to restrictions on resale.
The Trust may purchase securities on a “when-issued” basis and may purchase or sell securities on a “forward commitment” basis in order to acquire the security or to hedge against anticipated changes in interest rates and prices. When-issued securities and forward commitments may be sold prior to the settlement date, but the Trust will enter into when-issued and forward commitments only with the intention of actually receiving or delivering the securities, as the case may be.
The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to banks, brokers and other financial institutions.
As temporary investments, the Trust may invest in repurchase agreements. The Trust will only enter into repurchase agreements with registered securities dealers or domestic banks that, in the opinion of the Manager, present minimal credit risk.
The Trust may deviate from its investment strategy and invest all or any portion of its assets in cash, cash equivalents or short-term debt securities when the Manager determines that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so or pending re-investment of proceeds received in connection with the sale of a security. The Trust may not achieve its investment objective when it does so. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent. Short-term debt investments include U.S. Government securities, including bills, notes and bonds differing as to maturity and rates of interest that are either issued or guaranteed by the U.S. Treasury or by U.S. Government agencies or instrumentalities, certificates of deposit issued against funds deposited in a bank or a savings and loan association, repurchase agreements, which involve purchases of debt securities, and commercial paper, which consists of short-term unsecured promissory notes, including variable rate master demand notes issued by corporations to finance their current operations. Investments in commercial paper will be limited to commercial paper rated in the highest categories by a major rating agency and which mature within one year of the date of purchase or carry a variable or floating rate of interest.
Leverage:
The Trust does not currently borrow money for investment purposes or have preferred shares outstanding, and has no present intention of borrowing money for investment purposes or issuing preferred shares in the future.
The Trust may enter into derivative transactions that have leverage embedded in them.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  187

Investment Objectives, Policies and Risks  
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may enter into reverse repurchase agreements and “dollar roll” transactions.
BlackRock Health Sciences Trust II (BMEZ)
The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.
BlackRock Advisors, LLC (the “Manager”) believes that the knowledge and experience of its Health Sciences Team enable it to evaluate the macro environment and assess its impact on health sciences companies and the various sub-industries within the health sciences group of industries. Within this framework, the Manager identifies stocks with attractive characteristics, evaluates the use of options and provides ongoing portfolio risk management.
The top-down or macro component of the investment process is designed to assess the various interrelated macro variables affecting the health sciences group of industries as a whole. The Manager evaluates health sciences sub-industries (i.e., pharmaceuticals, biotechnology, medical devices, healthcare services, etc.). Selection of sub-industries within the health sciences group of industries is a result of both the Manager’s sub-industry analysis, as well as the Manager’s bottom-up fundamental company analysis. Risk/reward analysis is a key component of both top-down and bottom-up analysis.
Bottom-up security selection is focused on identifying companies with the most attractive characteristics within each sub-industry of the health sciences group of industries. The Manager seeks to identify companies with strong product potential, solid earnings growth and/or earnings power which are under appreciated by investors, a quality management team and compelling relative and absolute valuation. The Manager believes that the knowledge and experience of its Health Sciences Team enables it to identify attractive health sciences securities.
The Manager intends to utilize option strategies that consist of writing (selling) call options on a portion of the common stocks in the Trust’s portfolio, as well as other option strategies such as writing other calls and puts or using options to manage risk. The portfolio management team will work closely to determine which option strategies to pursue to seek to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.
Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests as part of this non-fundamental investment policy include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.
The Trust will consider a company to be principally engaged in the health sciences group of industries if (i) it is classified in an industry within the health sciences group of industries by a third-party industry classification system or (ii) it is not classified in any industry by such third-party industry classification system and the Manager determines that the company is principally engaged in the health sciences group of industries.
Companies in the health sciences group of industries include health care providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or financial support. Other companies in the health sciences group of industries in which the Trust may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. The Trust will concentrate its investments in the health sciences group of industries.
While the Trust will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences companies include those engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance; improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health.
The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Trust will focus its investments in mid- and small-capitalization companies. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.
The Trust invests primarily in equity securities, including common stocks, preferred stocks, convertible securities, warrants and depositary receipts, of health sciences companies and limited partnership interests in REITs that own hospitals.
The Trust may invest in shares of companies through IPOs. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. The Trust intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “late-stage private securities,” which are securities of private companies that have demonstrated sustainable business operations and generally have a well-known product or service with a strong market presence. Late-stage private companies have generally had large cash flows from their core business operations and are expanding into new markets with their products or services. Late-stage private companies may also be referred to as “pre-IPO companies.”
The Trust may invest up to 20% of its total assets in other investments, including equity securities issued by companies that are not principally engaged in the health sciences group of industries and debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities. The Trust has no set policy regarding portfolio maturity or duration of the fixed-income securities it may hold, and such securities may be of any maturity.
 
 
188
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks  
(continued)
 
Investment Objectives and Policies
(continued)
As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter (“OTC”) options.
During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.
The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and OTC put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.
The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.
The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).
Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s investment objectives may be changed by the Board without prior shareholder approval; however, the Trust will not change its policy of investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries unless it provides shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.
Leverage:
The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objectives and policies.
The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.
The Trust may enter into “dollar roll” transactions.
The Trust may enter into derivative transactions that have leverage embedded in them.
The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.
BlackRock Innovation and Growth Trust (BIGZ)
The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust is not intended as, and you should not construe it to be, a complete investment program. There can be no assurance that the Trust’s investment objectives will be achieved or that the Trust’s investment program will be successful. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.
In selecting investments for the Trust, BlackRock Advisors, LLC (the “Manager”) focuses on equity securities of mid- and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. In evaluating innovative companies, the Manager seeks to identify, using its own internal research and analysis, companies capitalizing on innovation or that are enabling the further development of the theme of innovation in the markets in which they operate.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  189

Investment Objectives, Policies and Risks 
(continued)
 
Investment Objectives and Policies
(continued)
Among other things, common criteria for innovative companies across industries may include developing new products, selling in new markets or channels, applying a new or superior technology to legacy industries, refining existing processes for efficiency, changing or pivoting business model, or creating tools that empower new breakthroughs.
In addition, the Trust seeks to invest in companies where, in the opinion of the Manager, free cash flow is likely to grow for a sustained period. Factors considered in the Manager’s analysis of a company may include 1) a large and underpenetrated addressable market, 2) a technology or service model that creates recurring demand for product, and 3) a competitive landscape that allows for stable or expanding margins. The Manager’s outlook for a company based upon these and other factors is then compared to the outlook of the company implied in the current share price of the company. The Manager looks to invest in companies where its view of future cash flows is more favorable than that which it believes is reflected by the current price.
The Manager will identify trends that have ramifications for individual companies or entire industries. Risk/reward analysis is a key component of both top-down and bottom-up analysis.
Bottom-up security selection is focused on identifying innovative companies with the most attractive growth characteristics. The Manager seeks to identify companies with strong product potential, solid earnings growth and/or earnings power which are under appreciated by investors, a quality management team and compelling relative and absolute valuation. The Manager believes that the knowledge and experience of its investment team enables it to identify attractive innovative companies.
The Trust intends to utilize option strategies that consist of writing (selling) call options on a portion of the common stocks in its portfolio, as well as other option strategies such as writing other calls and puts or using options to manage risk. The portfolio management team will work closely to determine which option strategies to pursue to seek to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.
The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Manager believes have above-average earnings growth potential.
Equity securities include common stocks, preferred stocks, convertible securities, warrants and depositary receipts, though the Trust seeks to buy primarily common stock. Although universal definitions of mid-capitalization companies and small-capitalization companies do not exist, the Trust generally defines mid-capitalization and small-capitalization companies as those companies with market capitalizations, at the time of the Trust’s investment, comparable in size to the companies in the Russell 2500™ Growth Index (between $3.89 million and $20.48 billion as of December 31, 2022). In the future, the Trust may define mid- and small-capitalization companies using a different index or classification system.
The Trust may invest in shares of companies through IPOs. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Exchange Act. Under normal market conditions, the Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “late-stage private securities,” which are securities of private companies that have demonstrated sustainable business operations and generally have a well-known product or service with a strong market presence. Late-stage private companies have generally had large cash flows from their core business operations and are expanding into new markets with their products or services. Late-stage private companies may also be referred to as “pre-IPO companies.”
The Trust may invest up to 25% of its assets in securities of foreign companies, including companies located in emerging markets. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.
The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.
As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, including uncovered call and put options, and, to a lesser extent, writing (selling) covered and uncovered call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.
The Trust may also purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter (“OTC”) put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.
During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.
The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
 
 
190
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may engage in active and frequent trading of portfolio securities to achieve its investment objectives.
Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described in this prospectus apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s investment objectives may be changed by the Board without prior shareholder approval.
Leverage:
The Trust currently does not intend to borrow money or issue debt securities or preferred shares. The Trust is, however, permitted to borrow money or issue debt securities in an amount up to 33 1/3% of its Managed Assets (50% of its net assets), and issue preferred shares in an amount up to 50% of its Managed Assets (100% of its net assets). “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes). Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares.
The Trust is permitted to leverage its portfolio by entering into one or more credit facilities.
The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to the Trust’s investment restrictions.
The Trust may enter into “dollar roll” transactions.
The Trust may enter into derivative transactions that have leverage embedded in them.
The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.
BlackRock Resources & Commodities Strategy Trust (BCX)
The Trust’s primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its objectives by investing substantially all of its assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives. The Trust’s investment objectives are not fundamental and may be changed by the Board of Trustees of the Trust (the “Board”).
The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives. Commodities and natural resources include, without limitation, minerals, metals (including precious, industrial and rare metals), steel, agricultural products and commodities, livestock, environmental commodities, wool, ethanol, chemicals, forest products (including wood, pulp and paper), plastic, rubber, sugar, cotton, cocoa, coffee, basic materials, building materials, water, oil, gas, consumable fuel, energy and other natural resources. Commodity and natural resources companies, include, but are not limited to, companies in commodities, natural resources and energy businesses and in associated businesses and companies that provide services or have exposure to such businesses (collectively, the “Commodities and Natural Resources Sector”). These companies include, without limitation, companies engaged in the exploration, ownership, production, refinement, processing, transportation, distribution or marketing of commodities or natural resources, companies that use commodities and natural resources extensively in their products, including companies that are engaged in businesses such as integrated oil, oil and gas exploration and production, gold, metals and minerals, steel and iron ore production, aluminum and related products, energy services, and technology, metal production, forest products, including timber and related wood and paper products, chemicals, fertilizer and agricultural chemicals, building materials, coal and other consumable fuel, alternative energy sources, environmental services and agricultural products (including crop growers, owners of plantations, and companies that produce and process foods), as well as related transportation companies and equipment manufacturers. The Trust will consider a company to be a commodity or natural resources company if: (i) at least 50% of the company’s assets, income, sales or profits are committed to or derived from the Commodities and Natural Resources Sector; or (ii) a third party classification (such as (a) Standard Industry Classifications and the North American Industry Classification System, each of which is published by the Executive Office of the President, Office of Management and Budget and (b) classifications used by third party data providers including, without limitation, FactSet Research Systems Inc. and MSCI Barra), has given the company an industry or sector classification consistent with the Commodities and Natural Resources Sector.
Equity securities held by the Trust may include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, equity interests in Canadian Royalty Trusts, and equity interests in master limited partnerships (“MLPs”). The Trust will not invest more than 25% of the value of its total assets in MLPs. The Trust’s economic exposure to securities and derivatives linked to the underlying price movements of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives (“Commodity-Related Instruments”) will not exceed 20% of its total assets. Commodity-Related Instruments may include, but will not be limited to, investments in structured notes, partnership interests, exchange-traded funds that make commodity-related or natural resources-related investments, mutual funds and strategic transactions, including futures contracts on commodities and natural resources, forward contracts on commodities and natural resources and swap contracts on commodities and natural resources.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  191

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may invest in such Commodity-Related Instruments either directly or indirectly through the BlackRock Cayman Resources & Commodities Strategy Fund, Ltd., a wholly-owned subsidiary of the Trust formed in the Cayman Islands (the “Subsidiary”). Investments in the Subsidiary are intended to provide the Trust with exposure to commodities market returns within the limitations of the federal tax requirements that apply to the Trust. The Trust may gain exposure to certain Commodity-Related Instruments and certain other commodity-related and natural resources-related investments that, if the Trust invested in such investments directly, would not produce qualifying income for purposes of the income tests applicable to regulated investment companies under the Internal Revenue Code of 1986, as amended, by investing in the Subsidiary. The Manager is the manager of the Subsidiary. The Subsidiary (unlike the Trust) may invest without limitation in commodity-related instruments.
The Subsidiary will be managed pursuant to compliance policies and procedures that are the same, in all material respects, as the policies and procedures adopted by the Trust. As a result, the Manager, in managing the Subsidiary’s portfolio, will be subject to the same investment policies and restrictions that apply to the management of the Trust, and, in particular, to the requirements relating to portfolio leverage, liquidity, brokerage, and the timing and method of the valuation of the Subsidiary’s portfolio investments and shares of the Subsidiary. The Trust’s Chief Compliance Officer will oversee implementation of the Subsidiary’s policies and procedures, and make periodic reports to the Board regarding the Subsidiary’s compliance with its policies and procedures. The Trust and Subsidiary will test for compliance with certain investment restrictions on a consolidated basis, except that with respect to the Subsidiary’s investments in certain securities that may involve leverage, the Subsidiary will comply with asset segregation requirements to the same extent as the Trust.
The Manager will provide investment management and other services to the Subsidiary pursuant to the investment management agreement among the Manager, the Trust and the Subsidiary. The Trust and the Subsidiary will pay the Manager based on the Trust’s assets (excluding the value of the Trust’s interest in the Subsidiary) and the Subsidiary’s assets, respectively. The Subsidiary has also entered into separate contracts for the provision of custody and audit services with the same or with affiliates of the same service providers that provide those services to the Trust. The financial statements of the Subsidiary are consolidated with the Trust’s financial statements in the Trust’s annul and semi-annual reports.
Although the Trust is permitted to invest up to 20% of its total assets in Commodity-Related Instruments, the Trust is not required to invest in Commodity-Related Instruments and does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust may invest in Commodity-Related Instruments (either directly or through the Subsidiary) when BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, believes it is advantageous for the Trust to do so.
While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources; therefore, the Trust does not currently intend to invest any assets in the Subsidiary.
The Commodity Futures Trading Commission (the “CFTC”) subjects advisers to registered investment companies to regulation by the CFTC if a fund that is advised by the investment adviser either (i) invests directly or indirectly more than a prescribed level of its liquidation value in CFTC-regulated futures, options and swaps (“CFTC Derivatives”), or (ii) markets itself as providing investment exposure to such instruments. To the extent the Trust uses CFTC Derivatives, it intends to do so below such prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. Accordingly, the Manager has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”) pursuant to Rule 4.5 under the CEA. The Manager is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA in respect of the Trust.
The Trust may invest in companies of any market capitalization located anywhere in the world. The Trust expects to invest primarily in companies located in developed countries, but may invest in companies located in emerging markets.
The Trust may invest up to 20% of its total assets in debt securities issued by companies in the Commodities and Natural Resources Sector or any type of securities issued by companies that are not in the Commodities and Natural Resources Sector.
As part of its investment strategy, the Trust may employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) covered put options and, to a lesser extent, writing (selling) covered call and put options on indices of securities and sectors of securities. This option strategy is intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders.
In addition to the option strategies discussed above, the Trust may engage in strategic transactions for hedging purposes or to enhance total return. The Trust may also engage in short sales of securities.
The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
The Trust may implement various temporary “defensive” strategies at times when the Advisors determine that conditions in the markets make pursuing the Trust’s basic investment strategy inconsistent with the best interests of its shareholders. These strategies may include investing all or a portion of the Trust’s assets in U.S. Government obligations and short-term debt securities that may be either tax-exempt or taxable.
Under current market conditions, the Trust currently does not intend to engage in short sales or incur indebtedness or issue preferred shares for investment purposes, except the Trust may engage for hedging purposes, risk management, or to enhance total return, including engaging in transactions, such as options, futures, swaps, foreign currency transactions, such as forward foreign currency contracts, currency swaps or options on currency and currency futures and other derivatives transactions , repurchase agreements, reverse repurchase agreements, when issued or forward commitment transactions and similar investment strategies, which may give rise to a form of leverage.
Unless otherwise stated herein, the Trust’s investment objectives and investment policies are non-fundamental policies and may be changed by the Board. In addition, the percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment, and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns.
 
 
192
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
BlackRock Science and Technology Trust (BST)
The Trust’s investment objectives are to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees (the “Board”) without prior shareholder approval.
BlackRock Advisors, LLC (the “Manager”) may consider a variety of factors when choosing investments for the Trust, such as:
 
   
selecting companies with the potential for rapid and sustainable growth from the development, advancement and use of science and/or technology (high growth science and technology stocks); and
 
   
identifying companies that have above-average return potential based on factors such as revenue and earnings growth, profitability, valuation and dividend yield (cyclical science and technology stocks).
In addition, a variety of countries, including emerging market countries, and industries are likely to be represented in the Trust’s portfolio.
The Trust generally will sell a stock when, in the Manager’s opinion, the stock is fully valued, there is a need to rebalance the portfolio or there is a better opportunity elsewhere.
The Trust may engage in active and frequent trading of portfolio securities to seek to achieve its investment objectives.
Under normal market conditions, the Trust invests at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks).
Science and technology companies are companies whose products, processes or services, in the Manager’s view, are being, or are expected to be, significantly benefited by the use or commercial application of scientific or technological developments or discoveries. These companies include companies that, in the Manager’s view, derive a competitive advantage by the application of scientific or technological developments or discoveries to grow their business or increase their competitive advantage, as well as companies that utilize science and/or technology as an agent of change to significantly enhance their business opportunities.
Science, technology and science- or technology-related companies may include companies operating in any industry, including, but not limited to software, internet software & services, IT services, hardware, communications equipment, semiconductors and semiconductor equipment, media, internet retail, consumer finance, life sciences tools & services, biotechnology, pharmaceuticals, energy, defense/aerospace, diversified telecom services and wireless telecom services. Examples of potential high growth companies include those operating in IT services, the internet, software and sciences; examples of potential cyclical companies include those operating in hardware, telecom, semiconductors and components. The Manager determines, in its discretion, whether a company is a science, technology or science- or technology-related company.
The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds and equity interests in real estate investment trusts and master limited partnerships. From time to time, the Trust may invest in shares of companies through initial public offerings. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. The Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.
The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.
The Trust will concentrate its investments in companies operating in one or more industries within the technology group of industries.
The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not science or technology companies and in debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.
As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.
During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.
The Trust may invest in structured instruments (such as equity-linked notes) for investment purposes, as an alternative or complement to its options writing strategy or for risk management or leveraging purposes.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  193

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.
The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).
Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.
Leverage:
The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares.
The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.
The Trust may enter into “dollar roll” transactions.
The Trust may enter into derivative transactions that have leverage embedded in them.
The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.
BlackRock Science & Technology Trust II (BSTZ)
The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.
BlackRock Advisors, LLC (the “Manager”) may consider a variety of factors when choosing investments for the Trust, but expects to select companies with the potential for rapid and sustainable growth from the development, advancement and use of science and/or technology.
In addition, a variety of countries, including emerging market countries, and industries are likely to be represented in the Trust’s portfolio.
The Trust generally will sell a stock when, in the Manager’s opinion, the stock is fully valued, there is a need to rebalance the portfolio or there is a better opportunity elsewhere.
The Trust may engage in active and frequent trading of portfolio securities to seek to achieve its investment objectives.
Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology.
Science and technology companies are companies whose products, processes or services, in the Manager’s view, are being, or are expected to be, significantly benefited by the use or commercial application of scientific or technological developments or discoveries. These companies include companies that, in the Manager’s view, derive a competitive advantage by the application of scientific or technological developments or discoveries to grow their business or increase their competitive advantage, as well as companies that utilize science and/or technology as an agent of change to significantly enhance their business opportunities.
Science, technology and science- or technology-related companies may include companies operating in any industry, including, but not limited to software, internet software & services, IT services, hardware, communications equipment, semiconductors and semiconductor equipment, media, internet retail, consumer finance, life sciences tools & services, biotechnology, pharmaceuticals, energy, defense/aerospace, diversified telecom services and wireless telecom services. It is anticipated that the Trust’s investments will be focused on companies within such industries that the Manager expects will generate a majority of their revenues from the development, advancement, use or sale of new and emerging, or “next generation,” science- or technology-related products, processes or services. There is no assurance, however, that any of the Trust’s assets will be invested in such companies at any time. The Manager determines, in its discretion, whether a company is a science, technology or science- or technology-related company.
 
 
194
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds (“ETFs”) and equity interests in real estate investment trusts (“REITs”) and master limited partnerships. The Trust may invest in shares of companies through initial public offerings (“IPOs”). The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. Under normal market conditions, the Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “pre-IPO securities,” which are securities of new and early stage companies, often funded by venture capital, whose securities have not been offered to the public and are not publicly traded. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.
The Trust may also invest in securities of other open- or closed-end investment companies, including ETFs and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.
The Trust will concentrate its investments in companies operating in one or more industries within the technology group of industries.
The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not science or technology companies and in debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.
As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.
During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.
The Trust may invest in structured instruments (such as equity-linked notes) for investment purposes, as an alternative or complement to its options writing strategy or for risk management or leveraging purposes.
The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.
The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).
Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.
Leverage:
The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objectives and policies.
The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.
The Trust may enter into “dollar roll” transactions.
The Trust may enter into derivative transactions that have leverage embedded in them.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  195

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
The Trust’s investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objective may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.
The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities, Infrastructure or Power Opportunities business segments (as defined below) anywhere in the world and by employing a strategy of writing (selling) covered call and put options.
Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure or Power Opportunities business segments. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets (as described herein), and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Such companies may include, among others, electrical equipment producers (such as wind turbine manufacturers), producers of industrial and specialty chemicals (such as building insulation producers) and semi-conductor and equipment companies (such as solar panel manufacturers).
The Trust may invest in companies of any market capitalization. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. Although the Trust expects to invest primarily in companies located in developed countries, it may invest in companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds, equity interests in real estate investment trusts, Canadian Royalty Trusts and master limited partnerships (“MLPs”). The Trust will not invest more than 25% of the value of its total assets in MLPs. The Trust may invest directly in equity securities or synthetically through the use of derivatives.
The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not engaged in the Utilities, Infrastructure or Power Opportunities business segments and debt securities issued by any issuer, including up to 10% of its total assets in non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.
As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.
During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objective under these circumstances. BlackRock Advisors, LLC’s (the “Manager”) and BlackRock International Limited’s (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, determination that they are temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.
The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.
The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.
The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 15% of the value of its total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 15% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security.
Unless otherwise stated herein, the Trust’s investment objective and policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.
 
 
196
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
Leverage:
The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objective and policies.
The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.
The Trust may enter into derivative transactions that have leverage embedded in them.
The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.
Risk Factors
This section contains a discussion of the general risks of investing in each Trust. The net asset value and market price of, and dividends paid on, the common shares will fluctuate with and be affected by, among other things, the risks more fully described below. As with any fund, there can be no guarantee that a Trust will meet its investment objective or that the Trust’s performance will be positive for any period of time. Each risk noted below is applicable to each Trust unless the specific Trust or Trusts are noted in a parenthetical. The order of the below risk factors does not indicate the significance of any particular risk factor.
Non-Diversification Risk (BGR, BMEZ, BIGZ, BCX and BSTZ):
The Trust is a non-diversified fund. Because the Trust may invest in securities of a smaller number of issuers, it may be more exposed to the risks associated with and developments affecting an individual issuer than a fund that invests more widely.
Limited Term Risk (BMEZ, BIGZ and BSTZ):
In accordance with the Trust’s Agreement and Declaration of Trust, the Trust intends to dissolve as of the first business day following the twelfth anniversary of the effective date of the Trust’s initial registration statement (the “Dissolution Date”); provided that the Board may, by a vote of a majority of the Board and seventy-five percent (75%) of the members of the Board who either (i) have been a member of the Board for a period of at least thirty-six months (or since the commencement of the Trust’s operations, if less than thirty-six months) or (ii) were nominated to serve as a member of the Board by a majority of the Continuing Trustees then members of the Board (a “Board Action Vote”), without shareholder approval, extend the Dissolution Date: (i) once for up to one year, and (ii) once for up to an additional six months, to a date up to and including eighteen months after the initial Dissolution Date (which date shall then become the Dissolution Date). As of a date within twelve months preceding the Dissolution Date (as may be extended as described above), the Board may, by a Board Action Vote, cause the Trust to conduct a tender offer to all common shareholders to purchase 100% of the then outstanding common shares of the Trust at a price equal to the net asset value (“NAV”) per common share on the expiration date of the tender offer (an “Eligible Tender Offer”). The Board has established that the Trust must have at least $200 million of aggregate net assets immediately following the completion of an Eligible Tender Offer to ensure the continued viability of the Trust (the “Dissolution Threshold”). In an Eligible Tender Offer, the Trust will offer to purchase all common shares held by each common shareholder; provided that if the payment for properly tendered common shares would result in the Trust having aggregate net assets below the Dissolution Threshold, the Eligible Tender Offer will be canceled and no common shares will be repurchased pursuant to the Eligible Tender Offer. Instead, the Trust will begin (or continue) liquidating its portfolio and proceed to dissolve on or about the Dissolution Date. If the payment for properly tendered common shares would result in the Trust having aggregate net assets greater than or equal to the Dissolution Threshold, all common shares properly tendered and not withdrawn will be purchased by the Trust pursuant to the terms of the Eligible Tender Offer. Following the completion of an Eligible Tender Offer, the Board may, by a Board Action Vote, eliminate the Dissolution Date without shareholder approval and provide for the Trust’s perpetual existence.
Unless the limited term provision of the Trust’s Agreement and Declaration of Trust is amended by shareholders in accordance with the Agreement and Declaration of Trust, or unless the Trust completes an Eligible Tender Offer and converts to perpetual existence, the Trust will dissolve on or about the first business day following the Dissolution Date.
TheTrust is not a so called “target date” or “life cycle” fund whose asset allocation becomes more conservative over time as its target date, often associated with retirement, approaches. In addition, the Trust is not a “target term” fund and thus does not seek to return its initial public offering price per common share upon dissolution.
As the assets of the Trust will be liquidated in connection with its dissolution, the Trust may be required to sell portfolio securities when it otherwise would not, including at times when market conditions are not favorable, which may cause the Trust to lose money. In addition, as the Trust approaches the Dissolution Date, the Manager may invest the proceeds of sold, matured or called securities in money market mutual funds, cash, cash equivalents, securities issued or guaranteed by the U.S. government or its instrumentalities or agencies, high quality, short-term money market instruments, short-term debt securities, certificates of deposit, bankers’ acceptances and other bank obligations, commercial paper or other liquid debt securities, which may adversely affect the Trust’s investment performance. Rather than reinvesting proceeds received from sales of or payments received in respect of portfolio securities, the Trust may distribute such proceeds in one or more liquidating distributions prior to the final dissolution, which may cause the Trust’s fixed expenses to increase when expressed as a percentage of net assets attributable to common shares, or the Trust may invest the proceeds in lower yielding securities or hold the proceeds in cash or cash equivalents, which may adversely affect the performance of the Trust. The final distribution of net assets upon dissolution may be more than, equal to or less than $20.00 per common share. Because the Trust may adopt a plan of liquidation and make liquidating distributions in advance of the Dissolution Date, the total value of the Trust’s assets returned to common shareholders upon dissolution will be impacted by decisions of the Board and the Manager regarding the timing of adopting a plan of liquidation and making liquidating distributions. This may result in common shareholders receiving liquidating distributions with a value more or less than the value that would have been received if the Trust had liquidated all of its assets on the Dissolution Date, or any other potential date for liquidation, and distributed the proceeds thereof to shareholders.
If the Trust conducts an Eligible Tender Offer, the Trust anticipates that funds to pay the aggregate purchase price of shares accepted for purchase pursuant to the tender offer will be first derived from any cash on hand and then from the proceeds from the sale of portfolio investments held by the Trust. The risks related to the disposition of securities in connection with the Trust’s dissolution also would be present in connection with the disposition of securities in connection with an Eligible Tender Offer. It is likely that during the pendency of a tender offer, and possibly for a time thereafter, the Trust will hold a greater than normal percentage of its total assets in cash and cash equivalents, which may impede the Trust’s ability to achieve its investment objectives and decrease returns to shareholders. The tax effect of any such dispositions of portfolio investments will depend on the difference between the price at which the investments are sold and the tax basis of the Trust in the investments.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  197

Investment Objectives,
Policies
and Risks
(continued)
 
Investment Objectives and Policies
(continued)
Any capital gains recognized on such dispositions, as reduced by any capital losses the Trust realizes in the year of such dispositions and by any available capital loss carryforwards, will be distributed to shareholders as capital gain dividends (to the extent of net long-term capital gains over net short-term capital losses) or ordinary dividends (to the extent of net short-term capital gains over net long-term capital losses) during or with respect to such year, and such distributions will generally be taxable to common shareholders. If the Trust’s tax basis for the investments sold is less than the sale proceeds, the Trust will recognize capital gains, which the Trust intends to distribute to common shareholders. In addition, the Trust’s purchase of tendered common shares pursuant to an Eligible Tender Offer will have tax consequences for tendering common shareholders and may have tax consequences for non-tendering common shareholders.
The purchase of common shares by the Trust pursuant to an Eligible Tender Offer will have the effect of increasing the proportionate interest in the Trust of non-tendering common shareholders. All common shareholders remaining after an Eligible Tender Offer will be subject to any increased risks associated with the reduction in the Trust’s assets resulting from payment for the tendered common shares, such as greater volatility due to decreased diversification and proportionately higher expenses. The reduced assets of the Trust as a result of an Eligible Tender Offer may result in less investment flexibility for the Trust and may have an adverse effect on the Trust’s investment performance. Such reduction in the Trust’s assets may also cause common shares of the Trust to become thinly traded or otherwise negatively impact secondary trading of common shares. A reduction in assets, and the corresponding increase in the Trust’s expense ratio, could result in lower returns and put the Trust at a disadvantage relative to its peers and potentially cause the Trust’s common shares to trade at a wider discount, or smaller premium, to NAV than they otherwise would. Furthermore, the portfolio of the Trust following an Eligible Tender Offer could be significantly different and, therefore, common shareholders retaining an investment in the Trust could be subject to greater risk. For example, the Trust may be required to sell its more liquid, higher quality portfolio investments to purchase common shares that are tendered in an Eligible Tender Offer, which would leave a less liquid, lower quality portfolio for remaining shareholders. The prospects of an Eligible Tender Offer may attract arbitrageurs who would purchase the common shares prior to the tender offer for the sole purpose of tendering those shares which could have the effect of exacerbating the risks described herein for shareholders retaining an investment in the Trust following an Eligible Tender Offer.
The Trust is not required to conduct an Eligible Tender Offer. If the Trust conducts an Eligible Tender Offer, there can be no assurance that the payment for tendered common shares would not result in the Trust having aggregate net assets below the Dissolution Threshold, in which case the Eligible Tender Offer will be canceled, no common shares will be repurchased pursuant to the Eligible Tender Offer and the Trust will liquidate on the Dissolution Date (subject to possible extensions). Following the completion of an Eligible Tender Offer in which the payment for tendered common shares would result in the Trust having aggregate net assets greater than or equal to the Dissolution Threshold, the Board may, by a Board Action Vote, eliminate the Dissolution Date without shareholder approval and provide for the Trust’s perpetual existence. Thereafter, the Trust will have a perpetual existence. There is no guarantee that the Board will eliminate the Dissolution Date following the completion of an Eligible Tender Offer so that the Trust will have a perpetual existence. The Manager may have a conflict of interest in recommending to the Board that the Dissolution Date be eliminated and the Trust have a perpetual existence. The Trust is not required to conduct additional tender offers following an Eligible Tender Offer and conversion to perpetual existence. Therefore, remaining common shareholders may not have another opportunity to participate in a tender offer. Shares of closed-end management investment companies frequently trade at a discount from their NAV, and as a result remaining common shareholders may only be able to sell their shares at a discount to NAV.
Although it is anticipated that the Trust will have distributed substantially all of its net assets to shareholders as soon as practicable after the Dissolution Date, securities for which no market exists or securities trading at depressed prices, if any, may be placed in a liquidating trust. Securities placed in a liquidating trust may be held for an indefinite period of time, potentially several years or longer, until they can be sold or pay out all of their cash flows. During such time, the shareholders will continue to be exposed to the risks associated with the Trust and the value of their interest in the liquidating trust will fluctuate with the value of the liquidating trust’s remaining assets. Additionally, the tax treatment of the liquidating trust’s assets may differ from the tax treatment applicable to such assets when held by the Trust. To the extent the costs associated with a liquidating trust exceed the value of the remaining securities, the liquidating trust trustees may determine to dispose of the remaining securities in a manner of their choosing. The Trust cannot predict the amount, if any, of securities that will be required to be placed in a liquidating trust or how long it will take to sell or otherwise dispose of such securities.
Investment and Market Discount Risk:
An investment in the Trust’s common shares is subject to investment risk, including the possible loss of the entire amount that you invest. As with any stock, the price of the Trust’s common shares will fluctuate with market conditions and other factors. If shares are sold, the price received may be more or less than the original investment. Common shares are designed for long-term investors and the Trust should not be treated as a trading vehicle. Shares of closed-end management investment companies frequently trade at a discount from their net asset value. This risk is separate and distinct from the risk that the Trust’s net asset value could decrease as a result of its investment activities. At any point in time an investment in the Trust’s common shares may be worth less than the original amount invested, even after taking into account distributions paid by the Trust. During periods in which the Trust may use leverage, the Trust’s investment, market discount and certain other risks will be magnified.
Equity Securities Risk:
Stock markets are volatile. The price of equity securities fluctuates based on changes in a company’s financial condition and overall market and economic conditions.
Common Stock Risk:
Common stocks represent equity ownership in a company. Stock markets are volatile. The price of common stock will fluctuate and can decline and reduce the value of a portfolio investing in equities. The value of common stock purchased by the Trust could decline if the financial condition of the companies the Trust invests in declines or if overall market and economic conditions deteriorate. The value of equity securities may also decline due to factors that affect a particular industry or industries, such as labor shortages or an increase in production costs and competitive conditions within an industry. In addition, the value may decline due to general market conditions that are not specifically related to a company or industry, such as real or perceived adverse economic conditions, changes in the general outlook for corporate earnings, changes in interest or currency rates or generally adverse investor sentiment.
Small and Mid-Capitalization Company Risk:
Companies with small or mid-size market capitalizations will normally have more limited product lines, markets and financial resources and will be dependent upon a more limited management group than larger capitalized companies. In addition, it is more difficult to get information on smaller companies, which tend to be less well known, have shorter operating histories, do not have significant ownership by large investors and are followed by relatively few securities analysts.
 
 
198
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(
continued
)
Preferred Securities Risk:
Preferred securities may pay fixed or adjustable rates of return. Preferred securities are subject to issuer-specific and market risks applicable generally to equity securities. In addition, a company’s preferred securities generally pay dividends only after the company makes required payments to holders of its bonds and other debt. For this reason, the value of preferred securities will usually react more strongly than bonds and other debt to actual or perceived changes in the company’s financial condition or prospects. Preferred securities of smaller companies may be more vulnerable to adverse developments than preferred securities of larger companies.
Convertible Securities Risk (BGR, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI)
: The market value of a convertible security performs like that of a regular debt security; that is, if market interest rates rise, the value of a convertible security usually falls. In addition, convertible securities are subject to the risk that the issuer will not be able to pay interest or dividends when due, and their market value may change based on changes in the issuer’s credit rating or the market’s perception of the issuer’s creditworthiness. Since it derives a portion of its value from the common stock into which it may be converted, a convertible security is also subject to the same types of market and issuer risks that apply to the underlying common stock.
Warrants Risk (BGR, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI)
: If the price of the underlying stock does not rise above the exercise price before the warrant expires, the warrant generally expires without any value and the Trust will lose any amount it paid for the warrant. Thus, investments in warrants may involve substantially more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.
Depositary Receipts Risk (BGR, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI):
Depositary receipts are generally subject to the same risks as the foreign securities that they evidence or into which they may be converted. In addition to investment risks associated with the underlying issuer, depositary receipts expose the Trust to additional risks associated with the non-uniform terms that apply to depositary receipt programs, credit exposure to the depository bank and to the sponsors and other parties with whom the depository bank establishes the programs, currency risk and the risk of an illiquid market for depositary receipts. The issuers of unsponsored depositary receipts are not obligated to disclose information that is, in the United States, considered material. Therefore, there may be less information available regarding these issuers and there may not be a correlation between such information and the market value of the depositary receipts.
REIT Investment Risk (BDJ, BOE, BGY, BME, BMEZ, BST, BSTZ and BUI)
: Investments in REITs involve unique risks. REITs may have limited financial resources, may trade less frequently and in limited volume, may engage in dilutive offerings of securities and may be more volatile than other securities. REIT issuers may also fail to maintain their exemptions from investment company registration or fail to qualify for the “dividends paid deduction” under the Internal Revenue Code of 1986, as amended, which allows REITs to reduce their corporate taxable income for dividends paid to their shareholders.
Master Limited Partnerships Risk (BGR, BCX, BST, BSTZ and BUI):
The common units of a master limited partnership (“MLP”) are listed and traded on U.S. securities exchanges and their value fluctuates predominantly based on prevailing market conditions and the success of the MLP. Unlike owners of common stock of a corporation, owners of common units have limited voting rights and have no ability to annually elect directors. In the event of liquidation, common units have preference over subordinated units, but not over debt or preferred units, to the remaining assets of the MLP.
Canadian Royalty Trust Risk (BGR, BCX and BUI):
Canadian Royalty Trusts are exposed to many of the same risks as energy and natural resources companies, such as commodity pricing risk, supply and demand risk and depletion and exploration risk.
Initial Public Offerings (“IPOs”) Risk (BOE, BME, BMEZ, BIGZ, BST, BSTZ):
The Trust may invest in shares of companies through IPOs. Securities issued in IPOs have no trading history, and information about the companies may be available for limited periods of time. In addition, the prices of securities sold in IPOs may be highly volatile or may decline shortly after the IPO.
Investments in Unseasoned Companies (BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BSTZ):
The Trust may invest in the securities of smaller, less seasoned companies. These investments may present greater opportunities for growth, but also involve greater risks than customarily are associated with investments in securities of more established companies. Some of the companies in which the Trust may invest may be start-up companies which may have insubstantial operational or earnings histories or may have limited products, markets, financial resources or management depth. Some may also be emerging companies at the research and development stage with no products or technologies to market or approved for marketing. Securities of emerging companies may lack an active secondary market and may be subject to more abrupt or erratic price movements than securities of larger, more established companies or stock market averages in general. Competitors of certain companies may have substantially greater financial resources than many of the companies in which the Trust may invest. Further, an unseasoned company is more at risk of loss in an adverse market due to its lack of financial resources and ability to sustain itself for an extended period of time in such a market.
Dividend-Paying Equity Securities Risk (CII, BDJ, BOE, BGY and BME):
Dividends on common equity securities that the Trust may hold are not fixed but are declared at the discretion of an issuer’s board of directors. Companies that have historically paid dividends on their securities are not required to continue to pay dividends on such securities. There is no guarantee that the issuers of the common equity securities in which the Trust invests will declare dividends in the future or that, if declared, they will remain at current levels or increase over time. Therefore, there is the possibility that such companies could reduce or eliminate the payment of dividends in the future. Dividend producing equity securities, in particular those whose market price is closely related to their yield, may exhibit greater sensitivity to interest rate changes. The Trust’s investments in dividend producing equity securities may also limit its potential for appreciation during a broad market advance.
The prices of dividend producing equity securities can be highly volatile. Investors should not assume that the Trust’s investments in these securities will necessarily reduce the volatility of the Trust’s NAV or provide “protection,” compared to other types of equity securities, when markets perform poorly.
Investment Style Risk:
Under certain market conditions, growth investments have performed better during the later stages of economic expansion and value investments have performed better during periods of economic recovery. Therefore,
these
investment styles may over time go in and out of favor. At times when the investment style used by the Trust is out of favor, the Trust may underperform other equity funds that use different investment styles.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  199

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
Risks Associated with the Trust’s Options Strategy:
The ability of the Trust to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns is partially dependent on the successful implementation of its options strategy. There are several risks associated with transactions in options on securities. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.
 
   
Risks of Writing Options – As the writer of a covered call option, the Trust forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the sum of the premium and the strike price of the call, but has retained the risk of loss should the price of the underlying security decline. In other words, as the Trust writes covered calls over more of its portfolio, the Trust’s ability to benefit from capital appreciation becomes more limited.
If the Trust writes call options on individual securities or index call options that include securities, in each case, that are not in the Trust’s portfolio or that are not in the same proportion as securities in the Trust’s portfolio, the Trust will experience loss, which theoretically could be unlimited, if the value of the individual security, index or basket of securities appreciates above the exercise price of the index option written by the Trust.
When the Trust writes put options, it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Trust could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Trust received when it wrote the option. While the Trust’s potential gain in writing a put option is limited to the premium received from the purchaser of the put option, the Trust risks a loss equal to the entire exercise price of the option minus the put premium.
 
   
Exchange-Listed Options Risks – There can be no assurance that a liquid market will exist when the Trust seeks to close out an exchange-listed option position. Reasons for the absence of a liquid secondary market on an exchange include the following: (i) there may be insufficient trading interest in certain options; (ii) restrictions may be imposed by an exchange on opening transactions or closing transactions or both; (iii) trading halts, suspensions or other restrictions may be imposed with respect to particular classes or series of options; (iv) unusual or unforeseen circumstances may interrupt normal operations on an exchange; (v) the facilities of an exchange or the Options Clearing Corporation (the “OCC”) may not at all times be adequate to handle current trading volume; or (vi) one or more exchanges could, for economic or other reasons, decide or be compelled at some future date to discontinue the trading of options (or a particular class or series of options).
 
   
Over-the-Counter Options Risk – The Trust may write (sell) unlisted OTC options. OTC options differ from exchange-listed options in that they are two-party contracts, with exercise price, premium and other terms negotiated between buyer and seller, and generally do not have as much market liquidity as exchange-listed options. The OTC options written by the Trust will not be issued, guaranteed or cleared by the OCC. In addition, the Trust’s ability to terminate OTC options may be more limited than with exchange-traded options. Banks, broker-dealers or other financial institutions participating in such transactions may fail to settle a transaction in accordance with the terms of the option as written. In the event of default or insolvency of the counterparty, the Trust may be unable to liquidate an OTC option position.
 
   
Index Options Risk – The Trust may sell index put and call options from time to time. The purchaser of an index put option has the right to any depreciation in the value of the index below the exercise price of the option on or before the expiration date. The purchaser of an index call option has the right to any appreciation in the value of the index over the exercise price of the option on or before the expiration date. Because the exercise of index options is settled in cash, sellers of index call options, such as the Trust, cannot provide in advance for their potential settlement obligations by acquiring and holding the underlying securities. The Trust will lose money if it is required to pay the purchaser of an index option the difference between the cash value of the index on which the option was written and the exercise price and such difference is greater than the premium received by the Trust for writing the option.
 
   
Limitation on Options Writing Risk – The number of call options the Trust can write is limited by the total assets the Trust holds. Furthermore, the Trust’s exchange-listed options transactions will be subject to limitations established by each of the exchanges, boards of trade or other trading facilities, if any, on which such options are traded and cleared.
 
   
Tax Risk – Income on options on individual stocks will generally not be recognized by the Trust for tax purposes until an option is exercised, lapses or is subject to a “closing transaction” (as defined by applicable regulations) pursuant to which the Trust’s obligations with respect to the option are otherwise terminated. If the option lapses without exercise or is otherwise subject to a closing transaction, the premiums received by the Trust from the writing of such options will generally be characterized as short-term capital gain. If an option written by the Trust is exercised, the Trust may recognize taxable gain depending on the exercise price of the option, the option premium, and the tax basis of the security underlying the option. The character of any gain on the sale of the underlying security as short-term or long-term capital gain will depend on the holding period of the Trust in the underlying security. In general, distributions received by shareholders of the Trust that are attributable to short-term capital gains recognized by the Trust from its options writing activities will be taxed to such shareholders as ordinary income and will not be eligible for the reduced tax rate applicable to qualified dividend income.
Index options will generally be “marked-to-market” for U.S. federal income tax purposes. As a result, the Trust will generally recognize gain or loss on the last day of each taxable year equal to the difference between the value of the index option on that date and the adjusted basis of the index option. The adjusted basis of the index option will consequently be increased by such gain or decreased by such loss. Any gain or loss with respect to index options will be treated as short-term capital gain or loss to the extent of 40% of such gain or loss and long-term capital gain or loss to the extent of 60% of such gain or loss. Because the mark-to-market rules may cause the Trust to recognize gain in advance of the receipt of cash, the Trust may be required to dispose of investments in order to meet its U.S. federal income tax distribution requirements.
Debt Securities Risk (BGR, BOE, BME, BMEZ, BCX,
BST
, BSTZ and BUI):
Debt securities, such as bonds, involve interest rate risk, credit risk, extension risk, and prepayment risk, among other things.
 
 
200
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
   
Interest Rate Risk — The market value of bonds and other fixed-income securities changes in response to interest rate changes and other factors. Interest rate risk is the risk that prices of bonds and other fixed-income securities will increase as interest rates fall and decrease as interest rates rise.
The Trust may be subject to a greater risk of rising interest rates due to the recent period of historically low interest rates. For example, if interest rates increase by 1%, assuming a current portfolio duration of ten years, and all other factors being equal, the value of the Trust’s investments would be expected to decrease by 10%. (Duration is a measure of the price sensitivity of a debt security or portfolio of debt securities to relative changes in interest rates.) The magnitude of these fluctuations in the market price of bonds and other fixed-income securities is generally greater for those securities with longer maturities. Fluctuations in the market price of the Trust’s investments will not affect interest income derived from instruments already owned by the Trust, but will be reflected in the Trust’s net asset value. The Trust may lose money if short-term or long-term interest rates rise sharply in a manner not anticipated by Trust management.
To the extent the Trust invests in debt securities that may be prepaid at the option of the obligor (such as mortgage-backed securities), the sensitivity of such securities to changes in interest rates may increase (to the detriment of the Trust) when interest rates rise. Moreover, because rates on certain floating rate debt securities typically reset only periodically, changes in prevailing interest rates (and particularly sudden and significant changes) can be expected to cause some fluctuations in the net asset value of the Trust to the extent that it invests in floating rate debt securities.
These basic principles of bond prices also apply to U.S. Government securities. A security backed by the “full faith and credit” of the U.S. Government is guaranteed only as to its stated interest rate and face value at maturity, not its current market price. Just like other fixed-income securities, government-guaranteed securities will fluctuate in value when interest rates change.
A general rise in interest rates has the potential to cause investors to move out of fixed-income securities on a large scale, which may increase redemptions from funds that hold large amounts of fixed-income securities. Heavy redemptions could cause the Trust to sell assets at inopportune times or at a loss or depressed value and could hurt the Trust’s performance.
 
   
Credit Risk — Credit risk refers to the possibility that the issuer of a debt security (i.e., the borrower) will not be able to make payments of interest and principal when due. Changes in an issuer’s credit rating or the market’s perception of an issuer’s creditworthiness may also affect the value of the Trust’s investment in that issuer. The degree of credit risk depends on both the financial condition of the issuer and the terms of the obligation.
 
   
Extension Risk — When interest rates rise, certain obligations will be paid off by the obligor more slowly than anticipated, causing the value of these obligations to fall.
 
   
Prepayment Risk — When interest rates fall, certain obligations will be paid off by the obligor more quickly than originally anticipated, and the Trust may have to invest the proceeds in securities with lower yields.
Junk Bonds Risk (BGR, BOE, BME, BMEZ, BCX, BST, BSTZ and
BUI
):
Although junk bonds generally pay higher rates of interest than investment grade bonds, junk bonds are high risk investments that are considered speculative and may cause income and principal losses for the Trust.
U.S. Government Obligations Risk (CII, BME, BMEZ, BCX, BSTZ and BUI):
Certain securities in which the Trust may invest, including securities issued by certain U.S. Government agencies and U.S. Government sponsored enterprises, are not guaranteed by the U.S. Government or supported by the full faith and credit of the United States.
Structured Products Risk (BME, BMEZ, BCX, BSTand BSTZ):
Holders of structured products bear risks of the underlying investments, index or reference obligation and are subject to counterparty risk. The Trust may have the right to receive payments only from the structured product, and
generally
does not have direct rights against the issuer or the entity that sold the assets to be securitized. Certain structured products may be thinly traded or have a limited trading market. In addition to the general risks associated with debt securities discussed herein, structured products carry additional risks, including, but not limited to: the possibility that distributions from collateral securities will not be adequate to make interest or other payments; the quality of the collateral may decline in value or default; and the possibility that the structured products are subordinate to other classes. Structured notes are based upon the movement of one or more factors, including currency exchange rates, interest rates, reference bonds and stock indices, and changes in interest rates and impact of these factors may cause significant price fluctuations. Additionally, changes in the reference instrument or security may cause the interest rate on the structured note to be reduced to zero.
Derivatives Risk:
The Trust’s use of derivatives may increase its costs, reduce the Trust’s returns and/or increase volatility. Derivatives involve significant risks, including:
 
   
Leverage Risk — The Trust’s use of derivatives can magnify the Trust’s gains and losses. Relatively small market movements may result in large changes in the value of a derivatives position and can result in losses that greatly exceed the amount originally invested.
 
   
Market Risk — Some derivatives are more sensitive to interest rate changes and market price fluctuations than other securities. The Trust could also suffer losses related to its derivatives positions as a result of unanticipated market movements, which losses are potentially unlimited. Finally, the Manager may not be able to predict correctly the direction of securities prices, interest rates and other economic factors, which could cause the Trust’s derivatives positions to lose value.
 
   
Counterparty Risk — Derivatives are also subject to counterparty risk, which is the risk that the other party in the transaction will be unable or unwilling to fulfill its contractual obligation, and the related risks of having concentrated exposure to such a counterparty.
 
   
Illiquidity Risk — The possible lack of a liquid secondary market for derivatives and the resulting inability of the Trust to sell or otherwise close a derivatives position could expose the Trust to losses and could make derivatives more difficult for the Trust to value accurately.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  201

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
   
Operational Risk — The use of derivatives includes the risk of potential operational issues, including documentation issues, settlement issues, systems failures, inadequate controls and human error
 
   
Legal Risk — The risk of insufficient documentation, insufficient capacity or authority of counterparty, or legality or enforceability of a contract.
 
   
Volatility and Correlation Risk — Volatility is defined as the characteristic of a security, an index or a market to fluctuate significantly in price within a short time period. A risk of the Trust’s use of derivatives is that the fluctuations in their values may not correlate with the overall securities markets.
 
   
Valuation Risk — Valuation for derivatives may not be readily available in the market. Valuation may be more difficult in times of market turmoil since many investors and market makers may be reluctant to purchase complex instruments or quote prices for them.
 
   
Hedging Risk — Hedges are sometimes subject to imperfect matching between the derivative and the underlying security, and there can be no assurance that the Trust’s hedging transactions will be effective. The use of hedging may result in certain adverse tax consequences.
 
   
Tax Risk — Certain aspects of the tax treatment of derivative instruments, including swap agreements and commodity-linked derivative instruments, are currently unclear and may be affected by changes in legislation, regulations or other legally binding authority. Such treatment may be less favorable than that given to a direct investment in an underlying asset and may adversely affect the timing, character and amount of income the Trust realizes from its investments.
 
   
Regulatory Risk — Derivative contracts are subject to regulation under the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) in the United States and under comparable regimes in Europe, Asia and other non-U.S. jurisdictions. Under the Dodd-Frank Act, with respect to uncleared swaps, swap dealers are required to collect variation margin from the Trust and may be required by applicable regulations to collect initial margin from the Trust. Both initial and variation margin may be comprised of cash and/or securities, subject to applicable regulatory haircuts. Shares of investment companies (other than certain money market funds) may not be posted as collateral under applicable regulations. In addition, regulations adopted by global prudential regulators that are now in effect require certain bank-regulated counterparties and certain of their affiliates to include in certain financial contracts, including many derivatives contracts, terms that delay or restrict the rights of counterparties, such as the Trust, to terminate such contracts, foreclose upon collateral, exercise other default rights or restrict transfers of credit support in the event that the counterparty and/or its affiliates are subject to certain types of resolution or insolvency proceedings. The implementation of these requirements with respect to derivatives, as well as regulations under the Dodd-Frank Act regarding clearing, mandatory trading and margining of other derivatives, may increase the costs and risks to the Trust of trading in these instruments and, as a result, may affect returns to investors in the Trust.
Foreign Securities Risk:
Foreign investments often involve special risks not present in U.S. investments that can increase the chances that the Trust will lose money. These risks include:
 
   
The Trust generally holds its foreign securities and cash in foreign banks and securities depositories, which may be recently organized or new to the foreign custody business and may be subject to only limited or no regulatory oversight.
 
   
Changes in foreign currency exchange rates can affect the value of the Trust’s portfolio.
 
   
The economies of certain foreign markets may not compare favorably with the economy of the United States with respect to such issues as growth of gross national product, reinvestment of capital, resources and balance of payments position.
 
   
The governments of certain countries, or the U.S. Government with respect to certain countries, may prohibit or impose substantial restrictions through capital controls and/or sanctions on foreign investments in the capital markets or certain industries in those countries, which may prohibit or restrict the ability to own or transfer currency, securities, derivatives or other assets.
 
   
Many foreign governments do not supervise and regulate stock exchanges, brokers and the sale of securities to the same extent as does the United States and may not have laws to protect investors that are comparable to U.S. securities laws.
 
   
Settlement and clearance procedures in certain foreign markets may result in delays in payment for or delivery of securities not typically associated with settlement and clearance of U.S. investments.
 
   
The Trust’s claims to recover foreign withholding taxes may not be successful, and if the likelihood of recovery of foreign withholding taxes materially decreases, due to, for example, a change in tax regulation or approach in the foreign country, accruals in the Trust’s net asset value for such refunds may be written down partially or in full, which will adversely affect the Trust’s net asset value.
 
   
The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trust’s investments.
Foreign CurrencyTransactions Risk (BGR, BDJ, BME and BCX):
The Trust may invest in forward foreign currency exchange contracts. Forward foreign currency exchange contracts do not eliminate movements in the value of non-U.S. currencies and securities but rather allow the Trust to establish a fixed rate of exchange for a future point in time. This strategy can have the effect of reducing returns and minimizing opportunities for gain.
 
 
202
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(
continued
)
Emerging Markets Risk
: Emerging markets are riskier than more developed markets because they tend to develop unevenly and may never fully develop. Investments in emerging markets may be considered speculative. Emerging markets are more likely to experience hyperinflation and currency devaluations, which adversely affect returns to U.S. investors. In addition, many emerging securities markets have far lower trading volumes and less liquidity than developed markets.
Concentration Risk (BGR, BME, BMEZ, BCX, BST and BSTZ):
The Trust’s strategy of concentrating a particular industry means that its performance will be closely tied to the performance of a particular market segment. The Trust’s concentration in these companies may present more risks than if it were broadly diversified over numerous industries and sectors of the economy. A downturn in these companies would have a larger impact on the Trust than on a fund that does not concentrate in such companies. At times, the performance of these companies will lag the performance of other industries or the broader market as a whole.
Science and Technology Risk (BST and BSTZ):
The Trust’s investments in science and technology companies expose the Trust to special risks. For example, rapid advances in science and technology might cause existing products to become obsolete, and the Trust’s returns could suffer to the extent it holds an affected company’s shares. Companies in a number of science and technology industries are also subject to more government regulations and approval processes than many other industries. This fact may affect a company’s overall profitability and cause its stock price to be more volatile. Additionally, science and technology companies are dependent upon consumer and business acceptance as new technologies evolve.
Health Sciences and Healthcare Companies Risk (BME and BMEZ):
The Trust’s investments in health sciences companies are subject to a number of risks, including the adverse impact of legislative actions and government regulations. These actions and regulations can affect the approval process for patents, medical devices and drugs, the funding of research and medical care programs, and the operation and licensing of facilities and personnel. The goods and services of health sciences companies are subject to risks of rapid technological change and obsolescence, product liability litigation, and intense price and other competitive pressures.
Energy Sector Risk (BGR):
The market value of securities in the energy sector may decline for many reasons, including, among others, changes in energy prices, energy supply and demand, government regulations and energy conservation efforts. Energy companies can be significantly affected by the supply of, and demand for, specific products (e.g., oil and natural gas) and services, exploration and production spending, government subsidization, world events and general economic conditions. In 2020, the energy sector has experienced increased volatility. In particular, significant market volatility occurred and is continuing in the crude oil markets as well as the oil futures markets, which resulted in the market price of the front month futures contract falling fell below zero for a period of time.
Energy and Natural Resources Risk (BCX):
The Trust’s investments in energy and natural resources companies are especially affected by variations in the commodities markets (that may be due to market events, regulatory developments or other factors that the Trust cannot control) and these companies may lack the resources and the broad business lines to weather hard times. Energy companies can be significantly affected by the supply of and demand for specific products and services, the supply of and demand for oil and gas, the price of oil and gas, exploration and production spending, government regulation, world events and economic conditions. Natural resources companies can be significantly affected by events relating to international political developments, energy conservation, the success of exploration projects, commodity prices, and tax and government regulations.
Commodities Related Investments Risk (BCX):
Exposure to the commodities markets may subject the Trust to greater volatility than investments in traditional securities. The value of commodity-linked derivative investments may be affected by changes in overall market movements, commodity index volatility, changes in interest rates, or factors affecting a particular industry or commodity, such as drought, floods, weather, embargoes, tariffs and international economic, political and regulatory developments.
Commodities Market Risk (BCX):
Stocks of companies engaged in commodities related industries, such as energy or natural resources companies, are especially affected by variations in the commodities markets (that may be due to market events, regulatory developments or other factors that the Trust cannot control) and these companies may lack the resources and the broad business lines to weather hard times.
Risks of Investing in Utilities, Infrastructure and Power Opportunities Issuers (BUI):
Investments in issuers in the Utilities, Infrastructure and Power Opportunities business segments are subject to certain risks, including the following, among others:
 
   
Utilities Companies Risk — A variety of factors may adversely affect the business or operations of Utilities issuers, including, but not limited to: high interest costs in connection with capital construction and improvement programs; governmental regulation of rates charged to customers (including the potential that costs incurred by the utility change more rapidly than the rate the utility is permitted to charge its customers); costs associated with compliance with and changes in environmental and other regulations; effects of economic slowdowns and surplus capacity; increased competition from other providers of utility services; inexperience with and potential losses resulting from a developing deregulatory environment; costs associated with reduced availability of certain types of fuel; the effects of energy conservation policies; effects of a national energy policy; technological innovations; potential impact of terrorist activities; the impact of natural or man-made disasters; regulation by various governmental authorities, including the imposition of special tariffs; and changes in tax laws, regulatory policies and accounting standards.
 
   
Infrastructure Companies Risk — Infrastructure issuers may be susceptible to a variety of factors that may adversely affect their business and operations, including, but not limited to: high interest costs in connection with capital construction programs; high leverage; costs associated with environmental and other regulations; surplus capacity costs; and reduced investment in public and private infrastructure projects. A slowdown in new infrastructure projects in developing or developed markets may constrain the abilities of Infrastructure issuers to grow in global markets. Other developments, such as significant changes in population levels or changes in the urbanization and industrialization of developing countries, may reduce demand for products or services provided by Infrastructure issuers.
 
   
Power Opportunities Companies Risk — A variety of factors may adversely affect the business or operations of Power Opportunities issuers, including, but not limited to: research and development costs related to new technologies; the success or failure of efforts to develop or implement new or existing technologies; government regulation (including environmental regulation); world events and economic conditions, the cyclical nature of the energy sector; intense competition; events relating to domestic and international political developments; energy conservation; environmental costs and liabilities; and the success of exploration projects.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  203

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(
continued
)
Innovative Securities Risk (BIGZ):
There can be no assurance that a company identified as innovative by the Manager will ultimately introduce a new product or service or that such product or service may not be significantly delayed.
Supply and Demand Risk (BGR):
A decrease in the production of natural gas, natural gas liquids (“NGLs”), crude oil, coal or other energy commodities or a decrease in the volume of such commodities available for transportation, mining, processing, storage or distribution may adversely impact the financial performance of energy and natural resources companies. Production declines and volume decreases could be caused by various factors, including catastrophic events affecting production, depletion of resources, labor difficulties, environmental proceedings, increased regulations, equipment failures and unexpected maintenance problems, import supply disruption, increased competition from alternative energy sources or commodity prices. Alternatively, a sustained decline in demand for such commodities could also adversely affect the financial performance of energy and natural resources companies. Factors which could lead to a decline in demand include economic recession or other adverse economic conditions, higher fuel taxes or governmental regulations, increases in fuel economy, consumer shifts to the use of alternative fuel sources, changes in commodity prices, or weather.
Depletion and Exploration Risk (BGR):
Many energy and natural resources companies are either engaged in the production of natural gas, NGLs, crude oil, refined petroleum products or coal, or are engaged in transporting, storing, distributing and processing these items on behalf of shippers. To maintain or grow their revenues, these companies or their customers need to maintain or expand their reserves through exploration of new sources of supply, through the development of existing sources, through acquisitions, or through long-term contracts to acquire reserves. The financial performance of energy and natural resources companies may be adversely affected if they, or the companies to whom they provide the service, are unable to cost-effectively acquire additional reserves sufficient to replace the natural decline.
Commodity Pricing Risk (BGR):
The operations and financial performance of energy and natural resources companies may be directly affected by energy commodity prices, especially those energy and natural resources companies which own the underlying energy commodity. Commodity prices fluctuate for several reasons, including changes in market and economic conditions, the impact of weather on demand, levels of domestic production and imported commodities, energy conservation, domestic and foreign governmental regulation and taxation and the availability of local, intrastate and interstate transportation systems. Volatility of commodity prices, which may lead to a reduction in production or supply, may also negatively impact the performance of energy and natural resources companies which are solely involved in the transportation, processing, storing, distribution or marketing of commodities. Volatility of commodity prices may also make it more difficult for energy and natural resources companies to raise capital to the extent the market perceives that their performance may be directly or indirectly tied to commodity prices.
Leverage Risk:
The Trust’s use of leverage may increase or decrease from time to time in its discretion and the Trust may, in the future, determine not to use leverage.
The use of leverage creates an opportunity for increased common share net investment income dividends, but also creates risks for the holders of common shares. The Trust cannot assure you that the use of leverage will result in a higher yield on the common shares. Any leveraging strategy the Trust employs may not be successful.
Leverage involves risks and special considerations for common shareholders, including:
 
   
the likelihood of greater volatility of net asset value, market price and dividend rate of the common shares than a comparable portfolio without leverage;
 
   
the risk that fluctuations in interest rates or dividend rates on any leverage that the Trust must pay will reduce the return to the common shareholders;
 
   
the effect of leverage in a declining market, which is likely to cause a greater decline in the net asset value of the common shares than if the Trust were not leveraged, which may result in a greater decline in the market price of the common shares;
 
   
leverage may increase operating costs, which may reduce total return.
Any decline in the net asset value of the Trust’s investments will be borne entirely by the holders of common shares. Therefore, if the market value of the Trust’s portfolio declines, leverage will result in a greater decrease in net asset value to the holders of common shares than if the Trust were not leveraged. This greater net asset value decrease will also tend to cause a greater decline in the market price for the common shares.
Reverse Repurchase Agreements Risk (BDJ, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI):
Reverse repurchase agreements involve the sale of securities held by the Trust with an agreement to repurchase the securities at an agreed-upon price, date and interest payment. Reverse repurchase agreements involve the risk that the other party may fail to return the securities in a timely manner or at all. The Trust could lose money if it is unable to recover the securities and the value of the collateral held by the Trust, including the value of the investments made with cash collateral, is less than the value of the securities. These events could also trigger adverse tax consequences for the Trust. In addition, reverse repurchase agreements involve the risk that the interest income earned in the investment of the proceeds will be less than the interest expense.
Dollar Rolls Risk (BME, BMEZ, BIGZ, BST and BSTZ):
Dollar rolls involve the risk that the market value of the securities that the Trust is committed to buy may decline below the price of the securities the Trust has sold. These transactions may involve leverage.
When-Issued and Delayed Delivery Securities and Forward Commitments Risk (BDJ, BME, BMEZ, BCX and BSTZ):
When-issued and delayed delivery securities and forward commitments involve the risk that the security the Trust buys will lose value prior to its delivery. There also is the risk that the security will not be issued or that the other party to the transaction will not meet its obligation. If this occurs, the Trust may lose both the investment opportunity for the assets it set aside to pay for the security and any gain in the security’s price.
Short Sales Risk (BDJ, BGY, BME, BMEZ, BCX, BST, BSTZ and BUI):
Because making short sales in securities that it does not own exposes the Trust to the risks associated with those securities, such short sales involve speculative exposure risk. The Trust will incur a loss as a result of a short sale if the price of the security increases between the date of the short sale and the date on which the Trust replaces the security sold short.
 
 
204
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
Repurchase Agreements and Purchase and Sale Contracts Risk (BDJ, BME, BMEZ, BCX and BSTZ):
If the other party to a repurchase agreement or purchase and sale contract defaults on its obligation under the agreement, the Trust may suffer delays and incur costs or lose money in exercising its rights under the agreement. If the seller fails to repurchase the security in either situation and the market value of the security declines, the Trust may lose money.
Risks Associated with Private Company Investments (BDJ, BMEZ, BIGZ, BST and BSTZ):
Private companies are generally not subject to SEC reporting requirements, are not required to maintain their accounting records in accordance with generally accepted accounting principles, and are not required to maintain effective internal controls over financial reporting. As a result, the Manager may not have timely or accurate information about the business, financial condition and results of operations of the private companies in which the Trust invests. There is risk that the Trust may invest on the basis of incomplete or inaccurate information, which may adversely affect the Trust’s investment performance. Private companies in which the Trust may invest may have limited financial resources, shorter operating histories, more asset concentration risk, narrower product lines and smaller market shares than larger businesses, which tend to render such private companies more vulnerable to competitors’ actions and market conditions, as well as general economic downturns.
These companies generally have less predictable operating results, may from time to time be parties to litigation, may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence, and may require substantial additional capital to support their operations, finance expansion or maintain their competitive position. These companies may have difficulty accessing the capital markets to meet future capital needs, which may limit their ability to grow or to repay their outstanding indebtedness upon maturity. In addition, the Trust’s investment also may be structured as pay-in-kind securities with minimal or no cash interest or dividends until the company meets certain growth and liquidity objectives.
Typically, investments in private companies are in restricted securities that are not traded in public markets and subject to substantial holding periods, so that the Trust may not be able to resell some of its holdings for extended periods, which may be several years. There can be no assurance that the Trust will be able to realize the value of private company investments in a timely manner.
 
   
Late-Stage Private Companies Risk (BMEZ and BIGZ) – Investments in late-stage private companies involve greater risks than investments in shares of companies that have traded publicly on an exchange for extended periods of time. These investments may present significant opportunities for capital appreciation but involve a high degree of risk that may result in significant decreases in the value of these investments. The Trust may not be able to sell such investments when the Manager deems it appropriate to do so because they are not publicly traded. As such, these investments are generally considered to be illiquid until a company’s public offering (which may never occur) and are often subject to additional contractual restrictions on resale following any public offering that may prevent the Trust from selling its shares of these companies for a period of time. See “Illiquid Investments Risk.” Market conditions, developments within a company, investor perception or regulatory decisions may adversely affect a late-stage private company and delay or prevent such a company from ultimately offering its securities to the public. If a company does issue shares in an IPO, IPOs are risky and volatile and may cause the value of the Trust’s investment to decrease significantly.
 
   
Pre-IPO Securities Risk (BSTZ) – Investments in pre-IPO securities involve greater risks than investments in shares of companies that have traded publicly on an exchange for extended periods of time. These investments may present significant opportunities for capital appreciation but involve a high degree of risk that may result in significant decreases in the value of these investments. Issuers of pre-IPO securities may not have established products, experienced management or earnings history. The Trust may not be able to sell such investments when the Manager deems it appropriate to do so because they are not publicly traded. As such, these investments are generally considered to be illiquid until a company’s public offering (which may never occur) and are often subject to additional contractual restrictions on resale following any public offering that may prevent the Trust from selling its shares of these companies for a period of time. See “Illiquid Investments Risk.” Market conditions, developments within a company, investor perception or regulatory decisions may adversely affect an issuer of pre-IPO securities and delay or prevent such an issuer from ultimately offering its securities to the public. If a company does issue shares in an IPO, IPOs are risky and volatile and may cause the value of the Trust’s investment to decrease significantly.
Illiquid Investments Risk:
The Trust may invest in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. The Trust may not be able to readily dispose of such investments at prices that approximate those at which the Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, the Trust may have to sell other investments or engage in borrowing transactions if necessary to raise cash to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting the Trust’s net asset value and ability to make dividend distributions. The financial markets in general, and certain segments of the mortgage-related securities markets in particular, have in recent years experienced periods of extreme secondary market supply and demand imbalance, resulting in a loss of liquidity during which market prices were suddenly and substantially below traditional measures of intrinsic value. During such periods, some investments could be sold only at arbitrary prices and with substantial losses. Periods of such market dislocation may occur again at any time. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.
Investment Companies and ETFs Risk (BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI):
Subject to the limitations set forth in the Investment Company Act of 1940, as amended (the “1940 Act”), and the rules thereunder, the Trust may acquire shares in other investment companies and in exchange-traded funds (“ETFs”), some of which may be affiliated investment companies. The market value of the shares of other investment companies and ETFs may differ from their net asset value. As an investor in investment companies and ETFs, the Trust would bear its ratable share of that entity’s expenses, including its investment advisory and administration fees, while continuing to pay its own advisory and administration fees and other expenses (to the extent not offset by the Manager through waivers). As a result, shareholders will be absorbing duplicate levels of fees with respect to investments in other investment companies and ETFs (to the extent not offset by the Manager through waivers).
The securities of other investment companies and ETFs in which the Trust may invest may be leveraged. As a result, the Trust may be indirectly exposed to leverage through an investment in such securities. An investment in securities of other investment companies and ETFs that use leverage may expose the Trust to higher volatility in the market value of such securities and the possibility that the Trust’s long-term returns on such securities (and, indirectly, the long-term returns of shares of the Trust) will be diminished.
 
 
I
N
V
E
S
T
M
E
N
T   
O
B
J
E
C
T
I
V
E
S
,   P
O
L
I
C
I
E
S   A
N
D   
R
I
S
K
S
  205

Investment Objectives, Policies and Risks
(continued)
 
Investment Objectives and Policies
(continued)
As with other investments, investments in other investment companies, including ETFs, are subject to market and selection risk. To the extent the Trust is held by an affiliated fund, the ability of the Trust itself to hold other investment companies may be limited.
Subsidiary Risk (BCX):
By investing in the Subsidiary, the Trust is indirectly exposed to the risks associated with the Subsidiary’s investments. The commodity-related instruments held by the Subsidiary are generally similar to those that are permitted to be held by the Trust and are subject to the same risks that apply to similar investments if held directly by the Trust (see “Commodities Related Investments Risk” above). There can be no assurance that the investment objective of the Subsidiary will be achieved. The Subsidiary is not registered under the 1940 Act, and, unless otherwise noted, is not subject to all the investor protections of the 1940 Act. However, the Trust wholly owns and controls the Subsidiary, and the Trust and the Subsidiary are both managed by the Manager, making it unlikely that the Subsidiary will take action contrary to the interests of the Trust and its shareholders. The Board has oversight responsibility for the investment activities of the Trust, including its investment in the Subsidiary, and the Trust’s role as sole shareholder of the Subsidiary. The Subsidiary is subject to the same investment restrictions and limitations, and follows the same compliance policies and procedures, as the Trust. Changes in the laws of the United States and/or the Cayman Islands could result in the inability of the Trust and/or the Subsidiary to operate as described and could adversely affect the Trust.
Securities Lending Risk (BDJ, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI)
: Securities lending involves the risk that the borrower may fail to return the securities in a timely manner or at all. As a result, the Trust may lose money and there may be a delay in recovering the loaned securities. The Trust could also lose money if it does not recover the securities and/or the value of the collateral falls, including the value of investments made with cash collateral. These events could trigger adverse tax consequences for the Trust.
Market Risk and
Selection
Risk:
Market risk is the risk that one or more markets in which the Trust invests will go down in value, including the possibility that the markets will go down sharply and unpredictably. The value of a security or other asset may decline due to changes in general market conditions, economic trends or events that are not specifically related to the issuer of the security or other asset, or factors that affect a particular issuer or issuers, exchange, country, group of countries, region, market, industry, group of industries, sector or asset class. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues like pandemics or epidemics, recessions, or other events could have a significant impact on the Trust and its investments. Selection risk is the risk that the securities selected by Trust management will underperform the markets, the relevant indices or the securities selected by other funds with similar investment objectives and investment strategies. This means you may lose money.
An outbreak of an infectious coronavirus (COVID-19) that was first detected in December 2019 developed into a global pandemic that has resulted in numerous disruptions in the market and has had significant economic impact leaving general concern and uncertainty. Although vaccines have been developed and approved for use by various governments, the duration of the pandemic and its effects cannot be predicted with certainty. The impact of this coronavirus, and other epidemics and pandemics that may arise in the future, could affect the economies of many nations, individual companies and the market in general ways that cannot necessarily be foreseen at the present time.
 
 
206
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Shareholder Update
 
The following includes additional required disclosures for certain Trusts, each of which has filed a shelf offering registration statement.
Summary of Expenses
BlackRock Health Sciences Trust (BME)
The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BME’s common shares.
 
    
BME
 
Shareholder Transaction Expenses
 
Maximum sales load (as a percentage of offering price)
(a)
    1.00
Offering expenses borne by the Trust (as a percentage of offering price)
(a)
    0.02
Dividend reinvestment plan fees
   


$0.02 per share
for open market
purchases of
common shares
(b)
 
 
 
 
Estimated Annual Expenses
(as a percentage of net assets attributable to common shares)
 
Investment advisory fees
(c),(d)
    1.00
Other expenses
    0.08  
Total annual expenses
    1.08  
Fee waiver
(d)
    0.01  
Total annual Trust operating expenses after fee waiver
(d)
    1.07  
 
 
(a)
 
If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.
 
(b)
 
Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by the Trust. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.
 
(c)
 
The Trust currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on the Trust’s average weekly net assets.
 
(d)
 
The Trust and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of the Trust’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2024. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees the Trust pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2024. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by the Trust (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of the Trust or a majority of the outstanding voting securities of the Trust), upon 90 days’ written notice by the Trust to the Manager.
The following example illustrates the expenses (including the sales load of $10.00 and offering costs of $0.15) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.07% of net assets attributable to common shares and (ii) a 5% annual return:
 
    
1 Year
    
3 Years
    
5 Years
    
10 Years
 
Total expenses incurred
  $ 21      $ 44      $ 69      $ 140  
The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. The Trust’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.
 
 
S
H
A
R
E
H
O
L
D
E
R   
U
P
D
A
T
E
  207

Shareholder Update  
(continued)
 
BlackRock Science and Technology Trust (BST)
The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BST’s common shares.
 
    
BST
 
Shareholder Transaction Expenses
 
Maximum sales load (as a percentage of offering price)
(a)
    1.00
Offering expenses borne by the Trust (as a percentage of offering price)
(a)
    0.02
Dividend reinvestment plan fees
   


$0.02 per share
for open market
purchases of
common shares
(b)
 
 
 
 
Dividend reinvestment plan sale transaction fee
(b)
  $ 2.50  
Estimated Annual Expenses
(as a percentage of net assets attributable to common shares)
 
Investment advisory fees
(c),(d)
    1.00
Other expenses
    0.11  
Total annual expenses
    1.11  
Fee waiver
(d)
     
Total annual Trust operating expenses after fee waiver
(d)
    1.11  
 
(a)
 
If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.
(b)
 
Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by the Trust. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $2.50 sales fee and pay a $0.15 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.
(c)
 
The Trust currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on the Trust’s average daily managed assets. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).
(d)
 
The Trust and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of the Trust’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2024. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees the Trust pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2024. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by the Trust (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of the Trust or a majority of the outstanding voting securities of the Trust), upon 90 days’ written notice by the Trust to the Manager.
The following example illustrates the expenses (including the sales load of $10.00 and offering costs of $0.16) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.11% of net assets attributable to common shares and (ii) a 5% annual return:
 
    
1 Year
    
3 Years
    
5 Years
    
10 Years
 
Total expenses incurred
  $ 21      $ 45      $ 71      $ 144  
The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. The Trust’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.
 
 
208
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Shareholder Update  
(continued)
 
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BUI’s common shares.
 
    
BUI
 
Shareholder Transaction Expenses
 
Maximum sales load (as a percentage of offering price)
(a)
    1.00
Offering expenses borne by the Trust (as a percentage of offering price)
(a)
    0.02
Dividend reinvestment plan fees
   


$0.02 per share
for open market
purchases of
common shares
(b)
 
 
 
 
Estimated Annual Expenses
(as a percentage of net assets attributable to common shares)
 
Investment advisory fees
(c),(d)
    1.00
Other expenses
    0.08  
Total annual expenses
    1.08  
Fee waiver
(d)
     
Total annual Trust operating expenses after fee waiver
(d)
    1.08  
 
(a)
 
If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth
any
applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.
(b)
 
Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by the Trust. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.
(c)
 
The Trust currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on the Trust’s average daily managed assets. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).
(d)
 
The Trust and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of the Trust’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2024. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees the Trust pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2024. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by the Trust (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment
Company
Act) of the Trust or a majority of the outstanding voting securities of the Trust), upon 90 days’ written notice by the Trust to the Manager.
The following example illustrates the expenses (including the sales load of $10.00 and offering costs of $0.20) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.08% of net assets attributable to common shares and (ii) a 5% annual return:
 
    
1 Year
    
3 Years
    
5 Years
    
10 Years
 
Total expenses incurred
  $ 21      $ 44      $ 69      $ 141  
The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. The Trust’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.
 
 
S
H
A
R
E
H
O
L
D
E
R   
U
P
D
A
T
E
  209

Shareholder Update  
(continued)
 
Share Price Data
The following tables summarize each Trust’s highest and lowest daily closing market prices on the NYSE per common share, the NAV per common share, and the premium to or discount from NAV, on the date of each of the high and low market prices. The trading volume indicates the number of common shares traded on the NYSE during the respective quarters.
 
   
NYSE Market Price
Per Common Share
    
NAV per Common
Share on Date of
Market Price
    
Premium/
(Discount)
on Date of
Market Price
       
BME — During Quarter Ended
    High        Low        High        Low        High       Low       Trading Volume  
December 31, 2022
  $ 44.88      $ 38.85      $ 42.39      $ 40.17        5.87     (3.29 )%      2,275,787  
September 30, 2022
    44.96        38.27        43.41        39.41        3.57       (2.89     2,093,916  
June 30, 2022
    46.86        39.97        46.49        39.35        0.80       1.58       2,651,572  
March 31, 2022
    48.20        41.70        47.26        42.50        1.99       (1.88     2,486,253  
December 31, 2021
    49.44        45.50        48.16        45.37        2.66       0.29       1,702,234  
September 30, 2021
    48.62        47.27        47.86        46.37        1.59       1.94       1,609,758  
June 30, 2021
    48.20        46.22        47.04        45.81        2.47       0.90       1,844,866  
March 31, 2021
    46.86        44.61        47.12        43.57        (0.55     2.39       2,193,438  
As of December 31, 2022, BME’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $43.58, $43.30, and 0.65%, respectively.
 
   
NYSE Market
Price Per
Common Share
    
NAV per Common
Share on Date of
Market Price
    
Premium/
(Discount)
on Date of
Market Price
       
BST — During Quarter Ended
    High        Low        High        Low        High       Low       Trading Volume  
December 31, 2022
  $ 32.45      $ 28.07      $ 31.69      $ 28.47        2.40     (1.40 )%      9,877,821  
September 30, 2022
    38.73        29.38        37.18        31.02        4.17       (5.29     9,463,720  
June 30, 2022
    44.15        31.25        45.87        33.58        (3.75     (6.94     9,431,070  
March 31, 2022
    50.99        40.14        52.59        42.32        (3.04     (5.15     11,617,438  
December 31, 2021
    55.87        47.30        58.61        50.49        (4.67     (6.32     10,212,196  
September 30, 2021
    59.51        51.84        55.80        54.24        6.65       (4.42     10,053,189  
June 30, 2021
    60.19        53.81        53.77        49.61        11.94       8.47       5,123,462  
March 31, 2021
    61.14        50.99        57.77        49.26        5.83       3.51       6,483,722  
As of December 31, 2022, BST’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $28.37, $29.11, and (2.54)%, respectively.
 
   
NYSE Market Price
Per Common Share
    
NAV per Common
Share on Date of
Market Price
    
Premium/
(Discount)
on Date of
Market Price
       
BUI — During Quarter Ended
    High        Low        High        Low        High       Low       Trading Volume  
December 31, 2022
  $ 22.24      $ 19.02      $ 23.13      $ 19.61        (3.85 )%      (3.01 )%      3,657,444  
September 30, 2022
    24.47        20.06        23.61        20.19        3.64       (0.64     3,404,776  
June 30, 2022
    25.79        20.46        25.13        21.06        2.63       (2.85     3,775,619  
March 31, 2022
    27.28        22.88        25.09        23.27        8.73       (1.68     4,035,794  
December 31, 2021
    27.77        24.61        25.72        24.18        7.97       1.78       3,783,084  
September 30, 2021
    27.07        24.69        26.11        24.92        3.68       (0.92     3,538,595  
June 30, 2021
    27.19        25.13        25.12        24.76        8.24       1.49       3,629,357  
March 31, 2021
    26.94        24.03        24.34        23.63        10.68       1.69       4,226,813  
As of December 31, 2022, BUI’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $20.77, $22.37, and (7.15)%, respectively.
Common shares of each Trust have historically traded at both a premium and discount to NAV.
Shares of closed-end funds frequently trade at a discount to their NAV. Because of this possibility and the recognition that any such discount may not be in the interest of shareholders, the Board might consider from time to time engaging in open-market repurchases, managed distribution plans, or other programs intended to reduce the discount. We cannot guarantee or assure, however, that the Board will decide to engage in any of these actions. Nor is there any guarantee or assurance that such actions, if undertaken, would result in the shares trading at a price equal or close to the NAV.
 
 
210
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Automatic Dividend Reinvestment Plan
 
Pursuant to BGR, CII, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI’s Dividend Reinvestment Plan (the “Reinvestment Plan”), Common Shareholders are automatically enrolled to have all distributions of dividends and capital gains and other distributions reinvested by Computershare Trust Company, N.A. (the “Reinvestment Plan Agent”) in the respective Trust’s Common Shares pursuant to the Reinvestment Plan. Shareholders who do not participate in the Reinvestment Plan will receive all distributions in cash paid by check and mailed directly to the shareholders of record (or if the shares are held in street name or other nominee name, then to the nominee) by the Reinvestment Plan Agent, which serves as agent for the shareholders in administering the Reinvestment Plan.
After BGR, CII, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI declare a dividend or determine to make a capital gain or other distribution, the Reinvestment Plan Agent will acquire shares for the participants’ accounts, depending upon the following circumstances, either (i) through receipt of unissued but authorized shares from the Trusts (“newly issued shares”) or (ii) by purchase of outstanding shares on the open market or on the Trust’s primary exchange (“open-market purchases”). If, on the dividend payment date, the net asset value (“NAV”) per share is equal to or less than the market price per share plus estimated brokerage commissions (such condition often referred to as a “market premium”), the Reinvestment Plan Agent will invest the dividend amount in newly issued shares acquired on behalf of the participants. The number of newly issued shares to be credited to each participant’s account will be determined by dividing the dollar amount of the dividend by the NAV on the date the shares are issued. However, if the NAV is less than 95% of the market price on the dividend payment date, the dollar amount of the dividend will be divided by 95% of the market price on the dividend payment date. If, on the dividend payment date, the NAV is greater than the market price per share plus estimated brokerage commissions (such condition often referred to as a “market discount”), the Reinvestment Plan Agent will invest the dividend amount in shares acquired on behalf of the participants in open-market purchases. If the Reinvestment Plan Agent is unable to invest the full dividend amount in open-market purchases, or if the market discount shifts to a market premium during the purchase period, the Reinvestment Plan Agent will invest any un-invested portion in newly issued shares. Investments in newly issued shares made in this manner would be made pursuant to the same process described above and the date of issue for such newly issued shares will substitute for the dividend payment date.
You may elect not to participate in the Reinvestment Plan and to receive all dividends in cash by contacting the Reinvestment Plan Agent, at the address set forth below.
Participation in the Reinvestment Plan is completely voluntary and may be terminated or resumed at any time without penalty by notice if received and processed by the Reinvestment Plan Agent prior to the dividend record date. Additionally, the Reinvestment Plan Agent seeks to process notices received after the record date but prior to the payable date and such notices often will become effective by the payable date. Where late notices are not processed by the applicable payable date, such termination or resumption will be effective with respect to any subsequently declared dividend or other distribution.
The Reinvestment Plan Agent’s fees for the handling of the reinvestment of distributions will be paid by each Trust. However, each participant will pay a pro rata share of brokerage commissions incurred with respect to the Reinvestment Plan Agent’s open-market purchases in connection with the reinvestment of all distributions. The automatic reinvestment of all distributions will not relieve participants of any U.S. federal, state or local income tax that may be payable on such dividends or distributions.
Each Trust reserves the right to amend or terminate the Reinvestment Plan. There is no direct service charge to participants in the Reinvestment Plan; however, each Trust reserves the right to amend the Reinvestment Plan to include a service charge payable by the participants. Participants in BMEZ, BIGZ, BST and BSTZ that request a sale of shares are subject to a $2.50 sales fee and a $0.15 per share sold fee. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay. Participants in BGR, CII, BDJ, BOE, BGY, BME, BME, BCX and BUI that request a sale of shares are subject to a $0.02 per share sold brokerage commission. All correspondence concerning the Reinvestment Plan should be directed to Computershare Trust Company, N.A. through the internet at computershare.com/blackrock, or in writing to Computershare, P.O. Box 43006, Providence, RI 02940-3078, Telephone: (800) 699-1236. Overnight correspondence should be directed to the Reinvestment Plan Agent at Computershare, 150 Royall Street, Suite 101, Canton, MA 02021.
 
 
A
U
T
O
M
A
T
I
C  
D
I
V
I
D
E
N
D  
R
E
I
N
V
E
S
T
M
E
N
T  
P
L
A
N
  211

Trustee and Officer Information
 
         
Independent Trustees
(a)
         
         
Name
Year of Birth
(b)
  
Position(s) Held
(Length of Service)
(c)
  
Principal Occupation(s) During Past 5 Years
  
Number of BlackRock-Advised
Registered Investment
Companies (“RICs”)
Consisting of
Investment Portfolios
(“Portfolios”) Overseen
  
Public Company
and Other
Investment
Company
Directorships Held
During
Past 5 Years
R. Glenn Hubbard
1958
  
Chair of the Board (Since 2022)
Trustee
(Since 2007)
  
Dean, Columbia Business School from 2004 to 2019; Faculty member, Columbia Business School since 1988.
   70 RICs consisting of 102 Portfolios    ADP (data and information services) from 2004 to 2020; Metropolitan Life Insurance Company (insurance); TotalEnergies SE (multi-energy)
W. Carl Kester
(d)
1951
  
Vice Chair of the Board
(Since 2022)
Trustee
(Since 2007)
   George Fisher Baker Jr. Professor of Business Administration, Harvard Business School since 2008; Deputy Dean for Academic Affairs from 2006 to 2010; Chairman of the Finance Unit, from 2005 to 2006; Senior Associate Dean and Chairman of the MBA Program from 1999 to 2005; Member of the faculty of Harvard Business School since 1981.    72 RICs consisting of 104 Portfolios    None
Cynthia L. Egan
1955
  
Trustee
(Since 2016)
   Advisor, U.S. Department of the Treasury from 2014 to 2015; President, Retirement Plan Services, for T. Rowe Price Group, Inc. from 2007 to 2012; executive positions within Fidelity Investments from 1989 to 2007.    70 RICs consisting of 102 Portfolios    Unum (insurance); The Hanover Insurance Group (Board Chair); Huntsman Corporation (Lead Independent Director and non Executive Vice Chair of the Board) (chemical products)
Frank J. Fabozzi
(d)
1948
  
Trustee
(Since 2007)
   Editor of The Journal of Portfolio Management since 1986; Professor of Finance, EDHEC Business School (France) from 2011 to 2022; Professor of Practice, Johns Hopkins University since 2021; Professor in the Practice of Finance, Yale University School of Management from 1994 to 2011 and currently a Teaching Fellow in Yale’s Executive Programs; Visiting Professor, Rutgers University for the Spring 2019 semester; Visiting Professor, New York University for the 2019 academic year; Adjunct Professor of Finance, Carnegie Mellon University in fall 2020 semester.    72 RICs consisting of 104 Portfolios    None
Lorenzo A. Flores
1964
  
Trustee
(Since 2021)
   Vice Chairman, Kioxia, Inc. since 2019; Chief Financial Officer, Xilinx, Inc. from 2016 to 2019; Corporate Controller, Xilinx, Inc. from 2008 to 2016.    70 RICs consisting of 102 Portfolios    None
Stayce D. Harris
1959
  
Trustee
(Since 2021)
   Lieutenant General, Inspector General, Office of the Secretary of the United States Air Force from 2017 to 2019; Lieutenant General, Assistant Vice Chief of Staff and Director, Air Staff, United States Air Force from 2016 to 2017; Major General, Commander, 22nd Air Force, AFRC, Dobbins Air Reserve Base, Georgia from 2014 to 2016; Pilot, United Airlines from 1990 to 2020.    70 RICs consisting of 102 Portfolios    The Boeing Company (airplane manufacturer)
J. Phillip Holloman
1955
  
Trustee
(Since 2021)
   President and Chief Operating Officer, Cintas Corporation from 2008 to 2018.    70 RICs consisting of 102 Portfolios    PulteGroup, Inc. (home construction); Rockwell Automation Inc. (industrial automation)
 
 
212
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Trustee and Officer Information  
(continued)
 
Independent Trustees
(a)
(continued)
         
Name
Year of Birth
(b)
  
Position(s) Held
(Length of Service)
(c)
  
Principal Occupation(s) During Past 5 Years
  
Number of BlackRock-Advised
Registered Investment
Companies
(“RICs”) Consisting of
Investment Portfolios
(“Portfolios”) Overseen
  
Public Company
and Other
Investment
Company
Directorships Held
During Past 5
Years
Catherine A. Lynch
(d)
1961
  
Trustee
(Since 2016)
   Chief Executive Officer, Chief Investment Officer and various other positions, National Railroad Retirement Investment Trust from 2003 to 2016; Associate Vice President for Treasury Management, The George Washington University from 1999 to 2003; Assistant Treasurer, Episcopal Church of America from 1995 to 1999.    72 RICs consisting of 104 Portfolios    PennyMac Mortgage Investment Trust
         
           
Interested Trustees
(a)(e)
           
         
Name
Year of Birth
(b)
  
Position(s) Held
(Length of Service)
(c)
  
Principal Occupation(s) During Past 5 Years
  
Number of BlackRock-Advised
Registered Investment
Companies
(“RICs”) Consisting of
Investment Portfolios
(“Portfolios”) Overseen
  
Public Company
and Other
Investment
Company
Directorships Held
During Past 5
Years
Robert Fairbairn
1965
  
Trustee
(Since 2018)
   Vice Chairman of BlackRock, Inc. since 2019; Member of BlackRock’s Global Executive and Global Operating Committees; Co-Chair of BlackRock’s Human Capital Committee; Senior Managing Director of BlackRock, Inc. from 2010 to 2019; oversaw BlackRock’s Strategic Partner Program and Strategic Product Management Group from 2012 to 2019; Member of the Board of Managers of BlackRock Investments, LLC from 2011 to 2018; Global Head of BlackRock’s Retail and iShares
®
businesses from 2012 to 2016.
   98 RICs consisting of 266 Portfolios    None
John M. Perlowski
(d)
1964
  
Trustee
(Since 2015)
President and Chief Executive Officer (Since 2010)
   Managing Director of BlackRock, Inc. since 2009; Head of BlackRock Global Accounting and Product Services since 2009; Advisory Director of Family Resource Network (charitable foundation) since 2009.    100 RICs consisting of 268 Portfolios    None
(a)
 
 
The address of each Trustee is c/o BlackRock, Inc., 55 East 52nd Street, New York, New York 10055.
(b)
 
 
Each Independent Trustee holds office until his or her successor is duly elected and qualifies or until his or her earlier death, resignation, retirement or removal as provided by the Trust’s by-laws or charter or statute, or until December 31 of the year in which he or she turns 75. Trustees who are “interested persons,” as defined in the Investment Company Act serve until their successor is duly elected and qualifies or until their earlier death, resignation, retirement or removal as provided by the Trust’s by-laws or statute, or until December 31 of the year in which they turn 72. The Board may determine to extend the terms of Independent Trustees on a case-by-case basis, as appropriate.
(c)
 
 
Following the combination of Merrill Lynch Investment Managers, L.P. (“MLIM”) and BlackRock, Inc. in September 2006, the various legacy MLIM and legacy BlackRock fund boards were realigned and consolidated into three new fund boards in 2007. Certain Independent Trustees first became members of the boards of other legacy MLIM or legacy BlackRock funds as follows: Frank J. Fabozzi, 1988; R. Glenn Hubbard, 2004; and W. Carl Kester, 1995.
(d)
 
 
Dr. Fabozzi, Dr. Kester, Ms. Lynch and Mr. Perlowski are also trustees of the BlackRock Credit Strategies Fund and BlackRock Private Investments Fund.
(e)
 
 
Mr. Fairbairn and Mr. Perlowski are both “interested persons,” as defined in the 1940 Act, of the Fund based on their positions with BlackRock, Inc. and its affiliates. Mr. Fairbairn and Mr. Perlowski are also board members of the BlackRock Multi-Asset Complex.
 
 
T
R
U
S
T
E
E   
A
N
D   
O
F
F
I
C
E
R   
I
N
F
O
R
M
A
T
I
O
N
  213

Trustee and Officer Information  
(continued)
 
Officers Who Are Not Trustees
(a)
     
Name
Year of Birth
(b)
  
Position(s) Held
(Length of Service)
  
Principal Occupation(s) During Past 5 Years
Jonathan Diorio
1980
  
Vice President
(Since 2015)
  
Managing Director of BlackRock, Inc. since 2015; Director of BlackRock, Inc. from 2011 to 2015.
Trent Walker
1974
   Chief Financial Officer (Since 2021)   
Managing Director of BlackRock, Inc. since September 2019; Executive Vice President of PIMCO from 2016 to 2019; Senior Vice President of PIMCO from 2008 to 2015; Treasurer from 2013 to 2019 and Assistant Treasurer from 2007 to 2017 of PIMCO Funds, PIMCO Variable Insurance Trust, PIMCO ETF Trust, PIMCO Equity Series, PIMCO Equity Series VIT, PIMCO Managed Accounts Trust, 2 PIMCO-sponsored interval funds and 21 PIMCO-sponsored closed-end funds.
Jay M. Fife
1970
  
Treasurer
(Since 2007)
  
Managing Director of BlackRock, Inc. since 2007.
Charles Park
1967
  
Chief Compliance Officer
(Since 2014)
  
Anti-Money Laundering Compliance Officer for certain BlackRock-advised Funds from 2014 to 2015; Chief Compliance Officer of BlackRock Advisors, LLC and the BlackRock-advised Funds in the BlackRock Multi-Asset Complex and the BlackRock Fixed-Income Complex since 2014; Principal of and Chief Compliance Officer for iShares® Delaware Trust Sponsor LLC since 2012 and BlackRock Fund Advisors (“BFA”) since 2006; Chief Compliance Officer for the BFA-advised iShares
®
exchange traded funds since 2006; Chief Compliance Officer for BlackRock Asset Management International Inc. since 2012.
Janey Ahn
1975
  
Secretary
(Since 2012)
  
Managing Director of BlackRock, Inc. since 2018; Director of BlackRock, Inc. from 2009 to 2017.
 
(a)
 
 
The address of each Officer is c/o BlackRock, Inc., 55 East 52nd Street, New York, New York 10055.
(b)
 
 
Officers of the Trust serve at the pleasure of the Board.
Further information about the BME’s, BST’s and BUI’s Trustees and Officers is available in the Trust’s Statement of Additional Information, which can be obtained without charge by calling (800) 882-0052.
 
Effective May 31, 2022, Karen P. Robards retired as a Trustee of the Trusts.
Effective September 22, 2022, BST’s and BSTZ’s portfolio managers are Tony Kim, Kyle McClements, Chris Accettella, Reid Menge and Caroline Tall. Ms. Tall has been a Director at BlackRock since 2022.
Effective January 12, 2022, BOE’s and BGY’s portfolio managers are Chris Accettella, Kyle McClements, Oliver Treharne and Molly Greenen. Ms Greenen has been a Director at BlackRock since 2013.
Effective January 12, 2023, BIGZ’s portfolio managers are William Broadbent, Chris Accettella, Kyle McClements and Phil Ruvinsky.
 
 
214
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Additional Information
 
Proxy Results
The Annual Meeting of Shareholders was held on July 25, 2022 for shareholders of record on May 27, 2022, to elect trustee nominees for each Trust. There were no broker non-votes with regard to any of the Trusts.
Shareholders elected the Class III Trustees as follows:
 
Trust Name
  Cynthia L. Egan     Robert Fairbairn     Stayce D. Harris  
 
Votes For
   
Votes Withheld
   
Votes For
   
Votes Withheld
   
Votes For
   
Votes Withheld
 
BDJ
    141,756,807       4,194,712       141,948,288       4,003,231       141,738,774       4,212,745  
BGR
    21,914,722       1,262,602       21,934,399       1,242,925       21,891,635       1,285,689  
BOE
    52,206,004       2,153,088       52,190,747       2,168,345       52,228,347       2,130,745  
BME
    10,107,434       260,151       10,092,765       274,820       10,104,625       262,960  
BGY
    86,257,532       2,483,755       86,081,187       2,660,100       86,258,313       2,482,974  
BCX
    67,140,144       1,571,728       67,189,293       1,522,579       67,220,023       1,491,849  
BUI
    15,903,509       525,825       15,901,154       528,180       15,885,881       543,453  
BST
    23,279,646       914,401       23,181,339       1,012,708       23,252,722       941,325  
For the Trusts listed above, Trustees whose term of office continued after the Annual Meeting of Shareholders because they were not up for election are Lorenzo A. Flores, J. Phillip Holloman, R. Glenn Hubbard, Catherine A. Lynch, John M. Perlowski, Frank J. Fabozzi and W. Carl Kester.
Shareholders elected the Class III Trustees as follows:
 
Trust Name
  Frank J. Fabozzi     Robert Fairbairn     J. Phillip Holloman  
 
Votes For
   
Votes Withheld
   
Votes For
   
Votes Withheld
   
Votes For
   
Votes Withheld
 
BIGZ
    191,788,764       8,916,741       192,192,671       8,512,834       191,283,701       9,421,804  
BSTZ
    65,440,529       1,982,496       65,412,502       2,010,523       65,452,015       1,971,010  
BMEZ
    98,057,623       2,421,624       98,259,282       2,219,965       97,630,537       2,848,710  
CII
    34,069,922       1,308,964       34,412,934       965,952       34,397,360       981,526  
For the Trusts listed above, Trustees whose term of office continued after the Annual Meeting of Shareholders because they were not up for election are Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris, R. Glenn Hubbard, Catherine A. Lynch, John M. Perlowski and W. Carl Kester.
Trust Certification
The Trusts are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE’s listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act.
Environmental, Social and Governance (“ESG”) Integration
Although a Trust does not seek to implement a specific sustainability strategy unless otherwise disclosed, Trust management will consider ESG characteristics as part of the investment process for actively managed Trusts. These considerations will vary depending on a Trust’s particular investment strategies and may include consideration of third-party research as well as consideration of proprietary BlackRock research across the ESG risks and opportunities regarding an issuer. Trust management will consider such ESG characteristics it deems relevant or additive, if any, when making investment decisions for a Trust. The ESG characteristics utilized in a Trust’s investment process are anticipated to evolve over time and one or more characteristics may not be relevant with respect to all issuers that are eligible for investment. ESG characteristics are not the sole considerations when making investment decisions for a Trust. Further, investors can differ in their views of what constitutes positive or negative ESG characteristics. As a result, a Trust may invest in issuers that do not reflect the beliefs and values with respect to ESG of any particular investor. ESG considerations may affect a Trust’s exposure to certain companies or industries and a Trust may forego certain investment opportunities. While Trust management views ESG considerations as having the potential to contribute to a Trust’s long-term performance, there is no guarantee that such results will be achieved.
Dividend Policy
Each Trust’s policy is to make monthly distributions to shareholders. In order to provide shareholders with a more stable level of dividend distributions, each Trust employs a managed distribution plan (the “Plan”), the goal of which is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of each Trust.
The distributions paid by a Trust for any particular month may be more or less than the amount of net investment income earned by a Trust during such month. Furthermore, the final tax characterization of distributions is determined after the year-end of a Trust and is reported in each Trust’s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. Each Trust’s taxable net investment income and net realized capital gains (“taxable income”) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust’s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital.
 
 
A
D
D
I
T
I
O
N
A
L   
I
N
F
O
R
M
A
T
I
O
N
  215

Additional Information  
(continued)
 
Dividend Policy (continued)
A return of capital is a return of a portion of an investor’s original investment. A return of capital is not expected to be taxable, but it reduces a shareholder’s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.
Such distributions, under certain circumstances, may exceed a Trust’s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust’s total assets and net asset value (“NAV”) per share and, therefore, could have the effect of increasing the Trust’s expense ratio and reducing the amount of assets the Trust has available for long term investment.
General Information
The Trusts, other than BME, BST and BUI, do not make available copies of their Statements of Additional Information because the Trusts’ shares, other than BME, BST and BUI, are not continuously offered, which means that the Statement of Additional Information of each Trust, other than BME, BST and BUI, has not been updated after completion of the respective Trust’s offerings and the information contained in each Trust’s Statement of Additional Information may have become outdated.
BME’s, BST’s and BUI’s Statements of Additional Information include additional information about the Board and are available, without charge upon request by calling (800)882-0052.
The following information is a summary of certain changes since December 31, 2021. This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.
Except if noted otherwise herein, there were no changes to the Trusts’ charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders. Except if noted otherwise herein, there have been no changes in the persons who are primarily responsible for the day-to-day management of the Trusts’ portfolios.
Effective August 1, 2022, the State of Delaware enacted new control beneficial interest acquisition provisions of the Delaware Statutory Trust Act (the “Delaware CBIA Statute”) that automatically applies to Delaware statutory trusts that are registered as closed-end management investment companies under the Investment Company Act of 1940, such as BGR, BDJ, BOE, BGY, BME, BCX, BST, BSTZ and BUI. In general, the Delaware CBIA Statute limits the right of holders who acquire “control beneficial interests” of a statutory trust to vote those beneficial interests on matters under the Delaware Statutory Trust Act or the governing instrument of BGR, BDJ, BOE, BGY, BME, BCX, BST, BSTZ and BUI unless approved by disinterested shareholders holding two-thirds of the votes entitled to be cast. The Delaware CBIA Statute generally defines “control beneficial interests” to include beneficial interests that, in the absence of the Delaware CBIA Statute, if aggregated with all other beneficial interests of the statutory trust that are either (i) owned by the acquiring person (or an associate) or (ii) in respect of which the acquiring person (or an associate) is entitled to exercise or direct the exercise of voting power, would entitle that person to exercise or direct the exercise of voting power of beneficial interests in the election of trustees, within any of certain specified ranges of voting power starting at 10%. The Delaware CBIA Statute requires acquiring persons to disclose to the statutory trust any control beneficial interest acquisition within 10 days of such acquisition. The Delaware CBIA Statute allows a statutory trust’s governing instrument or board of trustees to provide exemptions from the statute’s limitations to acquisitions of beneficial interests, including as to any series or classes of beneficial interests. The foregoing is only a summary of certain aspects of the Delaware CBIA Statute. Shareholders should consult their own legal counsel to determine the application of the Delaware CBIA Statute with respect to their beneficial interests of BGR, BDJ, BOE, BGY, BME, BCX, BST, BSTZ and BUI and any subsequent acquisitions of beneficial interests.
In accordance with Section 23(c) of the Investment Company Act of 1940, each Trust may from time to time purchase shares of its common stock in the open market or in private transactions.
Quarterly performance, semi-annual and annual reports, current net asset value and other information regarding the Trusts may be found on BlackRock’s website, which can be accessed at
blackrock.com
. Any reference to BlackRock’s website in this report is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.
Electronic Delivery
Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports and, for BME, BST and BUI only, prospectuses, by enrolling in the electronic delivery program. Electronic copies of shareholder reports and, for BME, BST and BUI only, prospectuses, are available on BlackRock’s website.
To enroll in electronic delivery:
Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:
Please contact your financial adviser. Please note that not all investment advisers, banks or brokerages may offer this service.
 
 
216
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Additional Information  
(continued)
 
Householding
The Trusts will mail only one copy of shareholder documents, including for BME, BST and BUI only, prospectuses, annual and semi-annual reports, Rule 30e-3 notices and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called “householding” and is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts at (800) 882-0052.
Availability of Quarterly Schedule of Investments
The Trusts file their complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year as an exhibit to their reports on Form N-PORT. The Trusts’ Forms N-PORT are available on the SEC’s website at
sec.gov
. Additionally, each Trust makes its portfolio holdings for the first and third quarters of each fiscal year available at
blackrock.com/fundreports
.
Availability of Proxy Voting Policies, Procedures and Voting Records
A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities and information about how the Trusts voted proxies relating to securities held in the Trusts’ portfolios during the most recent 12-month period ended June 30 is available without charge, upon request (1) by calling (800) 882-0052; (2) on the BlackRock website at
blackrock.com
; and (3) on the SEC’s website at
sec.gov
.
Availability of Trust Updates
BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the “Closed-end Funds” section of
blackrock.com
as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.
Shelf Offering Program
From time to time, BME, BST and BUI may seek to raise additional equity capital through a Shelf Offering. In a Shelf Offering, BME, BST and BUI may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above BME’s, BST’s and BUI’s net asset value (“NAV”) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow BME, BST and BUI to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks – including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.
BME, BST and BUI filed final prospectuses with the SEC in connection with its Shelf Offering on April 26, 2002, May 10, 2022 and March 10, 2002, respectively. This report and the prospectuses of BME, BST and BUI are not offers to sell BME, BST and BUI Common Shares or solicitations of an offer to buy BME, BST and BUI Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectuses of BME, BST and BUI contains important information about BME, BST and BUI, including their investment objectives, risks, charges and expenses. Investors are urged to read the prospectuses of BME, BST and BUI carefully and in their entirety before investing. Copies of the final prospectuses for BME, BST and BUI can be obtained from BlackRock at
blackrock.com
.
BlackRock Privacy Principles
BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, “Clients”) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.
If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.
BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.
BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.
We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.
 
 
A
D
D
I
T
I
O
N
A
L   
I
N
F
O
R
M
A
T
I
O
N
  217

Additional Information  (continued)
 
Trust and Service Providers
 
Investment Adviser
BlackRock Advisors, LLC
Wilmington, DE 19809
Sub-Adviser
BlackRock International Limited
(a)
Edinburgh, EH3 8BL
United Kingdom
Accounting Agent and Custodian
State Street Bank and Trust Company
Boston, MA 02111
Transfer Agent
Computershare Trust Company, N.A.
Canton, MA 02021
(a)
 For BGR, BOE, BGY, BCX and BUI.
(b)
 For BME, BST and BUI.
 
Distributor
BlackRock Investments, LLC
(b)
New York, NY 10022
Independent Registered Public Accounting Firm
Deloitte & Touche LLP
Boston, MA 02116
Legal Counsel
Willkie Farr & Gallagher LLP
New York, NY 10019
Address of the Trusts
100 Bellevue Parkway
Wilmington, DE 19809
 
 
218
 
2 0 2 2
   B
L
A
C
K
R
O
C
K   
A
N
N
U
A
L   
R
E
P
O
R
T   T
O   
S
H
A
R
E
H
O
L
D
E
R
S

Glossary of Terms Used in this Report
 
Currency Abbreviation
 
AUD    Australian Dollar
BRL    Brazilian Real
CAD    Canadian Dollar
CHF    Swiss Franc
CNY    Chinese Yuan
DKK    Danish Krone
EUR    Euro
GBP    British Pound
HKD    Hong Kong Dollar
JPY    Japanese Yen
KRW    South Korean Won
MXN    Mexican Peso
NOK    Norwegian Krone
SEK    Swedish Krona
SGD    Singapore Dollar
TWD    New Taiwan Dollar
USD    United States Dollar
Portfolio Abbreviation
ADR    American Depositary Receipt
GDR    Global Depositary Receipt
LP    Limited Partnership
PJSC    Public Joint Stock Company
S&P    Standard & Poor’s
SAB    Special Assessment Bonds
 
 
G
L
O
S
S
A
R
Y   O
F   
T
E
R
M
S   
U
S
E
D   I
N   T
H
I
S   
R
E
P
O
R
T
  219

 
Want to know more?
blackrock.com | 800-882-0052
This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.
CEF-BK9-12/22-AR
 
 
LOGO
   LOGO


(b) Not Applicable

 

Item 2 –

Code of Ethics – The registrant (or the “Fund”) has adopted a code of ethics, as of the end of the period covered by this report, applicable to the registrant’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. During the period covered by this report, the code of ethics was amended to update certain information and to make other non-material changes. During the period covered by this report, there have been no waivers granted under the code of ethics. The registrant undertakes to provide a copy of the code of ethics to any person upon request, without charge, who calls 1-800-882-0052, option 4.

 

Item 3 –

Audit Committee Financial Expert – The registrant’s board of directors (the “board of directors”), has determined that (i) the registrant has the following audit committee financial experts serving on its audit committee and (ii) each audit committee financial expert is independent:

Frank J. Fabozzi

Lorenzo A. Flores

Catherine A. Lynch

Under applicable securities laws, a person determined to be an audit committee financial expert will not be deemed an “expert” for any purpose, including without limitation for the purposes of Section 11 of the Securities Act of 1933, as a result of being designated or identified as an audit committee financial expert. The designation or identification of a person as an audit committee financial expert does not impose on such person any duties, obligations, or liabilities greater than the duties, obligations, and liabilities imposed on such person as a member of the audit committee and board of directors in the absence of such designation or identification. The designation or identification of a person as an audit committee financial expert does not affect the duties, obligations, or liability of any other member of the audit committee or board of directors.

 

Item 4 –

Principal Accountant Fees and Services

The following table presents fees billed by Deloitte & Touche LLP (“D&T”) in each of the last two fiscal years for the services rendered to the Fund:

 

     (a) Audit Fees   (b) Audit-Related Fees1   (c) Tax Fees2   (d) All Other Fees

Entity Name

 

Current

Fiscal Year
End

 

Previous

Fiscal Year
End

 

Current

Fiscal Year
End

 

Previous

Fiscal Year
End

 

Current

Fiscal Year
End

 

Previous

Fiscal Year
End

 

Current

Fiscal Year
End

 

Previous

Fiscal Year
End

BlackRock Utilities, Infrastructure & Power Opportunities Trust   $36,516   $36,158   $4,000   $4,207   $16,200   $18,400   $431   $0

The following table presents fees billed by D&T that were required to be approved by the registrant’s audit committee (the “Committee”) for services that relate directly to the operations or financial reporting of the Fund and that are rendered on behalf of BlackRock Advisors, LLC ( the “Investment Adviser” or “BlackRock”) and entities controlling, controlled by, or under common control with BlackRock (not including any sub-adviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser) that provide ongoing services to the Fund (“Affiliated Service Providers”):


     Current Fiscal Year End   Previous Fiscal Year End

(b) Audit-Related Fees1

  $0   $0

(c) Tax Fees2

  $0   $0

(d) All Other Fees3

  $2,098,000   $2,032,000

1 The nature of the services includes assurance and related services reasonably related to the performance of the audit or review of financial statements not included in Audit Fees, including accounting consultations, agreed-upon procedure reports, attestation reports, comfort letters, out-of-pocket expenses and internal control reviews not required by regulators.

2 The nature of the services includes tax compliance and/or tax preparation, including services relating to the filing or amendment of federal, state or local income tax returns, regulated investment company qualification reviews, taxable income and tax distribution calculations.

3 Non-audit fees of $2,098,000 and $2,032,000 for the current fiscal year and previous fiscal year, respectively, were paid to the Fund’s principal accountant in their entirety by BlackRock, in connection with services provided to the Affiliated Service Providers of the Fund and of certain other funds sponsored and advised by BlackRock or its affiliates for a service organization review and an accounting research tool subscription. These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.

(e)(1) Audit Committee Pre-Approval Policies and Procedures:

The Committee has adopted policies and procedures with regard to the pre-approval of services. Audit, audit-related and tax compliance services provided to the registrant on an annual basis require specific pre-approval by the Committee. The Committee also must approve other non-audit services provided to the registrant and those non-audit services provided to the Investment Adviser and Affiliated Service Providers that relate directly to the operations and the financial reporting of the registrant. Certain of these non-audit services that the Committee believes are (a) consistent with the SEC’s auditor independence rules and (b) routine and recurring services that will not impair the independence of the independent accountants may be approved by the Committee without consideration on a specific case-by-case basis (“general pre-approval”). The term of any general pre-approval is 12 months from the date of the pre-approval, unless the Committee provides for a different period. Tax or other non-audit services provided to the registrant which have a direct impact on the operations or financial reporting of the registrant will only be deemed pre-approved provided that any individual project does not exceed $10,000 attributable to the registrant or $50,000 per project. For this purpose, multiple projects will be aggregated to determine if they exceed the previously mentioned cost levels.

Any proposed services exceeding the pre-approved cost levels will require specific pre-approval by the Committee, as will any other services not subject to general pre-approval (e.g., unanticipated but permissible services). The Committee is informed of each service approved subject to general pre-approval at the next regularly scheduled in-person board meeting. At this meeting, an analysis of such services is presented to the Committee for ratification. The Committee may delegate to the Committee Chairman the authority to approve the provision of and fees for any specific engagement of permitted non-audit services, including services exceeding pre-approved cost levels.

(e)(2) None of the services described in each of Items 4(b) through (d) were approved by the Committee pursuant to the de minimis exception in paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

(f) Not Applicable


(g) The aggregate non-audit fees, defined as the sum of the fees shown under “Audit-Related Fees,” “Tax Fees” and “All Other Fees,” paid to the accountant for services rendered by the accountant to the registrant, the Investment Adviser and the Affiliated Service Providers were:

 

Entity Name

 

Current Fiscal Year

End

 

Previous Fiscal Year

End

    
BlackRock Utilities, Infrastructure & Power Opportunities Trust   $20,631   $22,607

Additionally, the amounts billed by D&T in connection with services provided to the Affiliated Service Providers of the Fund and of other funds sponsored or advised by BlackRock or its affiliates during the current and previous fiscal years for a service organization review and an accounting research tool subscription were:

 

Current Fiscal

Year End

 

Previous Fiscal Year

End

    

$2,098,000

  $2,032,000

These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.

(h) The Committee has considered and determined that the provision of non-audit services that were rendered to the Investment Adviser, and the Affiliated Service Providers that were not pre-approved pursuant to paragraph (c)(7)(ii) of Rule 2-01 of Regulation S-X is compatible with maintaining the principal accountant’s independence.

(i) – Not Applicable

(j) – Not Applicable

 

Item 5 –

Audit Committee of Listed Registrants

(a) The following individuals are members of the registrant’s separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (15 U.S.C. 78c(a)(58)(A)):

Frank J. Fabozzi

Lorenzo A. Flores

J. Phillip Holloman

Catherine A. Lynch

(b) Not Applicable

 

Item 6 –

Investments


(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.

(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.

 

Item 7 –

Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – The board of directors has delegated the voting of proxies for the Fund’s portfolio securities to the Investment Adviser pursuant to the Investment Adviser’s proxy voting guidelines. Under these guidelines, the Investment Adviser will vote proxies related to Fund securities in the best interests of the Fund and its stockholders. From time to time, a vote may present a conflict between the interests of the Fund’s stockholders, on the one hand, and those of the Investment Adviser, or any affiliated person of the Fund or the Investment Adviser, on the other. In such event, provided that the Investment Adviser’s Equity Investment Policy Oversight Committee, or a sub-committee thereof (the “Oversight Committee”) is aware of the real or potential conflict or material non-routine matter and if the Oversight Committee does not reasonably believe it is able to follow its general voting guidelines (or if the particular proxy matter is not addressed in the guidelines) and vote impartially, the Oversight Committee may retain an independent fiduciary to advise the Oversight Committee on how to vote or to cast votes on behalf of the Investment Adviser’s clients. If the Investment Adviser determines not to retain an independent fiduciary, or does not desire to follow the advice of such independent fiduciary, the Oversight Committee shall determine how to vote the proxy after consulting with the Investment Adviser’s Portfolio Management Group and/or the Investment Adviser’s Legal and Compliance Department and concluding that the vote cast is in its client’s best interest notwithstanding the conflict. A copy of the Fund’s Proxy Voting Policy and Procedures are attached as Exhibit 99.PROXYPOL, a copy of the Fund’s Global Corporate Governance & Engagement Principles are attached as Exhibit 99.GLOBAL.CORP.GOV and a copy of the Fund’s Corporate Governance and Proxy Voting Guidelines for U.S. Securities are attached as Exhibit 99.US.CORP.GOV. Information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available without charge, (i) at www.blackrock.com and (ii) on the SEC’s website at http://www.sec.gov.

 

Item 8 –

Portfolio Managers of Closed-End Management Investment Companies

(a)(1) As of the date of filing this Report:

The registrant is managed by a team of investment professionals comprised of Kyle G. McClements, CFA, Managing Director at BlackRock, Christopher Accettella, Director at BlackRock and Alastair Bishop, Managing Director at BlackRock. Messrs. McClements, Accettella and Bishop are the Fund’s portfolio managers and are responsible for the day-to-day management of the Fund’s portfolio and the selection of its investments. Messrs. McClements and Accettella have been members of the Fund’s portfolio management team since 2011. Mr. Bishop has been a member of the Fund’s portfolio management team since 2017.


Portfolio Manager

 

Biography

Kyle G. McClements, CFA   Managing Director of BlackRock since 2009; Director of BlackRock from 2006 to 2008; Vice President of BlackRock in 2005; Vice President of State Street Research & Management from 2004 to 2005.
Christopher Accettella   Director of BlackRock since 2008; Vice President of BlackRock, Inc. from 2005 to 2008.
Alastair Bishop   Managing Director of BlackRock since 2019; Director of BlackRock from 2010 to 2018.

(a)(2) As of December 31, 2022:

 

    

(ii) Number of Other Accounts Managed

and Assets by Account Type

 

(iii) Number of Other Accounts and

Assets for Which Advisory Fee is

Performance-Based

(i) Name of

Portfolio Manager

 

Other

Registered

Investment

Companies

 

Other
Pooled

Investment

Vehicles

 

Other

Accounts

 

Other

Registered

Investment

Companies

  

Other
Pooled

Investment

Vehicles

  

Other

Accounts

Kyle G. McClements, CFA

  14   11   0   0    0    0
    $14.80 Billion   $2.17 Billion   $0   $0    $0    $0

Christopher Accettella

  14   7   0   0    0    0
    $14.80 Billion   $1.56 Billion   $0   $0    $0    $0

Alastair Bishop

  7   14   3   0    1    0
    $5.34 Billion   $12.57 Billion   $285.4 Million   $0    $7.03 Million    $0

(iv) Portfolio Manager Potential Material Conflicts of Interest

BlackRock has built a professional working environment, firm-wide compliance culture and compliance procedures and systems designed to protect against potential incentives that may favor one account over another. BlackRock has adopted policies and procedures that address the allocation of investment opportunities, execution of portfolio transactions, personal trading by employees and other potential conflicts of interest that are designed to ensure that all client accounts are treated equitably over time. Nevertheless, BlackRock furnishes investment management and advisory services to numerous clients in addition to the Fund, and BlackRock may, consistent with applicable law, make investment recommendations to other clients or accounts (including accounts which are hedge funds or have performance or higher fees paid to BlackRock, or in which portfolio managers have a personal interest in the receipt of such fees), which may be the same as or different from those made to the Fund. In addition, BlackRock, Inc., its affiliates and significant shareholders and any officer, director, shareholder or employee may or may not have an interest in the securities whose purchase and sale BlackRock recommends to the Fund. BlackRock, Inc., or any of its affiliates or significant shareholders, or any officer, director, shareholder, employee or any member of their families may take different actions than those recommended to the Fund by BlackRock with respect to the same securities. Moreover, BlackRock may refrain from rendering any advice or services concerning securities of companies of which any of BlackRock, Inc.’s (or its affiliates’ or significant shareholders’) officers, directors or employees are directors or officers, or companies as to which BlackRock, Inc. or any of its affiliates or significant shareholders or the officers, directors and employees of any of them has any substantial economic interest or possesses material non-public information. Certain portfolio managers also may manage accounts whose investment strategies may at times be opposed to the strategy utilized for a fund. It should also be noted that Mr. Bishop may be managing hedge fund and/or long only accounts, or may be part of a team managing hedge fund and/or long only accounts, subject to incentive fees. Mr. Bishop may therefore be entitled to receive a portion of any incentive fees earned on such accounts.


As a fiduciary, BlackRock owes a duty of loyalty to its clients and must treat each client fairly. When BlackRock purchases or sells securities for more than one account, the trades must be allocated in a manner consistent with its fiduciary duties. BlackRock attempts to allocate investments in a fair and equitable manner among client accounts, with no account receiving preferential treatment. To this end, BlackRock, Inc. has adopted policies that are intended to ensure reasonable efficiency in client transactions and provide BlackRock with sufficient flexibility to allocate investments in a manner that is consistent with the particular investment discipline and client base, as appropriate.

(a)(3) As of December 31, 2022:

Portfolio Manager Compensation Overview

The discussion below describes the portfolio managers’ compensation as of December 31, 2022.

BlackRock’s financial arrangements with its portfolio managers, its competitive compensation and its career path emphasis at all levels reflect the value senior management places on key resources. Compensation may include a variety of components and may vary from year to year based on a number of factors. The principal components of compensation include a base salary, a performance-based discretionary bonus, participation in various benefits programs and one or more of the incentive compensation programs established by BlackRock.

Base Compensation. Generally, portfolio managers receive base compensation based on their position with the firm.

Discretionary Incentive Compensation - Mr. Bishop

Generally, discretionary incentive compensation for Active Equity portfolio managers is based on a formulaic compensation program. BlackRock’s formulaic portfolio manager compensation program is based on team revenue and pre-tax investment performance relative to appropriate competitors or benchmarks over 1-, 3- and 5-year performance periods, as applicable. In most cases, these benchmarks are the same as the benchmark or benchmarks against which the performance of the funds or other accounts managed by the portfolio managers are measured. BlackRock’s Chief Investment Officers determine the benchmarks or rankings against which the performance of funds and other accounts managed by each portfolio management team is compared and the period of time over which performance is evaluated. With respect to this portfolio manager, such benchmarks for the Fund and other accounts are: Bloomberg Commodity Index Total Return; FTSE Gold Mines Index (Gross Total Return); FTSE Gold Mining Index - expressed in JPY; FTSE Gold Mining Index - GBP Price; LIBOR 3 Month Index; MSCI 10/40 DW Energy (Net); MSCI ACWI Metals & Mining 30% Buffer 10/40 (1994) GBP Net TR; MSCI ACWI Metals & Mining 30% Buffer 10/40 (1994) USD Net TR; MSCI World Energy Net Daily TR Index; NYSE Arca Gold Miners Index EUR Net Total Return; S&P Global Natural Resources Index; S&P Global Natural Resources Index – In GBP; S&P Global Natural Resources Net Return.


A smaller element of portfolio manager discretionary compensation may include consideration of: financial results, expense control, profit margins, strategic planning and implementation, quality of client service, market share, corporate reputation, capital allocation, compliance and risk control, leadership, technology and innovation. These factors are considered collectively by BlackRock management and the relevant Chief Investment Officers.

Discretionary Incentive Compensation - Messrs. Accettella and McClements

Discretionary incentive compensation is a function of several components: the performance of BlackRock, Inc., the performance of the portfolio manager’s group within BlackRock, the investment performance, including risk-adjusted returns, of the firm’s assets or strategies under management or supervision by that portfolio manager, and/or the individual’s performance and contribution to the overall performance of these portfolios and BlackRock. Among other things, BlackRock’s Chief Investment Officers make a subjective determination with respect to each portfolio manager’s compensation based on the performance of the funds, other accounts or strategies managed by each portfolio manager. Performance is generally measured on a pre-tax basis over various time periods including 1-, 3- and 5- year periods, as applicable. The performance of some funds, other accounts or strategies may not be measured against a specific benchmark.

Distribution of Discretionary Incentive Compensation. Discretionary incentive compensation is distributed to portfolio managers in a combination of cash, deferred BlackRock, Inc. stock awards, and/or deferred cash awards that notionally track the return of certain BlackRock investment products.

Portfolio managers receive their annual discretionary incentive compensation in the form of cash. Portfolio managers whose total compensation is above a specified threshold also receive deferred BlackRock, Inc. stock awards annually as part of their discretionary incentive compensation. Paying a portion of discretionary incentive compensation in the form of deferred BlackRock, Inc. stock puts compensation earned by a portfolio manager for a given year “at risk” based on BlackRock’s ability to sustain and improve its performance over future periods. In some cases, additional deferred BlackRock, Inc. stock may be granted to certain key employees as part of a long-term incentive award to aid in retention, align interests with long-term shareholders and motivate performance. Deferred BlackRock, Inc. stock awards are generally granted in the form of BlackRock, Inc. restricted stock units that vest pursuant to the terms of the applicable plan and, once vested, settle in BlackRock, Inc. common stock. The portfolio managers of this Fund have deferred BlackRock, Inc. stock awards.

For certain portfolio managers, a portion of the discretionary incentive compensation is also distributed in the form of deferred cash awards that notionally track the returns of select BlackRock investment products they manage, which provides direct alignment of portfolio manager discretionary incentive compensation with investment product results. Deferred cash awards vest ratably over a number of years and, once vested, settle in the form of cash. Only portfolio managers who manage specified products and whose total compensation is above a specified threshold are eligible to participate in the deferred cash award program.


Other Compensation Benefits. In addition to base salary and discretionary incentive compensation, portfolio managers may be eligible to receive or participate in one or more of the following:

Incentive Savings Plans — BlackRock, Inc. has created a variety of incentive savings plans in which BlackRock, Inc. employees are eligible to participate, including a 401(k) plan, the BlackRock Retirement Savings Plan (RSP), and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution components of the RSP include a company match equal to 50% of the first 8% of eligible pay contributed to the plan capped at $5,000 per year, and a company retirement contribution equal to 3-5% of eligible compensation up to the Internal Revenue Service limit ($305,000 for 2022). The RSP offers a range of investment options, including registered investment companies and collective investment funds managed by the firm. BlackRock, Inc. contributions follow the investment direction set by participants for their own contributions or, absent participant investment direction, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock, Inc. common stock at a 5% discount on the fair market value of the stock on the purchase date. Annual participation in the ESPP is limited to the purchase of 1,000 shares of common stock or a dollar value of $25,000 based on its fair market value on the purchase date. Messrs. Accettella and McClements are eligible to participate in these plans.

United Kingdom-based portfolio managers are also eligible to participate in broad-based plans offered generally to BlackRock employees, including broad-based retirement, health and other employee benefit plans. For example, BlackRock has created a variety of incentive savings plans in which BlackRock employees are eligible to participate, including the BlackRock Retirement Savings Plan (RSP) and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution to the RSP is between 10% and 15% of eligible pay capped at £160,000 per annum. The RSP offers a range of investment options, including several collective investment funds managed by the firm. BlackRock contributions follow the investment direction set by participants for their own contributions or, in the absence of an investment election being made, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock common stock at a 5% discount on the fair market value of the stock on the purchase date. Annual participation in the ESPP is limited to the purchase of 1,000 shares of common stock or a US dollar value of $25,000 based on its fair market value on the purchase date. Mr. Bishop is eligible to participate in these plans.

(a)(4) Beneficial Ownership of Securities – As of December 31, 2022.

 

Portfolio Manager

 

Dollar Range of Equity Securities of the Fund Beneficially Owned

Kyle G. McClements, CFA

 

$50,001 - $100,000  

Christopher Accettella

 

$10,001 - $50,000  

Alastair Bishop

 

$50,001 - $100,000  

(b) Not Applicable

 

Item 9 –

Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers – Not Applicable due to no such purchases during the period covered by this report.


Item 10 –

Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures.

 

Item 11 –

Controls and Procedures

(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Item 12 –

Disclosure of Securities Lending Activities for Closed-End Management Investment Companies

(a) The following table shows the dollar amounts of income, and dollar amounts of fees and/or compensation paid, relating to the Fund’s securities lending activities during the fiscal year ended December 31, 2022.

 

BlackRock Utilities, Infrastructure & Power Opportunities Trust  
(1)  

Gross income from securities lending activities

   $ 11,341  
(2)  

Fees and/or compensation for securities lending activities and related services

  
  (a)    Securities lending income paid to BIM for services as securities lending agent    $ 1,697  
  (b)    Collateral management expenses (including fees deducted from a pooled cash collateral vehicle) not included in (a)    $ 26  
  (c)    Administrative fees not included in (a)    $ 0  
  (d)    Indemnification fees not included in (a)    $ 0  
  (e)    Rebate (paid to borrowers)    $ 0  
  (f)    Other fees not included in (a)    $ 0  
(3)  

Aggregate fees/compensation for securities lending activities

   $ 1,723  
(4)  

Net income from securities lending activities

   $ 9,618  

(b) BlackRock Investment Management, LLC (“BIM”) serves as securities lending agent for the Fund and in that role administers the Fund’s securities lending program pursuant to the terms of a securities lending agency agreement entered into between the Fund and BIM.

 

Item 13 –

Exhibits attached hereto

(a)(1) Code of Ethics – See Item 2

(a)(2) Section 302 Certifications are attached

(a)(3) Any written solicitation to purchase securities under Rule 23c-1 – Not Applicable


(a)(4) Change in Registrant’s independent public accountant – Not Applicable

(b) Section 906 Certifications are attached

(c) Notices to the registrant’s common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 20091

(d) Consent of Independent Registered Public Accounting Firm

(101) Inline Interactive Data File -the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.

 

1 The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.


Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Utilities, Infrastructure & Power Opportunities Trust

 

  By:     

/s/ John M. Perlowski                            

       John M. Perlowski
       Chief Executive Officer (principal executive officer) of
       BlackRock Utilities, Infrastructure & Power Opportunities Trust

Date: February 23, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

  By:     

/s/ John M. Perlowski                            

       John M. Perlowski
       Chief Executive Officer (principal executive officer) of
       BlackRock Utilities, Infrastructure & Power Opportunities Trust

Date: February 23, 2023

 

  By:     

/s/ Trent Walker                            

       Trent Walker
       Chief Financial Officer (principal financial officer) of
       BlackRock Utilities, Infrastructure & Power Opportunities Trust

Date: February 23, 2023